CA2473461C - Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these - Google Patents

Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these Download PDF

Info

Publication number
CA2473461C
CA2473461C CA2473461A CA2473461A CA2473461C CA 2473461 C CA2473461 C CA 2473461C CA 2473461 A CA2473461 A CA 2473461A CA 2473461 A CA2473461 A CA 2473461A CA 2473461 C CA2473461 C CA 2473461C
Authority
CA
Canada
Prior art keywords
group
chx
methyl
amino
och2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2473461A
Other languages
French (fr)
Other versions
CA2473461A1 (en
Inventor
Takahide Nishi
Takaichi Shimozato
Futoshi Nara
Shojiro Miyazaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Publication of CA2473461A1 publication Critical patent/CA2473461A1/en
Application granted granted Critical
Publication of CA2473461C publication Critical patent/CA2473461C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

The present invention relates to amino alcohol derivatives or phosphonic acid derivatives having excellent immunosuppressive activity, pharmacologically acceptable salts thereof or pharmacologically acceptable esters thereof, and to pharmaceutical compositions comprising said compounds as an active ingredient: (see formula I) [wherein, R1 and R 2 each represent a hydrogen atom, or a protecting group of the amino group; R3 represents a hydrogen atom, or a protecting group of the hydroxyl group; R4 represents a lower alkyl group; n represents an integer of from 1 to 6; X represents an oxygen atom or a nitrogen atom unsubstituted or substituted with a lower alkyl group or the like; Y represents an ethylene group; Z represents a C1-C10 alkylene group; R5 represents an aryl group, or an aryl group substituted with substituents; R6 and R7 each represents a hydrogen atom; provided that when R5 represents a hydrogen atom, then Z represents a group other than a single bond or a straight chain C1-C20 alkylene group].

Description

DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.
CECI EST LE TOME DE _2 NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.

JUMBO APPLICATIONS / PATENTS

THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.

NOTE: For additional volumes please contact the Canadian Patent Office.

Amino Alcohol Derivative Or Phosphonic Acid Derivative And Medicinal Composition Containing These [Technical field]
The present invention relates to amino alcohol derivatives or phosphonic acid derivatives having excellent immunosuppressive activity, pharmacologically acceptable salts of amino alcohol derivatives or phosphonic acid derivatives, pharmacologically acceptable esters of amino alcohol derivatives or phosphonic acid derivatives, and to pharmaceutical compositions comprising said compounds as an active ingredient.
The present invention also relates to pharmaceutical compositions comprising, as active ingredients, one or more immunosuppressants and one or more compounds selected from the group consisting of amino alcohol derivatives or phosphonic acid derivatives having excellent immunosuppressive activity, pharmacologically acceptable salts thereof, and pharmacologically acceptable esters thereof. Said compositions are useful as preventive or therapeutic agents for autoimmune diseases such as rejection of transplanted tissues or cells, rheumatoid arthritis, or other immune activity-related autoimmune diseases.

[Background of the Invention]
In the past, anti-inflammatory agents such as steroids have been used for inflammatory reactions arising from abnormal immune response in treatment of immune-related diseases such as rheumatoid arthritis and other autoimmune diseases. These are, however, a symptomatic therapy, but not a fundamental remedy.
Furthermore, it has been reported that immune system abnormalities are also involved in the development of diabetes and nephritis, but agents that improve these abnormalities have not yet been developed.
On the other hand, it is critical to develop an approach to suppress the immune response for avoiding rejection in transplanted tissues or cells, as well as for treating and preventing various autoimmune diseases.

However, immunosuppressants, such as cyclosporin A (CsA) and tacrolimus (TRL) that have been known in the past, are known to show toxicity against the kidney and liver. Although treatments that also use steroids are commonly used for the relief of such adverse reactions, it is. presently the case that such agents have not necessarily led to producing a satisfactory immunosuppressive effect without showing any adverse reaction.
In light of this background, it has been attempted to find excellent compounds with immunosuppressive effects that are less toxic.

As to immunosuppressants, the following compounds are known.

(1) Compounds having the general formula (a) disclosed in WO
94/08943 (page 371) 3RX2RXN-CH2ORX5 (a) RX

{in the above compounds (a), Rx represents a straight or branched carbon chain which may optionally be substituted with one or more substituents [said chain may contain a double bond, a triple bond, an oxygen atom, a sulfur atom, a group of formula -N (RX6)- (wherein RX6 represents a hydrogen atom), an arylene group which may optionally be substituted with one or more substituents, or a heteroarylene group which may optionally be substituted with one or more substituents, and may contain, at the end of said chain, an aryl group which may optionally be substituted with one or more substituents, a cycloalkyl group which may S:/Chemical/Sankyo/FP200301 /FP0301 a l .doc P8 7892/FP-0301 /corrected pages/gds-mg/02.07.04 optionally be substituted with one or more substituents, or an aromatic heterocyclic group which may optionally be substituted with one or more substituents],and RX2, Rx3, Rx4, and RX5 are the same or different and each represents a hydrogen atom or an alkyl group] are known as immunosuppressants.
The above compounds (a) of the prior art contain two oxymethyl groups (-CH2ORX9 and -CH2ORX5) as essential groups substituted on the same carbon atom. The compounds of the present invention, however, contain one -CH2OR3 group and one lower alkyl group as essential groups substituted on the same carbon atom and are different from the compounds (a) in these substituents.

(2) Compounds having the general formula (b) disclosed in WO
96/06068 (page 271) Y Y
X
i W Zy ;, ~ Y (b) v (CH2)mORy3 [in the above compounds (b), ' 2 a RY, RY, and Ry each represent a hydrogen atom or the like, W represents a hydrogen atom, an alkyl group or the like, Zy represents a single bond or an alkylene group, XY represents a hydrogen atom or an alkoxy group, and Yy represents a hydrogen atom, an alkyl, alkoxy, acyl, acyloxy, amino, acylamino group or the like] are known as immunosuppressants.
The above compounds (b) contain a phenyl group as an essential group in the basic skeleton. The compounds of the present invention contain a heterocyclic group such as a furyl group, a pyrrolyl group, or a pyrrolyl group having a substituent on the nitrogen atom instead of the phenyl group of compounds (b) and are different from the compounds (b).
However, compounds having a similar chemical structure to compounds (I) of the present invention have heretofore not been disclosed concretely in that publication.

S:/ChemicaUS ankyo/FP20030I /FP0301 a l .doc P87892/FP-0301 /corrected pages/gds-mg/02.07.04 (3) Compounds having the general formula (c) disclosed in WO

CH2ORz3 0 1 2RN-C- (C H2)2 C-(CH2)4 (c) CH2ORZa (in the above compounds (c), R11, RZ2, RZ3, and RZ4 are the same or different and each represents a hydrogen atom or an acyl group) are known as immunosuppressants.
The above compounds (c) contain two oxymethyl groups (-CH2ORZ3 and -CH2ORZ4) as essential groups substituted on the same carbon atom. The compounds of the present invention, however, contain one -CH2OR3 group and one lower alkyl group as essential groups substituted on the same carbon atom and are different from the compounds (c) in these substituents.
In addition, above compounds (c) contain a phenyl group between the -(CH2)2- group and the -CO-(CH2)4 group as an essential group in the basic skeleton. The compounds of the present invention contain a heterocyclic group such as a furyl group, a pyrrolyl group, or a pyrrolyl group having a substituent on the nitrogen atom instead of the phenyl group of compound (c) and are different from the compounds (c).
On the other hand, a compound having the general formula (II) of the present invention shown below wherein X represents a sulfur atom is disclosed in WO 02/06268 as a compound wherein the protecting group of the hydroxyl group is a residual group of an ester of phosphoric acid.
Furthermore, as to combinations of immunosuppressants, combinations of immunosuppressants such as FTY-720 and cyclosporin A or FTY-720 and tacrolimus are disclosed in Japanese Patent Publication (Kokai) Number Hei 11-80026.
In light of this background, it has been desired to find excellent pharmaceutical compositions with immuno-suppressive effects that are less toxic.

[Disclosure of the Invention]

S:/ChemicaUSankyo/FP200301/FP030Ial.doc P87892/FP-0301/corrected pages/gds-mg/02.07.04 The present inventors have eagerly studied new compounds having excellent immunosuppressive activity with low toxicity and found new compounds which are useful as preventive or therapeutic agents for autoimmune diseases or other immunology-related diseases such as rejection caused by transplantation of various organs or skin, systemic lupus erythematosus, rheumatoid arthritis, polymyositis, fibrositis, skeletal muscle inflammation, arthrosteitis, osteoarthritis, dermatomyositis, scleoderma, Behcet's syndrome, Crohn's disease, ulcerative colitis, autoimmune hepatitis, aplastic anemia, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, multiple sclerosis, autoimmune bullosis, psoriasis vulgaris, vasculitis syndrome, Wegener's granuloma, uveitis, Sjogren's syndrome, idiopathic interstitial pneumonia, Goodpasture's syndrome, sarcoidosis, allergic granulomatous anaitis. brnnr.hial asthma, myocarditis, cardiomyopathv, aortitis syndrome, post myocardial infarction syndrome, primary pulmonary nyperLension, minimal cnange nepnrotic syndrome, membranous nephropathy, membranoproliferative glomerulonephritis, focal glomerular sclerosis, crescentic glomerulonephritis, myasthenia gravis, inflammatory neuropathy, atopic dermatitis, chronic actinic dermatitis, photosensitivity, pressure sores, Sydenham's chorea, sclerosis, adult-onset type diabetes mellitus, insulin dependent diabetes mellitus, juvenile diabetes mellitus, atherosclerosis, glomerular nephritis, IgA nephropathy, tubulointerstitial nephritis, primary biliary cirrhosis, primary sclerosing cholangitis, fulminant hepatitis, viral hepatitis, GVHD, contact dermatitis, and sepsis; diseases of infection by fungus, mycoplasma, virus, and protozoon and the like;
cardiovascular diseases such as cardiac failure, cardiac hypertrophy, arrhythmia, angina pectoris, cardiac ischemia, arterial embolism, aneurysm, varix, and circulation disorders;
brain diseases such as Alzheimer's disease, dementia, Parkinson's disease, stroke, brain infarction, brain ischemia, depression, manic-depressive illness, schizophrenia, Huntington's chorea, epilepsy, convulsion, attention deficit disorder, encephalitis, cerebral meningitis, loss of appetite, S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 and hyperphagia; and various diseases such as lymphoma, leukemia, diuresis, pollakisuria, and diabetic retinopathy (particularly, autoimmune diseases such as rejection caused by transplantation of various organs or skin, systemic lupus erythematosus, rhematoid arthritis, multiple sclerosis, and atopic dermatitis), and completed the present invention.
Furthermore, the present inventors have studied eagerly pharmaceutical compositions having immunosuppressive activity and found that the pharmaceutical compositions of the present invention comprising, as active ingredients, one or more immunosuppressants and one or more compounds of the present invention exhibit excellent immunosuppressive activity with low toxicity. The pharmaceutical compositions increase activity more than that of the individual immunosuppressants and decrease adverse reactions so that they are less than that of the individual immunosuppressants. As a result, the pharmaceutical compositions of the present invention are useful as preventive or therapeutic agents for autoimmune diseases or other immunology-related diseases such as rejection caused by transplantation of various organs or skin, systemic lupus erythematosus, rheumatoid arthritis, polymyositis, fibrositis, skeletal muscle inflammation, arthrosteitis, osteoarthritis, dermatomyositis, scleoderma, Behcet's syndrome, Crohn's disease, ulcerative colitis, autoimmune hepatitis, aplastic anemia, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, multiple sclerosis, autoimmune bullosis, psoriasis vulgaris, vasculitis syndrome, Wegener's granuloma, uveitis, Sjogren's syndrome, idiopathic interstitial pneumonia, Goodpasture's syndrome, sarcoidosis, allergic granulomatous angitis, bronchial asthma, tnyocarditis, cardiomyopathy, aortitis syndrome, post myocardial infarction syndrome, primary pulmonary hypertension, minimal change nepnrotic synarome, membranous nephropathy, membranoproliferative glomerulonephritis, focal glomerular sclerosis, crescentic glomerulonephritis, myasthenia gravis, inflammatory neuropathy, atopic dermatitis, chronic actinic dermatitis, photosensitivity, pressure sores, Sydenham's chorea, sclerosis, S:/ChemicaUSankyo/FP20030I /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 adult-onset type diabetes mellitus, insulin dependent diabetes mellitus, juvenile diabetes mellitus, atherosclerosis, glomerular nephritis, IgA nephropathy, tubulointerstitial nephritis, primary biliary cirrhosis, primary sclerosing cholangitis, fulminant hepatitis, viral hepatitis, GVHD, contact dermatitis, and sepsis; diseases of infection by fungus, mycoplasma, virus, and protozoon and the like;
cardiovascular diseases such as cardiac failure, cardiac hypertrophy, arrhythmia, angina pectoris, cardiac ischemia, arterial embolism, aneurysm, varix, and circulation disorders;
brain diseases such as Alzheimer's disease, dementia, Parkinson's disease, stroke, brain infarction, brain ischemia, depression, manic-depressive illness, schizophrenia, Huntington's chorea, epilepsy, convulsion, attention deficit disorder, encephalitis, cerebral meningitis, loss of appetite, and hyperphagia; and various diseases such as lymphoma, leukemia, diuresis, pollakisuria, and diabetic retinopathy (particularly, autoimmune diseases such as rejection caused by transplantation of various organs or skin, systemic lupus erythematosus, rhematoid arthritis, multiple sclerosis, and atopic dermatitis) and the present inventors completed the present invention.

The present invention is explained in detail.
(1) Amino alcohol derivatives of the present invention are compounds of the general formula (I) shown below:

a R30 R (CH2)n Y-Z_R5 (I) X

[wherein, R1 and R2 are the same or different and each represents a hydrogen atom, a lower alkyl group, or a protecting group of the amino group;
R3 represents a hydrogen atom, a lower alkyl group, or a S:/Chernical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 protecting group of the hydroxyl group;
R4 represents a lower alkyl group;
n represents an integer of from 1 to 6;

X represents an oxygen atom or a group of formula =N_R14 (wherein R14 represents a hydrogen atom, a C6-C10 aryl group, a lower alkylsulfonyl"group, a C6-Clo arylsulfonyl group, or a group selected from Substituent group (a));
Y represents an ethylene group, a vinylene group, an ethynylene group, a group of formula: -E-CH2- (wherein E
represents a carbonyl group or a group of formula: -CH(OH)-), a C6-C10 arylene group, or a C6-Clo arylene group substituted with from 1 to 3 substituents selected from Substituent group (a);
Z represents a single bond, a Cl-Clo alkylene group, a C1-Clo alkylene group substituted with from 1 to 3 substituents selected from Substituent group (a) and Substituent group (b), a C1-C10 alkylene group which has an oxygen atom or a sulfur atom in said carbon chain or at the end of said carbon chain, or a C1-Clo alkylene group substituted with from 1 to 3 substituents selected from the group consisting of Substituent group (a) and Substituent group (b) which has an oxygen atom or a sulfur atom in said carbon chain or at the end of said carbon chain;
R5 represents a hydrogen atom, a C3-C10 cycloalkyl group, a C6-C10 aryl group, a 5- to 7-membered heterocyclic group containing-from I to 3 heteroatoms selected from the group consisting of a sulfur atom, an oxygen atom, and a nitrogen atom, a C3-C10 cycloalkyl group substituted with from I to 3 substituents selected from the group consisting of Substituent group (a) and Substituent group (b), a C6-C10 aryl group substituted with from 1 to 3 substituents selected from the group consisting of Substituent group (a) and Substituent group (b), or a 5- to 7-membered heterocyclic group containing from 1 to 3 heteroatoms selected from the group consisting of a sulfur atom, an oxygen atom,. and a nitrogen atom in which said heterocyclic group is substituted with from 1 to 3 substituents selected from Substituent group (a) and Substituent group (b);
R6 and R7 are the same or different and each represents a hydrogen atom or a group selected from Substituent group (a);
Substituent group (a) represents the group consisting of a halogen atom, a lower alkyl group, a halogeno lower alkyl group, a lower alkoxy group, a lower alkylthio group, a carboxyl group, a lower alkoxycarbonyl group, a hydroxyl group, a lower aliphatic acyl group, an amino group, a mono-lower alkylamino group, a di-lower alkylamino group, a lower aliphatic acylamino group, a cyano group, and a nitro group;
and Substituent group (b) represents the group consisting of a C3-C10 cycloalkyl group, a C6-C10 aryl group, a 5- to 7-membered heterocyclic group containing from 1 to 3 heteroatoms selected from the group consisting of a sulfur atom, an oxygen atom, and a nitrogen atom, a C3-C10 cycloalkyl group substituted with from 1 to 3 substituents selected from Substituent group (a), a C6-C10 aryl group substituted with from 1 to 3 substituents selected from Substituent group (a), and a 5- to 7-membered heterocyclic group containing from 1 to 3 heteroatoms selected from the group consisting of a sulfur atom, an oxygen atom, and a nitrogen atom in which said heterocyclic group is substituted with from 1 to 3 substituents selected from Substituent group (a);
provided that when R5 represents a hydrogen atom, then Z
represents a branched chain C1-C10 alkylene group, a C1-C10 alkylene group substituted with from 1 to 3 substituents selected from the group consisting of Substituent group (a) and Substituent group (b), a C1-C10 alkylene group which has an oxygen atom or a sulfur atom in said carbon chain or at the end of said carbon chain, or a C1-C10 alkylene group substituted with from 1 to 3 substituents selected from the group consisting of Substituent group (a) and Substituent group (b) which has an oxygen atom or a sulfur atom in said carbon chain or at the end of said carbon chain].

The present invention provides compounds of formula (I), S:/Chemical/Sankyo/FP20030I/FP0301s.doc P87892/FP-030]/Description/gds-mg/30.06.04 pharmacologically acceptable salts thereof, and pharmacologically acceptable esters thereof.

Of these, preferred compounds are:
(2) a compound according to (1) wherein said compound of formula (I) has the formula (Ia):

R
R3O (CH2n X \ Y-Z-R5 (Ia) -~~ '--~ Z/

(wherein, R1, R2, R3, R4, R5, R6, R', X, Y, Z and n have the same meanings as those indicated hereinbefore), a pharmacologically acceptable salt thereof, or a pharmacologically acceptable ester thereof, (3) a compound according to (1) wherein said compound of formula (I) has the formula (Ib):

R3O R (CH /X \ R7 (Ib) 2n (wherein, R1, R2, R3, R4, R5, R6, R', X, Y, Z and n have the same meanings as those indicated hereinbefore), a pharmacologically acceptable salt thereof, or a pharmacologically acceptable ester thereof, (4) a pharmacologically acceptable ester of the compound of formula (I) according to (1) wherein said compound of formula (I) has the formula (II):

S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 O R 4 (CH2)n ` `~ Y`Z_Rs (II) (wherein, R1, R2, R4, R5, R6, R7, X, Y, Z and n have the same meanings as those indicated hereinbefore; R10 and R11 are the same or different and each represents a hydrogen atom or a protecting group of phosphoric acid), or a pharmacologically acceptable salt thereof, (5) a pharmacologically acceptable ester of the compound of formula (II) according to (4) wherein said ester of formula (II) has the formula (IIa):

O R 4 S (IIa) (CHA Y-Z-R
~X\
R"'O-P 0 ~/

(wherein, R1, R2, R4, R5, R6, R7, X, Y, Z and n have the same meanings as those indicated hereinbefore; R10 and R11 are the same or different and each represents a hydrogen atom or a protecting group of phosphoric acid), or a pharmacologically acceptable salt thereof, and (6) a pharmacologically acceptable ester of the compound of formula (II) according to (4) wherein said ester of formula (II) has the formula (Iib):

4 7 (11b) ~o O R (CHA R
R O- X
I
OR'~ NR1R2 (wherein, R1, R2, - R4, R5, R6, R', X, Y, Z and n have the same meanings as those indicated hereinbefore; R10 and R11 are the S:JChemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 same or different and each represents a hydrogen atom or a protecting group of phosphoric acid), or a pharmacologically acceptable salt thereof.
(7) Phosphonic acid derivatives of the present invention are compounds of the general formula (III) shown below:

O R4 //`& 5 ) I Y-Z-R III
~o II (CH2)n j R O, X
OR" NR1R2 (wherein, R1, R2, R4, R5, R6, R7, R10, R11, X, Y, Z and n have the same meanings as those indicated hereinbefore).

The present invention provides compounds of formula (III), pharmacologically acceptable salts thereof, and pharmacologically acceptable esters thereof.

Of these, preferred compounds are:
(8) a compound according to (7) wherein said compound of formula (III) has the formula (IIIa):

O
11 R4 (CHA Y-Z-R5 (IIIa) R100- ~X\
OR1 NR'R2 (wherein, R1, R2, R4, R5, R6, R7, R10, R11, X, Y, Z and n have the same meanings as those indicated hereinbefore), a pharmacologically acceptable salt thereof, or a pharmacologically acceptable ester thereof, and (9) a compound according to (7) wherein said compound of formula (III) has the formula (Ilib):

S:/Chemical/Sankyo/FP20030I /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 O R 4 \ (IIIb) 11 (CH2)n R7 RiOO-P X
t OR's NR'R2 (wherein, R', R2, R4, R5, R6, R7, R' , R11, X, Y, Z and n have the same meanings as those indicated hereinbefore), a pharmacologically acceptable salt thereof, or a pharmacologically acceptable ester thereof.

Of these, preferred compounds are:
(10) a compound according to any one of (1) to (9) wherein R1 and R2 are the same or different and each represents a hydrogen atom, a lower aliphatic acyl group, a lower alkoxycarbonyl group, an aralkyloxycarbonyl group, or an aralkyloxycarbonyl group substituted with from 1 to 3 substituents selected from Substituent group (a), or a pharmacologically acceptable salt thereof, (11) a compound according to any one of (1) to (9) wherein R1 and R2 are the same or different and each represents a hydrogen atom, a lower aliphatic acyl group, or a lower alkoxycarbonyl group, or a pharmacologically acceptable salt thereof, (12) a compound according to any one of (1) to (9) wherein R1 and R2 are the same or different and each represents a hydrogen atom, a C1-C4 aliphatic acyl group, or a C1-C4 alkoxycarbonyl group, or a pharmacologically acceptable salt thereof, (13) a compound according to any one of (1) to (9) wherein R1 and R2 are the same or different and each represents a hydrogen atom, a C1-C2 aliphatic acyl group, or a C1-C2 alkoxycarbonyl group, or a pharmacologically acceptable salt thereof, (14) a compound according to any one of (1) to (9) wherein R1 and R2 are the same or different and each represents a hydrogen atom, an acetyl group, or a methoxycarbonyl group, or a S:/ChemicaVSankyo/FP200301/FP0301 s.doc P87892/FP-0301/Description gds-mg/30.06.04 pharmacologically acceptable salt thereof, (15) a compound according to any one of (1) to (9) wherein each of R1 and R2 represents a hydrogen atom, or a pharmacologically acceptable salt thereof, (16) a compound according to any one of (1) to (3) and (10) to (15) wherein R3 represents a hydrogen atom, a lower alkyl group, a lower aliphatic acyl group, an aromatic acyl group, an aromatic acyl group substituted with from 1 to 3 substituents selected from Substituent group (a), or a silyl group, or a pharmacologically acceptable salt thereof, (17) a compound according to any one of (1) to (3) and (10) to (15) wherein R3 represents a hydrogen atom or a lower alkyl group, or a pharmacologically acceptable salt thereof, (18) a compound according to any one of (1) to (3) and (10) to (15) wherein R3 represents a hydrogen atom or a C1-C4 alkyl group, or a pharmacologically acceptable salt thereof, (19) a compound according to any one of (1) to (3) and (10) to (15) wherein R3 represents a hydrogen atom, a methyl group, or an ethyl group, or a pharmacologically acceptable salt thereof, (20) a compound according to any one of (1) to (3) and (10) to (15) wherein R3 represents a hydrogen atom, or a pharmacologically acceptable salt thereof, (21) a compound according to any one of (1) to (20) wherein R4 represents a C1-C4 alkyl group, or a pharmacologically acceptable salt thereof, (22) a compound according to any one of (1) to (20) wherein R4 represents a C1-C2 alkyl group, or a pharmacologically acceptable salt thereof, S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 (23) a compound according to any one of (1) to (20) wherein R4 represents a methyl group, or a pharmacologically acceptable salt thereof, (24) a compound according to any one of (1) to (23) wherein n represents an integer 2 or 3, or a pharmacologically acceptable salt thereof, (25) a compound according to any one of (1) to (23) wherein n represents an integer 2,, or a pharmacologically acceptable salt thereof, (26) a compound according to any one of (1) to (25) wherein X
represents an oxygen atom, or a pharmacologically acceptable salt thereof, (27) a compound according to any one of (1) to (25) wherein X
represents a group of formula: =N-R14 (wherein R14 represents a hydrogen atom, a C1-C4 alkyl group, or a phenyl group), or a pharmacologically acceptable salt thereof, (28) a compound according to any one of (1) to (25) wherein X
represents a group of formula: =N-CH31 or a pharmacologically acceptable salt thereof, (29) a compound according to any one of (1) to (28) wherein Y
represents an ethylene group, an ethynylene group, a group of formula: -CO-CH2-, a group of formula: -CH(OH)-CH2-, a phenylene group, or a phenylene group substituted with from 1 to 3 substituents selected from the group consisting of a halogen atom and a lower alkyl group, or a pharmacologically acceptable salt thereof, (30) a compound according to any one of (1) to (28) wherein Y
represents an ethylene group, an ethynylene group, a group of formula: -CO-CH2-, or a phenylene group, or a pharmacologically acceptable salt thereof, (31) a compound according to any one of (1) to (30) wherein Z
represents a C1-Cl0 alkylene group or a C1-Clo alkylene group substituted with from 1 to 3 substituents selected from the group consisting of Substituent group (a) and Substituent group (b), or a pharmacologically acceptable salt thereof, (32) a compound according to any one of (1) to (30) wherein Z
represents a C1-C6 alkylene group or a C1-C6 alkylene group substituted with from 1 to 3 hydroxyl groups, or a pharmacologically acceptable salt thereof, (33) a compound according to any one of (1) to (30) wherein Z
represents a Cl-Cs alkylene group or a C1-C5 alkylene group substituted with from 1 to 3 hydroxyl groups, or a pharmacologically acceptable salt thereof, (34) a compound according to any one of (1) to (30) wherein Z
represents an ethylene group, a trimethylene group, a tetramethylene group, or an ethylene, trimethylene, or tetramethylene group substituted with one hydroxyl group, or a pharmacologically acceptable salt thereof, (35) a compound according to any one of (1) to (30) wherein Z
represents an ethylene group, a trimethylene group, or a tetramethylene group, or a pharmacologically acceptable salt thereof, (36) a compound according to any one of (1) to (30) wherein Z
represents an ethylene group or a trimethylene group, or a pharmacologically acceptable salt thereof, (37) a compound according to any one of (1) to (30) wherein Z
represents a C1-Clo alkylene group which has an oxygen atom or a sulfur atom in said carbon chain or at the end of said carbon chain or a C1-C10 alkylene group substituted with one substituent which has an oxygen atom or a sulfur atom in said carbon S:/ChemicaVSankyo/FP200301/FP0301al.doc P87892/FP-0301/corrected pages/gds-mg/02.07.04 chain or at the end of said carbon chain (said substituent is selected from the group consisting of a lower alkyl group and a hydroxyl group), or a pharmacologically acceptable salt thereof, (38) a compound according to any one of (1) to (30) wherein Z
represents a C1-C10 alkylene group which has an oxygen atom or a sulfur atom in said carbon chain or at the end of said carbon chain, or a pharmacologically acceptable salt thereof, (39) a compound according to any one of (1) to (30) wherein Z
represents a C1-C10 alkylene group which has an oxygen atom in said carbon chain or at the end of said carbon chain, or a pharmacologically acceptable salt thereof, (40) a compound according to any one of (1) to (30) wherein Z
represents a C1-C6 alkylene group which has an oxygen atom in said carbon chain or at the end of said carbon chain, or a pharmacologically acceptable salt thereof, (41) a compound according to any one of (1) to (30) wherein Z
represents a group of formula -O-CH2-, -O-(CH2)2-, -O-(CH2)3-1 -CH2-O-, - (CH2) 2-0-, or - (CH2) 3-0-, or a pharmacologically acceptable salt thereof, (42) a compound according to any one of (1) to (30) wherein Z
represents a group of formula -CH2-O- or -(CH2)2-0-, or a pharmacologically acceptable salt thereof, (43) a compound according to any one of (1) to (42) wherein R5 represents a hydrogen atom, or a pharmacologically acceptable salt thereof, (44) a compound according to any one of (1) to (42) wherein R5 represents a C3-C10 cycloalkyl group, a C6-C10 aryl group, or a C3-C10 cycloalkyl or C6-C10 aryl group substituted with from 1 to 3 substituents selected from the group consisting of a halogen S:/ChemicaUSankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 atom, a lower alkyl group, a halogeno lower alkyl group, a lower alkoxy group, and a lower alkylthio group, or a pharmacologically acceptable salt thereof, (45) a compound according to any one of (1) to (42) wherein R5 represents a C3-C10 cycloalkyl group, a C6-C10 aryl group, or a C3-C10 cycloalkyl or C6-C10 aryl group substituted with from 1 to 3 substituents selected from the group consisting of a halogen atom, a lower alkyl group, a halogeno lower alkyl group, and a lower alkoxy group, or a pharmacologically acceptable salt thereof, (46) a compound according to any one of (1) to (42) wherein R5 represents a C5-C6 cycloalkyl group, a phenyl group, or a naphthyl group, or a pharmacologically acceptable salt thereof, (47) a compound according to any one of (1) to (42) wherein R5 represents a cyclohexyl group or a phenyl group, or a pharmacologically acceptable salt thereof, (48) a compound according to any one of (1) to (47) wherein R6 and R7 are the same or different and each represents a hydrogen atom, a halogen atom, a lower alkyl group, a halogeno lower alkyl group, a lower alkoxy group, or a lower alkylthio group, or a pharmacologically acceptable salt thereof, (49) a compound according to any one of (1) to (47) wherein each of R6 and R7 represents a hydrogen atom, or a pharmacologically acceptable salt thereof, (50) a compound according to any one of (4) to (15) and (21) to (49) wherein R10 and R" are the same or different and each represents a hydrogen atom or a lower alkyl group, or a pharmacologically acceptable salt thereof, (51) a compound according to any one of (4) to (15) and (21) to (49) wherein R10 and R" are the same or different and each S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 represents a hydrogen atom or a C1-C4 alkyl group, or a pharmacologically acceptable salt thereof, (52) a compound according to any one of (4) to (15) and (21) to (49) wherein R10 and R" are the same or different and each represents a hydrogen atom, a methyl group, or an ethyl group, or a pharmacologically acceptable salt thereof, and (53) a compound according to any one of (4) to (15) and (21) to (49) wherein each of R10 and R" represents a hydrogen atom, or a pharmacologically acceptable salt thereof.

Compounds according to (1) above which comprise any combination selected freely from the groups consisting of (2) and (3) ; (10) to (15) ; (16) to (20) ; (21) to (23) ; (24) and (25); (26) to (28); (29) and (30); (31) to (42); (43) to (47);
and (48) and (49) are preferred.
Compounds according to (4) above which comprise any combination selected freely from the groups consisting of (5) and (6); (10) to (15); (21) to (23); (24) and (25); (26) to (28) ; (29) and (30) ; (31) to (42) ; (43) to (47) ; (48) and (49); and (50) to (53) are preferred.
Compounds according to (7) above which comprise any combination selected freely from the groups consisting of (8) and (9) ; (10) to (15) ; (21) to (23) ; (24) and (25) ; (26) to (28); (29) and (30); (31) to (42); (43) to (47); (48) and (49); and (50) to (53) are preferred.

Of these, the most preferred compounds are:
(54) a compound selected from the following compounds, a pharmacologically acceptable salt thereof, or a pharmacologically acceptable ester thereof:
2-amino-2-methyl-4-[5-(5-phenylpentyl)furan-2-yl]butan-l-ol, 2-amino-2-methyl-4-[5-(5-cyclohexylpent-1-ynyl)furan-2-yl]butan-l-ol, 2-amino-2-methyl-4-[5-(5-phenylpent-l-ynyl)furan-2-yl]butan-l-ol, S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 2-amino-2-methyl-4-[5-(4-cyclohexyloxybut-l-ynyl)furan-2-yl]butan-1-ol, 2-amino-2-methyl-4-[5-(5-cyclohexylpentanoyl)furan-2-yl]butan-1-ol, and 2-amino-2-methyl-4-{5-[3-(3,4-dimethylphenoxy)prop-l-ynyl]furan-2-yl}butan-1-ol, (55) a compound selected from the following compounds, a pharmacologically acceptable salt thereof, or a pharmacologically acceptable ester thereof:
2-amino-2-methyl-4-[l-methyl-5-(5-phenylpent-1-ynyl)pyrrol-2-yl]butan-1-ol, 2-amino-2-methyl-4-{1-methyl-5-[3-(4-methylphenoxy)prop-l-ynyl]pyrrol-2-yl}butan-l-ol, 2-amino-2-methyl-4-[1-methyl-5-(4-cyclohexyloxybut-l-ynyl) pyrrol-2-yl]butan-l-ol, 2-amino-2-methyl-4-{1-methyl-5-[3-(3,4-dimethylphenoxy)prop-l-ynyl]pyrrol-2-yl}butan-l-ol, 2-amino-2-methyl-4-[1-methyl-5-(5-phenylpentanoyl)pyrrol-2-yl]butan-1-ol, 2-amino-2-methyl-4-[1-methyl-5-(5-cyclohexylpentanoyl)pyrrol-2-yl]butan-1-ol, 2-amino-2-methyl-4-[1-methyl-5-(4-phenylbutanoyl)pyrrol-2-yl]butan-l-ol, 2-amino-2-methyl-4-[1-methyl-5-(4-cyclohexylbutanoyl)pyrrol-2-yl]butan-l-ol, 2-amino-2-methyl-4-{1-methyl-5-[4-(4-methylphenyl)butanoyl]pyrrol-2-yl}butan-l-ol, 2-amino-2-methyl-4-[1-ethyl-5-(5-phenylpentanoyl)pyrrol-2-yl]butan-l-ol, 2-amino-2-methyl-4-[1-ethyl-5-(5-cyclohexylpentanoyl)pyrrol-2-yl]butan-l-ol, 2-amino-2-methyl-4-[1-ethyl-5-(4-phenylbutanoyl)pyrrol-2-yl]butan-l-ol, and 2-amino-2-methyl-4-[l-ethyl-5-(4-cyclohexylbutanoyl)pyrrol-2-yl]butan-l-ol, 2-amino-2-methyl-4-{1-methyl-5-[4-(3,4-dimethylphenyl)butanoyl]pyrrol-2-yl}butan-l-ol, 2-amino-2-methyl-4-{1-methyl-5-[4-(3,5-dimethylphenyl)butanoyl]pyrrol-2-yl}butan-l-ol, S:/ChemicaUS ankyo/FP200301 /FP0301 a 1. doc P87892/FP-0301 /corrected pages/gds-mg/02.07.04 2-amino-2-methyl-4-{l-methyl-5-[4-(3-trifluoromethylphenyl)butanoyl]pyrrol-2-yl}butan-l-ol, 2-amino-2-methyl-4-{1-methyl-5-[4-(4-trifluoromethylphenyl)butanoyl]pyrrol-2-yl}butan-l-ol, 2-amino-2-methyl-4-(1-methyl-5-[4-(4-methoxyphenyl)butanoyl]pyrrol-2-yl}butan-l-ol, 2-amino-2-methyl-4-(1-methyl-5-[4-(3-methylphenyl)butyllpyrrol-2-yl}butan-l-ol, 2-amino-2-methyl-4-{l-methyl-5-[4-(3,4-dimethylphenyl)butyl]pyrrol-2-yl}butan-l-ol, 2-amino-2-methyl-4-{l-methyl-5-[4-(3,5-dimethylphenyl)butyl]pyrrol-2-yl}butan-i-ol, 2-amino-2-methyl-4-{l-methyl-5-[4-(3-trifluoromethylphenyl)butyllpyrrol-2-yl}butan-l-ol.
(56) a compound according to (4) wherein said compound is selected from the following compounds or a pharmacologically S:/Chemical/Sankyo/FP200301 IFP0301 al.doc P87892/FP-0301/corrected pageslgds-mg/05.07.04 acceptable salt thereof:
mono 2-amino-2-methyl-4-[5-(5-phenylpentyl)furan-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-[5-(5-cyclohexylpent-1-ynyl)furan-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-[5-(5-phenylpent-1-ynyl)furan-2-yl]-l-butyl phosphate, mono 2-amino-2-methyl-4-[5-(4-cyclohexyloxybut-1-ynyl)furan-2-yl)-1-butyl phosphate, mono 2-amino-2-methyl-4-[5-(5-cyclohexylpentanoyl)furan-2-yl]-1-butyl phosphate, and mono 2-amino-2-methyl-4-{5-[3-(3,4-dimethylphenoxy)prop-l-ynyl]furan-2-yl}-1-butyl phosphate, (57) a compound according to (4) wherein said compound is selected from the following compounds or a pharmacologically acceptable salt thereof:
mono 2-amino-2-methyl-4-[l-methyl-5-(5-phenylpent-l-ynyl)pyrrol-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-{i-methyl-5-[3-(4-methylphenoxy)prop-1-ynyl)pyrrol-2-yl}-1-butyl phosphate, mono 2-amino-2-methyl-4-[l-methyl-5-(4-cyclohexyloxybut-l-ynyl)pyrrol-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-{1-methyl-5-[3-(3,4-dimethylphenoxy)prop-l-ynyl]pyrrol-2-yl}-1-butyl phosphate, mono 2-amino-2-methyl-4-[1-methyl-5-(5-phenylpentanoyl)pyrrol-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-[1-methyl-5-(5-cyclohexylpentanoyl)pyrrol-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-[1-methyl-5-(4-phenylbutanoyl)pyrrol-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-[1-methyl-5-(4-cyclohexylbutanoyl)pyrrol-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-{1-methyl-5-[4-(4-methylphenyl)butanoyl]pyrrol-2-yl}-1-butyl phosphate, mono 2-amino-2-methyl-4-[1-ethyl-5-(5-phenylpentanoyl)pyrrol-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-[1-ethyl-5-(5-cyclohexylpentanoyl)pyrrol-2-yl]-1-butyl phosphate, S:/ChemicaUSankyo/FP200301 /FPO301 a I.doc P87892/FP-0301 /corrected pages/gds-mg/02.07.04 mono 2-amino-2-methyl-4-[l-ethyl-5-(4-phenylbutanoyl)pyrrol-2-yl]-l-butyl phosphate, and mono 2-amino-2-methyl-4-[1-ethyl-5-(4-cyclohexylbutanoyl)pyrrol-2-yl]-l-butyl phosphate, (58) a compound according to (7) wherein said compound is selected from the following compounds or a pharmacologically acceptable salt thereof:
3-amino-3-methyl-5-[5-(5-phenylpentyl)furan-2-yl] pentylphosphonic acid, 3-amino-3-methyl-5-[5-(5-cyclohexylpent-l-ynyl)furan-2 -yl]pentylphosphonic acid, 3-amino-3-methyl-5-[5-(5-phenylpent-l-ynyl)furan-2-yl]pentylphosphonic acid, 3-amino-3-methyl-5-[5-(4-cyclohexyloxybut-1-ynyl)furan-2-yl] pentylphosphonic acid, 3-amino-3-methyl-5-[5-(5-cyclohexylpentanoyl)furan-2-yl]pentylphosphonic acid, and 3-amino-3-methyl-5-{5-[3-(3,4-dimethylphenoxy)prop-l-ynyl] furan-2-yl}pentylphosphonic acid, and (59) a compound according to (7) wherein said compound is selected from the following compounds or a pharmacologically acceptable salt thereof:
3-amino-3-methyl-5-[l-methyl-5-(5-phenylpent-l-ynyl)pyrrol-2-yl] pentylphosphonic acid, 3-amino-3-methyl-5-{l-methyl-5-[3-(4-methylphenoxy)prop-l-ynyl] pyrrol-2-yl}pentylphosphonic acid, 3-amino-3-methyl-5-[l-methyl-5-(4-cyclohexyloxybut-l-ynyl)pyrrol-2-yl]pentylphosphonic acid, 3-amino-3-methyl-5-{1-methyl-5-[3-(3,4-dimethylphenoxy)prop-l-ynyl]pyrrol-2-yl}pentylphosphonic acid, 3-amino-3-methyl-5-[l-methyl-5-(5-phenylpentanoyl)pyrrol-2-yl] pentylphosphonic acid, 3-amino-3-methyl-5-[1-methyl-5-(5-cyclohexylpentanoyl)pyrrol-2-yl]pentylphosphonic acid, 3-amino-3-methyl-5-[l-methyl-5-(4-phenylbutanoyl)pyrrol-2-S:/Chemical/Sankyo/FP200301 /FP030I s.doc P87892/FP-0301/Description/gds-mg/30.06.04 yl]pentylphosphonic acid, 3-amino-3-methyl-5-[1-methyl-5-(5-cyclohexylpentanoyl)pyrrol-2-yl]pentylphosphonic acid, 3-amino-3-methyl-5-[1-methyl-5-(4-phenylbutanoyl)pyrrol-2-S:/Chemical/Sankyo/FP20030I /FP0301 a l .doc P87892/FP-0301 /corrected pages/gds-mg/02.07.04 yl]pentylphosphonic acid, 3-amino-3-methyl-5-[1-methyl-5-(4-cyclohexylbutanoyl)pyrrol-2-yl] pentylphosphonic acid, 3-amino-3-methyl-5-[l-ethyl-5-(5-phenylpentanoyl)pyrrol-2-yl]pentylphosphonic acid, 3-amino-3-methyl-5-[l-ethyl-5-(5-cyclohexylpentanoyl)pyrrol-2-yl] pentylphosphonic acid, 3-amino-3-methyl-5-[l-ethyl-5-(4-phenylbutanoyl)pyrrol-2-yl]pentylphosphonic acid, and 3-amino-3-methyl-5-[l-ethyl-5-(4-cyclohexylbutanoyl)pyrrol-2-yl]pentylphosphonic acid.

Furthermore, the present invention provides the following pharmaceutical compositions:
(60) a pharmaceutical composition containing at least one immunosuppressant selected from the group consisting of an agent having the action of inhibiting intracellular signal transduction involved in cytokine expression of T-cells, an agent having the action of inhibiting nucleoside synthesis in immune cells, an agent having the action of inhibiting the action of cytokines on immune cells and having antirheumatic action, an alkylating agent causing cell death by breakdown of DNA
chains or blocking DNA synthesis, a metabolic antagonist inhibiting the metabolism of nucleic acids by blocking folic acid production, a protein drug having the suppression action of TNF-a, a steroid hormone agent that binds to intracellular steroid receptors to form a complex which binds to reaction sites on chromosomes, resulting in the synthesis of proteins which show immunosuppressive activity, a substance suppressing prostaglandin production and/or nonsteroidal anti-inflammatory drug antagonizing the action of prostaglandin, and at least one compound selected from the group consisting of compounds of the general formula (I):

S:/Chemical/Sankyo/FP200301/FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 NR'R2 R6 R7 zn ) Y-Z-R
R4 (CH [1-f\ 5 ~I) X

[wherein, R1 and R2 are the same or different and each represents a hydrogen atom, a lower alkyl group, or a protecting group of the amino group;
R3 represents a hydrogen atom, a lower alkyl group, or a protecting group of the hydroxyl group;
R4 represents a lower alkyl group;
n represents an integer of from 1 to 6;
X represents a sulfur atom, an oxygen atom, or a group of formula =N-R1A (wherein R14 represents a hydrogen atom, an aryl group, a lower alkylsulfonyl group, an arylsulfonyl group, or a group selected from Substituent group (a));
Y represents an ethylene group, a vinylene group, an ethynylene group, a group of formula -E-CH2- (wherein E
represents a carbonyl group or a group of formula -CH(OH)-), a C6-Clo arylene group, or a C6-C10 arylene group substituted with from 1 to 3 substituents selected from Substituent group (a);
Z represents a single bond, a C1-C10 alkylene group, a C1-C10 alkylene group substituted with from 1 to 3 substituents selected from the group consisting of Substituent group (a) and Substituent group (b), a C1-Clo alkylene group which has an oxygen atom or a sulfur atom in said carbon chain or at the end of said carbon chain, or a C1-C10 alkylene group substituted with from 1 to 3 substituents selected from the group consisting of Substituent group (a) and Substituent group (b) which has an oxygen atom or a sulfur atom in said carbon chain or at the end of said carbon chain;
R5 represents a hydrogen atom, a C3-C10 cycloalkyl group, a C6-C10 aryl group, a 5- to 7-membered heterocyclic group containing from 1 to 3 heteroatoms selected from the group consisting of a sulfur atom, an oxygen atom, and a nitrogen atom, a C3-C10 cycloalkyl group substituted with from 1 to 3 substituents selected from the group consisting of Substituent group (a) and Substituent group (b), a C6-C10 aryl group substituted with from 1 to 3 substituents selected from the group consisting of Substituent group (a) and Substituent group (b), or a 5- to 7-membered heterocyclic group containing from 1 to 3 heteroatoms selected from the group consisting of a sulfur atom, an oxygen atom, and a nitrogen atom in which said heterocyclic group is substituted with from 1 to 3 substituents selected from the group consisting of Substituent group (a) and Substituent group (b);
R6 and R' are the same or different and each represents a hydrogen atom or a group selected from Substituent group (a);
Substituent group (a) represents the group consisting of a halogen atom, a lower alkyl group, a halogeno lower alkyl group, a lower alkoxy group, a lower alkylthio group, a carboxyl group, a lower alkoxycarbonyl group, a hydroxyl group, a lower aliphatic acyl group, an amino group, a mono-lower alkylamino group, a di-lower alkylamino group, a lower aliphatic acylamino group, a cyano group, and a nitro group;
and Substituent group (b) represents the group consisting of a C6-C10 cycloalkyl group, a C6-C10 aryl group, a 5- to 7-membered heterocyclic group containing from 1 to 3 heteroatoms selected from the group consisting of a sulfur atom, an oxygen atom, and a nitrogen atom, a C3-C10 cycloalkyl group substituted with from 1 to 3 substituents selected from Substituent group (a), a C6-C10 aryl group substituted with from 1 to 3 substituents selected from Substituent group (a), and a 5- to 7-membered heterocyclic group containing from 1 to 3 heteroatoms selected from the group consisting of a sulfur atom, an oxygen atom, and a nitrogen atom in which said heterocyclic group is substituted with from 1 to 3 substituents selected from Substituent group (a);
provided that when R5 represents a hydrogen atom, then Z
represents a branched chain C1-C10 alkylene group, a C1-Clo alkylene group substituted with from 1 to 3 substituents selected from the group consisting of Substituent group (a) S:/Chemica1/Sankyo/FP20030I/FP0301a1.doc P87892/FP-0301/corrected pages/gds-mg/02.07.04 and Substituent group (b), a C1-Clo alkylene group which has an oxygen atom or a sulfur atom in said carbon chain or at the end of said carbon chain, or a C1-Clo alkylene group substituted with from 1 to 3 substituents selected from the group consisting of Substituent group (a) and Substituent group (b) which has an oxygen atom or a sulfur atom in said carbon chain or at the end of said carbon chain], a pharmacologically acceptable salt thereof, or a pharmacologically acceptable ester thereof.

Of these, preferred pharmaceutical compositions are:
(61) a pharmaceutical composition according to (60) wherein said compound of general formula (I) has the general formula (Ia) shown below:

NR'R2 R J(CH2)nY_ZR5 (Ia) X

(wherein, R1, R2, R3, R4, R5, R6, R', X, Y, Z and n have the same meanings as those indicated hereinbefore), (62) a pharmaceutical composition according to (60) wherein said compound of general formula (I) has the general formula (Ib) shown below:

NR' R2 R4 (CH2n 7 (1b) (wherein, R1, R2, R3, R4, R5, R6, R', X, Y, Z and n have the same meanings as those indicated hereinbefore), (63) a pharmaceutical composition according to (60) wherein the pharmacologically acceptable ester of the compound of S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 formula (I) has the formula (II):

Re R7 O R4 /k AN 5 100-11- (CH2)n ` YZ-R (II) R PO X
OR'1 NR1R2 (wherein, R1, R2, . R4, R5, R6, R', X, Y, Z and n have the same meanings as those indicated hereinbefore; R10 and R11 are the same or different and each represents a hydrogen atom or a protecting group of phosphoric acid) or a pharmacologically acceptable salt thereof, (64) a pharmaceutical composition according to (63) wherein the ester of the compound of formula (II) has the formula (IIa) :

O R a (CH2)n ~\Y-Z-R5 (IIa) R'00-P-O X
OR" NR1R2 (wherein, R1, R2, R4, R5, R6, R', R10, R11, X, Y, Z and n have the same meanings as those indicated hereinbefore) or a pharmacologically acceptable salt thereof, and (65) a pharmaceutical composition according to (63) wherein the ester of the compound of formula (II) has the formula (Irb):

X/ X (IIb) 100 O R (CH2)n R7 -P

(wherein, R1, R2, R4, R5, R6, R, R10, R", X, Y, Z and n have the same meanings as those indicated hereinbefore) or a S:/ChemicaVSankyo/FP200301 /FP0301 s.doc P87892/FP-030]/Description/gds-mg/30.06.04 pharmacologically acceptable salt thereof.

Furthermore, the present invention provides the following pharmaceutical compositions:
(66) a pharmaceutical composition containing at least one immunosuppressant selected from the group consisting of an agent having the action of inhibiting intracellular signal transduction involved in cytokine expression of T-cells, an agent having the action of inhibiting nucleoside synthesis in immune cells, an agent having the action of inhibiting the action of cytokines on immune cells and having antirheumatic action, an alkylating agent causing cell death by breakdown of DNA
chains or blocking DNA synthesis, a metabolic antagonist inhibiting the metabolism of nucleic acids by blocking folic acid production, a protein drug having the suppression action of TNF-a, a steroid hormone agent that binds to intracellular steroid receptors to form a complex which binds to reaction sites on chromosomes, resulting in the synthesis of proteins which show immunosuppressive activity, and a substance suppressing prostaglandin production and/or nonsteroidal anti-inflammatory drug antagonizing the action of prostaglandin, and at least one compound selected from the group consisting of compounds of the general formula (III) shown below:

~o O R (CH2)n ` -YZ-RS (III) R O-P X
OR's NR1R2 [wherein, R1 and R2 are the same or different and each represents a hydrogen atom, a lower alkyl group, or a protecting group of the amino group;
R4 represents a lower alkyl group;

S:/ChemicaVSankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 n represents an integer of from 1 to 6;
X represents a sulfur atom, an oxygen atom or a group of formula =N-R14 (wherein R14 represents a hydrogen atom, a C6-C10 aryl group, a lower alkylsulfonyl group, a C6-C10 arylsulfonyl group, or a group selected from Substituent group (a));
Y represents an ethylene group, a vinylene group, an ethynylene group, a group of formula -E-CH2- (wherein E
represents a carbonyl group or a group of formula -CH(OH)-), a C6-C10 arylene group, or a C6-C10 arylene group substituted with from 1 to 3 substituents selected from Substituent group (a);
Z represents a single bond, a C1-Clo alkylene group, a C1-C10 alkylene group substituted with from 1 to 3 substituents selected from the group consisting of Substituent group (a) and Substituent group (b), a C1-Clo alkylene group which has an oxygen atom or a sulfur atom in said carbon chain or at the end of said carbon chain, or a C1-C10 alkylene group substituted with from 1 to 3 substituents selected from the group consisting of Substituent group (a) and Substituent group (b) which has an oxygen atom or a sulfur atom in said carbon chain or at the end of said carbon chain;
R5 represents a hydrogen atom, a C3-C10 cycloalkyl group, a C6-C10 aryl group, a 5- to 7-membered heterocyclic group containing from 1 to 3 heteroatoms selected from the group consisting of a sulfur atom, an oxygen atom, and a nitrogen atom, a C3-C10 cycloalkyl group substituted with from I to 3 substituents selected from the group consisting of Substituent group (a) and Substituent group (b), a C6-C10 aryl group substituted with from 1 to 3 substituents selected from the group consisting of Substituent group (a) and Substituent group (b), or a 5- to 7-membered heterocyclic group containing from 1 to 3 heteroatoms selected from the group consisting of a sulfur atom, an oxygen atom, and a nitrogen atom in which said heterocyclic group is substituted with from 1 to 3 substituents selected from the group consisting of Substituent group (a) and Substituent group (b);
R6 and R7 are the same or different and each represents a hydrogen atom or a group selected from Substituent group (a);

R10 and R" are the same or different and each represents a hydrogen atom or a protecting group of phosphoric acid;
Substituent group (a) represents the group consisting of a halogen atom, a lower alkyl group, a halogeno lower alkyl group, a lower alkoxy group, a lower alkylthio group, a carboxyl group, a lower alkoxycarbonyl group, a hydroxyl group, a lower aliphatic acyl group, an amino group, a mono-lower alkylamino group, a di-lower alkylamino group, a lower aliphatic acylamino group, a cyano group, and a nitro group;
and Substituent group (b) represents the group consisting of a C3-C10 cycloalkyl group, a C6-C10 aryl group, a 5- to 7-membered heterocyclic group containing from 1 to 3 heteroatoms selected from the group consisting of a sulfur atom, an oxygen atom, and a nitrogen atom, a C3-C10 cycloalkyl group substituted with from 1 to 3 substituents selected from Substituent group (a), a C6-C10 aryl group substituted with from 1 to 3 substituents selected from Substituent group (a), and a 5- to 7-membered heterocyclic group containing from 1 to 3 heteroatoms selected from the group consisting of a sulfur atom, an oxygen atom, and a nitrogen atom in which said heterocyclic group is substituted with from 1 to 3 substituents selected from Substituent group (a);
provided that when R5 represents a hydrogen atom, then Z
represents a branched chain C1-C10 alkylene group, a C1-Cl0 alkylene group substituted with from 1 to 3 substituents selected from the group consisting of Substituent group (a) and Substituent group (b), a C1-C10 alkylene group which has an oxygen atom or a sulfur atom in said carbon chain or at the end of said carbon chain, or a C1-C10 alkylene group substituted with from 1 to 3 substituents selected from the group consisting of Substituent group (a) and Substituent group (b) which has an oxygen atom or a sulfur atom in said carbon chain or at the end of said carbon chain], a pharmacologically acceptable salt thereof, or a pharmacologically acceptable ester thereof.
S:/ChemicaUSankyo/FP200301/FP0301 s.doc P87892/FP-0301/Desciiption/gds-mgl30.06.04 Of these, preferred pharmaceutical compositions are:
(67) a pharmaceutical composition according to (66) wherein the compound of formula (III) has the formula (IIIa):

O
11 Ra (CH2)n Y-Z-RS (IIIa) RIOO- I

OR' NR1R2 (wherein, R1, R2, R4, R5, R6, R7, R' , R'1, X, Y, Z and n have the same meanings as those indicated hereinbefore), and (68) a pharmaceutical composition according to (66) wherein the compound of formula (III) has the formula (IIIb):

a (111b) O R (CH2n R7 R10O~ X

OR" NR1R2 (wherein, R1, R2, . R4, R5, R6, R7, R10, R11, X, Y, Z and n have the same meanings as those indicated hereinbefore).

Of these, more preferred pharmaceutical compositions are:
(69) a pharmaceutical composition according to any one of (60) to (68) containing a compound wherein R1 and R2 are the same or different and each represents a hydrogen atom, a lower aliphatic acyl group, a lower alkoxycarbonyl group, an aralkyloxycarbonyl group, or an aralkyloxycarbonyl group substituted with from 1 to 3 substituents selected from Substituent group (a), or a pharmacologically acceptable salt thereof, (70) a pharmaceutical composition according to any one of (60) to (68) containing a compound wherein R1 and R2 are the same or different and each represents a hydrogen atom, a lower aliphatic acyl group, or a lower alkoxycarbonyl group, or a S:/ChemicallSankyo/FP200301/FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 pharmacologically acceptable salt thereof, (71) a pharmaceutical composition according to any one of (60) to (68) containing a compound wherein R1 and R2 are the same or different and each represents a hydrogen atom, a C1-C4 aliphatic acyl group, or a C1-C4 alkoxycarbonyl group, or a pharmacologically acceptable salt thereof, (72) a pharmaceutical composition according to any one of (60) to (68) containing a compound wherein R1 and R2 are the same or different and each represents a hydrogen atom, a C1-C2 aliphatic acyl group, or a C1-C2 alkoxycarbonyl group, or a pharmacologically acceptable salt thereof, (73) a pharmaceutical composition according to any one of (60) to (68) containing a compound wherein R1 and R2 are the same or different and each represents a hydrogen atom, an acetyl group, or a methoxycarbonyl group, or a pharmacologically acceptable salt thereof, (74) a pharmaceutical composition according to any one of (60) to (68) containing a compound wherein each of R1 and R2 represents a hydrogen atom, or a pharmacologically acceptable salt thereof, (75) a pharmaceutical composition according to any one of (60) to (62) and (69) to (74) containing a compound wherein R3 represents a hydrogen atom, a lower alkyl group, a lower aliphatic acyl group, an aromatic acyl group, an aromatic acyl group substituted with from 1 to 3 substituents selected from Substituent group (a), or a silyl group, or a pharmacologically acceptable salt thereof, (76) a pharmaceutical composition according to any one of (60) to (62) and (69) to (74) containing a compound wherein R3 represents a hydrogen atom or a lower alkyl group, or a pharmacologically acceptable salt thereof, S:/Chemical/Sankyo/FP200301/FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 (77) a pharmaceutical composition according to any one of (60) to (62) and (69) to (74) containing a compound wherein R3 represents a hydrogen atom or a C1-C4 alkyl group, or a pharmacologically acceptable salt thereof, (78) a pharmaceutical composition according to any one of (60) to (62) and (69) to (74) containing a compound wherein R3 represents a hydrogen atom, a methyl group, or an ethyl group, or a pharmacologically acceptable salt thereof, (79) a pharmaceutical composition according to any one of (60) to (62) and (69) to (74) containing a compound wherein R3 represents a hydrogen atom, or a pharmacologically acceptable salt thereof, (80) a pharmaceutical composition according to any one of (60) to (79) containing a compound wherein R4 represents a C1-C4 alkyl group, or a pharmacologically acceptable salt thereof.
(81) a pharmaceutical composition according to any one of (60) to (79) containing a compound wherein R4 represents a C1-C2 alkyl group, or a pharmacologically acceptable salt thereof, (82) a pharmaceutical composition according to any one of (60) to (79) containing a compound wherein R4 represents a methyl group, or a pharmacologically acceptable salt thereof, (83) a pharmaceutical composition according to any one of (60) to (82) containing a compound wherein n represents an integer 2 or 3, or a pharmacologically acceptable salt thereof, (84) a pharmaceutical composition according to any one of (60) to (82) containing a compound wherein n represents an integer 2, or a pharmacologically acceptable salt thereof, (85) a pharmaceutical composition according to any one of (60) S:/Chemical/Sankyo/FP20030 I /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 to (84) containing a compound wherein X represents a sulfur atom, or a pharmacologically acceptable salt thereof, (86) a pharmaceutical composition according to any one of (60) to (84) containing a compound wherein X represents an oxygen atom, or a pharmacologically acceptable salt thereof, (87) a pharmaceutical composition according to any one of (60) to (84) containing a compound wherein X represents a group of formula =N-D (wherein D represents a hydrogen atom, a Cl-C4 alkyl group, or a phenyl group), or a pharmacologically acceptable salt thereof, (88) a pharmaceutical composition according to any one of (60) to (84) containing a compound wherein X represents a group of formula =N-CH3, or a pharmacologically acceptable salt thereof, (89) a pharmaceutical composition according to any one of (60) to (88) containing a compound wherein Y represents an ethylene group, an ethynylene group, a group of formula -CO-CH2-, a group of formula -CH(OH)-CH2-, a phenylene group, or a phenylene group substituted with from 1 to 3 substituents selected from the group consisting of a halogen atom and a lower alkyl group, or a pharmacologically acceptable salt thereof, (90) a pharmaceutical composition according to any one of (60) to (88) containing a compound wherein Y represents an ethylene group, an ethynylene group, a group of formula -CO-CH2-, or a phenylene group, or a pharmacologically acceptable salt thereof, (91) a pharmaceutical composition according to any one of (60) to (90) containing a compound wherein Z represents a Cl-Clo alkylene group or a C1-Clo alkylene group substituted with from 1 to 3 substituents selected from the group consisting of Substituent group (a) and Substituent group (b), or a S:/ChemicalSankyo/FP20030] /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 pharmacologically acceptable salt thereof, (92) a pharmaceutical composition according to any one of (60) to (90) containing a compound wherein Z represents a C1-C6 alkylene group or a C1-C6 alkylene group substituted with from 1 to 3 hydroxyl groups, or a pharmacologically acceptable salt thereof, (93) a pharmaceutical composition according to any one of (60) to (90) containing a compound wherein Z represents a C1-C5 alkylene group or a C1-C5 alkylene group substituted with from 1 to 3 hydroxyl groups, or a pharmacologically acceptable salt thereof, (94) a pharmaceutical composition according to any one of (60) to (90) containing a compound wherein Z represents an ethylene group, a trimethylene group, a tetramethylene group, or an ethylene, trimethylene, or tetramethylene group substituted with one hydroxyl group, or a pharmacologically acceptable salt thereof, (95) a pharmaceutical composition according to any one of (60) to (90) containing a compound wherein Z represents an ethylene group, a trimethylene group, or a tetramethylene group, or a pharmacologically acceptable salt thereof, (96) a pharmaceutical composition according to any one of (60) to (90) containing a compound wherein Z represents an ethylene group or a trimethylene group, or a pharmacologically acceptable salt thereof, (97) a pharmaceutical composition according to any one of (60) to (90) containing a compound wherein Z represents a C1-Clo alkylene group which has an oxygen atom or a sulfur atom in said carbon chain or at the end of said carbon chain or a C1-C10 alkylene group substituted with one substituent which has an oxygen atom or a sulfur atom in said carbon chain or at the S:/Chemical/Sankyo/FP200301/FP0301 al.doc P87892/FP-0301/corrected pages/gds-mg/02.07.04 end of said carbon chain (said substituent is selected from the group consisting of lower alkyl groups and hydroxyl groups), or a pharmacologically acceptable salt thereof, (98) a pharmaceutical composition according to any one of (60) to (90) containing a compound wherein Z represents a C1-Clo alkylene group which has an oxygen atom or a sulfur atom in said carbon chain or at the end of said carbon chain, or a pharmacologically acceptable salt thereof, (99) a pharmaceutical composition according to any one of (60) to (90) containing a compound wherein Z represents a C1-Clo alkylene group which has an oxygen atom in said carbon chain or at the end of said carbon chain, or a pharmacologically acceptable salt thereof, (100) a pharmaceutical composition according to any one of (60) to (90) containing a compound wherein Z represents a C1-C6 alkylene group which has an oxygen atom in said carbon chain or at the end of said carbon chain, or a pharmacologically acceptable salt thereof, (101) a pharmaceutical composition according to any one of (60) to (90) containing a compound wherein Z represents a group of formula -0-CH2-, -0- (CH2) 2-1 -0- (CH2) 3-1 -CH2-0-1 -(CH2)2-0-, or -(CH2)3-0-, or a pharmacologically acceptable salt thereof, (102) a pharmaceutical composition according to any one of (60) to (90) containing a compound wherein Z represents a group of formula -CH2-O- or -(CH2)2-0-, or a pharmacologically acceptable salt thereof, (103) a pharmaceutical composition according to any one of (60) to (102) containing a compound wherein R5 represents a hydrogen atom, or a pharmacologically acceptable salt thereof, S:/Chemical/Sankyo/FP20030I /FP030 ] s.doc P87892/FP-0301/Descniption/gds-mg/30.06.04 (104) a pharmaceutical composition according to any one of (60) to (102) containing a compound wherein R5 represents a C3-C10 cycloalkyl group, a C6-C10 aryl group, or a C3-C10 cycloalkyl or C6-C10 aryl group substituted with from 1 to 3 substituents selected from the group consisting of a halogen atom, a lower alkyl group, a halogeno lower alkyl group, a lower alkoxy group, and a lower alkylthio group, or a pharmacologically acceptable salt thereof, (105) a pharmaceutical composition according to any one of (60) to (102) containing a compound wherein R5 represents a C3-C10 cycloalkyl group, a C6-C10 aryl group, or a C3-C10 cycloalkyl or C6-C10 aryl group substituted with from 1 to 3 substituents selected from the group consisting of a halogen atom, a lower alkyl group, a halogeno lower alkyl group, and a lower alkoxy group, or a pharmacologically acceptable salt thereof, (106) a pharmaceutical composition according to any one of (60) to (102) containing a compound wherein R5 represents a C5-C6 cycloalkyl group, a phenyl group, or a naphthyl group, or a pharmacologically acceptable salt thereof, (107) a pharmaceutical composition according to any one of (60) to (102) containing a compound wherein R5 represents a cyclohexyl group or a phenyl group, or a pharmacologically acceptable salt thereof, (108) a pharmaceutical composition according to any one of (60) to (107) containing a compound wherein R6 and R7 are the same or different and each represents a hydrogen atom, a halogen atom, a lower alkyl group, a halogeno lower alkyl group, a lower alkoxy group, or a lower alkylthio group, or a pharmacologically acceptable salt thereof, (109) a pharmaceutical composition according to any one of (60) to (107) containing a compound wherein each of R6 and R7 represents a hydrogen atom, or a pharmacologically acceptable S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 salt thereof, (110) a pharmaceutical composition according to any one of (63) to (74) and (80) to (109) containing a compound wherein R10 and R" are the same or different and each represents a hydrogen atom or a lower alkyl group, or a pharmacologically acceptable salt thereof, (111) a pharmaceutical composition according to any one of (63) to (74) and (80) to (109) containing a compound wherein R10 and R" are the same or different and each represents a hydrogen atom or a Cl-C4 alkyl group, or a pharmacologically acceptable salt thereof, (112) a pharmaceutical composition according to any one of (63) to (74) and (80) to (109) containing a compound wherein R10 and R" are the same or different and each represents a hydrogen atom, a methyl group or an ethyl group, or a pharmacologically acceptable salt thereof, and (113) a pharmaceutical composition according to any one of (63) to (74) and (80) to (109) containing a compound wherein each of R10 and R1' represents a hydrogen atom, or a pharmacologically acceptable salt thereof.

Of these, particularly preferred pharmaceutical compositions are:
(114) a pharmaceutical composition according to (60), wherein the compound of general formula (I), or pharmacologically acceptable salt thereof, or pharmacologically acceptable ester thereof is selected from the group consisting of the compounds described below, pharmacologically acceptable salts thereof, and pharmacologically acceptable esters thereof:
2-amino-2-methyl-4-[5-(4-cyclohexylbutyl)thiophen-2-yl]butan-1-01, 2-amino-2-methyl-4-[5-(5-cyclohexylpentyl)thiophen-2-yl]butan-1-01, S:/ChemicaI/Sankyo/FP200301/FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 2-amino-2-methyl-4-[5-(5-phenylpentyl)thiophen-2-yl]butan-l-ol, 2-amino-2-methyl-4-[5-(4-cyclohexyloxybutyl)thiophen-2-yl]butan-1-ol, 2-amino-2-methyl-4-{5-[4-(4-fluorophenoxy)butyl]thiophen-2-yl}butan-l-ol, 2-amino-2-methyl-4-{5-[4-(4-methoxyphenoxy)butyl]thiophen-2-yl}butan-1-ol 2-amino-2-methyl-4-[5-(4-benzyloxybutyl)thiophen-2-yl]butan-l-01, 2-amino-2-methyl-4-[5-(4-cyclohexylbut-1-ynyl)thiophen-2-yl]butan-1-ol, 2-amino-2-methyl-4-[5-(4-phenylbut-1-ynyl)thiophen-2-yl]butan-1-01, 2-amino-2-methyl-4-[5-(4-cyclohexylpent-l-ynyl)thiophen-2-yl]butan-1-ol, 2-amino-2-methyl-4-[5-(5-phenylpent-1-ynyl)thiophen-2-yl]butan-1-ol, 2-amino-2-methyl-4-{5-[5-(4-fluorophenyl)pent-1-ynyl]thiophen-2-yl}butan-1-ol, 2-amino-2-methyl-4-{5-[5-(4-methoxyphenyl)pent-l-ynyl] thiophen-2-yl}butan-l-ol, 2-amino-2-methyl-4-{5-[3-(4-methylphenoxy)prop-l-ynyl]thiophen-2-yl}butan-l-ol, 2-amino-2-methyl-4-{5-[3-(4-ethylphenoxy)prop-1-ynyl]thiophen-2-yl}butan-l-ol, 2-amino-2-methyl-4-{5-[3-(4-methylthiophenoxy)prop-l-ynyl]thiophen-2-yl]butan-1-ol, 2-amino-2-methyl-4-[5-(4-cyclohexyloxybut-1-ynyl)thiophen-2-yl]butan-l-ol, 2-amino-2-methyl-4-{5-[4-(4-fluorophenoxy)but-1-ynyl]thiophen-2-yl}butan-l-ol, 2-amino-2-methyl-4-{5-[4-(4-methylphenoxy)but-1-ynyl]thiophen-2-yl}butan-1-ol, 2-amino-2-methyl-4-[5-(3-cyclohexylmethoxyprop-l-ynyl)thiophen-2-yl]butan-1-ol, 2-amino-2-methyl-4-[5-(4-benzyloxybut-1-ynyl)thiophen-2-yl]butan-1-ol, S:/Chemical/Sankyo/FP200301/FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 2-amino-2-methyl-4-[5-(4-cyclohexylbutanoyl)thiophen-2-yl]butan-1-ol, 2-amino-2-methyl-4-[5-(4-phenylbutanoyl)thiophen-2-yl]butan-l-01, 2-amino-2-methyl-4-[5-(5-cyclohexylpentanoyl)thiophen-2-yl]butan-1-ol, 2-amino-2-methyl-4-[5-(5-phenylpentanoyl)thiophen-2-yl]butan-1-01, 2-amino-2-methyl-4-{5-[5-(4-fluorophenyl)pentanoyl]thiophen-2-yl}butan-l-ol, 2-amino-2-ethyl-4-[5-(5-cyclohexylpentyl)thiophen-2-yl]butan-1-01, 2-amino-2-ethyl-4-[5-(5-cyclohexylpent-1-ynyl)thiophen-2-yl]butan-1-ol, 2-amino-2-ethyl-4-[5-(5-cyclohexylpentanoyl)thiophen-2-yl]butan-1-ol, 2-amino-2-methyl-4-{5-[3-(4-chlorophenoxy)prop-l-ynyl]thiophen-2-yl}butan-1-ol, 2-amino-2-methyl-4-{5-[3-(3-methylphenoxy)prop-l-ynyl] thiophen-2-yl}butan-l-ol, 2-amino-2-methyl-4-{5-[3-(3,4-dimethylphenoxy)prop-l-ynyl] thiophen-2-yl}butan-l-ol, 2-amino-2-methyl-4-{5-[3-(3-methoxyphenoxy)prop-l-ynyl]thiophen-2-yl}butan-1-ol, 2-amino-2-methyl-4-{5-[3-(3,4-dimethoxyphenoxy)prop-l-ynyl] thiophen-2-yl}butan-l-ol, 2-amino-2-methyl-4-{5-[3-(3,5-dimethoxyphenoxy)prop-l-ynyl]thiophen-2-yl}butan-1-ol, 2-amino-2-methyl-4-{5-[3-(3-acetylphenoxy)prop-l-ynyl] thiophen-2-yl}butan-l-ol, and 2-amino-2-methyl-4-{5-[3-(4-acetylphenoxy)prop-l-ynyl] thiophen-2-yl}butan-l-ol, (115) a pharmaceutical composition according to (60), wherein the compound of general formula (I), or pharmacologically acceptable salt thereof, or pharmacologically acceptable ester thereof is selected from the group consisting of the compounds S:/Chemical/Sankyo/FP20030I /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 described below, pharmacologically acceptable salts thereof, and pharmacologically acceptable esters thereof:
2-amino-2-methyl-4-[5-(5-phenylpentyl)furan-2-yl]butan-l-ol, 2-amino-2-methyl-4-[5-(5-cyclohexylpent-1-ynyl)furan-2-yl]butan-l-ol, 2-amino-2-methyl-4-[5-(5-phenylpent-1-ynyl)furan-2-yl]butan-l-ol, 2-amino-2-methyl-4-[5-(4-cyclohexyloxybut-1-ynyl)furan-2-yl]butan-l-ol, 2-amino-2-methyl-4-[5-(5-cyclohexylpentanoyl)furan-2-yl]butan-1-01, and 2-amino-2-methyl-4-{5-[3-(3,4-dimethylphenoxy)prop-l-ynyl]furan-2-yl}butan-1-ol, (116) a pharmaceutical composition according to (60), wherein the compound of general formula (I), or pharmacologically acceptable salt thereof, or pharmacologically acceptable ester thereof is selected from the group consisting of the compounds described below, pharmacologically acceptable salts thereof, and pharmacologically acceptable esters thereof:
2-amino-2-methyl-4-[1-methyl-5-(5-phenylpent-l-ynyl)pyrrol-2-yl]butan-l-ol, 2-amino-2-methyl-4-{1-methyl-5-[3-(4-methylphenoxy)prop-l-ynyl]pyrrol-2-yl}butan-l-ol, 2-amino-2-methyl-4-[1-methyl-5-(4-cyclohexyloxybut-l-ynyl)pyrrol-2-yl]butan-1-ol, 2-amino-2-methyl-4-{1-methyl-5-[3-(3,4-dimethylphenoxy)prop-l-ynyl]pyrrol-2-yl}butan-1-ol, 2-amino-2-methyl-4-[l-methyl-5-(5-phenylpentanoyl)pyrrol-2-yl]butan-l-ol, 2-amino-2-methyl-4-[l-methyl-5-(5-cyclhexylpentanoyl)pyrrol-2-yl]butan-l-ol, 2-amino-2-methyl-4-[1-methyl-5-(4-phenylbutanoyl)pyrrol-2-yl]butan-1-ol, 2-amino-2-methyl-4-[1-methyl-5-(4-cyclohexylbutanoyl)pyrrol-2-yl]butan-1-ol, 2-amino-2-methyl-4-{1-methyl-5-[4-(4-methylphenyl)butanoyl]pyrrol-2-yl}butan-l-ol, 2-amino-2-methyl-4-[1-ethyl-5-(5-phenylpentanoyl)pyrrol-2-S:/Chemical/Sankyo/FP20030]/FP0301aI.doc P87892/FP-030]/corrected pages/gds-mg/02.07.04 yl]butan-l-ol, 2-amino-2-methyl-4-[l-ethyl-5-(5-cyclohexylpentanoyl)pyrrol-2-yl]butan-l-ol, 2-amino-2-methyl-4-[l-ethyl-5-(4-phenylbutanoyl)pyrrol-2-yl]butan-l-ol, and 2-amino-2-methyl-4-[l-ethyl-5-(4-cyclohexylbutanoyl)pyrrol-2-yl]butan-l-ol, 2-amino-2-methyl-4-{l-methyl-5-[4-(3,4-dimethylphenyl)butanoyl]pyrrol-2-yl}butan-l-ol, 2-amino-2-methyl-4-{1-methyl-5-[4-(3,5-dimethylphenyl)butanoyl]pyrrol-2-yl}butan-l-ol 2-amino-2-methyl-4-{1-methyl-5-[4-(3-trifluoromethylphenyl)butanoyl]pyrrol-2-yl}butan-l-ol, 2-amino-2-methyl-4-{1-methyl-5-[4-(4-trifluoromethylphenyl)butanoyl]pyrrol-2-yl}butan-l-ol, 2-amino-2-methyl-4-{1-methyl-5-[4-(4-methoxyphenyl)butanoyl]pyrrol-2-yl}butan-l-ol, 2-amino-2-methyl-4-{1-methyl-5-[4-(3-methylphenyl)butyl]pyrrol-2-yl}butan-1-ol, 2-amino-2-methyl-4-{1-methyl-5-[4-(3,4-dimethylphenyl)butyl]pyrrol-2-yl}butan-1-ol, 2-amino-2-methyl-4-{l-methyl-5-[4-(3,5-dimethylphenyl)butyl]pyrrol-2-yl}butan-l-ol, 2-amino-2-methyl-4-{l-methyl-5-[4-(3-trifluoromethylphenyl)butyl]pyrrol-2-yl}butan-1-ol.
(117) a pharmaceutical composition according to (63), wherein the compound of general formula (II), or pharmacologically acceptable salt thereof, or pharmacologically acceptable ester thereof is selected from the group consisting of the compounds described below, pharmacologically acceptable salts thereof, and pharmacologically acceptable esters thereof:
mono 2-amino-2-methyl-4-[5-(4-cyclohexylbutyl)thiophen-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-[5-(5-cyclohexylpentyl)thiophen-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-[5-(5-phenylpentyl)thiophen-2-yl]-1-S:/Chemical/Sankyo/FP200301/FP0301a1.doc P87892/FP-0301/corrected pages/gds-mg/05.07.04 butyl phosphate, mono 2-amino-2-methyl-4-[5-(4-cyclohexyloxybutyl)thiophen-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-{5-[4-(4-fluorophenoxy)butyl]thiophen-2-yl}-1-butyl phosphate, mono 2-amino-2-methyl-4-{5-[4-(4-methoxyphenoxy)butyl]thiophen-2-yl}-1-butyl phosphate, mono 2-amino-2-methyl-4-[5-(4-benzyloxybutyl)thiophen-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-[5-(4-cyclohexylbut-1-ynyl)thiophen-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-[5-(4-phenylbut-1-ynyl)thiophen-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-[5-(5-cyclohexylpent-1-ynyl)thiophen-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-[5-(5-phenylpent-1-ynyl)thiophen-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-{5-[5-(4-fluorophenyl)pent-l-S:/Chemical/S ankyo/FP200301 /FP0301 a l .doc P87892/FP-0301 /corrected pages/gds-mg/02.07.04 ynyl]thiophen-2-yl}-1-butyl phosphate, mono 2-amino-2-methyl-4-{5-[5-(4-methoxyphenyl)pent-l-ynyl]thiophen-2-yl}-1-butyl phosphate, mono 2-amino-2-methyl-4-{5-[3-(4-methylphenoxy)prop-l-ynyl]thiophen-2-yl}-1-butyl phosphate, mono 2-amino-2-methyl-4-{5-[3-(4-ethylphenoxy)prop-l-ynyl]thiophen-2-yl}-1-butyl phosphate, mono 2-amino-2-methyl-4-{5-[3-(4-methylthiophenoxy)prop-l-ynyl]thiophen-2-yl}-1-butyl phosphate, mono 2-amino-2-methyl-4-[5-(4-cyclohexyloxybut-l-ynyl)thiophen-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-{5-[4-(4-fluorophenoxy)but-1-ynyl]thiophen-2-yl}-1-butyl phosphate, mono 2-amino-2-methyl-4-{5-[4-(4-methylphenoxy)but-1-ynyl]thiophen-2-yl}-1-butyl phosphate, mono 2-amino-2-methyl-4-[5-(3-cyclohexylmethoxy)prop-l-ynyl]thiophen-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-[5-(4-benzyloxybut-l-ynyl)thiophen-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-[5-(4-cyclohexylbutanoyl)thiophen-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-[5-(4-phenylbutanoyl)thiophen-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-[5-(5-cyclohexylpentanoyl)thiophen-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-[5-(5-phenylpentanoyl)thiophen-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-{5-[5-(4-fluorophenyl)pentanoyl]thiophen-2-yl}-1-butyl phosphate, mono 2-amino-2-ethyl-4-[5-(5-cyclohexylpentyl)thiophen-2-yl]-1-butyl phosphate, mono 2-amino-2-ethyl-4-[5-(5-cyclohexylpent-l-ynyl)thiophen-2-yl]-1-butyl phosphate, mono 2-amino-2-ethyl-4-[5-(5-cyclohexylpentanoyl)thiophen-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-{5-[3-(4-chlorophenoxy)prop-l-ynyl]thiophen-2-yl}-1-butyl phosphate, S:/Chemical/Sankyo/FP20030I /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 mono 2-amino-2-methyl-4-{5-[3-(3-mettylphenoxy)prop-l-ynyl]thiophen-2-yl}-1-butyl phosphate, mono 2-amino-2-methyl-4-{5-[3-(3,4-dimethylphenoxy)prop-l-ynyl]thiophen-2-yl}-1-butyl phosphate, mono 2-amino-2-methyl-4-{5-[3-(3-methoxyphenoxyl)prop-l-ynyl]thiophen-2-yl}-1-butyl phosphate, mono 2-amino-2-methyl-4-{5-[3-(3,4-dimethoxyphenoxy)prop-l-ynyl]thiophen-2-yl}-1-butyl phosphate, mono 2-amino-2-methyl-4-{5-[3-(3,5-dimethoxyphenoxyl)prop-l-ynyl]thiophen-2-yl}-1-butyl phosphate, mono 2-amino-2-methyl-4-{5-[3-(3-acetylphenoxy)prop-l-ynyl]thiophen-2-yl}-1-butyl phosphate, and mono 2-amino-2-methyl-4-{5-[3-(4-acetylphenoxy)prop-l-ynyl]thiophen-2-yl}-1-butyl phosphate, (118) a pharmaceutical composition according to (63), wherein the compound of general formula (II), or pharmacologically acceptable salt thereof, or pharmacologically acceptable ester thereof is selected from the group consisting of the compounds described below, pharmacologically acceptable salts thereof, and pharmacologically acceptable esters thereof:
mono 2-amino-2-methyl-4-[5-(5-phenylpentyl)furan-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-[5-(5-cyclohexylpent-l-ynyl)furan-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-[5-(5-phenylpent-1-ynyl)furan-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-[5-(4-cyclohexyloxybut-l-ynyl)furan-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-[5-(5-cyclohexylpentanoyl)furan-2-yl]-1-butyl phosphate, and mono 2-amino-2-methyl-4-{5-[3-(3,4-dimethylphenoxy)prop-l-ynyl]furan-2-yl}-1-butyl phosphate, (119) a pharmaceutical composition according to (63), wherein the compound of general formula (II), or pharmacologically acceptable salt thereof, or pharmacologically acceptable ester S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Desci iption/gds-mg/30.06.04 thereof is selected from the group consisting of the compounds described below, pharmacologically acceptable salts thereof, and pharmacologically acceptable esters thereof:
mono 2-amino-2-methyl-4-[l-methyl-5-(5-phenylpent-l-ynyl)pyrrol-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-{1-methyl-5-[3-(4-methylphenoxy)prop-1-ynyl]pyrrol-2-yl}-1-butyl phosphate, mono 2-amino-2-methyl-4-[1-methyl-5-(4-cyclohexyloxybut-l-ynyl)pyrrol-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-{1-methyl-5-[3-(3,4-dimethylphenoxy)prop-1-ynyl)pyrrol-2-yl}-l-butyl phosphate, mono 2-amino-2-methyl-4-[1-methyl-5-(5-phenylpentanoyl)pyrrol-2-y1]-1-butyl phosphate, mono 2-amino-2-methyl-4-[l-methyl-5-(5-cyclohexylpentanoyl)pyrrol-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-[l-methyl-5-(4-phenylbutanoyl)pyrrol-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-[1-methyl-5-(4-cyclohexylbutanoyl)pyrrol-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-{1-methyl-5-[4-(4-methylphenyl)butanoyl]pyrrol-2-yl}-l-butyl phosphate, mono 2-amino-2-methyl-4-[l-ethyl-5-(5-phenylpentanoyl)pyrrol-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-[l-ethyl-5-(5-cyclohexylpentanoyl)pyrrol-2-yl]-l-butyl phosphate, mono 2-amino-2-methyl-4-[l-ethyl-5-(4-phenylbutanoyl)pyrrol-2-yl]-1-butyl phosphate, and mono 2-amino-2-methyl-4-[1-ethyl-5-(4-cyclohexylbutanoyl)pyrrol-2-yl]-1-butyl phosphate, mono 2-amino-2-methyl-4-{1-methyl-5-[4-(3,4-dimethylphenyl)butanoyl]pyrrol-2-yl}-l-butyl phosphate, mono 2-amino-2-methyl-4-{1-methyl-5-[4-(3,5-dimethylphenyl)butanoyl]pyrrol-2-yl}-1-butyl phosphate.
(120) a pharmaceutical composition according to (66), wherein the compound of general formula (III), or pharmacologically acceptable salt thereof, or pharmacologically acceptable ester thereof is selected from the group consisting of the compounds described below, pharmacologically acceptable salts thereof, and pharmacologically acceptable esters thereof:
S:/ChemicaFSankyo/FP200301 /FP0301 a l .doc P87892/FP-0301 /corrected pages/gds-mg/02.07.04 3-amino-3-methyl-5-[5-(4-cyclohexylbutyl)thiophen-2-yl]pentylphosphonic acid, 3-amino-3-methyl-5-[5-(5-cyclohexylpentyl)thiophen-2-S:/Chemical/Sankyo/FP200301 /FP0301 a L doe P87892/FP-0301 /corrected pages/gds-mg/02.07.04 yl]pentylphosphonic acid, 3-amino-3-methyl-5-[5-(5-phenylpentyl)thiophen-2-yl] pentylphosphonic acid, 3-amino-3-methyl-5-[5-(4-cyclohexyloxybutyl)thiophen-2-yl] pentylphosphonic acid, 3-amino-3-methyl-5-{5-[4-(4-fluorophenoxy)butyl]thiophen-2-yl}pentylphosphonic acid, 3-amino-3-methyl-5-{5-[4-(4-methoxyphenoxy)butyl]thiophen-2-yl}pentylphosphonic acid, 3-amino-3-methyl-5-[5-(4-benzyloxybutyl)thiophen-2-yl] pentylphosphonic acid, 3-amino-3-methyl-5-[5-(4-cyclohexylbut-1-ynyl)thiophen-2-yl] pentylphosphonic acid, 3-amino-3-methyl-5-[5-(4-phenylbut-1-ynyl)thiophen-2-yl] pentylphosphonic acid, 3-amino-3-methyl-5-[5-(5-cyclohexylpent-1-ynyl)thiophen-2-yl] pentylphosphonic acid, 3-amino-3-methyl-5-[5-(5-phenylpent-1-ynyl)thiophen-2-yl] pentylphosphonic acid, 3-amino-3-methyl-5-{5-[5-(4-fluorophenyl)pent-1-ynyl]thiophen-2-yl}pentylphosphonic acid, 3-amino-3-methyl-5-{5-[5-(4-methoxyphenyl)pent-l-ynyl] thiophen-2-yl}pentylphosphonic acid, 3-amino-3-methyl-5-{5-[3-(4-methylphenoxy)prop-l-ynyl]thiophen-2-yl}pentylphosphonic acid, 3-amino-3-methyl-5-{5-[3-(4-ethylphenoxy)prop-l-ynyl]thiophen-2-yl}pentylphosphonic acid, 3-amino-3-methyl-5-{5-[3-(4-methylthiophenoxy)prop-l-ynyl]thiophen-2-yl}pentylphosphonic acid, 3-amino-3-methyl-5-[5-(4-cyclohexyloxybut-l-ynyl)thiophen-2-yl] pentylphosphonic acid, 3-amino-3-methyl-5-{5-[4-(4-fluorophenoxy)but-l-ynyl]thiophen-2-yl}pentylphosphonic acid, 3-amino-3-methyl-5-{5-[4-(4-methylphenoxy)but-1-ynyl]thiophen-2-yl}pentylphosphonic acid, 3-amino-3-methyl-5-[5-(3-cyclohexylmethoxy)prop-l-ynyl]thiophen-2-yl]pentylphosphonic acid, S:/ChemicallSankyo/FP200301 /FP0301 s.doc P8 7892/FP-0301 /Desci iption/gds-mg/30.06.04 3-amino-3-methyl-5-[5-(4-benzyloxybut-1-ynyl)thiophen-2-yl] pentylphosphonic acid, 3-amino-3-methyl-5-[5-(4-cyclohexylbutanoyl)thiophen-2-yl] pentylphosphonic acid, 3-amino-3-methyl-5-[5-(4-phenylbutanoyl)thiophen-2-yl]pentylphosphonic acid, 3-amino-3-methyl-5-[5-(5-cyclohexylpentanoyl)thiophen-2-yl] pentylphosphonic acid, 3-amino-3-methyl-5-[5-(5-phenylpentanoyl)thiophen-2-yl]pentylphosphonic acid, 3-amino-3-methyl-5-{5-[5-(4-fluorophenyl)pentanoyl]thiophen-2-yl}pentylphosphonic acid, 3-amino-3-ethyl-5-[5-(5-cyclohexylpentyl)thiophen-2-yl] pentylphosphonic acid, 3-amino-3-ethyl-5-[5-(5-cyclohexylpent-l-ynyl)thiophen-2-yl] pentylphosphonic acid, 3-amino-3-ethyl-5-[5-(5-cyclohexylpentanoyl)thiophen-2-yl] pentylphosphonic acid, 3-amino-3-methyl-5-{5-[3-(4-chlorophenoxy)prop-l-ynyl] thiophen-2-yl}pentylphosphonic acid, 3-amino-3-methyl-5-{5-[3-(3-methylphenoxy)prop-l-ynyl]thiophen-2-yl}pentylphosphonic acid, 3-amino-3-methyl-5-(5-[3-(3,4-dimethylphenoxy)prop-l-ynyl]thiophen-2-yl}pentylphosphonic acid, 3-amino-3-methyl-5-(5-[3-(3-methoxyphenoxyl)prop-l-ynyl]thiophen-2-yl}pentylphosphonic acid, 3-amino-3-methyl-5-{5-[3-(3,4-dimethoxyphenoxy)prop-l-ynyl]thiophen-2-yl}pentyiphosphonic acid, 3-amino-3-methyl-5-{5-[3-(3,5-dimethoxyphenoxyl)prop-l-ynyl]thiophen-2-yl}pentylphosphonic acid, 3-amino-3-methyl-5-{5-[3-(3-acetylphenoxy)prop-l-ynyl]thiophen-2-yl}pentylphosphonic acid, and 3-amino-3-methyl-5-{5-[3-(4-acetylphenoxy)prop-l-ynyl]thiophen-2-yl}pentylphosphonic acid, (121) a pharmaceutical composition according to (66), wherein the compound of general formula (III), or pharmacologically S:/Chemica1/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 acceptable salt thereof, or pharmacologically acceptable ester thereof is selected from the group consisting of the compounds described below, pharmacologically acceptable salts thereof, and pharmacologically acceptable esters thereof:
3-amino-3-methyl-5-[5-(5-phenylpentyl)furan-2-yl] pentylphosphonic acid, 3-amino-3-methyl-5-[5-(5-cyclohexylpent-l-ynyl)furan-2-yl] pentylphosphonic acid, 3-amino-3-methyl-5-[5-(5-phenylpent-1-ynyl)furan-2-yl]pentylphosphonic acid, 3-amino-3-methyl-5-[5-(4-cyclohexyloxybut-l-ynyl)furan-2-yl]pentylphosphonic acid, 3-amino-3-methyl-5-[5-(5-cyclohexylpentanoyl)furan-2-yl]pentylphosphonic acid, and 3-amino-3-methyl-5-{5-[3-(3,4-dimethylphenoxy)prop-l-ynyl] furan-2-yl}pentylphosphonic acid, (122) a pharmaceutical composition according to (66), wherein the compound of general formula (III), or pharmacologically acceptable salt thereof, or pharmacologically acceptable ester thereof is selected from the group consisting of the compounds described below, pharmacologically acceptable salts thereof, and pharmacologically acceptable esters thereof:
3-amino-3-methyl-5-[1-methyl-5-(5-phenylpent-l-ynyl)pyrrol-2-yl]pentylphosphonic acid, 3-amino-3-methyl-5-{1-methyl-5-[3-(4-methylphenoxy)prop-l-ynyl]pyrrol-2-yl}pentylphosphonic acid, 3-amino-3-methyl-5-[1-methyl-5-(4-cyclohexyloxybut-l-ynyl)pyrrol-2-yl]pentylphosphonic acid, 3-amino-3-methyl-5-{1-methyl-5-[3-(3,4-dimethylphenoxy)prop-l-ynyl]pyrrol-2-yl}pentylphosphonic acid, 3-amino-3-methyl-5-[1-methyl-5-(5-phenylpentanoyl)pyrrol-2-yl] pentylphosphonic acid, 3-amino-3-methyl-5-[1-methyl-5-(5-cyclohexylpentanoyl)pyrrol-2-yl] pentylphosphonic acid, 3-amino-3-methyl-5-[1-methyl-5-(4-phenylbutanoyl)pyrrol-2-yl] pentylphosphonic acid, S:/Chemical/Sankyo/FP20030I /FP0301 s.doc P87892/FP-0301/Desci iption/gds-mg/30.06.04 3-amino-3-methyl-5-[1-methyl-5-(4-cyclohexylbutanoyl)pyrrol-2-yl]pentylphosphonic acid, 3-amino-3-methyl-5-[1-ethyl-5-(5-phenylpentanoyl)pyrrol-2-yl]pentylphosphonic acid, 3-amino-3-methyl-5-[1-ethyl-5-(5-cyclohexylpentanoyl)pyrrol-2-yl] pentylphosphonic acid, 3-amino-3-methyl-5-[1-ethyl-5-(4-phenylbutanoyl)pyrrol-2-yl]pentylphosphonic acid, and 3-amino-3-methyl-5-[1-ethyl-5-(4-cyclohexylbutanoyl)pyrrol-2-yl]pentylphosphonic acid, (123) a pharmaceutical composition according to any one of (60) to (122) wherein said composition contains at least one immunosuppressant selected from the group consisting of agents having the action of inhibiting intracellular signal transduction involved in cytokine expression of T-cells (said agents are cyclosporin A, tacrolimus, rapamycin, gusperimus, everolimus, tresperimus, anisperimus, SDZ-281-240, ABT-281, tigderimus, A-119435, or 17-ethyl-1,14-dihydroxy-12-[2-[4-(2-phenylhydrazinocarbonyloxy)-3-methoxycyclohexyl]-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0''9]octacos-18-ene-2,3,10,16-tetrone), agents having the action of inhibiting nucleoside synthesis in immune cells (said agents are mizoribine, azathioprine, mycophenolate Mofetil, leflunomide, merimempodib, HMR-1279, TSK-204, or SP-100030), agents having the action of inhibiting the action of cytokines on immune cells and having antirheumatic action (said agents are T-614, actarit, salazosulfapyridine, or CDC-801), alkylating agents causing cell death by breakdown of DNA
chains or blocking DNA synthesis (said alkylating agent is cyclophosphamide), metabolic antagonists inhibiting the metabolism of nucleic acids by blocking folic acid production (said metabolic antagonist is methotrexate), protein drugs having the suppression action of TNF-a (said S:/Chemical/Sankyo/FP200301/FP0301a1.doc P87892/FP-0301/corrected pages/gds-mg/02.07.04 = CA 02473461 2004-07-12 protein drugs are remicade, enbrel, daclizumab, basiliximab, alemtuzumab, omalizumab, BMS-188667, CDP-571, inolimomab, ATM-027, or BTI-322), steroid hormone agents that bind to intracellular steroid receptors to form a complex which binds to reaction sites on chromosomes, resulting in the synthesis of proteins which show immunosuppressive activity (said steroid hormone agent is prednisolone), and substances suppressing prostaglandin production and/or nonsteroidal anti-inflammatory drugs antagonizing the action of prostaglandin (said nonsteroidal anti-inflammatory drugs are loxoprofen sodium, diclofenac sodium, meloxicam, celecoxib, or rofecoxib), and (124) a pharmaceutical composition according to any one of (60) to (122) wherein said composition contains at least one immunosuppressant selected from the group consisting of cyclosporin A, tacrolimus, rapamycin, leflunomide, methotrexate, remicade, and enbrel.

Another object of the present invention is to provide the following pharmaceutical compositions and methods:
(125) a pharmaceutical composition comprising as an active ingredient a compound, a pharmacologically acceptable salt thereof or a pharmacologically acceptable ester thereof according to any one of (1) to (59), (126) a pharmaceutical composition according to (125) for the prevention or treatment of autoimmune diseases, (127) a pharmaceutical composition according to (126) wherein said autoimmune disease is rheumatoid arthritis, a pharmaceutical composition according to (126) wherein said autoimmune disease is Crohn's disease or ulcerative colitis, S:/Chemical/Sankyo/FP200301 /FP0301 al .doc P87892/FP-0301 /corrected pages/gds-mg/02.07.04 a pharmaceutical composition according to (126) wherein said autoimmune disease is multiple sclerosis, a pharmaceutical composition according to (126) wherein said autoimmune disease is psoriasis, a pharmaceutical composition according to (126) wherein said autoimmune disease is atopic dermatitis, a pharmaceutical composition according to (126) wherein said autoimmune disease is insulin dependent diabetes mellitus, a pharmaceutical composition according to (126) wherein said autoimmune disease is glomerular nephritis, (128) a pharmaceutical composition according to (125) for suppression of rejection caused by transplantation of various organs or skin, S:/ChemicallSankyo/FP20030I/FP0301aI.doc P87842/FP-0301/corrected pages/gds-mg/02.07.04 (129) a method for the prevention or treatment of autoimmune diseases in a mammal which comprises administering to said mammal an effective amount of a pharmaceutical composition according to any one of (60) to (125), (130) a method for the prevention or treatment of rheumatoid arthritis in a mammal which comprises administering to said mammal an effective amount of a pharmaceutical composition according to any one of (60) to (125), and a method for the prevention or treatment of psoriasis in a mammal which comprises administering to said mammal an effective amount of a pharmaceutical composition according to any one of (60) to (125), a method for the prevention or treatment of Crohn's disease or ulcerative colitis in a mammal which comprises administering to said mammal an effective amount of a pharmaceutical composition according to any one of (60) to (125), a method for the prevention or treatment of multiple sclerosis in a mammal which comprises administering to said mammal an effective amount of a pharmaceutical composition according to any one of (60) to (125), a method for the prevention or treatment of atopic dermatitis in a mammal which comprises administering to said mammal an effective amount of a pharmaceutical composition according to.
any one of (60) to (125).

a method for the prevention or treatment of insulin dependent diabetes mellitus in a mammal which comprises administering to said mammal an effective amount of a pharmaceutical composition according to any one of (60) to (125).

a method for the prevention or treatment of glomerular nephritis in a mammal which comprises administering to said mammal an effective amount of a pharmaceutical composition according to any one of (60) to (125).
(131) a method for the prevention or treatment of rejection caused by transplantation of various organs or skin in a mammal which comprises administering to said mammal an effective amount of a pharmaceutical composition according to any one of (60) to (125).

In the formulae (I), (II) and (III), the aryl moiety of the "C6-C10 aryl group", the "C6-C10 aryl group which is substituted with from 1 to 3 substituents selected from Substituent group (a)", or the "C6-C10 aryl group which is substituted with from 1 to 3 substituents selected from the group consisting of Substituent group (a) and Substituent group (b)" in the definition of D, R5 or Substituent group (b) can be, for example, a group such as a phenyl, indenyl, or naphthyl group, and is preferably a phenylene or naphthylene group, and most preferably a phenylene group.

The arylene moiety of the "C6-C10 arylene group", the "C6-C10 arylene group which is substituted with from 1 to 3 substituents selected from Substituent group (a)", or the "C6-C10 arylene group which is substituted with from 1 to 3 substituents selected from the group consisting of Substituent group (a) and Substituent group (b)" in the definition of Y or E can be, for example, a group such as a phenylene, indenylene, or naphthylene group, and is preferably a phenylene or naphthylene group, and most preferably a phenylene group.

The C1-Clo alkylene moiety of the "C1-Clo alkylene group" or the "C1-C1o alkylene group which is substituted with from 1 to 3 substituents selected from the group consisting of Substituent group (a) and Substituent group (b)", in the definition of Z
includes straight or branched chain alkylene groups having from 1 to 10 carbon atoms, and can be, for example, a group such as a methylene, methylmethylene, ethylene, propylene, trimethylene, 1-methylethylene, tetramethylene, 1-methyltrimethylene, 2-methyltrimethylene, 3-methyltrimethylene, 1-methylpropylene, 1,1-dimethylethylene, pentamethylene, 1-methyltetramethylene, 2-methyltetramethylene, 3-methyltetramethylene, 4-methyltetramethylene, 1,1-dimethyltrimethylene, 2,2-dimethyltrimethylene, 3,3-dimethyltrimethylene, hexamethylene, 1-methylpentamethylene, 2-methylpentamethylene, 3-methylpentamethylene, 4-methylpentamethylene, 5-methylpentamethylene, 1,1-dimethyltetramethylene, 2,2-dimethyltetramethylene, 3,3-dimethyltetramethylene, 4,4-dimethyltetramethylene, heptamethylene, 1-methylhexamethylene, 2-methylhexamethylene, 5-methylhexamethylene, 3-ethylpentamethylene, octamethylene, 2-methylheptamethylene, 5-methylheptamethylene, 2-ethylhexamethylene, 2-ethyl-3-methylpentamethylene, 3-ethyl-2-methylpentamethylene, nonamethylene, 2-methyloctamethylene, 7-methyloctamethylene, 4-ethylheptamethylene, 3-ethyl-2-methylhexamethylene, 2-ethyl-l-methylhexamethylene or decamethylene group, and is preferably a C1-C6 alkylene group, more preferably a C1-C5 alkylene group, still more preferably an ethylene, trimethylene, or tetramethylene group, and most preferably an ethylene or trimethylene group.

The "C1-Cio alkylene moiety which contains an oxygen atom or a sulfur atom in the carbon chain or at the end of the carbon chain" of the "C1-C1o alkylene group which has an oxygen atom or a sulfur atom in said carbon chain or at the end of said carbon chain" or the "C1-Cio alkylene group substituted with from 1 to 3 substituents selected from the group S:/ChemicalSankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 consisting of Substituent group (a) and Substituent group (b) which has an oxygen atom or a sulfur atom in said carbon chain or at the end of said carbon chain" in the definition of Z
represents a "C1-010 alkylene group" described above which contains an oxygen atom or a sulfur atom in the carbon chain or at the end of the carbon chain, and can be, for example, a -0-CH2-, -0- (CHz) 2-, -0- (CHZ) 3-, -0- (CH2) 4-, -0- (CH2) 5-, -0-(CH2) 6-, -0- (CH2) 7-1 -0- (CH2) 8-1 -0- (CH2) 9-, -0- (CH2) 10-, -CH2-0-CH2-, -CH2-0- (CH2) 2-, -CH2-0- (CH2) 3-, -CH2-0- (CH2) 4-, - (CH2) 2-0-CH2-, - (CH2) 2-0- (CH2) 2-, - (CH2) 2-0- (CH2) 3-, - (CH2) 2-0- (CH2) 4-, -(CH2) 3-0-CH2-1 - (CH2) 3-0- (CH2) 2-, - (CH2) 3-0- (CH2) 3-, - (CH2) 4-0-CH2-, - (CH2) 4-0- (CH2) 2-, - (CH2) 5-0-CH2-, -CH2-0-, - (CH2) 2-0-, - (CHz) 3-0-, - (CH2) 4-0-, - (CH2) 5-0-, - (CHz) 6-0-, - (CH2) 7-0-, - (CH2) 8-0-, -(CH2) 9-0-, - (CH2) 10-0-, -S-CH2-, -S- (CH2) 2-, -S- (CH2) 3-, -S- (CH2) 4-, -S- (CH2) 5-, -S- (CH2) 6-, -S- (CH2) 7-, -S- (CH2) 8-, -S- (CH2) 9-, -S-(CH2) 10-, -CH2-S-CH2-1 -CH2-S- (CH2) 2-, -CH2-S- (CH2) 3-, -CH2-S-(CH2) 4-1 - (CH2) 2-S-CH2-, - (CH2) 2-S- (CH2) 2-, - (CH2) 2-S- (CH2) 3-, -(CH2) 2-S- (CH2) 4-, - (CH2) 3-S-CH2-, - (CH2) 3-S- (CH2) 2-, - (CH2) 3-S-(CH2) 3-, - (CH2) 4-S-CH2-, - (CH2) 4-S- (CH2) 2-, - (CH2) 5-S-CH2-, -CH2-S-, - (CH2) 2-S-, - (CH2) 3-5-, - (CH2) 4-S-, - (CH2) 5-S-, - (CH2) 6-S-, -(CH2) 7-S-, - (CH2) 8-S-, -(0H2)9-S-, or - (CH2) 10-S- group, and is preferably a C1-C6 alkylene group which contains an oxygen atom in the carbon chain or at the end of the carbon chain, more preferably a -0-CH2-1 -0- (CH2) 2-, -0- (CH2) 3-, -CH2-0-1 - (CH2) 2-0-, or - (CH2) 3-0- group, and most preferably a -CH2-0- or - (CH2) 2-0-group.

The C3-Clo cycloalkyl moiety of the "C3-Clo cycloalkyl group", the "C3-C10 cycloalkyl group substituted with from 1 to 3 substituents selected from Substituent group (a)", or the "C3-C10 cycloalkyl group substituted with from 1 to 3 substituents selected from the group consisting of Substituent group (a) and Substituent group (b)" in the definition of R5 or Substituent group (b), may optionally be fused with other cyclic groups, and can be, for example, a group such as a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, -norbornyl, adamantyl, or indanyl group, and is preferably a O5 S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 C6 cycloalkyl group, and most preferably a cyclohexyl group.
The 5- to 7-membered heterocyclic moiety containing from 1 to 3 heteroatoms selected from the group consisting of a sulfur atom, an oxygen atom, and a nitrogen atom in the "5- to 7-membered heterocyclic group containing from 1 to 3 heteroatoms selected from the group consisting of a sulfur atom, an oxygen atom, and a nitrogen atom", the "5- to 7-membered heterocyclic group containing from 1 to 3 heteroatoms selected from the group consisting of a sulfur atom, an oxygen atom, and a nitrogen atom in which said heterocyclic group is substituted with from 1 to 3 substituents selected from Substituent group (a)", or the "5- to 7-membered heterocyclic group containing from 1 to 3 heteroatoms selected from the group consisting of a sulfur atom, an oxygen atom, and a nitrogen atom in which said heterocyclic group is substituted with from 1 to 3 substituents selected from the group consisting of Substituent group (a) and Substituent group (b)"
in the definition of R5 or substituent group (b) can be, for example, a 5- to 7-membered aromatic heterocyclic or partially or fully hydrogenated saturated heterocyclic group containing from 1 to 3 heteroatoms selected from the group consisting of a sulfur atom, an oxygen atom, and a nitrogen atom.

The heterocyclic group can be a furyl, thienyl, pyrrolyl, azepinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,3-oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyranyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperadinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, or pyrazolidinyl group, and is preferably a 5- or 6-membered aromatic heterocyclic group, more preferably a furyl, thienyl, or pyrrolyl group, still more preferably a furyl or thienyl group, and most preferably a thienyl group.

S:/Chemical/Sankyo/FP20030 I /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 The "aromatic heterocyclic group" described above may optionally be fused with other cyclic groups, and can be, for example, a benzothienyl,isobenzofuranyl1 chromenyl, xanthenyl, phenoxathiinyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolizinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, carbazolyl, carbolinyl, acridinyl, or isoindolinyl group, and is preferably a benzothienyl group.

The "halogen atom" in the definition of Substituent group (a) can be a fluorine, chlorine, bromine or iodine atom, of which a fluorine or chlorine atom is preferred.

The "lower alkyl group" in the definition of R1, R2, R3, R4, or Substituent group (a) can be, for example, a straight or branched chain alkyl group having from 1 to 6 carbon atoms.
Said lower alkyl group can be, for example, a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, s-butyl, tert-butyl, pentyl, isopentyl, 2-methylbutyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 1-ethylbutyl or 2-ethylbutyl group, and is preferably a C1-C4 alkyl group, more preferably a C1-C2 alkyl group, and most preferably a methyl group.

The "halogeno lower alkyl group" in the definition of Substituent group (a) is a group wherein said "lower alkyl group" is substituted with a halogen atom. Said halogeno lower alkyl group can be, for example, a halogeno C1-C6 alkyl group such as a trifluoromethyl, trichloromethyl, difluoromethyl, dichloromethyl, dibromomethyl, fluoromethyl, 2,2,2-trifluoroethyl, 2,2,2-trichloroethyl, 2-bromoethyl, 2-chloroethyl, 2-fluoroethyl, 2-iodoethyl, 3-chloropropyl, 4-fluorobutyl, 6-iodohexyl, or 2,2-dibromoethyl group, and is preferably a halogeno C1-C4 alkyl group, more preferably a trifluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, or S:/ChemicallSankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 2,2,2-trichloroethyl group, and most preferably a trifluoromethyl group.

The "lower alkoxy group" in the definition of Substituent group (a) is a group wherein said "lower alkyl group" is bonded to an oxygen atom. Said lower alkoxy group can be, for example, a straight or branched chain alkoxy group having from 1 to 6 carbon atoms such as a methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, s-butoxy, tert-butoxy, pentoxy, isopentoxy, 2-methylbutoxy, 1-ethylpropoxy, 2-ethylpropoxy, neopentoxy, hexyloxy, 4-methylpentoxy, 3-methylpentoxy, 2-methylpentoxy, 3,3-dimethylbutoxy, 2,2-dimethylbutoxy, 1,1-dimethylbutoxy, 1,2-dimethylbutoxy, 1,3-dimethylbutoxy, or 2,3-dimethylbutoxy group, and is preferably a C1-C4 alkoxy group, more preferably a C1-C2 alkoxy group, and most preferably a methoxy group.

The "lower alkylthio group" in the definition of Substituent group (a) is a group wherein said "lower alkyl group" is bonded to a sulfur atom. Said lower alkylthio group can be, for example, a straight or branched chain alkylthio group having from 1 to 6 carbon atoms such as a methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, s-butylthio, tert-butylthio, pentylthio, isopentylthio, 2-methylbutylthio, neopentylthio, hexylthio, 4-methylpentylthio, 3-methylpentylthio, 2-methylpentylthio, 3,3-dimethylbutylthio, 2,2-dimethylbutylthio, 1,1-dimethylbutylthio, 1,2-dimethylbutylthio, 1,3-dimethylbutylthio, or 2,3-dimethylbutylthio group, and is preferably a C1-C4 alkylthio group, more preferably a C1-C2 alkylthio group, and most preferably a methylthio group.

The "lower alkoxycarbonyl group" in the definition of Substituent group (a) is a group wherein said "lower alkoxy group" is bonded to a carbonyl group. Said lower alkoxycarbonyl group can be, for example, a straight or branched chain alkoxycarbonyl group having from 1 to 6 carbon S:/ChemicaUSankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 atoms such as a methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, s-butoxycarbonyl, tert-butoxycarbonyl, pentoxycarbonyl, isopentoxycarbonyl, 2-methylbutoxycarbonyl, neopentoxycarbonyl, hexyloxycarbonyl, 4-methylpentoxycarbonyl, 3-methylpentoxycarbonyl, 2-methylpentoxycarbonyl, 3,3-dimethylbutoxycarbonyl, 2,2-dimethylbutoxycarbonyl, 1,1-dimethylbutoxycarbonyl, 1,2-dimethylbutoxycarbonyl, 1,3-dimethylbutoxycarbonyl, or 2,3-dimethylbutoxycarbonyl group, and is preferably a Cl-C4 alkoxycarbonyl group, more preferably a C1-C2 alkoxycarbonyl group, and most preferably a methoxycarbonyl group.

The "lower aliphatic acyl group" in the definition of Substituent group (a) is a group wherein a hydrogen atom or a saturated or unsaturated aliphatic hydrocarbon group is bonded to a carbonyl group. Said lower aliphatic hydrocarbon group can be, for example, a straight or branched chain lower aliphatic acyl group having from 1 to 8 carbon atoms such as a formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, acryloyl, methacryloyl, or crotonoyl group, and is preferably a C1-C4 lower aliphatic acyl group, more preferably an acetyl or propionyl group, and most preferably an acetyl group.

The "mono lower alkylamino group" in the definition of Substituent group (a) is a group wherein said "lower alkyl group" is bonded to one amino group. Said mono lower alkylamino group can be, for example, a mono-C1-C4 alkylamino group such as a methylamino, ethylamino, propylamino, isopropylamino, butylamino, isobutylamino, s-butylamino, tert-butylamino, pentylamino, isopentylamino, 2-methylbutylamino, neopentylamino, l-ethylpropylamino, hexylamino, isohexylamino, 4-methylpentylamino, 3-methylpentylamino, 2-methylpentylamino, 1-methylpentylamino, 3,3-dimethylbutylamino, 2,2-dimethylbutylamino, 1,1-dimethylbutylamino, 1,2-dimethylbutylamino, 1,3-dimethylbutylamino, 2,3-S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 dimethylbutylamino, or 2-ethylbutylamino group, and is preferably a mono-C1-C4 alkylamino group, more preferably a mono-C1-C2 alkylamino group, and most preferably a methylamino group.

The "di-lower alkylamino group" in the definition of Substituent group (a) is a group wherein two said "lower alkyl groups" are bonded to an amino group. Said di-lower alkylamino group can be, for example, a di-C1-C6 alkylamino group such as a dimethylamino, diethylamino, N-ethyl-N-methylamino, dipropylamino, dibutylamino, dipentylamino, or dihexylamino group, and is preferably a di-C1-C4 alkylamino group, more preferably a di-C1-C2 alkylamino group, and most preferably a dimethylamino group.

The "lower aliphatic acylamino group" in the definition of Substituent group (a) is a group wherein said "lower aliphatic acyl group" is bonded to an amino group. Said lower aliphatic acylamino group can be, for example, a straight or branched chain lower aliphatic acylamino group having from 1 to 7 carbon atoms such as a formylamino, acetylamino, propionylamino, butyrylamino, isobutyrylamino, valerylamino, isovalerylamino, pivaloylamino, hexanoylamino, acryloylamino, methacryloylamino, or crotonoylamino group, and is preferably a C1-C4 lower aliphatic acylamino group, more preferably an acetylamino or propionylamino group, and most preferably an acetylamino group.

The "lower alkylsulfonyl group" in the definition of D is a group wherein said "lower alkyl group" is bonded to a sulfonyl group. Said lower alkylsulfonyl group can be, for example, a straight or branched chain alkylsulfonyl group having from 1 to 6 carbon atoms such as a methanesulfonyl, ethanesulfonyl, propanesulfonyl, isopropanesulfonyl, butanesulfonyl, isobutanesulfonyl, s-butanesulfonyl, tert-butanesulfonyl, pentanesulfonyl, isopentanesulfonyl, 2-methylbutanesulfonyl, neopentanesulfonyl, hexanesulfonyl, 4-S:/Chemicai/S ankyo/FP200301 /FP0301 a l .doc P87892/FP-0301 /corrected pages/gds-mg/02.07.04 methylpentanesulfonyl, 3-methylpentanesulfonyl, 2-methylpentanesulfonyl, 3,3-dimethylbutanesulfonyl, 2,2-dimethylbutanesulfonyl, 1,1-dimethylbutanesulfonyl, 1,2-dimethylbutanesulfonyl, 1,3-dimethylbutanesulfonyl, or 2,3-dimethylbutanesulfonyl group, and is preferably a C1-C4 alkylsulfonyl group, more preferably a C1-C2 alkylsulfonyl group, and most preferably a methanesulfonyl group.

The "arylsulfonyl group" in the definition of D is a group wherein said "aryl group" is bonded to a sulfonyl group. Said arylsulfonyl group can be, for example, an arylsulfonyl group having from 6 to 10 carbon atoms such as a benzenesulfonyl, p-toluenesulfonyl, o-xylene-4-sulfonyl, m-xylene-4-sulfonyl, p-xylenesulfonyl, or naphthalenesulfonyl group, and is preferably a benzenesulfonyl group.

The "protecting group of the amino group" in the definitions of R1 and R2 is a protecting group for an amino group which is generally used in the field of synthetic organic chemistry, and can be:
an "aliphatic acyl group", for example, a "lower aliphatic acyl group" described above, a halogeno lower aliphatic acyl group such as a chloroacetyl, dichloroacetyl, trichioroacetyl, or trifluoroacetyl group, or a lower aliphatic acyl group substituted with a lower alkoxy such as a methoxyacetyl group;
an "aromatic acyl group", for example, an aromatic acyl group such as a benzoyl, 1-indanecarbonyl,2-indanecarbonyl, or 1- or 2-naphthoyl group, or an aromatic acyl group substituted with from 1 to 3 substituents selected from Substituent group (a) described above such as a 4-chlorobenzoyl, 4-fluorobenzoyl, 2,4,6-trimethylbenzoyl, 4-toluoyl, 4-anisoyl, 4-nitrobenzoyl, 2-nitrobenzoyl, 2-(methoxycarbonyl)benzoyl, or 4-phenylbenzoyl group;
an "alkoxycarbonyl group", for example, a "lower alkoxycarbonyl group" described above, or a lower alkoxycarbonyl group substituted with one or more halogen atoms or one or more tri-lower alkylsilyl groups such as a S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 2,2,2-trichloroethoxycarbonyl or 2-trimethylsilylethoxycarbonyl group;
an "alkenyloxycarbonyl group" such as a vinyloxycarbonyl or allyloxycarbonyl group;
an "aralkyloxycarbonyl group", for example, an aralkyloxycarbonyl group such as a benzyloxycarbonyl group, or an aralkyloxycarbonyl group substituted with 1 to 3 substituents selected from Substituent group (a) described above such as a 4-methoxybenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, or 4-nitrobenzyloxycarbonyl group;
a "silyl group", for example, a tri-lower alkylsilyl group such as a trimethylsilyl, triethylsilyl, isopropyldimethylsilyl, tert-butyldimethylsilyl, methyldiisopropylsilyl, methyldi(tert-butyl)silyl, or triisopropylsilyl group, or a silyl group substituted with 3 substituents selected from aryl groups or aryl groups and lower alkyl groups such as a diphenylmethylsilyl, diphenylbutylsilyl, diphenylisopropylsilyl, or phenyldiisopropylsilyl group;
an "aralkyl group", for example, a lower alkyl group substituted with from 1 to 3 aryl groups such as a benzyl, phenethyl, 3-phenylpropyl, a-naphthylmethyl, 0-naphthylmethyl, diphenylmethyl, triphenylmethyl, a-naphthyldiphenylmethyl, or 9-anthrylmethyl group, or a lower alkyl group substituted with from 1 to 3 aryl groups, wherein said aryl group is substituted with a lower alkyl group, a lower alkoxy group, a nitro group, a halogen atom, or a cyano group, such as a 4-methylbenzyl, 2,4,6-trimethylbenzyl, 3,4,5-trimethylbenzyl, 4-methoxybenzyl, 4-methoxyphenyldiphenylmethyl, 2-nitrobenzyl, 4-nitrobenzyl, 4-chlorobenzyl, 4-bromobenzyl, 4-cyanobenzyl, 4-cyanobenzyldiphenylmethyl, bis(2-nitrophenyl)methyl, or piperonyl group; or a "substituted methylene group forming a Schiff base" such as a N,N-dimethylaminomethylene, benzylidene, 4-methoxybenzylidene, 4-nitrobenzylidene, salicylidene, 5-chlorosalicylidene, diphenylmethylene, or (5-chloro-2-S:/ChemicaYSankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 hydroxyphenyl)phenylmethylene group.
The "protecting group of the amino group" is preferably a lower aliphatic acyl group, a lower alkoxycarbonyl group, an aralkyloxycarbonyl group, or an aralkyloxycarbonyl group substituted with from 1 to 3 substituents selected from Substituent group (a), particularly preferably an acetyl or tert-butoxycarbonyl group.

The "protecting group of the hydroxyl group" in the definition of R3 represents a "general protecting group in chemical reactions" which can be cleaved by a chemical process such as hydrogenolysis, hydrolysis, electrolysis, and photolysis, or a "protecting group which can be cleaved by a biological process such as hydrolysis in vivo".
The "general protecting group in chemical reactions" can be, for example, an "aliphatic acyl group" described above;
an "aromatic acyl group" described above;
a "tetrahydropyranyl or tetrahydrothiopyranyl group" such as a tetrahydropyran-2-yl, 3-bromotetrahydropyran-2-yl, 4-methoxytetrahydropyran-4-yl, tetrahydrothiopyran-2-yl, or 4-methoxytetrahydrothiopyran-4-yl group;
a "tetrahydrofuranyl or tetrahydrothiofuranyl group" such as a tetrahydrofuran-2-yl or tetrahydrothiofuran-2-yl group;
a "silyl group" described above;
an "alkoxymethyl group", for example, a lower alkoxymethyl group such as a methoxymethyl, 1,1-dimethyl-l-methoxymethyl, ethoxymethyl, propoxymethyl, isopropoxymethyl, butoxymethyl, or tert-butoxymethyl group, a lower alkoxylated lower alkoxymethyl group such as a 2-methoxyethoxymethyl group, or a halogeno lower alkoxymethyl group such as a 2,2,2-trichloroethoxymethyl or bis(2-chloroethoxy)methyl group;
a "substituted ethyl group", for example, a lower alkoxylated ethyl group such as a 1-ethoxyethyl or 1-(isopropoxy)ethyl group, or a halogenated ethyl group such as a 2,2,2-trichloroethyl group;
an "aralkyl group" described above;
S:/Chemical/Sankyo/FP200301/FP0301s.doc P87892/FP-0301/Description/gds-mg/30.06.04 an "alkoxycarbonyl group" described above;
an "alkenyloxycarbonyl group" described above; or an "aralkyloxycarbonyl group" described above.

On the other hand, the "protecting group which can be cleaved by a biological process such as hydrolysis in vivo"
can be, for example, a "carbonyloxyalkyl group", for example, an acyloxyalkyl group such as an ethylcarbonyloxymethyl, pivaloyloxymethyl, dimethylaminoacetoxymethyl, or 1-acetoxyethyl group;
a 1-(alkoxycarbonyloxy)alkyl group such a 1-(methoxycarbonyloxy) ethyl, 1-(ethoxycarbonyloxy)ethyl, ethoxycarbonyloxymethyl, 1-(isopropoxycarbonyloxy)ethyl, 1-(tert-butoxycarbonyloxy)ethyl, 1-(ethoxycarbonyloxy)propyl, or 1-(cyclohexyloxycarbonyloxy) ethyl group;
a phthalidyl group; or an oxodioxolenylmethyl group such as a 4-methyl-oxodioxolenylmethyl, 4-phenyl-oxodioxolenylmethyl, or oxodioxolenylmethyl group;
an "aliphatic acyl group" described above;
an "aromatic acyl group" described above;
a "residual group of a succinic acid half-ester";
a "residual group of a phosphoric acid ester";
a "residual group forming an amino acid ester or the like";
a carbamoyl group;
a "protecting group of two hydroxyl groups", for example, an aralkylidene group such as a benzylidene group, an alkoxyethylidene group such as a methoxyethylidene or ethoxyethylidene group, an oxomethylene group, or a thioxomethylene group; or a "carbonyloxyalkyloxycarbonyl group" such as a pivaloyloxymethyloxycarbonyl group.
The suitability of such a derivative can be determined by administering it to an experimental animal such as a rat or a S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892JFP-0301 /Description/gds-mg/30.06.04 mouse by an intravenous injection, measuring a body fluid of the animal thereafter and detecting the original compound or a pharmacologically acceptable salt thereof.
The "protecting group of the hydroxyl group" is preferably a lower aliphatic acyl group, an aromatic acyl group, an aromatic acyl group substituted with from 1 to 3 substituents selected from Substituent group (a), or a silyl group, particularly preferably an acetyl group or a tert-butyldimethylsilyl group.

The "protecting group of phosphoric acid" in the definition of R10 or R11 can be, for example, a lower alkyl group such as a methyl, ethyl, isopropyl, or butyl group, a lower alkyl group substituted with one or more cyano groups such as a 2-cyanoethyl or 2-cyano-l,1-dimethylethyl group, a lower alkyl group substituted with one or more silyl groups wherein said silyl group is substituted with 3 substituents selected from the group consisting of lower alkyl groups or aryl groups and lower alkyl groups such as a 2-(methyldiphenylsilyl)ethyl or 2-trimethylsilylethyl group, a lower alkyl group substituted with one or more heterocyclyl groups such as a 2-(2'-pyridyl)ethyl or 2-(4'-pyridyl) ethyl group, a lower alkyl group substituted with one or more arylthio groups such as a 2-phenylthioethyl, 2-(4'-nitrophenylthio)ethyl, or 2-(4'-triphenylmethylphenylthio) ethyl group, a lower alkyl group substituted with one or more alkylsulfonyl groups, arylsulfonyl groups, or arylalkylsulfonyl groups such as a 2-(tert-butylsulfonyl)ethyl, 2-(phenylsulfonyl)ethyl, or 2-(benzylsulfonyl)ethyl group, or a halogeno lower alkyl group such as a 2,2,2-S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P878921FP-0301/Descniption/gds-mg/30.06.04 trichloroethyl, 2,2,2-trichloroethyl-1,1-dimethylethyl, 2,2,2-tribromoethyl, 2,3-dibromopropyl, or 2,2,2-trifluoroethyl group;
an aralkyl group, for example, a lower alkyl group substituted with from 1 to 3 aryl groups, such as a benzyl, phenethyl, 3-phenylpropyl, a-naphthylmethyl, (3-naphthylmethyl, diphenylmethyl, triphenylmethyl, a-naphthyldiphenylmethyl, or 9-anthrylmethyl group, a lower alkyl group substituted with one or more aryl groups wherein said aryl moiety is substituted with one or more nitro groups, halogen atoms, or lower aliphatic acyl groups, such as an o-nitrobenzyl, 4-nitrobenzyl, 2,4-dinitrobenzyl, 4-chlorobenzyl, 4-chloro-2-nitrobenzyl, or 4-acyloxybenzyl group, a lower alkyl group substituted with one or more aryl groups having one or more substituents such as a 2-nitrophenylethyl group, or a lower alkyl group substituted with one or more fluorenyl groups such as a 9-fluorenylmethyl group;
a lower alkenyl group such as an allyl or propenyl group;
a lower alkenyl group substituted with one or more cyano groups such as a 4-cyano-2-butenyl group;
an aryl group such as a phenyl group;
an aryl group substituted with one or more substituents selected from the group consisting of a lower alkyl group, a lower alkyl group substituted with 3 aryl groups, a lower alkoxy group, a nitro group, and a halogen atom, such as a 2-methylphenyl, 2,6-dimethylphenyl, 2-chlorophenyl, 4-chlorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-dichlorophenyl, 2-bromophenyl, 4-nitrophenyl, 3,5-dinitrophenyl, 4-chloro-2-nitrophenyl, or 2-methoxy-5-nitrophenyl group; or an amide such as an anilidate, 4-triphenylmethylanilidate, [N-(2-trityloxy)ethyl]anilidate, p-(N,N-dimethylamino)anilidate, or 3-(N,N-diethylaminomethyl)anilidate.

S:/Chemical/Sankyo/FP200301/FP0301s.doc P87892/FP-0301/Description/gds-mg/30.06.04 The "protecting group of phosphoric acid" is preferably a lower alkyl group, a lower alkenyl group, or a methyl group substituted with from 1 to 3 substituents selected from the group consisting of a phenyl group and a naphthyl group, more preferably a methyl group, an ethyl group, an allyl group, or a benzyl group, and most preferably a methyl group or an ethyl group.

The "C3-C10 cycloalkyl group substituted with from 1 to 3 substituents selected from the group consisting of Substituent group (a) and Substituent group (b)" in the definition of R5 can be, for example, a 2-fluorocyclopropyl, 2-chlorocyclopropyl, 2- or 3-fluorocyclopentyl, 2- or 3-chlorocyclopentyl, 2-,3- or 4-fluorocyclohexyl, 2-,3- or 4-chlorocyclohexyl, 2-,3- or 4-bromocyclohexyl, 2-,3- or 4-iodocyclohexyl, 2-methylcyclopropyl, 2-ethylcyclopropyl, 2- or 3-methylcyclopentyl, 2- or 3-ethylcyclopentyl, 2-,3- or 4-methylcyclohexyl, 2-,3- or 4-ethylcyclohexyl, 2-trifluoromethylcyclopropyl, 2- or 3-trifluoromethylcyclobutyl, 2- or 3-trifluoromethylcyclopentyl, 2-,3- or 4-trifluoromethylcyclohexyl, 2-methoxycyclopropyl, 2- or 3-methoxycyclobutyl, 2- or 3-methoxycyclopentyl, 2-, 3- or 4-methoxycyclohexyl, 2-, 3- or 4-ethoxycyclohexyl, 2-, 3- or 4-propoxycyclohexyl, 2-, 3- or 4-isopropoxycyclohexyl, 2-, 3- or 4-(1-ethylpropoxy)cyclohexyl, 2-, 3- or 4-(2-ethylpropoxy)cyclohexyl, 2-carboxycyclopropyl, 2- or 3-carboxycyclopentyl, 2-,3- or 4-carboxycyclohexyl, 2-methoxycarbonylcyclopropyl, 2- or 3-methoxycarbonylcyclopentyl, 2-,3- or 4-methoxycarbonylcyclohexyl, 2-hydroxycyclopropyl, 2-or 3-hydroxycyclopentyl, 2-,3- or 4-hydroxycyclohexyl, 2-formylcyclopropyl, 2- or 3-formylcyclopentyl, 2-,3- or 4-formylcyclohexyl, 2-acetylcyclopropyl, 2- or 3-acetylcyclopentyl, 2-,3- or 4-acetylcyclohexyl, 2-aminocyclopropyl, 2- or 3-aminocyclopentyl, 2-,3- or 4-aminocyclohexyl, 2-methylaminocyclopropyl, 2- or 3-methylaminocyclobutyl, 2- or 3-methylaminocyclopentyl, 2-,3-or 4-methylaminocyclohexyl, 2-dimethylaminocyclopropyl, 2- or S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 3-dimethylaminocyclobutyl, 2- or 3-dimethylaminocyclopentyl, 2-,3- or 4-dimethylaminocyclohexyl, 2-cyanocyclopropyl, 2- or 3-cyanocyclopentyl, 2-,3- or 4-cyanocyclohexyl, 2- or 3-cyclohexylcyclopentyl, 2-,3- or 4-cyclohexylcyclohexyl, 2-phenylcyclopropyl, 2- or 3-phenylcyclopentyl, 2-, 3- or 4-phenylcyclohexyl, 3,4-difluorocyclohexyl, 3,4-dichlorocyclohexyl, 2,3-dimethoxycyclohexyl, 3,4-dimethoxycyclohexyl, 3,5-dimethoxycyclohexyl, or 3,4,5-trimethoxycyclohexyl group, and is preferably a C3-Clo cycloalkyl group substituted with from 1 to 3 substituents (said substituent(s) being selected from the group consisting of halogen atoms, lower alkyl groups, halogeno lower alkyl groups, lower alkoxy groups, lower alkylthio groups, and lower aliphatic acyl groups), more preferably a C3-C10 cycloalkyl group substituted with from 1 to 3 substituents (said substituent(s) being selected from the group consisting of halogen atoms, lower alkyl groups, halogeno lower alkyl groups, lower alkoxy groups, and lower aliphatic acyl groups), still more preferably a C3-Clo cycloalkyl group substituted with from 1 to 3 substituents (said substituent(s) being selected from the group consisting of halogen atoms, lower alkyl groups, halogeno lower alkyl groups, lower alkoxy groups, and lower aliphatic acyl groups), and most preferably a cyclohexyl group substituted with one substituent (said substituent is selected from the group consisting of a fluorine atom, a chlorine atom, methyl, trifluoromethyl, methoxy and acetyl groups).

The "C6-Clo aryl group substituted with from 1 to 3 substituents selected from the group consisting of Substituent group (a) and Substituent group (b)" in the definition of R5 can be, for example, a 2-,3- or 4-fluorophenyl, 2-,3- or 4-chlorophenyl, 2-,3- or 4-bromophenyl, 2-,3- or 4-iodophenyl, 2-,3- or 4-methylphenyl, 2-,3- or 4-ethylphenyl, 2-,3- or 4-propylphenyl, 2-,3- or 4-butylphenyl, 2-,3- or 4-pentylphenyl, 2-,3- or 4-trifluoromethylphenyl, 2-, 3- or 4-methoxyphenyl, 2-, 3- or 4-ethoxyphenyl, 2-, 3- or 4-propoxyphenyl, 2-, 3- or 4-isopropoxyphenyl, 2-, 3- or 4-butoxyphenyl, 2-, 3- or 4-(1-S:/Chemical/Sankyo/FP200301IFP0301 al .doc P87892/FP-0301/corrected pages/gds-mg/02.07.04 ethylpropoxy)phenyl, 2-, 3- or 4-(2-ethylpropoxy)phenyl, 2-,3-or 4-methylthiophenyl, 2-,3- or 4-ethylthiophenyl, 2-,3- or 4-carboxyphenyl, 2-,3- or 4-methoxycarbonylphenyl, 2-,3- or 4-ethoxycarbonylphenyl, 2-,3- or 4-hydroxyphenyl, 2-,3- or 4-formylphenyl, 2-,3- or 4-acetylphenyl, 2-,3- or 4-aminophenyl, 2-,3- or 4-methylaminophenyl, 2-,3- or 4-dimethylaminophenyl, 2-,3- or 4-cyanophenyl, 2-,3- or 4-cyclopentylphenyl, 2-,3- or 4-cyclohexylphenyl, 2-,3- or 4-biphenyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,4-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 3,4-dibromophenyl, 2,3-dimethylphenyl, 3,4-dimethylphenyl, 3,5-dimethylphenyl, 2,3-dimethoxyphenyl, 3,4-dimethoxyphenyl, 3,5-dimethoxyphenyl, 3,4,5-trimethoxyphenyl, 3-fluoro-4-methoxyphenyl, 4-methyl-2-methoxyphenyl, 6-fluoro-4-methyl-2-methoxyphenyl, 5-fluoroinden-3-yl, 5-methylinden-3-yl, 5-methoxyinden-3-yl, 5-fluoroinden-2-yl, 5-chloroinden-2-yl, 5-methylinden-2-yl, 5-methoxyinden-2-yl, 5-hydroxyinden-3-yl, 5-nitroinden-3-yl, 5-cyclohexylinden-3-yl, 5-phenylinden-3-yl, 5-phenoxyinden-3-yl, 5-benzyloxyinden-3-yl, 5-phenylthioinden-3-yl, 5-hydroxyinden-2-yl, 5-nitroinden-2-yl, 5-cyclohexylinden-2-yl, 5-phenylinden-2-yl, 5-fluoronaphthalen-2-yl, 5-methylnaphthalen-2-yl, 5-methoxynaphthalen-2-yl, 5-f luoronaphthalen-l-yl, 5-methylnaphthalen-1-yl, 5-methoxynaphthalen-l-yl, 5-hydroxynaphthalen-2-yl, 5-nitronaphthalen-2-yl, 5-cyclohexylnaphthalen-2-yl, 5-phenylnaphthalen-2-yl, 5-phenoxynaphthalen-2-yl, 5-benzyloxynaphthalen-2-yl, 5-phenylthionaphthalen-2-yl, 5-hydroxynaphthalen-l-yl, 5-nitronaphthalen-l-yl, 5-cyclohexylnaphthalen-l-yl, or 5-phenylnaphthalen-l-yl group, and is preferably a C6-C10 aryl group substituted with from 1 to 3 substituents (said substituent(s) being selected from the group consisting of halogen atoms, lower alkyl groups, halogeno lower alkyl groups, lower alkoxy groups, a lower alkylthio groups, and lower aliphatic acyl groups), more preferably a C6-Clo aryl group substituted with from 1 to 3 substituents (said substituent(s) being selected from the group consisting of halogen atoms, lower alkyl groups, halogeno lower alkyl groups, lower alkoxy S:/Chemical/Sankyo/FP200301/FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 groups, and lower aliphatic acyl groups), still more preferably a phenyl group substituted with from 1 to 3 substituents (said substituent(s) being selected from the group consisting of halogen atoms, lower alkyl groups, halogeno lower alkyl groups, lower alkoxy groups, and lower aliphatic acyl groups), particularly preferably a phenyl group substituted with 1 or 2 substituents (said substituent(s) being selected from the group consisting of fluorine atoms, chlorine atoms, methyl, trifluoromethyl, methoxy and acetyl groups; but, in the case of methoxy group, a phenyl group substituted with from 1 to 3 methoxy groups is preferred), and most preferably a 3-fluorophenyl, 4-fluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 3-methylphenyl, 4-mettylphenyl, 3,4-dimethylphenyl, 3,5-dimethylphenyl, 3-trifluoromethyiphenyl, 4-trifluoromethyiphenyl, 3,4-ditrifluoromethylphenyl, 3,5-ditrifluoromethylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 3,5-dimethoxyphenyl, 3,4,5-trimethoxyphenyl, 3-acetylphenyl, or 4-acetylphenyl group.
The "5- to 7-membered heterocyclic group containing from 1 to 3 heteroatoms selected from the group consisting of a sulfur atom, an oxygen atom, and a nitrogen atom in which said heterocyclic group is substituted with from 1 to 3 substituents selected from the group consisting of Substituent group (a) and Substituent group (b)" in the definition of R5 can be, for example, a 3-,4- or 5-methylfuran-2-yl, 2-,4- or 5-methylfuran-3-yl, 3-,4- or 5-fluorothiophen-2-yl, 2-,4- or 5-fluorofuran-3-yl, 3-,4- or 5-bromothiophen-2-yl, 2-,4- or 5-bromofuran-3-yl, 3-,4- or 5-methylthiophen-2-yl, 2-,4- or 5-methylthiophen-3-yl, 3-,4- or 5-ethylthiophen-2-yl, 2-,4- or 5-ethylthiophen-3-yl, 3-,4- or 5-methoxythiophen-2-yl, 2-,4-or 5-methoxythiophen-3-yl, 3- or 4-methylthiazol-5-yl, 3-,4-or 5-fluorobenzothiophen-2-yl, 3-,4- or 5-bromobenzothiophen-2-yl, 3-,4- or 5-methylbenzothiophen-2-yl, 3-,4- or 5-methoxybenzothiophen-2-yl, 2-,4- or 5-fluorobenzothiophen-3-yl, 2-,4- or 5-bromobenzothiophen-3-yl, 2-,4- or 5-S:/Chemical/Sankyo/FP200301/FP0301s.doc P87892/FP-0301/Description/gds-mg/30.06.04 methylbenzothiophen-3-yl, 2-,4- or 5-methoxybenzothiophen-3-yl, 4-,5-,6- or 7-methylbenzothiophen-2-yl, 3-,4- or 5-hydroxyfuran-2-yl, 2-,4- or 5-hydroxyfuran-3-yl, 3-,4- or 5-hydroxythiophen-2-yl, 3-,4- or 5-nitrothiophen-2-yl, 3-,4- or 5-phenylthiophen-2-yl, 2-,4- or 5-hydroxythiophen-3-yl, 2-,4-or 5-cyanothiophen-3-yl, l-,2- or 3-hydroxypyridin-4-yl, l-,2-or 3-cyanopyridin-4-yl, or l-,2- or 3-phenylpyridin-4-yl group, and is preferably a 3-,4- or 5-fluorothiophen-2-yl or 2-,4- or 5-fluorofuran-3-yl group.

The "pharmacologically acceptable salt thereof" means a salt which, when the compounds of general formula (I), (II), or (III) of the present invention have a basic group such as an amino group, can be prepared by reacting the compounds with an acid, and when the compounds of general formula (I), (II), or (III) of the present invention have an acidic group such as a carboxyl group or a phosphate group, can be prepared by reacting the compounds with a base.

The salt, when the compounds of general formula (I), (II), or (III) have a basic group, can be an inorganic acid salt, for example, a hydrohalide such as hydrofluoride, hydrochloride, hydrobromide, or hydroiodide, a nitrate, a perchlorate, a sulfate, a phosphate or the like; an organic acid salt, for example, a lower alkanesulfonate such as methanesulfonate, trifluoromethanesulfonate, or ethanesulfonate, an arylsulfonate such as benzenesulfonate or p-toluenesulfonate, an acetate, a malate, a fumarate, a succinate, a citrate, an ascorbate, a tartrate, an oxalate, a maleate, or the like; or an amino acid salt such as glycine salt, lysine salt, arginine salt, ornithine salt, glutamic acid salt, or aspartic acid salt. The salt is preferably an organic acid salt (particularly fumarate, oxalate or maleate) or a hydrohalide (particularly hydrochloride).

The salt, when the compounds of general formula (I), (II), S:/ChemicaUSankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 or (III) have an acidic group, can be a metal salt, for example, an alkali metal salt such as sodium salt, potassium salt, or lithium salt, an alkaline earth metal salt such as calcium salt or magnesium salt, an aluminum salt, an iron salt, or the like; an amine salt, for example, an inorganic amine salt such as ammonium salt, an organic amine salt such as t-octylamine salt, dibenzylamine salt, morpholine salt, glucosamine salt, phenylglycine alkyl ester salt, ethylenediamine salt, N-methylglucamine salt, guanidine salt, diethylamine salt, triethylamine salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, chloroprocaine salt, procaine salt, diethanolamine salt, N-benzylphenethylamine salt, piperazine salt, tetramethylammonium salt, tris(hydroxymethyl)aminomethane salt, or the like; or an amino acid salt such as glycine salt, lysine salt, arginine salt, ornithine salt, glutamic acid salt, or aspartic acid salt. The salt preferably is an alkali metal salt (particularly sodium salt).

When the compounds of general formula (I), (II), or (III), pharmacologically acceptable salts thereof, or pharmacologically acceptable esters thereof of the present invention are allowed to stand in contact with the atmosphere or to recrystallize, they may absorb water or water may attach to them to form a hydrate. The present invention encompasses such hydrates.

The compounds of general formula (I), (II), or (III), pharmacologically acceptable salts, or pharmacologically acceptable esters thereof of the present invention have one or more asymmetric carbon atoms in their structures, and can exist as optical isomers due to such asymmetric carbon atoms.
In the present invention, a single optical isomer and mixtures of optical isomers are represented as a single chemical formula (I), (II), or (III) individually. The present invention encompasses both individual optical isomers and mixtures thereof in any ratio.

S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description1gds-mg/30.06.04 The preferred compounds of general formula (I), (II), or (III) of the present invention have a group of formula -NR'R2 attached to an asymmetric carbon atom and the absolute configuration at this asymmetric carbon atom is the R
configuration.

The "ester thereof" described above indicates an ester of compounds of general formula (I), (II), or (III) of the present invention which have a group capable of being esterified. The ester can be an "ester of a hydroxyl group" or an "ester of a carboxyl group". Each ester residual group belongs to a "general protecting group in chemical reactions"
or a "protecting group which can be cleaved by a biological process such as hydrolysis in vivo".

The "general protecting group in chemical reactions" is a protecting group which can be cleaved by a chemical process such as hydrogenolysis, hydrolysis, electrolysis, and photolysis.

The "general protecting group in chemical reactions" and the "protecting group which can be cleaved by a biological process such as hydrolysis in vivo" related to the "ester of a hydroxyl group" have the same meanings as those described above for the "protecting group of the hydroxyl group".

The "general protecting group in chemical reactions"
related to the "ester of a carboxyl group" is preferably a "lower alkyl group" described above; a lower alkenyl group such as ethenyl, 1-propenyl, 2-propenyl, 1-methyl-2-propenyl, 1-methyl-l-propenyl, 2-methyl-l-propenyl, 2-methyl-2-propenyl, 2-ethyl-2-propenyl, 1-butenyl, 2-butenyl, 1-methyl-2-butenyl, 1-methyl-l-butenyl, 3-methyl-2-butenyl, 1-ethyl-2-butenyl, 3-butenyl, 1-methyl-3-butenyl, 2-methyl-3-butenyl, 1-ethyl-3-butenyl, 1-pentenyl, 2-pentenyl, 1-methyl-2-pentenyl, 2-methyl-2-pentenyl, 3-pentenyl, 1-methyl-3-pentenyl, 2-methyl-3-pentenyl, 4-pentenyl, 1-methyl-4-pentenyl, 2-methyl-4-S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, or 5-hexenyl; a lower alkynyl group such as ethynyl, 2-propynyl, 1-methyl-2-propynyl, 2-butynyl, 1-methyl-2-butynyl, 1-ethyl-2-butynyl, 3-butynyl, 1-methyl-3-butynyl, 2-methyl-3-butynyl, 1-ethyl-3-butynyl, 2-pentynyl, 1-methyl-2-pentynyl, 3-pentynyl, 1-methyl-3-pentynyl, 2-methyl-3-pentynyl, 4-pentynyl, 1-methyl-4-pentynyl, 2-methyl-4-pentynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, or 5-hexynyl; a "halogeno lower alkyl group"
described above; a hydroxy "lower alkyl group" such as 2-hydroxyethyl, 2,3-dihydroxypropyl, 3-hydroxypropyl, 3,4-dihydroxybutyl, or 4-hydroxybutyl; a "lower aliphatic acyl"-"lower alkyl group" such as acetylmethyl; an "aralkyl group"
described above; or a "silyl group" described above.

The "protecting group which can be cleaved by a biological process such as hydrolysis in vivo" related to the "ester of a carboxyl group" is preferably an "alkoxyalkyl group" such as a lower alkoxy lower alkyl group, e.g., methoxyethyl, 1-ethoxyethyl, 1-methyl-l-methoxyethyl, 1-(isopropoxy)ethyl, 2-methoxyethyl, 2-ethoxyethyl, ethoxymethyl, n-propoxymethyl, isopropoxymethyl, n-butoxymethyl, or t-butoxymethyl, a lower alkoxylated lower alkoxy lower alkyl group, e.g., 2-methoxyethoxymethyl, an "aryl"oxy "lower alkyl group", e.g., phenoxymethyl, or a halogenated lower alkoxy lower alkyl group, e.g., 2,2,2-trichloroethoxymethyl or bis(2-chloroethoxy)methyl; a "lower alkoxy"carbonyl"lower alkyl group" such as methoxycarbonylmethyl; a cyano "lower alkyl group" such as cyanomethyl or 2-cyanoethyl; a "lower alkyl"
thiomethyl group such as methylthiomethyl or ethylthiomethyl;
an "aryl" thiomethyl group such as phenylthiomethyl or naphthylthiomethyl; a "lower alkyl" sulfonyl "lower alkyl group" which may be substituted with one or more halogen atoms such as 2-methanesulfonylethyl or 2-trifluoromethanesulfonylethyl; an "aryl" sulfonyl "lower alkyl group" such as 2-benzenesulfonylethyl or 2-S:/Chemical/Sankyo/FP200301 /FP0301 a l .doc P87892/FP-0301 /corrected pages/gds-mg/02.07.04 toluenesulfonylethyl; a 1-(acyloxy)"lower alkyl group"
described above; a "phthalidyl group" described above;
an "aryl group" described above; a "lower alkyl group"
described above; a "carboxyalkyl group" such as carboxymethyl;
or an "amide forming residual group of an amino acid" such as phenylalanine.

The more preferred "general protecting group in chemical reactions" and "protecting group which can be cleaved by a biological process such as hydrolysis in vivo" related to the "ester of a carboxyl group" described above is a lower alkyl or aralkyl group.

"Immunosuppressants", which are an active ingredient of pharmaceutical compositions of the present invention, are agents preventing or inhibiting the progression of immune responses as well as compounds with immunosuppressive activity, and are classified into the following groups on the basis of mechanism of action:
(1) agents which have the action of inhibiting intracellular signal transduction involved in cytokine expression of T-cells, include those blocking cytokine production as well as those preventing cytokine signaling from acting on immune cells by inhibiting the intracellular signal transduction. Such agents, which have the action of inhibiting the intracellular signal transduction involved in cytokine expression of T-cells, include, for example, S7481/F-1 or a pharmacologically acceptable salt thereof disclosed in the specification of U.S. Patent Number 4,117,118 [preferably cyclosporin A, of which the chemical name is cyclo[3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl]-2-aminobutyryl-methylglycyl-methyl-leucyl-valyl-methyl-leucyl-alanyl-alanyl-methyl-leucyl-methyl-leucyl-methyl-valyl.], a compound having the general formula (I) or a pharmacologically acceptable salt thereof disclosed in the specification of E.P. Publication Number 184,162 {preferably tacrolimus, of which the chemical name is 17-allyl-1,14-S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.04'9]octacos-18-ene-2,3,10,16-tetrone.}, rapamycin disclosed in the specification of U.S. Patent Number 3,929,992 [of which the chemical name is 9,10,12,13,14,21,22,23,24,25,26,27,32,33,34, 34a-hexadecahydro-9,27-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H, 6H, 31H)-pentone.], a compound having the general formula (II) or a pharmacologically acceptable salt thereof disclosed in the specification of E.P. Publication Number 94,632 (Japanese Patent Publication (Kokai) Number Sho 58-62152) [preferably gusperimus, of which the chemical name is N-[4-(3-aminopropyl)aminobutyl1 carbamoylhydroxymethyl-7-guanidinoheptanamide, and in the present invention gusperimus includes a pharmacologically acceptable salt (trihydrochloride) thereof.], a compound having the general formula (I) or a pharmacologically acceptable salt thereof disclosed in the specification of U.S. Patent Number 5,912,253 {preferably everolimus, of which the chemical name is 9,10,12,13,14,21, 22, 23, 24, 25, 26, 27, 32, 33, 34, 34a-hexadecahydro-9,27-dihydroxy-3-[2-[4-hydroxyethoxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]azacyclohentriacontine-1,5,11,28,29(4H, 6H, 31H)-pentone.}, a compound having the general formula (I) or a pharmacologically acceptable salt thereof disclosed in the specification of E.P. Publication Number 600,762 {preferably tresperimus, of which the chemical name is 2-[4-(3-aminopropylamino)butyl]aminocarbonyloxy-N-[6-(aminoiminomethyl)aminohexyl]acetamide, and in the present invention tresperimus includes a pharmacologically acceptable salt thereof.}, S:/ChemicallSankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 LF15-0195 disclosed in Int. J. Immunopharmacol., vol. 21 (5), 349-358 (1999) {anisperimus, of which the chemical name is [(6-guanidinohexyl)carbamoyl]methyl[4-(3-aminobutyl)aminobutyl]carbamate.}, a compound having the general formula (I) or a pharmacologically acceptable salt thereof disclosed in the specification of E.P. Publication Number 626,385 (Japanese Patent Number 3076724 or U.S. Patent Number 5,493,019) {preferably SDZ-281-240, of which the chemical name is 17-ethyl-1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.09'9]octacos-18-ene-2,3,10,16-tetrone, and in the present invention SDZ-281-240 includes a pharmacologically acceptable salt thereof.}, a compound having the general formula (VII) or a pharmacologically acceptable salt thereof disclosed in the specification of WO Publication Number 93/04680 (E.P.
Publication Number 642,516) {preferably ABT-281, of which the chemical name is 17-ethyl-1,14-dihydroxy-12-[2-(4-tetrazolyl-3-methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.09'9]octacos-18-ene-2,3,10,16-tetrone.}, a compound having the general formula (A) or a pharmacologically acceptable salt thereof disclosed in the specification of E.P. Publication Number 414,632 {preferably tigderimus, of which the chemical name is cyclo[[3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl]-L-2-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-[3-0-(2-hydroxyethyl)-D-seryl]-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl.], a compound having the general formula (I) or a pharmacologically acceptable salt thereof disclosed in the specification of WO Publication Number 97/11080 {preferably A-119435, of which the chemical name is 17-ethyl-1,14-dihydroxy-12-[2-[4-(acetylaminoacetylthio)-3-methoxycyclohexyl]-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.04"]octacos-l8-ene-2,3,10,16-S:/ChemicaVSankyo/FP200301/FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 tetrone.}, and 17-ethyl-1,14-dihydroxy-12-[2-[4-(2-phenylhydrazinocarbonyloxy)-3-methoxycyclohexyl]-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.04'9]octacos-18-ene-2,3,10,16-tetrone disclosed in Bioorg. Med. Chem. Lett., vol. 9 (2), 227-232 (1999).

The planar chemical structures of the typical compounds are shown below.

S:/Chemica(/Sankyo/FP20030I /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 OH
I ~O
OHO O

N N
/N ON
0--c O NTO
N N N C? CH2 N 0 0 O Bp dl-TN i O

cyclosporin A tacrolimus p 00 N 0 O
\ \\ OOO N p p0 0 OH

I I OH
p p __O

OH I
rapamycin everolimus H O O NH
H2 N'---~N N N N NH2 H O H H

gusperimus H2N,,,,-,,_,N N)LO N NA NH2 tresperimus S:/Chemical/Sankyo/FP200301/FP0301al.doc P87892/FP-0301/corrected pages/gds-mg/02.07.04 NH H O H
H N~N N O~N CH3 H

anisperimus /=N
off N,,N,N
'~IO
O
Ci-O

OH O O"
/O O O

HO

N i N N
O
O
O O
0 , N\

N/ H N N
N N H

O
O
O

OH tigderimus S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 N
O Zy /
~-N
H
N
O O
S

N O O
40 p O
O OH
N fOH
O OH
OH
O
O

,- O /OO
17-ethyl-1,14-dihydroxy-12-[2-[4-A-119435 (2-phenyihydrazinocarbonyloxy)-3-methoxycyclohexyl]-1-methylvinyl]
-23,25-dimethoxy-13,19,21,27-tetr amethyl-11,28-dioxa-4-azatricyclo [22.3.1.04,9)octacos-18-ene-2,3,1 0,16-tetrone.

(2) Agents which have the action of inhibiting nucleoside synthesis in immune cells, depress lymphocytic proliferation by inhibiting nucleoside synthesis in the immune cells and show nonspecific immunosuppressive activity. Such agents, which have the action of inhibiting nucleoside synthesis in the immune cells, include, for example, a compound having the chemical structure disclosed in claim 1 of U.S. Patent Number 3,888,843 (mizoribine, of which the chemical name is 5-hydroxy-l-(3-D-ribofuranosyi-lH-imidazole-4-carboxamide.), a compound having the general formula disclosed in claim 7 of U.S. Patent Number 3,056,785 or a pharmacologically acceptable salt thereof [preferably azathioprine, of which the chemical name is 6-[(1-methyl-4-nitro-lH-imidazol-5-yl)thio]-1H-purine, and in the present invention azathioprine includes a pharmacologically acceptable salt (hydrochloride) thereof.], a compound having the general formula (A) or a pharmacologically acceptable salt thereof disclosed in the S:/Chemical/Sankyo/FP20030I /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 = CA 02473461 2004-07-12 specification of E.P. Publication Number 281,713 (U.S. Patent Number 4,753,935) [preferably mycophenolate Mofetil, of which the chemical name is 2-(4-morpholinyl)ethyl 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-(4E)-hexenoate.], a compound having the general formula (I) or a pharmacologically acceptable salt thereof disclosed in the specification of E.P. Publication Number 13376 (Japanese Patent Publication (Kokai) Number Sho 62-72614 or U.S. Patent Number 4,284,786) [preferably leflunomide, of which the chemical name is 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide.], a compound having the general formula (I) or a pharmacologically acceptable salt thereof disclosed in the specification of WO Publication Number 97/40028 {preferably merimempodib, of which the chemical name is (3s)-tetrahydro-3-furanyl [[3-[[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]carbonyl]amino]phenyl]methyl]carbamate.}, a compound having the general formula (I) or a pharmacologically acceptable salt thereof disclosed in the specification of FR Patent Publication Number 2,727,628 [preferably HMR-1279, of which the chemical name is a-cyano-N-(4-cyanophenyl)-(3-oxo-cyclopropanepropaneamide.], a compound having the general formula (I) or a pharmacologically acceptable salt thereof disclosed in the specification of WO Publication Number 93/22286 (Japanese Patent Number 2,928,385, E.P. Publication Number 601,191 or U.S. Patent Number 5,371,225) {preferably TSK-204, of which the chemical name is 6,7-dihydro-10-fluoro-3-(2-fluorophenyl)-5H-benzo[6,7]cyclohepta[1,2-b]quinoline-8-carboxylic acid.}, and a compound having the general formula (I) or a pharmacologically acceptable salt thereof disclosed in the specification of E.P. Publication Number 569,912 (Japanese Patent Publication (Kokai) Number Hei 6-32784) {preferably SP-100030, of which the chemical name is 2-chloro-N-[3,5-di(trifluoromethyl)phenyl]-4-(trifluoromethyl)pyrimidine--5-S:/ChemicaVSankyo/FP20030I /FP0301 a I .doc P87892/FP-0301 /corrccted pages/gds-mg/02.07.04 carboxyamide.}.
The planar chemical structures of the typical compounds are shown below.

S:/Chemical/Sankyo/FP20030 I IFP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 O

H+ \N=

OH
O N O_ l/N S O
O
HO H3C N ( O O
O
HO OH LN N I
H

mizoribine azathioprine mycophenolate Mofetil H H O
H ON O N N ~O
N I I y N O
I O O H
F O N

F F

leflunomide merimempodib F
N
O O /

HO N
H
it O F
F Y

N C~ TSK-204 F
F H
N /N

F
F F
F

(3) Agents which inhibit the action of cytokines on immune cells and have antirheumatic action, have the combination of suppression of cytokine production, suppression of lymphocytic S:/Chemical/Sankyo/FP200301/FP0301al.doc P87892/FP-0301/corrected pages/gds-mg/02.07.04 proliferation, and suppression of immunoglobulin production.
Furthermore, the agents include compounds having suppressive action on T-cell proliferation, suppression of NK cell activity, TNF-receptor antagonistic action, and the like.
Such agents, which inhibit the action of cytokine on immune cells and have antirheumatic action, include, for example, a compound having the general formula disclosed in claim (1) of Japanese Patent Publication (Kokai) Number Hei 2-49778 or a pharmacologically acceptable salt thereof (preferably T-614, of which the chemical name is N-[3-formylamino-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl]methanesulfonamide.), a compound having the general formula (I) disclosed in the specification of U.S. Patent Number 4,720,506 or a pharmacologically acceptable salt thereof [preferably actarit, of which the chemical name is 4-(acetylamino)phenylacetic acid.], a compound having the general formula disclosed in claim 1 of U.S. Patent Number 2,396,145 or a pharmacologically acceptable salt thereof {preferably salazosulfapyridine, of which the chemical name is 5-[[p-(2-pyridylsulfamoyl)-phenyl]azo]salicylic acid.}, and a compound having the general formula (I) disclosed in the specification of WO Publication Number 97/23457 {preferably CDC-801, of which the chemical name is 3-phthalimido-3-(3-cyclopentyloxy-4-methoxyphenyl) propionamide.}.

The planar chemical structures of the typical compounds are shown below.

S:/Chemical/Sankyo/FP20030I /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 HO
0=5=0 O NH H
O
H O

T-614 actarit O O "N N
0 cI7-HO
I / / ( N
N-N 0Ho salazosulfapyridine CDC-801 (4) Agents which are alkylating agents causing cell death by breakdown of DNA chains or blocking DNA synthesis, include, for example, a compound having the general formula (IIIa) or a pharmacologically acceptable salt thereof disclosed in the specification of U.S. Patent Number 3,018,302 [preferably cyclophosphamide, of which the chemical name is N,N'-bis-(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide.].

S:/ChemicaUSankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 CI~'OF~N~^Cj NHO

cyclophosphamide (5) Metabolic antagonists, which inhibit the metabolism of nucleic acids by blocking folic acid production, have the action of inhibiting the metabolism of nucleic acids by binding to dihydrofolate reductases and blocking the production of tetrahydrofolic acids that are essential to the synthesis of components of nucleic acids. Such metabolic antagonists, which inhibit the metabolism of nucleic acids by blocking folic acid production, include, for example, a compound having the general formula disclosed in claim 1 of U.S. Patent Number 2,512,572 or a pharmacologically acceptable salt thereof {preferably methotrexate, of which the chemical name is N-{4-[[2,4-diamino-6-pteridinyl]methyl]methylamino] benzoyl-L-glutamic acid.}.

N
I N

O
O OH
methotrexate (6) The group of protein drugs, which have the suppression action of TNF-alpha, includes compounds such as IL-1 receptor antagonists, soluble IL-1 receptors, and anti-IL-6 receptor antibodies, which suppress the action of TNF-alpha by inhibiting the neutralizing action of circulating TNF-alpha and its receptor-mediated intracellular TNF-alpha signaling.
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 Such protein drugs, which have the inhibitory action of TNF-alpha, include, for example, remicade (infliximab) disclosed in the specification of U.S. Patent Number 5,656,272 and Drugs, vol. 59(6), 1341-1359 (2000), enbrel (etanercept) disclosed in the specification of WO
Publication Number 94/06,476, U.S. Patent Number 5,605,690, and Expert. Opin. Pharmacother., July vol. 2(7), 1137-1148 (2000), daclizumab disclosed in the specification of WO
Publication Number 92/11,018, U.S. Patent Number 5,530,101, and N. Engl. J. Med., vol. 338(3), 161-165 (1997), basiliximab disclosed in the specification of E.P.
Publication Number 449,769 and Clin. Pharmacol. Ther., Vol.
64(1), 66-72 (1998), alemtuzumab disclosed in the specification of WO
Publication Number 89/07,452, U.S. Patent Number 5,846,534, and J. Clin. Oncol., vol. 15(4), 1567-1574 (1997), omalizumab disclosed in the specification of U.S. Patent Number 5,965,709 and Drugs vol. 61(2), 253-260 (2001), BMS-188667 disclosed in the specification of E.P.
Publication Number 613,944 and J. Pharm. Sci., vol. 84(12), 1488-1489 (1995), CDP-571 disclosed in Arthritis-Rheum., vol. 37(9), Suppl., S295 (1994), inolimomab and ATM-027 disclosed in Transplant., June, vol.
55, 1320-1327 (1993), and BTI-322 disclosed in Blood, Dec 1, vol. 92(11), 4066-4071 (1998).

(7) Agents which are steroid hormone agents that bind to intracellular steroid receptors to form a complex which binds to reaction sites on chromosomes, resulting in the synthesis of proteins which show immunosuppressive activity, include, for example, prednisolone (of which the chemical name is 1,4-pregnadiene-3,20-dione-11(3,17(x-21-triol.).
S:/ChemicaVSankyo/FP20030I/FP030IaI.doc P87892/FP-0301/corrected pages/gds-mg/02.07.04 OH
O

HO OH
O

prednisolone (8) Agents which are substances suppressing prostaglandin production and/or nonsteroidal anti-inflammatory drugs antagonizing the action of prostaglandin, include, for example, a compound having the general formula disclosed in claim 1 of Japanese Patent Publication (Kokoku) Number Sho 58-4699 or a pharmacologically acceptable salt thereof {preferably loxoprofen sodium, of which the chemical name is sodium 2-[4-(2-oxocyclopentan-l-ylmethyl)phenyl]propionate.}, a compound having the general formula I(A) or a pharmacologically acceptable salt thereof disclosed in the specification of U.S. Patent Number 3,558,690 {preferably diclofenac sodium, of which the chemical name is sodium [o-(2, 6-dichloroanilino)phenyl]acetate.}, a compound having the general formula (I) or a pharmacologically acceptable salt thereof disclosed in the specification of U.S. Patent Number 4,233,299 (E.P.
Publication Number 0,002,482 or Japanese Patent Publication (Kokai) Number Sho 58-92976) [preferably meloxicam, of which the chemical name is 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-l,2-benzothiazine-3-carboxamide 1,1-dioxide.], a compound having the general formula (II) or a pharmacologically acceptable salt thereof disclosed in the specification of WO Publication Number 95/15316 (U.S. Patent Number 5,521,207 or Japanese Patent Publication (Kokai) Number 2000-109466) {preferably celecoxib, of which the chemical name is 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-l-yl]benzenesulfonamide.}, and S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 a compound having the general formula (I) or a pharmacologically acceptable salt thereof disclosed in the specification of WO Publication Number 95/00501 (U.S. Patent Number 5,474,995) {preferably rofecoxib, of which the chemical name is 4-[4-(methylsulfonyl)phenyl}-3-phenyl-2(5H)-furanone.}.

0 COONa CI
I \ \
COONa I I
~ CI

loxoprofen sodium diclofenac sodium O,\ /O
O
O

N
H N~,N\ CF3 N ii CH3 Lrhyiy OH O N meloxicam C

celecoxib O S/O

O

rofecoxib Of the above immunosuppressants, more preferred are cyclosporin A, tacrolimus, rapamycin, leflunomide, methotrexate, remicade and enbrel.

S:/ChemicaVSankyo/FP200301/FP0301s.doc P87892/FP-0301/Description/gds-mg/30.06.04 The "pharmacologically acceptable salt thereof" described above means a salt into which the above immunosuppressants can be converted, by reacting a compound having a basic group such as an amino group with an acid or by reacting a compound having an acidic group such as a carboxyl group with a base.
Such salts are included in the present invention.

The salt formed with a basic group of the above immunosuppressants is preferably an inorganic acid salt, for example, a hydrohalide such as hydrofluoride, hydrochloride, hydrobromide, or hydroiodide, a nitrate, a perchlorate, a sulfate, a phosphate or the like; an organic acid salt, for example, a lower alkanesulfonate such as methanesulfonate, trifluoromethanesulfonate, or ethanesulfonate, an arylsulfonate such as benzenesulfonate or p-toluenesulfonate, an acetate, a malate, a fumarate, a succinate, a citrate, an ascorbate, a tartrate, a oxalate, a maleate, or the like; or an amino acid salt such as glycine salt, lysine salt, arginine salt, ornithine salt, glutamate, or aspartic acid salt. The salt is more preferably hydrochloride, acetate, fumarate, succinate, or maleate.

The salt formed with an acidic group of the above immunosuppressants is preferably a metal salt, for example, an alkali metal salt such as sodium salt, potassium salt, or lithium salt, an alkaline earth metal salt such as calcium salt or magnesium salt, an aluminum salt, an iron salt, or the like; an amine salt, for example, an inorganic salt such as ammonium salt, an organic acid salt such as t-octylamine salt, dibenzylamine salt, morpholine salt, glucosamine salt, phenylglycine alkyl ester salt, ethylenediamine salt, N-methylglucamine salt, guanidine salt, diethylamine salt, triethylamine salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, chloroprocaine salt, procaine salt, diethanolamine salt, N-benzylphenethylamine salt, piperazine salt, tetramethylammonium salt, tris(hydroxymethyl)aminomethane salt, or the like; or an amino S:/Chemica]/Sankyo/FP20030 ] /FP0301 s.doc P87892/FP-030 ] /Description/gds-mg/30.06.04 acid salt such as glycine salt, lysine salt, arginine salt, ornithine salt, glutamic acid salt, or aspartic acid salt. The salt is more preferably sodium salt, potassium salt, calcium salt, magnesium salt, or aluminum salt.

When the immunosuppressants, the active ingredients of the pharmaceutical compositions of the present invention, are allowed to stand in contact with the atmosphere or to recrystallize, they may absorb water or water may attach to them to form a hydrate. The present invention encompasses such hydrates.

When the immunosuppressants, the active ingredients of the pharmaceutical compositions of the present invention, have asymmetric carbons in their structures, these compounds can exist as various stereoisomers due to such asymmetric carbons.
In the present invention these compounds are represented as a single chemical formula individually. The present invention encompasses both individual stereoisomers and mixtures of two or more stereoisomers in any ratio.

Compounds shown in the following Table 1, Table 2, Table 3, Table 4, Table 5 and Table 6 are specifically illustrated as preferred compounds of general formula (I), (II), or (III) of the present invention. However, the compounds of the present invention are not limited to these.

The compounds represented by the same compound number in Table 1 and Table 2 include compounds wherein X is a sulfur atom (S), an oxygen atom (0), or a group of formula =N-CH3.

The compounds represented by the same compound number in Table 5 and Table 6 include the six types of compounds wherein X is a sulfur atom (S), an oxygen atom (0), or a group of formula =N-CH3, and the phosphate group is linked to an oxygen atom (0) or a -CH2- group.

S:/Chemical/Sankyo/FP200301/FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 The meaning of the abbreviations in the following Tables is shown below.
Bu represents a butyl group, iBu represents a isobutyl group, Bz represents a benzyl group, Et represents an ethyl group, cHx represents a cyclohexyl group, Me represents a methyl group, Np(1) represents a naphthalen-1-yl group, Np(2) represents a naphthalen-2-yl group, Ph represents a phenyl group, cPn represents a cyclopentyl group, Pr represents a propyl group, and iPr represents an isopropyl group.

S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 Table 1 R 301-1 (CH2)n Y-Z-R 5 , R3O(CH2)n I N\ Y-Z-RS

(la-1) (la-2) or (CH2)n / \ Y-Z-R5 S

(la-3) Compd. R R R R4 n -Y-Z-R R R
1-1 H H H Me 2 - (CH2) 3-cHx H H
1-2 H H H Me 2 - (CH2) 3- (4-F-cHx) H H
1-3 H H H Me 2 - (CH2) 3- (4-Me-cHx) H H
1-4 H H H Me 2 - (CH2) 3- (4-Et-cHx) H H
1-5 H H H Me 2 - (CH2) 3- (4-CF3-cHx) H H
1-6 H H H Me 2 - (CH2) 3- (4-MeO-cHx) H H
1-7 H H H Me 2 - (CH2) 3- (4-EtO-cHx) H H
1-8 H H H Me 2 - (CH2) 3- (4-MeS-cHx) H H
1-9 H H H Me 2 - (CH2) 3- (4-cHx-cHx) H H
1-10 H H H Me 2 - (CH2) 3- (4-Ph-cHx) H H
1-11 H H H Me 2 - (CH2) 3-Ph H H
1-12 H H H Me 2 - (CH2) 3- (4-F-Ph) H H
1-13 H H H Me 2 - (CH2) 3- (4-Me-Ph) H H
1-14 H H H Me 2 - (CH2) 3- (4-Et-Ph) H H
1-15 H H H Me 2 - (CH2) 3- (4-CF3-Ph) H H
1-16 H H H Me 2 - (CH2) 3- (4-MeO-Ph) H H
1-17 H H H Me 2 - (CH2) 3- (4-EtO-Ph) H H
1-18 H H H Me 2 - (CH2) 3- (4-MeS-Ph) H H
1-19 H H H Me 2 - (CH2) 3- (4-cHx-Ph) H H
S:/Chemicat/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 1-20 H H H Me 2 - (CH2) 3- (4-Ph-Ph) H H
1-21 H H H Me 2 - (CH2) 4-cHx H H
1-22 H H H Me 2 - (CH2) 4- (4-F-cHx) H H
1-23 H H H Me 2 - (CH2) 4- (4-Me-cHx) H H
1-24 H H H Me 2 - (CH2) 4- (4-Et-cHx) H H
1-25 H H H Me 2 - (CH2) 4- (4-CF3-cHx) H H
1-26 H H H Me 2 - (CH2) 4- (4-MeO-cHx) H H
1-27 H H H Me 2-(CH2)4-(4-EtO-cHx) H H
1-28 H H H Me 2 - (CH2) 4- (4-MeS-cHx) H H
1-29 H H H Me 2 - (CH2) 4- (4-cHx-cHx) H H
1-30 H H H Me 2 - (CH2) 4- (4-Ph-cHx) H H
1-31 H H H Me 2 - (CH2) 4-Ph H H
1-32 H H H Me 2 - (CH2) 4- (4-F-Ph) H H
1-33 H H H Me 2 - (CH2) 4- (4-Me-Ph) H H
1-34 H H H Me 2 - (CH2) 4- (4-Et-Ph) H H
1-35 H H H Me 2 - (CH2) 4- (4-CF3-Ph) H H
1-36 H H H Me 2 - (CH2) 4- (4-MeO-Ph) H H
1-37 H H H Me 2 - (CH2) 4- (4-EtO-Ph) H H
1-38 H H H Me 2 - (CH2) 4- (4-MeS-Ph) H H
1-39 H H H Me 2 - (CH2) 4- (4-cHx-Ph) H H
1-40 H H H Me 2 - (CH2) 4- (4-Ph-Ph) H H
1-41 H H H Me 2 - (CH2) 5-cPn H H
1-42 H H H Me 2 - (CH2) 5-cHx H H
1-43 H H H Me 2 - (CH2) 5-cHx Me H
1-44 H H H Me 2 - (CH2) 5-cHx H Me 1-45 H H H Me 2 - (CH2) 5-cHx F H
1-46 H H H Me 2 - (CH2) 5-cHx H F
1-47 H H H Me 2 - (CH2) 5- (3-F-cHx) H H
1-48 H H H Me 2 - (CH2) 5- (4-F-cHx) H H
1-49 H H H Me 2 - (CH2) 5- (4-Cl-cHx) H H
1-50 H H H Me 2 - (CH2) 5- (4-Br-cHx) H H
1-51 H H H Me 2 - (CH2) 5- (3-Me-cHx) H H
1-52 H H H Me 2 - (CH2) 5- (4-Me-cHx) H H
1-53 H H H Me 2 - (CH2) 5- (3-Et-cHx) H H
1-54 H H H Me 2 - (CH2) 5- (4-Et-cHx) H H
1-55 H H H Me 2 - (CH2) 5- (3-Pr-cHx) H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 1-56 H H H Me 2 - (CH2) 5- (4-Pr-cHx) H H
1-57 H H H Me 2 - (CH2) 5- (4-iPr-cHx) H H
1-58 H H H Me 2 - (CH2) 5- (3-Bu-cHx) H H
1-59 H H H Me 2 - (CH2) 5- (4-Bu-cHx) H H
1-60 H H H Me 2 - (CH2) 5- (3-CF3-cHx) H H
1-61 H H H Me 2 - (CH2) 5- (4-CF3-cHx) H H
1-62 H H H Me 2 - (CH2) 5- (3-MeO-cHx) H H
1-63 H H H Me 2 - (CH2) 5- (4-MeO-cHx) H H
1-64 H H H Me 2 - (CH2) 5- (3-EtO-cHx) H H
1-65 H H H Me 2 - (CH2) 5- (4-EtO-cHx) H H
1-66 H H H Me 2 - (CH2) 5- (3-PrO-cHx) H H
1-67 H H H Me 2 - (CH2) 5- (4-PrO-cHx) H H
1-68 H H H Me 2 - (CH2) 5- (3-iPrO-cHx) H H
1-69 H H H Me 2 - (CH2) 5- (4-iPrO-cHx) H H
1-70 H H H Me 2 - (CH2) 5- [ 3- (2-Et-PrO) -cHx] H H
1-71 H H H Me 2 - (CH2) 5- [4- (2-Et-PrO) -cHx] H H
1-72 H H H Me 2 - (CH2) 5- (3-iBuO-cHx) H H
1-73 H H H Me 2 - (CH2) 5- (4-iBuO-cHx) H H
1-74 H H H Me 2 - (CH2) 5- (3-MeS-cHx) H H
1-75 H H H Me 2 - (CH2) 5- (4-MeS-cHx) H H
1-76 H H H Me 2 - (CH2) 5- (3-EtS-cHx) H H
1-77 H H H Me 2 - (CH2) 5- (4-EtS-cHx) H H
1-78 H H H Me 2 - (CH2) 5- (3-PrS-cHx) H H
1-79 H H H Me 2 - (CH2) 5- (4-PrS-cHx) H H
1-80 H H H Me 2 - (CH2) 5- (3-iPrS-cHx) H H
1-81 H H H Me 2 - (CH2) 5- (4-iPrS-cHx) H H
1-82 H H H Me 2 - (CH2) 5- [3- (2-Et-PrS) -cHx] H H
1-83 H H H Me 2 - (CH2) 5- [4- (2-Et-PrS) -cHx] H H
1-84 H H H Me 2 - (CH2) 5- (3-iBuS-cHx) H H
1-85 H H H Me 2 - (CH2) 5- (4-iBuS-cHx) H H
1-86 H H H Me 2 - (CH2) 5- (3-cHx-cHx) H H
1-87 H H H Me 2 - (CH2) 5- (4-cHx-cHx) H H
1-88 H H H Me 2 - (CH2) 5- (3-Ph-cHx) H H
1-89 H H H Me 2 - (CH2) 5- (4-Ph-cHx) H H
1-90 H H H Me 2 - (CH2) 5- (2, 4-diMe-cHx) H H
1-91 H H H Me 2 - (CH2) 5- (3, 4-diMe-cHx) H H
S:/ChemicallSankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 1-92 H H H Me 2 - (CH2) 5- (3, 5-diMe-cHx) H H
1-93 H H H Me 2 - (CH2) 5-Ph H H
1-94 H H H Me 2 - (CH2) 5-Ph Me H
1-95 H H H Me 2 - (CH2) 5-Ph H Me 1-96 H H H Me 2 - (CH2) 5-Ph F H
1-97 H H H Me 2 - (CH2) 5-Ph H F
1-98 H H H Me 2 - (CH2) 5- (3-F-Ph) H H
1-99 H H H Me 2 - (CH2) 5- (4-F-Ph) H H
1-100 H H H Me 2 - (CH2) 5- (4-C1-Ph) H H
1-101 H H H Me 2-(CH2)5-(4-Br-Ph) H H
1-102 H H H Me 2 - (CH2) 5- (3-Me-Ph) H H
1-103 H H H Me 2 - (CH2) 5- (4-Me-Ph) H H
1-104 H H H Me 2 - (CH2) 5- (3-Et-Ph) H H
1-105 H H H Me 2 - (CH2) 5- (4-Et-Ph) H H
1-106 H H H Me 2 - (CH2) 5- (3-Pr-Ph) H H
1-107 H H H Me 2 - (CH2) 5- (4-Pr-Ph) H H
1-108 H H H Me 2 - (CH2) 5- (3-iPr-Ph) H H
1-109 H H H Me 2 - (CH2) 5- (4-iPr-Ph) H H
1-110 H H H Me 2 - (CH2) 5- (3-Bu-Ph) H H
1-111 H H H Me 2 - (CH2) 5- (4-Bu-Ph) H H
1-112 H H H Me 2 - (CH2) 5- (3-CF3-Ph) H H
1-113 H H H Me 2 - (CH2) 5- (4-CF3-Ph) H H
1-114 H H H Me 2 - (CH2) 5- (3-MeO-Ph) H H
1-115 H H H Me 2 - (CH2) 5- (4-MeO-Ph) H H
1-116 H H H Me 2 - (CH2) 5- (3-EtO-Ph) H H
1-117 H H H Me 2-(CH2)5-(4-EtO-Ph) H H
1-118 H H H Me 2 - (CH2) 5- (3-PrO-Ph) H H
1-119 H H H Me 2 - (CH2) 5- (4-Pro-Ph) H H
1-120 H H H Me 2 - (CH2) 5- (3-iPrO-Ph) H H
1-121 H H H Me 2 - (CH2) 5- (4-iPrO-Ph) H H
1-122 H H H Me 2 - (CH2) 5- [3- (2-Et-PrO) -Ph] H H
1-123 H H H Me 2 - (CH2) 5- [4- (2-Et-PrO) -Ph] H H
1-124 H H H Me 2 - (CH2) 5- (3-iBuO-Ph) H H
1-125 H H H Me 2 - (CH2) 5- (4-iBuO-Ph) H H
1-126 H H H Me 2 - (CH2) 5- (3-MeS-Ph) H H
1-127 H H H Me 2 - (CH2) 5- (4-MeS-Ph) H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 1-128 H H H Me 2- (CH2) 5- (3-EtS-Ph) H H
1-129 H H H Me 2 - (CH2) 5- (4-EtS-Ph) H H
1-130 H H H Me 2 - (CH2) 5- (3-PrS-Ph) H H
1-131 H H H Me 2 - (CH2) 5- (4-PrS-Ph) H H
1-132 H H H Me 2 - (CH2) 5- (3-iPrS-Ph) H H
1-133 H H H Me 2 - (CH2) 5- (4-iPrS-Ph) H H
1-134 H H H Me 2 - (CH2) 5- [3- (2-Et-PrS) -Ph] H H
1-135 H H H Me 2 - (CH2) 5- [4- (2-Et-PrS) -Ph] H H
1-136 H H H Me 2 - (CH2) 5- (3-iBuS-Ph) H H
1-137 H H H Me 2 - (CH2) 5- (4-iBuS-Ph) H H
1-138 H H H Me 2 - (CH2) 5- (3-cHx-Ph) H H
1-139 H H H Me 2 - (CH2) 5- (4-cHx-Ph) H H
1-140 H H H Me 2 - (CH2) 5- (3-Ph-Ph) H H
1-141 H H H Me 2 - (CH2) 5- (4-Ph-Ph) H H
1-142 H H H Me 2 - (CH2) 5- (2, 4-diMe-Ph) H H
1-143 H H H Me 2 - (CH2) 5- (3, 4-diMe-Ph) H H
1-144 H H H Me 2 - (CH2) 5- (3, 5-diMe-Ph) H H
1-145 H H H Me 2 - (CH2) 5-Np (1) H H
1-146 H H H Me 2 - (CH2) 5-Np (2) H H
1-147 H H H Me 2 - (CH2) 6-cPn H H
1-148 H H H Me 2 - (CH2) 6-cHx H H
1-149 H H H Me 2 - (CH2) 6-cHx Me H
1-150 H H H Me 2 - (CH2) 6-cHx H Me 1-151 H H H Me 2 - (CH2) 6-cHx F H
1-152 H H H Me 2-(CH2)6-cHx H F
1-153 H H H Me 2 - (CH2) 6- (3-F-cHx) H H
1-154 H H H Me 2 - (CH2) 6- (4-F-cHx) H H
1-155 H H H Me 2 - (CH2) 6- (4-Cl-cHx) H H
1-156 H H H Me 2 - (CH2) 6- (4-Br-cHx) H H
1-157 H H H Me 2 - (CH2) 6- (3-Me-cHx) H H
1-158 H H H Me 2 - (CH2) 6- (4-Me-cHx) H H
1-159 H H H Me 2 - (CH2) 6- (3-Et-cHx) H H
1-160 H H H Me 2 - (CH2) 6- (4-Et-cHx) H H
1-161 H H H Me 2 - (CH2) 6- (3-Pr-cHx) H H
1-162 H H H Me 2 - (CH2) 6- (4-Pr-cHx) H H
1-163 H H H Me 2 - (CH2) 6- (4-iPr-cHx) H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 r 1-164 H H H Me 2 - (CH2) 6- (3-Bu-cHx) H H
1-165 H H H Me 2-(CH2)6-(4-Bu-cHx) H H
1-166 H H H Me 2 - (CH2) 6- (3-CF3-cHx) H H
1-167 H H H Me 2 - (CH2) 6- (4-CF3-cHx) H H
1-168 H H H Me 2 - (CH2) 6- (3-MeO-cHx) H H
1-169 H H H Me 2 - (CH2) 6- (4-MeO-cHx) H H
1-170 H H H Me 2 - (CH2) 6- (3-EtO-cHx) H H
1-171 H H H Me 2 - (CH2) 6- (4-EtO-cHx) H H
1-172 H H H Me 2 - (CH2) 6- (3-PrO-cHx) H H
1-173 H H H Me 2 - (CH2) 6- (4-PrO-cHx) H H
1-174 H H H Me 2 - (CH2) 6- (3-iPrO-cHx) H H
1-175 H H H Me 2 - (CH2) 6- (4-iPrO-cHx) H H
1-176 H H H Me 2 - (CH2) 6-[3- (2-Et-PrO) -cHx] H H
1-177 H H H Me 2 - (CH2) 6- [4- (2-Et-PrO) -cHx] H H
1-178 H H H Me 2 - (CH2) 6- (3-iBuO-cHx) H H
1-179 H H H Me 2 - (CH2) 6- (4-iBuO-cHx) H H
1-180 H H H Me 2 - (CH2) 6- (3-MeS-cHx) H H
1-181 H H H Me 2 - (CH2) 6- (4-MeS-cHx) H H
1-182 H H H Me 2 - (CH2) 6- (3-EtS-cHx) H H
1-183 H H H Me 2 - (CH2) 6- (4-EtS-cHx) H H
1-184 H H H Me 2 - (CH2) 6- (3-PrS-cHx) H H
1-185 H H H Me 2 - (CH2) 6- (4-PrS-cHx) H H
1-186 H H H Me 2 - (CH2) 6- (3-iPrS-cHx) H H
1-187 H H H Me 2 - (CH2) 6- (4-iPrS-cHx) H H
1-188 H H H Me 2 - (CH2) 6- [ 3- (2-Et-PrS) -cHx] H H
1-189 H H H Me 2-(CH2)6-[4-(2-Et-PrS)-cHx] H H
1-190 H H H Me 2 - (CH2) 6- (3-iBuS-cHx) H H
1-191 H H H Me 2 - (CH2) 6- (4-iBuS-cHx) H H
1-192 H H H Me 2 - (CH2) 6- (3-cHx-cHx) H H
1-193 H H H Me 2 - (CH2) 6- (4-cHx-cHx) H H
1-194 H H H Me 2 - (CH2) 6- (3-Ph-cHx) H H
1-195 H H H Me 2 - (CH2) 6- (4-Ph-cHx) H H
1-196 H H H Me 2 - (CH2) 6- (2, 4-diMe-cHx) H H
1-197 H H H Me 2 - (CH2) 6- (3, 4-diMe-cHx) H H
1-198 H H H Me 2 - (CH2) 6- (3, 5-diMe-cHx) H H
1-199 H H H Me 2 - (CH2) 6-Ph H H
S:/Chemical/Sankyo/FP200301 /FP030I s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 1-200 H H H Me 2 - (CH2) 6-Ph Me H
1-201 H H H Me 2 - (CH2) 6-Ph H Me 1-202 H H H Me 2 - (CH2) 6-Ph F H
1-203 H H H Me 2 - (CH2) 6-Ph H F
1-204 H H H Me 2 - (CH2) 6- (3-F-Ph) H H
1-205 H H H Me 2 - (CH2) 6- (4-F- Ph) H H
1-206 H H H Me 2 - (CH2) 6- (4-Cl-Ph) H H
1-207 H H H Me 2 - (CH2) 6- (4-Br-Ph) H H
1-208 H H H Me 2 - (CH2) 6- (3-Me-Ph) H H
1-209 H H H Me 2 - (CH2) 6- (4-Me-Ph) H H
1-210 H H H Me 2 - (CH2) 6- (3-Et-Ph) H H
1-211 H H H Me 2 - (CH2) 6- (4-Et-Ph) H H
1-212 H H H Me 2 - (CH2) 6- (3-Pr-Ph) H H
1-213 H H H Me 2 - (CH2) 6- (4-Pr-Ph) H H
1-214 H H H Me 2 - (CH2) 6- (3-iPr-Ph) H H
1-215 H H H Me 2 - (CH2) 6- (4-iPr-Ph) H H
1-216 H H H Me 2 - (CH2) 6- (3-Bu-Ph) H H
1-217 H H H Me 2 - (CH2) 6- (4-Bu-Ph) H H
1-218 H H H Me 2 - (CH2) 6- (3-CF3-Ph) H H
1-219 H H H Me 2 - (CH2) 6- (4-CF3-Ph) H H
1-220 H H H Me 2 - (CH2) 6- (3-MeO-Ph) H H
1-221 H H H Me 2 - (CH2) 6- (4-MeO-Ph) H H
1-222 H H H Me 2-(CH2)6-(3-EtO-Ph) H H
1-223 H H H Me 2 - (CH2) 6- (4-EtO-Ph) H H
1-224 H H H Me 2 - (CH2) 6- (3-PrO-Ph) H H
1-225 H H H Me 2 - (CH2) 6- (4-PrO-Ph) H H
1-226 H H H Me 2 - (CH2) 6- (3-iPrO-Ph) H H
1-227 H H H Me 2 - (CH2) 6- (4-iPrO-Ph) H H
1-228 H H H Me 2 - (CH2) 6- [3- (2-Et-PrO) -Ph] H H
1-229 H H H Me 2 - (CH2) 6- [4- (2-Et-PrO) -Ph] H H
1-230 H H H Me 2 - (CH2) 6- (3-iBuO-Ph) H H
1-231 H H H Me 2 - (CH2) 6- (4-iBuO-Ph) H H
1-232 H H H Me 2 - (CH2) 6- (3-MeS-Ph) H H
1-233 H H H Me 2 - (CH2) 6- (4-MeS-Ph) H H
1-234 H H H Me 2 - (CH2) 6- (3-EtS-Ph) H H
1-235 H H H Me 2 - (CH2) 6- (4-EtS-Ph) H H
S:/ChemicaiSankyo/FP20030I/FP0301s.doc P87892/FP-0301/Desciiption/gds-mg/30.06.04 1-236 H H H Me 2 - (CH2) 6- (3-PrS-Ph) H H
1-237 H H H Me 2 - (CH2) 6- (4-PrS-Ph) H H
1-238 H H H Me 2 - (CH2) 6- (3-iPrS-Ph) H H
1-239 H H H Me 2 - (CH2) 6- (4-iPrS-Ph) H H
1-240 H H H Me 2-(CH2)6-[3-(2-Et-PrS)-Ph] H H
1-241 H H H Me 2 - (CH2) 6- [4- (2-Et-PrS) -Ph] H H
1-242 H H H Me 2 - (CH2) 6- (3-iBuS-Ph) H H
1-243 H H H Me 2 - (CH2) 6- (4-iBuS-Ph) H H
1-244 H H H Me 2 - (CH2) 6- (3-cHx-Ph) H H
1-245 H H H Me 2 - (CH2) 6- (4-cHx-Ph) H H
1-246 H H H Me 2 - (CH2) 6- (3-Ph-Ph) H H
1-247 H H H Me 2 - (CH2) 6- (4-Ph-Ph) H H
1-248 H H H Me 2 - (CH2) 6- (2, 4-diMe-Ph) H H
1-249 H H H Me 2 - (CH2) 6- (3, 4-diMe-Ph) H H
1-250 H H H Me 2-(CH2)6-(3,5-diMe-Ph) H H
1-251 H H H Me 2 - (CH2) 6-Np (1) H H
1-252 H H H Me 2- (CH2) 6-Np (2) H H
1-253 H H H Me 2-(CH2)7-cHx H H
1-254 H H H Me 2 - (CH2) 7- (4-F-cHx) H H
1-255 H H H Me 2 - (CH2) 7- (4-Me-cHx) H H
1-256 H H H Me 2-(CH2)7-(4-Et-cHx) H H
1-257 H H H Me 2 - (CH2) 7- (4-CF3-cHx) H H
1-258 H H H Me 2 - (CH2) 7- (4-MeO-cHx) H H
1-259 H H H Me 2 - (CH2) 7- (4-EtO-cHx) H H
1-260 H H H Me 2 - (CH2) 7- (4-MeS-cHx) H H
1-261 H H H Me 2 - (CH2) 7- (4-cHx-cHx) H H
1-262 H H H Me 2-(CH2)7-(4-Ph-cHx) H H
1-263 H H H Me 2 - (CH2) 7-Ph H H
1-264 H H H Me 2 - (CH2) 7- (4-F-Ph) H H
1-265 H H H Me 2 - (CH2) 7- (4-Me-Ph) H H
1-266 H H H Me 2 - (CH2) 7- (4-Et-Ph) H H
1-267 H H H Me 2 - (CH2) 7- (4-CF3-Ph) H H
1-268 H H H Me 2-(CH2)7-(4-MeO-Ph) H H
1-269 H H H Me 2 - (CH2) 7- (4-EtO-Ph) H H
1-270 H H H Me 2 - (CH2) 7- (4-MeS-Ph) H H
1-271 H H H Me 2 - (CH2) 7- (4-cHx-Ph) H H
S:/Chemical/Sankyo/FP200301/FP0301s.doc P87892/FP-0301/Description/gds-mg/30.06.04 1-272 H H H Me 2 - (CH2) 7- (4-Ph-Ph) H H
1-273 H H H Me 2 - (CH2) 3-0-cHx H H
1-274 H H H Me 2 - (CH2) 3-0- (4-F-cHx) H H
1-275 H H H Me 2 - (CH2) 3-0- (4-Me-cHx) H H
1-276 H H H Me 2 - (CH2) 3-0- (4-Et-cHx) H H
1-277 H H H Me 2 - (CH2) 3-0- (4-CF3-cHx) H H
1-278 H H H Me 2 - (CH2) 3-0- (4-Me0-cHx) H H
1-279 H H H Me 2 - (CH2) 3-0- (4-Et0-cHx) H H
1-280 H H H Me 2 - (CH2) 3-0- (4-MeS-cHx) H H
1-281 H H H Me 2 - (CH2) 3-0- (4-cHx-cHx) H H
1-282 H H H Me 2 - (CH2) 3-0- (4-Ph-cHx) H H
1-283 H H H Me 2 - (CH2) 3-0-Ph H H
1-284 H H H Me 2 - (CH2) 3-0- (4-F-Ph) H H
1-285 H H H Me 2 - (CH2) 3-0- (4-Me-Ph) H H
1-286 H H H Me 2 - (CH2) 3-0- (4-Et-Ph) H H
1-287 H H H Me 2 - (CH2) 3-0- (4-CF3-Ph) H H
1-288 H H H Me 2 - (CH2) 3-0- (4-MeO-Ph) H H
1-289 H H H Me 2 - (CH2) 3-0- (4-EtO-Ph) H H
1-290 H H H Me 2 - (CH2) 3-0- (4-MeS-Ph) H H
1-291 H H H Me 2 - (CH2) 3-0- (4-cHx-Ph) H H
1-292 H H H Me 2 - (CH2) 3-0- (4-Ph-Ph) H H
1-293 H H H Me 2-(CH2)4-O-cPn H H
1-294 H H H Me 2 - (CH2) 4-O-cHx H H
1-295 H H H Me 2 - (CH2) 4-O-cHx Me H
1-296 H H H Me 2-(CH2)4-O-cHx H Me 1-297 H H H Me 2-(CH2)4-O-cHx F H
1-298 H H H Me 2 - (CH2) 4-O-cHx H F
1-299 H H H Me 2 - (CH2) 4-0- (3-F-cHx) H H
1-300 H H H Me 2 - (CH2) 4-0- (4-F-cHx) H H
1-301 H H H Me 2 - (CH2) 4-0- (4-C1-cHx) H H
1-302 H H H Me 2 - (CH2) 4-0- (4-Br-cHx) H H
1-303 H H H Me 2 - (CH2) 4-0- (3-Me-cHx) H H
1-304 H H H Me 2 - (CH2) 4-0- (4-Me-cHx) H H
1-305 H H H Me 2 - (CH2) 4-0- (3-Et-cHx) H H
1-306 H H H Me 2 - (CH2) 4-0- (4-Et-cHx) H H
1-307 H H H Me 2 - (CH2) 4-0- (3-Pr-cHx) H H
S:/Chemical/Sankyo/FP200301/FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 1-308 H H H Me 2 - (CH2) 4-0- (4-Pr-cHx) H H
1-309 H H H Me 2 - (CH2) 4-0- (4-iPr-cHx) H H
1-310 H H H Me 2 - (CH2) 4-0- (3-Bu-cHx) H H
1-311 H H H Me 2 - (CH2) 4-0- (4-Bu-cHx) H H
1-312 H H H Me 2 - (CH2) 4-0- (3-CF3-cHx) H H
1-313 H H H Me 2 - (CH2) 4-0- (4-CF3-cHx) H H
1-314 H H H Me 2 - (CH2) 4-0- (3-MeO-cHx) H H
1-315 H H H Me 2 - (CH2) 4-0- (4-MeO-cHx) H H
1-316 H H H Me 2 - (CH2) 4-0- (3-EtO-cHx) H H
1-317 H H H Me 2 - (CH2) 4-0- (4-EtO-cHx) H H
1-318 H H H Me 2 - (CH2) 4-0- (3-PrO-cHx) H H
1-319 H H H Me 2 - (CH2) 4-0- (4-PrO-cHx) H H
1-320 H H H Me 2 - (CH2) 4-0- (3-iPrO-cHx) H H
1-321 H H H Me 2 - (CH2) 4-0- (4-iPrO-cHx) H H
1-322 H H H Me 2 - (CH2) 4-0- [3- (2-Et-PrO) -cHx] H H
1-323 H H H Me 2 - (CH2) 4-0- [4- (2-Et-PrO) -cHx] H H
1-324 H H H Me 2 - (CH2) 4-0- (3-iBuO-cHx) H H
1-325 H H H Me 2 - (CH2) 4-0- (4-iBuO-cHx) H H
1-326 H H H Me 2 - (CH2) 4-0- (3-MeS-cHx) H H
1-327 H H H Me 2 - (CH2) 4-0- (4-MeS-cHx) H H
1-328 H H H Me 2 - (CH2) 4-0- (3-EtS-cHx) H H
1-329 H H H Me 2 - (CH2) 4-0- (4-EtS-cHx) H H
1-330 H H H Me 2 - (CH2) 4-0- (3-PrS-cHx) H H
1-331 H H H Me 2 - (CH2) 4-0- (4-PrS-cHx) H H
1-332 H H H Me 2 - (CH2) 4-0- (3-iPrS-cHx) H H
1-333 H H H Me 2 - (CH2) 4-0- (4-iPrS-cHx) H H
1-334 H H H Me 2 - (CH2) 4-0-[3- (2-Et-PrS) -cHx] H H
1-335 H H H Me 2 - (CH2) 4-0- [4- (2-Et-PrS) -cHx] H H
1-336 H H H Me 2 - (CH2) 4-0- (3-iBuS-cHx) H H
1-337 H H H Me 2 - (CH2) 4-0- (4-iBuS-cHx) H H
1-338 H H H Me 2 - (CH2) 4-0- (3-cHx-cHx) H H
1-339 H H H Me 2 - (CH2) 4-0- (4-cHx-cHx) H H
1-340 H H H Me 2 - (CH2) 4-0- (3-Ph-cHx) H H
1-341 H H H Me 2 - (CH2) 4-0- (4-Ph-cHx) H H
1-342 H H H Me 2 - (CH2) 4-0- (2, 4-diMe-cHx) H H
1-343 H H H Me 2 - (CH2) 4-0- (3, 4-diMe-cHx) H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 1-344 H H H Me 2-(CH2)4-0-(3,5-diMe-CHx) H H
1-345 H H H Me 2 - (CH2) 4-0-Ph H H
1-346 H H H Me 2 - (CH2) 4-0-Ph Me H
1-347 H H H Me 2 - (CH2) 4-0-Ph H Me 1-348 H H H Me 2 - (CH2) 4-0-Ph F H
1-349 H H H Me 2 - (CH2) 4-0-Ph H F
1-350 H H H Me 2 - (CH2) 4-0- (3-F-Ph) H H
1-351 H H H Me 2 - (CH2) 4-0- (4-F-Ph) H H
1-352 H H H Me 2 - (CH2) 4-0- (4-C1-Ph) H H
1-353 H H H Me 2 - (CH2) 4-0- (4-Br-Ph) H H
1-354 H H H Me 2 - (CH2) 4-0- (3-Me-Ph) H H
1-355 H H H Me 2 - (CH2) 4-0- (4-Me-Ph) H H
1-356 H H H Me 2 - (CH2) 4-0- (3-Et-Ph) H H
1-357 H H H Me 2 - (CH2) 4-0- (4-Et-Ph) H H
1-358 H H H Me 2 - (CH2) 4-0- (3-Pr-Ph) H H
1-359 H H H Me 2 - (CH2) 4-0- (4-Pr-Ph) H H
1-360 H H H Me 2 - (CH2) 4-0- (3-iPr-Ph) H H
1-361 H H H Me 2 - (CH2) 4-0- (4-iPr-Ph) H H
1-362 H H H Me 2 - (CH2) 4-0- (3-Bu-Ph) H H
1-363 H H H Me 2 - (CH2) 4-0- (4-Bu-Ph) H H
1-364 H H H Me 2 - (CH2) 4-0- (3-CF3-Ph) H H
1-365 H H H Me 2 - (CH2) 4-0- (4-CF3-Ph) H H
1-366 H H H Me 2 - (CH2) 4-0- (3-MeO-Ph) H H
1-367 H H H Me 2 - (CH2) 4-0- (4-MeO-Ph) H H
1-368 H H H Me 2 - (CH2) 4-0- (3-EtO-Ph) H H
1-369 H H H Me 2 - (CH2) 4-0- (4-EtO-Ph) H H
1-370 H H H Me 2 - (CH2) 4-0- (3-PrO-Ph) H H
1-371 H H H Me 2-(CH2)4-0-(4-Pro-Ph) H H
1-372 H H H Me 2 - (CH2) 4-0- (3-iPrO-Ph) H H
1-373 H H H Me 2 - (CH2) 4-0- (4-iPrO-Ph) H H
1-374 H H H Me 2 - (CH2) 4-0- [3- (2-Et-PrO) -Ph] H H
1-375 H H H Me 2 - (CH2) 4-0- [4- (2-Et-PrO) -Ph] H H
1-376 H H H Me 2 - (CH2) 4-0- (3-iBuO-Ph) H H
1-377 H H H Me 2 - (CH2) 4-0- (4-iBuO-Ph) H H
1-378 H H H Me 2 - (CH2) 4-0- (3-MeS-Ph) H H
1-379 H H H Me 2 - (CH2) 4-0- (4-MeS-Ph) H H
S:/ChemicaUSankyo/FP200301/FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 1-380 H H H Me 2 - (CH2) 4-0- (3-EtS-Ph) H H
1-381 H H H Me 2 - (CH2) 4-0- (4-EtS-Ph) H H
1-382 H H H Me 2 - (CH2) 4-0- (3-PrS-Ph) H H
1-383 H H H Me 2-(CH2)4-0-(4-PrS-Ph) H H
1-384 H H H Me 2-(CH2)4-0-(3-iPrS-Ph) H H
1-385 H H H Me 2 - (CH2) 4-0- (4-iPrS-Ph) H H
1-386 H H H Me 2 - (CH2) 4-0- [3- (2-Et-PrS) -Ph] H H
1-387 H H H Me 2 - (CH2) 4-0- [4- (2-Et-PrS) -Ph] H H
1-388 H H H Me 2 - (CH2) 4-0- (3-iBuS-Ph) H H
1-389 H H H Me 2-(CH2)4-0-(4-iBuS-Ph) H H
1-390 H H H Me 2 - (CH2) 4-0- (3-cHx-Ph) H H
1-391 H H H Me 2 - (CH2) 4-0- (4-cHx-Ph) H H
1-392 H H H Me 2 - (CH2) 4-0- (3-Ph-Ph) H H
1-393 H H H Me 2 - (CH2) 4-0- (4-Ph-Ph) H H
1-394 H H H Me 2 - (CH2) 4-0- (2, 4-diMe-Ph) H H
1-395 H H H Me 2 - (CH2) 4-0- (3, 4-diMe-Ph) H H
1-396 H H H Me 2 - (CH2) 4-0- (3, 5-diMe-Ph) H H
1-397 H H H Me 2 - (CH2) 5-0-cHx H H
1-398 H H H Me 2 - (CH2) 5-0-Ph H H
1-399 H H H Me 2 - (CH2) 6-0-cHx H H
1-400 H H H Me 2 - (CH2) 6-0-Ph H H
1-401 H H H Me 2 - (CH2) 3-OCH2-cHx H H
1-402 H H H Me 2 - (CH2) 3-OCH2- (4-F-cHx) H H
1-403 H H H Me 2 - (CH2) 3-OCH2- (4-Me-cHx) H H
1-404 H H H Me 2 - (CH2) 3-OCH2- (4-Et-cHx) H H
1-405 H H H Me 2 - (CH2) 3-OCH2- (4-CF3-cHx) H H
1-406 H H H Me 2 - (CH2) 3-OCH2- (4-MeO-cHx) H H
1-407 H H H Me 2 - (CH2) 3-OCH2- (4-EtO-cHx) H H
1-408 H H H Me 2 - (CH2) 3-OCH2- (4-MeS-cHx) H H
1-409 H H H Me 2 - (CH2) 3-OCH2- (4-cHx-cHx) H H
1-410 H H H Me 2 - (CH2) 3-OCH2- (4-Ph-cHx) H H
1-411 H H H Me 2 - (CH2) 3-OCH2-Ph H H
1-412 H H H Me 2 - (CH2) 3-OCH2- (4-F-Ph) H H
1-413 H H H Me 2 - (CH2) 3-OCH2- (4-Me-Ph) H H
1-414 H H H Me 2 - (CH2) 3-OCH2- (4-Et-Ph) H H
1-415 H H H Me 2 - (CH2) 3-OCH2- (4-CF3-Ph) H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 1-416 H H H Me 2 - (CH2) 3-OCH2- (4-MeO-Ph) H H
1-417 H H H Me 2 - (CH2) 3-OCH2- (4-EtO-Ph) H H
1-418 H H H Me 2 - (CH2) 3-OCH2- (4-MeS-Ph) H H
1-419 H H H Me 2 - (CH2) 3-OCH2- (4-cHx-Ph) H H
1-420 H H H Me 2 - (CH2) 3-OCH2- (4-Ph-Ph) H H
1-421 H H H Me 2 - (CH2) 4-OCH2-cPn H H
1-422 H H H Me 2 - (CH2) 4-OCH2-cHx H H
1-423 H H H Me 2 - (CH2) 4-OCH2-cHx Me H
1-424 H H H Me 2 - (CH2) 4-OCH2-cHx H Me 1-425 H H H Me 2 - (CH2) 4-OCH2-cHx F H
1-426 H H H Me 2 - (CH2) 4-OCH2-cHx H F
1-427 H H H Me 2 - (CH2) 4-OCH2- (3-F-cHx) H H
1-428 H H H Me 2 - (CH2) 4-OCH2- (4-F-cHx) H H
1-429 H H H Me 2 - (CH2) 4-OCH2- (4-C1-cHx) H H
1-430 H H H Me 2 - (CH2) 4-OCH2- (4-Br-cHx) H H
1-431 H H H Me 2 - (CH2) 4-OCH2- (3-Me-cHx) H H
1-432 H H H Me 2 - (CH2) 4-OCH2- (4-Me-cHx) H H
1-433 H H H Me 2 - (CH2) 4-OCH2- (3-Et-cHx) H H
1-434 H H H Me 2 - (CH2) 4-OCH2- (4-Et-cHx) H H
1-435 H H H Me 2 - (CH2) 4-OCH2- (3-Pr-cHx) H H
1-436 H H H Me 2 - (CH2) 4-OCH2- (4-Pr-cHx) H H
1-437 H H H Me 2 - (CH2) 4-OCH2- (4-iPr-cHx) H H
1-438 H H H Me 2 - (CH2) 4-OCH2- (3-Bu-cHx) H H
1-439 H H H Me 2 - (CH2) 4-OCH2- (4-Bu-cHx) H H
1-440 H H H Me 2 - (CH2) 4-OCH2- (3-CF3-cHx) H H
1-441 H H H Me 2 - (CH2) 4-OCH2- (4-CF3-cHx) H H
1-442 H H H Me 2 - (CH2) 4-OCH2- (3-MeO-cHx) H H
1-443 H H H Me 2 - (CH2) 4-OCH2- (4-MeO-cHx) H H
1-444 H H H Me 2 - (CH2) 4-OCH2- (3-EtO-cHx) H H
1-445 H H H Me 2 - (CH2) 4-OCH2- (4-EtO-cHx) H H
1-446 H H H Me 2 - (CH2) 4-OCH2- (3-PrO-cHx) H H
1-447 H H H Me 2 - (CH2) 4-OCH2- (4-PrO-cHx) H H
1-448 H H H Me 2 - (CH2) 4-OCH2- (3-iPrO-cHx) H H
1-449 H H H Me 2 - (CH2) 4-OCH2- (4-iPrO-cHx) H H
1-450 H H H Me 2 - (CH2) 4-OCH2- [3- (2-Et-PrO) -cHx] H H
1-451 H H H Me 2 - (CH2) 4-OCH2- [4- (2-Et-PrO) -cHx] H H
S:/ChemicalSankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 1-452 H H H Me 2 - (CH2) 4-OCH2- (3-iBuO-cHx) H H
1-453 H H H Me 2 - (CH2) 4-OCH2- (4-iBuO-cHx) H H
1-454 H H H Me 2 - (CH2) 4-OCH2- (3-MeS-cHx) H H
1-455 H H H Me 2 - (CH2) 4-OCH2- (4-MeS-cHx) H H
1-456 H H H Me 2 - (CH2) 4-OCH2- (3-EtS-cHx) H H
1-457 H H H Me 2 - (CH2) 4-OCH2- (4-EtS-cHx) H H
1-458 H H H Me 2 - (CH2) 4-OCH2- (3-PrS-cHx) H H
1-459 H H H Me 2 - (CH2) 4-OCH2- (4-PrS-cHx) H H
1-460 H H H Me 2 - (CH2) 4-OCH2- (3-iPrS-cHx) H H
1-461 H H H Me 2 - (CH2) 4-OCH2- (4-iPrS-cHx) H H
1-462 H H H Me 2 - (CH2) 4-OCH2- [3- (2-Et-PrS) -cHx] H H
1-463 H H H Me 2 - (CH2) 4-OCH2- [4- (2-Et-PrS) -cHx] H H
1-464 H H H Me 2 - (CH2) 4-OCH2- (3-iBuS-cHx) H H
1-465 H H H Me 2 - (CH2) 4-OCH2- (4-iBuS-cHx) H H
1-466 H H H Me 2 - (CH2) 4-OCH2- (3-cHx-cHx) H H
1-467 H H H Me 2 - (CH2) 4-OCH2- (4-cHx-cHx) H H
1-468 H H H Me 2 - (CH2) 4-OCH2- (3-Ph-cHx) H H
1-469 H H H Me 2 - (CH2) 4-OCH2- (4-Ph-cHx) H H
1-470 H H H Me 2 - (CH2) 4-OCH2- (2, 4-diMe-cHx) H H
1-471 H H H Me 2 - (CH2) 4-OCH2- (3, 4-diMe-cHx) H H
1-472 H H H Me 2 - (CH2) 4-OCH2- (3, 5-diMe-cHx) H H
1-473 H H H Me 2 - (CH2) 4-OCH2-Ph H H
1-474 H H H Me 2 - (CH2) 4-OCH2-Ph Me H
1-475 H H H Me 2 - (CH2) 4-OCH2-Ph H Me 1-476 H H H Me 2 - (CH2) 4-OCH2-Ph F H
1-477 H H H Me 2 - (CH2) 4-OCH2-Ph H F
1-478 H H H Me 2 - (CH2) 4-OCH2- (3-F-Ph) H H
1-479 H H H Me 2 - (CH2) 4-OCH2- (4-F-Ph) H H
1-480 H H H Me 2 - (CH2) 4-OCH2- (4-C1-Ph) H H
1-481 H H H Me 2 - (CH2) 4-OCH2- (4-Br-Ph) H H
1-482 H H H Me 2 - (CH2) 4-OCH2- (3-Me-Ph) H H
1-483 H H H Me 2 - (CH2) 4-OCH2- (4-Me-Ph) H H
1-484 H H H Me 2 - (CH2) 4-OCH2- (3-Et-Ph) H H
1-485 H H H Me 2 - (CH2) 4-OCH2- (4-Et-Ph) H H
1-486 H H H Me 2 - (CH2) 4-OCH2- (3-Pr-Ph) H H
1-487 H H H Me 2 - (CH2) 4-OCH2- (4-Pr-Ph) H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 1-488 H H H Me 2 - (CH2) 4-OCH2- (3-iPr-Ph) H H
1-489 H H H Me 2 - (CHZ) 4-OCH2- (4-iPr-Ph) H H
1-490 H H H Me 2 - (CH2) 4-OCH2- (3-Bu-Ph) H H
1-491 H H H Me 2 - (CH2) 4-OCH2- (4-Bu-Ph) H H
1-492 H H H Me 2 - (CH2) 4-OCH2- (3-CF3-Ph) H H
1-493 H H H Me 2 - (CHZ) 4-OCH2- (4-CF3-Ph) H H
1-494 H H H Me 2 - (CH2) 4-OCH2- (3-MeO-Ph) H H
1-495 H H H Me 2 - (CH2) 4-OCH2- (4-MeO-Ph) H H
1-496 H H H Me 2 - (CH2) 4-OCH2- (3-EtO-Ph) H H
1-497 H H H Me 2 - (CH2) 4-OCH2- (4-EtO-Ph) H H
1-498 H H H Me 2 - (CH2) 4-OCH2- (3-Pro-Ph) H H
1-499 H H H Me 2 - (CH2) 4-OCH2- (4-Pro-Ph) H H
1-500 H H H Me 2 - (CHZ) 4-OCH2- (3-iPrO-Ph) H H
1-501 H H H Me 2 - (CHZ) 4-OCH2- (4-iPrO-Ph) H H
1-502 H H H Me 2 - (CH2) 4-OCH2- [3- (2-Et-PrO) -Ph] H H
1-503 H H H Me 2 - (CHZ) 4-OCH2- [4- (2-Et-PrO) -Ph] H H
1-504 H H H Me 2 - (CH2) 4-OCH2- (3-iBuO-Ph) H H
1-505 H H H Me 2 - (CH2) 4-OCH2- (4-iBuO-Ph) H H
1-506 H H H Me 2 - (CHZ) 4-OCH2- (3-MeS-Ph) H H
1-507 H H H Me 2 - (CH2) 4-OCH2- (4-MeS-Ph) H H
1-508 H H H Me 2 - (CH2) 4-OCH2- (3-EtS-Ph) H H
1-509 H H H Me 2 - (CH2) 4-OCH2- (4-EtS-Ph) H H
1-510 H H H Me 2 - (CH2) 4-OCH2- (3-PrS-Ph) H H
1-511 H H H Me 2 - (CH2) 4-OCH2- (4-PrS-Ph) H H
1-512 H H H Me 2 - (CH2) 4-OCH2- (3-iPrS-Ph) H H
1-513 H H H Me 2 - (CH2) 4-OCH2- (4-iPrS-Ph) H H
1-514 H H H Me 2 - (CH2) 4-OCH2- [3- (2-Et-PrS) -Ph] H H
1-515 H H H Me 2 - (CH2) 4-OCH2- [4- (2-Et-PrS) -Ph] H H
1-516 H H H Me 2 - (CH2) 4-OCH2- (3-iBuS-Ph) H H
1-517 H H H Me 2 - (CHZ) 4-OCH2- (4-iBuS-Ph) H H
1-518 H H H Me 2 - (CH2) 4-OCH2- (3-cHx-Ph) H H
1-519 H H H Me 2 - (CH2) 4-OCH2- (4-cHx-Ph) H H
1-520 H H H Me 2 - (CH2) 4-OCH2- (3-Ph-Ph) H H
1-521 H H H Me 2 - (CH2) 4-OCH2- (4-Ph-Ph) H H
1-522 H H H Me 2 - (CH2) 4-OCH2- (2, 4-diMe-Ph) H H
1-523 H H H Me 2 - (CH2) 4-OCH2- (3, 4-diMe-Ph) H H
S:/Chemical/Sankyo/FP20030I /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 1-524 H H H Me 2 - (CH2) 4-OCH2- (3, 5-diMe-Ph) H H
1-525 H H H Me 2 - (CH2) 5-OCH2-cHx H H
1-526 H H H Me 2 - (CH2) 5-OCH2-Ph H H
1-527 H H H Me 2 - (CH2) 6-OCH2-cHx H H
1-528 H H H Me 2 - (CH2) 6-OCH2-Ph H H
1-529 H H H Me 2 -C=C-cHx H H
1-530 H H H Me 2-C=C-(4-F-cHx) H H
1-531 H H H Me 2-C=C-(4-Me-cHx) H H
1-532 H H H Me 2-C=C-(4-Et-cHx) H H
1-533 H H H Me 2 -C=C- (4-CF3-cHx) H H
1-534 H H H Me 2-C=C-(4-MeO-cHx) H H
1-535 H H H Me 2-C=C-(4-EtO-cHx) H H
1-536 H H H Me 2-C=C-(4-MeS-cHx) H H
1-537 H H H Me 2-C=C-(4-cHx-cHx) H H
1-538 H H H Me 2-C=C-(4-Ph-cHx) H H
1-539 H H H Me 2-C=C-Ph H H
1-540 H H H Me 2-C=C-(4-F-Ph) H H
1-541 H H H Me 2-C=-C-(4-Me-Ph) H H
1-542 H H H Me 2-C=C-(4-Pr-Ph) H H
1-543 H H H Me 2-C=C-(4-Bu-Ph) H H
1-544 H H H Me 2-C=C-(4-MeO-Ph) H H
1-545 H H H Me 2-C=-C-(4-EtO-Ph) H H
1-546 H H H Me 2-C=C-(4-PrO-Ph) H H
1-547 H H H Me 2-C=C-(4-cHx-Ph) H H
1-548 H H H Me 2-C=C-(4-Ph-Ph) H H
1-549 H H H Me 2 -C=C- (CH2) 2-cHx H H
1-550 H H H Me 2-C=C-(CH2)2-(4-F-cHx) H H
1-551 H H H Me 2 -C-C- (CH2) 2- (4-Me-cHx) H H
1-552 H H H Me 2 -C=-C- (CH2) 2- (4-Et-cHx) H H
1-553 H H H Me 2 -C=C- (CH2) 2- (4-CF3-cHx) H H
1-554 H H H Me 2 -C=C- (CH2) 2- (4-MeO-cHx) H H
1-555 H H H Me 2 -C=C- (CH2) 2- (4-EtO-cHx) H H
S:/ChemicaUSankyo/FP200301 /FP030 ] s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 1-556 H H H Me 2 -C=C- (CH2) 2- (4-MeS-cHx) H H
1-557 H H H Me 2 -C=C- (CH2) 2- (4-cHx-cHx) H H
1-558 H H H Me 2 -C=C- (CH2) 2- (4-Ph-cHx) H H
1-559 H H H Me 2 -C=C- (CH2) 2-Ph H H
1-560 H H H Me 2 -C=C- (CH2) 2- (4-F-Ph) H H
1-561 H H H Me 2 -C=C- (CH2) 2- (4-Me-Ph) H H
1-562 H H H Me 2 -C=C- (CH2) 2- (4-Et-Ph) H H
1-563 H H H Me 2 -C=C- (CH2) 2- (4-CF3-Ph) H H
1-564 H H H Me 2 -C=C- (CH2) 2- (4-MeO-Ph) H H
1-565 H H H Me 2 -C=C- (CH2) 2- (4-EtO-Ph) H H
1-566 H H H Me 2 -C=C- (CH2) 2- (4-MeS-Ph) H H
1-567 H H H Me 2 -C=C- (CH2) 2- (4-cHx-Ph) H H
1-568 H H H Me 2 -C=-C- (CH2) 2- (4-Ph-Ph) H H
1-569 H H H Me 2 -C=C- (CH2) 3-cPn H H
1-570 H H H Me 2-C=C-(CH2)3-cHx H H
1-571 H H H Me 2 -C=C- (CH2) 3-cHx Me H
1-572 H H H Me 2 -C=C- (CH2) 3-cHx H Me 1-573 H H H Me 2 -C=C- (CH2) 3-cHx F H
1-574 H H H Me 2 -C=C- (CH2) 3-cHx H F
1-575 H H H Me 2 -C=-C- (CH2) 3- (3-F-cHx) H H
1-576 H H H Me 2 -C=C- (CH2) 3- (4-F-cHx) H H
1-577 H H H Me 2 -C-C- (CH2) 3- (4-C1-cHx) H H
1-578 H H H Me 2 -C=C- (CH2) 3- (4-Br-cHx) H H
1-579 H H H Me 2 -C=C- (CH2) 3- (3-Me-cHx) H H
1-580 H H H Me 2 -C=-C- (CH2) 3- (4-Me-cHx) H H
1-581 H H H Me 2 -C=C- (CH2) 3- (3-Et-cHx) H H
1-582 H H H Me 2 -C=C- (CH2) 3- (4-Et-cHx) H H
1-583 H H H Me 2-C=C-(CH2)3-(3-Pr-cHx) H H
1-584 H H H Me 2 -C=C- (CH2) 3- (4-Pr-cHx) H H
1-585 H H H Me 2 -C=C- (CH2) 3- (4-iPr-cHx) H H
1-586 H H H Me 2 -C=C- (CH2) 3- (3-Bu-cHx) H H
1-587 H H H Me 2-C=C-(CH2)3-(4-Bu-cHx) H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 1-588 H H H Me 2 -C=C- (CH2) 3- (3-CF3-cHx) H H
1-589 H H H Me 2 -C=C- (CH2) 3- (4-CF3-cHx) H H
1-590 H H H Me 2 -C=C- (CH2) 3- (3-MeO-cHx) H H
1-591 H H H Me 2 -C=C- (CH2) 3- (4-MeO-cHx) H H
1-592 H H H Me 2 -C=C- (CH2) 3- (3-EtO-cHx) H H
1-593 H H H Me 2 -C=C- (CH2) 3- (4-EtO-cHx) H H
1-594 H H H Me 2 -C=C- (CH2) 3- (3-PrO-cHx) H H
1-595 H H H Me 2 -C=C- (CH2) 3- (4-PrO-cHx) H H
1-596 H H H Me 2-C=C-(CH2)3-(3-iPrO-cHx) H H
1-597 H H H Me 2 -C=C- (CH2) 3- (4-iPrO-cHx) H H
1-598 H H H Me 2 -C=C- (CH2) 3- [3- (2-Et-PrO) -cHx] H H
1-599 H H H Me 2 -C=C- (CH2) 3- [4- (2-Et-PrO) -cHx] H H
1-600 H H H Me 2 -C=C- (CH2) 3- (3-iBuO-cHx) H H
1-601 H H H Me 2-C=C-(CH2)3-(4-iBuO-cHx) H H
1-602 H H H Me 2 -C=C- (CH2) 3- (3-MeS-cHx) H H
1-603 H H H Me 2 -C=C- (CH2) 3- (4-MeS-cHx) H H
1-604 H H H Me 2 -C=C- (CH2) 3- (3-EtS-cHx) H H
1-605 H H H Me 2 -C=C- (CH2) 3- (4-EtS-cHx) H H
1-606 H H H Me 2-C=C-(CH2)3-(3-PrS-cHx) H H
1-607 H H H Me 2 -C=C- (CH2) 3- (4-PrS-cHx) H H
1-608 H H H Me 2 -C=C- (CH2) 3- (3-iPrS-cHx) H H
1-609 H H H Me 2 -C=C- (CH2) 3- (4-iPrS-cHx) H H
1-610 H H H Me 2-C=C-(CH2)3-[3-(2-Et-PrS)-cHx] H H
1-611 H H H Me 2 -C=C- (CH2) 3- [4- (2-Et-PrS) -cHx] H H
1-612 H H H Me 2 -C=C- (CH2) 3- (3-iBuS-cHx) H H
1-613 H H H Me 2 -C=C- (CH2) 3- (4-iBuS-cHx) H H
1-614 H H H Me 2 -C=C- (CH2) 3- (3-cHx-cHx) H H
1-615 H H H Me 2-C=C-(CH2)3-(4-cHx-cHx) H H
1-616 H H H Me 2 -C=-C- (CH2) 3- (3-Ph-cHx) H H
1-617 H H H Me 2 -C=-C- (CH2) 3- (4-Ph-cHx) H H
1-618 H H H Me 2 -C=C- (CH2) 3- (2, 4 -diMe-cHx) H H
1-619 H H H Me 2 -C=C- (CH2) 3- (3, 4-diMe-cHx) H H
S:/Chcmical/Sankyo/FP200301/FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 1-620 IH H H Me 2-C=C-(CH2)3-(3,5-diMe-cHx) H H
1-621 H H H Me 2-C=C-(CH2)3-Ph H H
1-622 H H H Me 2 -C=C- (CH2) 3-Ph Me H
1-623 H H H Me 2 -C=C- (CH2) 3-Ph H Me 1-624 H H H Me 2 -C=C- (CH2) 3-Ph F H
1-625 H H H Me 2 -C-C- (CH2) 3-Ph H F
1-626 H H H Me 2 -C=C- (CH2) 3- (3-F-Ph) H H
1-627 H H H Me 2 -C=C- (CH2) 3- (4-F-Ph) H H
1-628 H H H Me 2 -C=C- (CH2) 3- (4-C1-Ph) H H
1-629 H H H Me 2 -C=C- (CH2) 3- (4-Br-Ph) H H
1-630 H H H Me 2 -C=C- (CH2) 3- (3-Me-Ph) H H
1-631 H H H Me 2 -C=-C- (CH2) 3- (4-Me-Ph) H H
1-632 H H H Me 2-C=C-(CH2)3-(3-Et-Ph) H H
1-633 H H H Me 2 -C=C- (CH2) 3- (4-Et-Ph) H H
1-634 H H H Me 2 -C=C- (CH2) 3- (3-Pr-Ph) H H
1-635 H H H Me 2 -C=C- (CH2.) 3- (4-Pr-Ph) H H
1-636 H H H Me 2 -C=C- (CH2) 3- (3-iPr-Ph) H H
1-637 H H H Me 2-C=C-(CH2)3-(4-iPr-Ph) H H
1-638 H H H Me 2 -C=C- (CH2) 3- (3-Bu-Ph) H H
1-639 H H H Me 2 -C=C- (CH2) 3- (4-Bu-Ph) H H
1-640 H H H Me 2 -C=C- (CH2) 3- (3-CF3-Ph) H H

-641 H H H Me 2 -C=C- (CH2) 3- (4-CF3-Ph) H H
1-641___H_ 1-642 H H H Me 2-C=_C-(CH2)3-(3-MeO-Ph) H H
1-643 H H H Me 2 -C=C- (CH2) 3- (4-MeO-Ph) H H
1-644 H H H Me 2-C=C-(CH2)3-(3-EtO-Ph) H H
1-645 H H H Me 2 -C=-C- (CH2) 3- (4-EtO-Ph) H H
1-646 H H H Me 2 -C=-C- (CH2) 3- (3-PrO-Ph) H H
1-647 H H H Me 2-C=C-(CH2)3-(4-PrO-Ph) H H
1-648 H H H Me 2 -C=C- (CH2) 3- (3-iPrO-Ph) H H
1-649 H H H Me 2 -C=C- (CH2) 3- (4-iPrO-Ph) H H
1-650 H H H Me 2 -C=C- (CH2) 3- [3- (2-Et-PrO) -Ph] H H
1-651 H H H Me 2 -C=C- (CH2) 3- [4- (2-Et-PrO) -Ph] H H
S:/Chemical/Sankyo/FP200301/FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06A4 1-652 H H H Me 2 -C-C- (CH2) 3- (3-iBuO-Ph) H H
1-653 H H H Me 2 -C=C- (CH2) 3- (4-iBuO-Ph) H H
1-654 H H H Me 2-C-C-(CH2)3-(3-MeS-Ph) H H
1-655 H H H Me 2 -C-C- (CH2) 3- (4-MeS-Ph) H H
1-656 H H H Me 2 -C-C- (CH2) 3- (3-EtS-Ph) H H
1-657 H H H Me 2 -C-C- (CH2) 3- (4-EtS-Ph) H H
1-658 H H H Me 2 -C-C- (CH2) 3- (3-PrS-Ph) H H
1-659 H H H Me 2 -C=-C- (CH2) 3- (4-PrS-Ph) H H
1-660 H H H Me 2 -C-C- (CH2) 3- (3-iPrS-Ph) H H
1-661 H H H Me 2 -C=C- (CH2) 3- (4-iPrS-Ph) H H
1-662 H H H Me 2 -C-C- (CH2) 3- [3- (2-Et-PrS) -Ph] H H
1-663 H H H Me 2 -C=-C- (CH2) 3- [4- (2-Et-PrS) -Ph] H H
1-664 H H H Me 2 -C-C- (CH2) 3- (3-iBuS-Ph) H H
1-665 H H H Me 2-C-C-(CH2)3-(4-iBuS-Ph) H H
1-666 H H H Me 2 -C=C- (CH2) 3- (3-cHx-Ph) H H
1-667 H H H Me 2 -C-C- (CH2) 3- (4-cHx-Ph) H H
1-668 H H H Me 2 -C=-C- (CH2) 3- (3-Ph-Ph) H H
1-669 H H H Me 2 -C-C- (CH2) 3- (4-Ph-Ph) H H
1-670 H H H Me 2 -C-C- (CH2) 3- (2, 4-diMe-Ph) H H
1-671 H H H Me 2-C-C-(CH2)3-(3,4-diMe-Ph) H H
1-672 H H H Me 2 -C=C- (CH2) 3- (3, 5-diMe-Ph) H H
1-673 H H H Me 2 -C-C- (CH2) 3-Np (1) H H
1-674 H H H Me 2 -C-C- (CH2) 3-Np (2) H H
1-675 H H H Me 2 -C-C- (CH2) 4-cPn H H
1-676 H H H Me 2 -C=-C- (CH2) 4-cHx H H
1-677 H H H Me 2 -C=C- (CH2) 4-cHx Me H
1-678 H H H Me 2 -C=C- (CH2) 4-cHx H Me 1-679 H H H Me 2-C=C-(CH2)4-cHx F H
1-680 H H H Me 2 -C-C- (CH2) 4-cHx H F
1-681 H H H Me 2 -C=C- (CH2) 4- (3-F-cHx) H H
1-682 H H H Me 2-C=C-(CH2)4-(4-F-cHx) H H
1-683 H H H Me 2 -C-C- (CH2) 4- (4-Cl-cHx) H H
S:/Chemicat/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Desci iption/gds-mg/30.06.04 1-684 H H H Me 2-C=C-(CH2)4-(4-Br-cHx) H H
1-685 H H H Me 2-C=C-(CH2)4-(3-Me-cHx) H H
1-686 H H H Me 2 -C=C- (CH2) 4- (4-Me-cHx) H H
1-687 H H H Me 2 -C=C- (CH2) 4- (3-Et-cHx) H H
1-688 H H H Me 2 -C=C- (CH2) 4- (4-Et-cHx) H H
1-689 H H H Me 2 -C=C- (CH2) 4- (3-Pr-cHx) H H
1-690 H H H Me 2 -C=C- (CH2) 4- (4-Pr-cHx) H H
1-691 H H H Me 2 -C=C- (CH2) 4- (4-iPr-cHx) H H
1-692 H H H Me 2 -C=C- (CH2) 4- (3-Bu-cHx) H H
1-693 H H H Me 2 -C=C- (CH2) 4- (4-Bu-cHx) H H
1-694 H H H Me 2 -C=C- (CH2) 4- (3-CF3-cHx) H H
1-695 H H H Me 2 -C=C- (CH2) 4- (4-CF3-cHx) H H
1-696 H H H Me 2 -C=C- (CH2) 4- (3-MeO-cHx) H H
1-697 H H H Me 2 -C=C- (CH2) 4- (4-MeO-cHx) H H
1-698 H H H Me 2 -C=C- (CH2) 4- (3-EtO-cHx) H H
1-699 H H H Me 2 -C=C- (CH2) 4- (4-EtO-cHx) H H
1-700 H H H Me 2-C=C-(CH2)4-(3-PrO-cHx) H H
1-701 H H H Me 2 -C=C- (CH2) 4- (4-PrO-cHx) H H
1-702 H H H Me 2 -C=C- (CH2) 4- (3-iPrO-cHx) H H
1-703 H H H Me 2 -C=-C- (CH2) 4- (4-iPrO-cHx) H H
1-704 H H H Me 2-C=C-(CH2)4-[3-(2-Et-PrO)-cHx] H H
1-705 H H H Me 2 -C=C- (CH2) 4- [4- (2-Et-PrO) -cHx] H H
1-706 H H H Me 2 -C=C- (CH2) 4- (3-iBuO-cHx) H H
1-707 H H H Me 2 -C=C- (CH2) 4- (4-iBuO-cHx) H H
1-708 H H H Me 2-C=C-(CH2)4-(3-MeS-cHx) H H
1-709 H H H Me 2-C=C-(CH2)4-(4-MeS-cHx) H H
1-710 H H H Me 2 -C=C- (CH2) 4- (3-EtS-cHx) H H
1-711 H H H Me 2-C=C-(CH2)4-(4-EtS-cHx) H H
1-712 H H H Me 2 -C=-C- (CH2) 4- (3-PrS-cHx) H H
1-713 H H H Me 2 -C=C- (CH2) 4- (4-PrS-cHx) H H
1-714 H H H Me 2-C=C-(CH2)4-(3-iPrS-cHx) H H
1-715 H H H Me 2 -C=C- (CH2) 4- (4-iPrS-cHx) H H
S:/ChemicaVSankyo/FP200301 /FP 0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 1-716 H H H Me 2 -C=C- (CH2) 4- [3- (2-Et-PrS) -cHx] H H
1-717 H H H Me 2-C-C-(CH2)4-[4-(2-Et-PrS)-cHx] H H
1-718 H H H Me 2 -C-C- (CH2) 4- (3-iBuS-cHx) H H
1-719 H H H Me 2-C=_C-(CH2)4-(4-iBuS-cHx) H H
1-720 H H H Me 2 -C-C- (CH2) 4- (3-cHx-cHx) H H
1-721 H H H Me 2 -C-C- (CH2) 4- (4-cHx-cHx) H H
1-722 H H H Me 2 -C-C- (CH2) 4- (3-Ph-cHx) H H
1-723 H H H Me 2 -C-C- (CH2) 4- (4-Ph-cHx) H H
1-724 H H H Me 2-C-C-(CH2)4-(2,4-diMe-cHx) H H
1-725 H H H Me 2-C=_C-(CH2)4-(3,4-diMe-cHx) H H
1-726 H H H Me 2 -C-C- (CH2) 4- (3, 5-diMe-cHx) H H
1-727 H H H Me 2 -C-C- (CH2) 4-Ph H H
1-728 H H H Me 2-C-C-(CH2)4-Ph Me H
1-729 H H H Me 2 -C=C- (CH2) 4-Ph H Me 1-730 H H H Me 2 -C-C- (CH2) 4-ph F H
1-731 H H H Me 2 -C-C- (CH2) 4-Ph H F
1-732 H H H Me 2 -C-C- (CH2) 4- (3-F-Ph) H H
1-733 H H H Me 2-C-C-(CH2)4-(4-F-Ph) H H
1-734 H H H Me 2 -C=C- (CH2) 4- (4-Cl-Ph) H H
1-735 H H H Me 2 -C=-C- (CH2) 4- (4-Br-Ph) H H
1-736 H H H Me 2-C-C-(CH2)4-(3-Me-Ph) H H
1-737 H H H Me 2 -C=-C- (CH2) 4- (4-Me-Ph) H H
1-738 H H H Me 2-C-C-(CH2)4-(3-Et-Ph) H H
1-739 H H H Me 2 -C=C- (CH2) 4- (4-Et-Ph) H H
1-740 H H H Me 2-C-C-(CH2)4-(3-Pr-Ph) H H
1-741 H H H Me 2 -C-C- (CH2) 4- (4-Pr-Ph) H H
1-742 H H H Me 2 -C=C- (CH2) 4- (3-iPr-Ph) H H
1-743 H H H Me 2 -C=C- (CH2) 4- (4-iPr-Ph) H H
1-744 H H H Me 2 -C=C- (CH2) 4- (3-Bu-Ph) H H
1-745 H H H Me 2-C-C-(CH2)4-(4-Bu-Ph) H H
1-746 H H H Me 2 -C=-C- (CH2) 4- (3-CF3-Ph) H H
1-747 H H H Me 2 -C=-C- (CH2) 4- (4-CF3-Ph) H H
S:/ChemicaVSankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 1-748 H H H Me 2-C=C-(CH2)4-(3-MeO-Ph) H H
1-749 H H H Me 2-C C-(CH2)4-(4-MeO-Ph) H H
1-750 H H H Me 2-C=C-(CH2)4-(3-EtO-Ph) H H
1-751 H H H Me 2-C=C-(CH2)4-(4-EtO-Ph) H H
1-752 H H H Me 2-C=C-(CH2)4-(3-Pro-Ph) H H
1-753 H H H Me 2 -C-C- (CH2) 4- (4-PrO-Ph) H H
1-754 H H H Me 2 -C=C- (CH2) 4- (3-iPrO-Ph) H H
1-755 H H H Me 2-C=C-(CH2)4-(4-iPrO-Ph) H H
1-756 H H H Me 2 -C=-C- (CH2) 4- [3- (2-Et-PrO) -Ph] H H
1-757 H H H Me 2 -C=C- (CH2) 4- [4- (2-Et-PrO) -Ph] H H
1-758 H H H Me 2-C=C-(CH2)4-(3-iBuO-Ph) H H
1-759 H H H Me 2 -C=C- (CH2) 4- (4-iBuO-Ph) H H
1-760 H H H Me 2-C=C-(CH2)4-(3-MeS-Ph) H H
1-761 H H H Me 2 -C=C- (CH2) 4- (4-MeS-Ph) H H
1-762 H H H Me 2-C=C-(CH2)4-(3-EtS-Ph) H H
1-763 H H H Me 2-C=C-(CH2)4-(4-EtS-Ph) H H
1-764 H H H Me 2 -C=C- (CH2) 4- (3-PrS-Ph) H H
1-765 H H H Me 2 -C=C- (CH2) 4- (4-PrS-Ph) H H
1-766 H H H Me 2 -C=C- (CH2) 4- (3-iPrS-Ph) H H
1-767 H H H Me 2 -C=C- (CH2) 4- (4-iPrS-Ph) H H
1-768 H H H Me 2 -C=C- (CH2) 4- [3- (2-Et-PrS) -Ph] H H
1-769 H H H Me 2 -C=C- (CH2) 4- [4- (2-Et-PrS) -Ph] H H
1-770 H H H Me 2 -C=-C- (CH2) 4- (3-iBuS-Ph) H H
1-771 H H H Me 2-C=C-(CH2)4-(4-iBuS-Ph) H H
1-772 H H H Me 2 -C=C- (CH2) 4- (3-cHx-Ph) H H
1-773 H H H Me 2 -C=C- (CH2) 4- (4-cHx-Ph) H H
1-774 H H H Me 2 -C=C- (CH2) 4- (3-Ph-Ph) H H
1-775 H H H Me 2 -C=-C- (CH2) 4- (4-Ph-Ph) H H
1-776 H H H Me 2 -C=-C- (CH2) 4- (2, 4-diMe-Ph) H H
1-777 H H H Me 2-C=C-(CH2)4-(3,4-diMe-Ph) H H
1-778 H H H Me 2-C=C-(CH2)4-(3,5-diMe-Ph) H H
1-779 H H H Me 2 -C=C- (CH2) 4-Np (1) H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 1-780 H H H Me 2 -C=C- (CH2) 4-Np (2) H H
1-781 H H H Me 2 -C=C- (CH2) 5-cHx H H
1-782 H H H Me 2 -C-C- (CH2) 5- (4-F-cHx) H H
1-783 H H H Me 2 -C-C- (CH2) 5- (4-Me-cHx) H H
1-784 H H H Me 2-C=_C-(CH2)5-(4-Et-cHx) H H
1-785 H H H Me 2 -C-C- (CH2) 5- (4-CF3-cHx) H H
1-786 H H H Me 2 -C-C- (CH2) 5- (4-MeO-cHx) H H
1-787 H H H Me 2-C-C-(CH2)5-(4-EtO-cHx) H H
1-788 H H H Me 2 -C-C- (CH2) 5- (4-MeS-cHx) H H
1-789 H H H Me 2 -C-C- (CH2) 5- (4-cHx-cHx) H H
1-790 H H H Me 2 -C=C- (CH2) 5- (4-Ph-cHx) H H
1-791 H H H Me 2 -C-C- (CH2) 5-Ph H H
1-792 H H H Me 2 -C-C- (CH2) 5- (4-F-Ph) H H
1-793 H H H Me 2 -C=C- (CH2) 5- (4-Me-Ph) H H
1-794 H H H Me 2 -C=C- (CH2) 5- (4-Et-Ph) H H
1-795 H H H Me 2 -C=C- (CH2) 5- (4-CF3-Ph) H H
1-796 H H H Me 2 -C=C- (CH2) 5- (4-MeO-Ph) H H
1-797 H H H Me 2 -C-C- (CH2) 5- (4-EtO-Ph) H H
1-798 H H H Me 2 -C-C- (CH2) 5- (4-MeS-Ph) H H
1-799 H H H Me 2 -C-C- (CH2) 5- (4-cHx-Ph) H H
1-800 H H H Me 2 -C=C- (CH2) 5- (4-Ph-Ph) H H
1-801 H H H Me 2 -C-C- (CH2) 6-cHx H H
1-802 H H H Me 2 -C=C- (CH2) 6- (4-F-cHx) H H
1-803 H H H Me 2 -C-C- (CH2) 6- (4-Me-cHx) H H
1-804 H H H Me 2 -C=C- (CH2) 6- (4-Et-cHx) H H
1-805 H H H Me 2 -C=C- (CH2) 6- (4-CF3-cHx) H H
1-806 H H H Me 2 -C=C- (CH2) 6- (4-MeO-cHx) H H
1-807 H H H Me 2 -C=C- (CH2) 6- (4-EtO-cHx) H H
1-808 H H H Me 2 -C=C- (CH2) 6- (4-MeS-cHx) H H
1-809 H H H Me 2 -C-C- (CH2) 6- (4-cHx-cHx) H H
1-810 H H H Me 2 -C=C- (CH2) 6- (4-Ph-cHx) H H
1-811 H H H Me 2 -C-C- (CH2) 6-Ph H H
S:/ChemicallSankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 1-812 H H H Me 2 -C=C- (CH2) 6- (4-F-Ph) H H
1-813 H H H Me 2 -C=C- (CH2) 6- (4-Me-Ph) H H
1-814 H H H Me 2 -C=C- (CH2) 6- (4-Et-Ph) H H
1-815 H H H Me 2 -C=C- (CH2) 6- (4-CF3-Ph) H H
1-816 H H H Me 2-C=C-(CH2)6-(4-MeO-Ph) H H
1-817 H H H Me 2 -C=C- (CH2) 6- (4-EtO-Ph) H H
1-818 H H H Me 2 -C=C- (CH2) 6- (4-MeS-Ph) H H
1-819 H H H Me 2 -C=C- (CH2) 6- (4-cHx-Ph) H H
1-820 H H H Me 2 -C=C- (CH2) 6- (4-Ph-Ph) H H
1-821 H H H Me 2 -C=-C-CH2-O-cHx H H
1-822 H H H Me 2 -C-C-CH2-0-(4-F-cHx) H H
1-823 H H H Me 2 -C=C-CH2-O-(4-Me-cHx) H H
1-824 H H H Me 2 -C=C-CH2-O-(4-Et-cHx) H H
1-825 H H H Me 2 -C=C-CH2-O-(4-CF3-cHx) H H
1-826 H H H Me 2 -C=C-CH2-0-(4-MeO-cHx) H H
1-827 H H H Me 2 -C=-C-CH2-0-(4-EtO-cHx) H H
1-828 H H H Me 2 -C=C-CH2-O-(4-MeS-cHx) H H
1-829 H H H Me 2 -C=C-CH2-O-(4-cHx-cHx) H H
1-830 H H H Me 2 -C=C-CH2-O-(4-Ph-cHx) H H
1-831 H H H Me 2 -C=C-CH2-O-Ph H H
1-832 H H H Me 2 -C=C-CH2-0-(4-F-Ph) H H
1-833 H H H Me 2 -C=C-CH2-0-(4-Me-Ph) H H
1-834 H H H Me 2 -C=C-CH2-O- (4-Et-Ph) H H
1-835 H H H Me 2 -C=C-CH2-O- (4-CF3-Ph) H H
1-836 H H H Me 2 -C=C-CH2-O-(4-MeO-Ph) H H
1-837 H H H Me 2 -C=C-CH2-0-(4-EtO-Ph) H H
1-838 H H H Me 2 -C=-C-CH2-O-(4-MeS-Ph) H H
1-839 H H H Me 2 -C=C-CH2-O-(4-cHx-Ph) H H
1-840 H H H Me 2 -C-C-CH2-O-(4-Ph-Ph) H H
1-841 H H H Me 2 -C=C- (CH2) 20-cPn H H
1-842 H H H Me 2 -C=-C- (CH2) 20-cHx H H
1-843 H H H Me 2 -C=C- (CH2) 20-cHx Me H
S:/ChemicaVSankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 1-844 H H H Me 2 -C=C- (CH2) 20-cHx H Me 1-845 H H H Me 2 -C=C- (CH2) 2O-cHx F H
1-846 H H H Me 2 -C=C- (CH2) 20-cHx H F
1-847 H H H Me 2-C-C-(CH2)2O-(3-F-cHx) H H
1-848 H H H Me 2-C=C-(CH2)2O-(4-F-cHx) H H
1-849 H H H Me 2-C-C-(CH2)20-(4-Cl-cHx) H H
1-850 H H H Me 2-C-C-(CH2)2O-(4-Br-cHx) H H
1-851 H H H Me 2-C=C-(CH2)2O-(3-Me-cHx) H H
1-852 H H H Me 2-C=-C-(CH2)20-(4-Me-cHx) H H
1-853 H H H Me 2 -C=-C- (CH2) 20- (3-Et-cHx) H H
1-854 H H H Me 2 -C=C- (CH2) 20- (4-Et-cHx) H H
1-855 H H H Me 2-C=C-(CH2)2O-(3-Pr-cHx) H H
1-856 H H H Me 2-C-C-(CH2)20-(4-Pr-cHx) H H
1-857 H H H Me 2-C-C-(CH2)20-(4-iPr-cHx) H H
1-858 H H H Me 2 -C=-C- (CH2) 20- (3-Bu-cHx) H H
1-859 H H H Me 2 -C=C- (CH2) 20- (4-Bu-cHx) H H
1-860 H H H Me 2 -C-C- (CH2) 20- (3-CF3-cHx) H H
1-861 H H H Me 2 -C=C- (CH2) 20- (4-CF3-cHx) H H
1-862 H H H Me 2 -C-C- (CH2) 20- (3-MeO-cHx) H H
1-863 H H H Me 2 -C=C- (CH2) 20- (4-MeO-cHx) H H
1-864 H H H Me 2 -C-C- (CH2) 20- (3-EtO-cHx) H H
1-865 H H H Me 2 -C=C- (CH2) 20- (4-EtO-cHx) H H
1-866 H H H Me 2 -C-C- (CH2) 20- (3-PrO-cHx) H H
1-867 H H H Me 2 -C-C- (CH2) 20- (4-PrO-cHx) H H
1-868 H H H Me 2-C-C-(CH2)20-(3-iPrO-cHx) H H
1-869 H H H Me 2-C-C-(CH2)20-(4-iPrO-cHx) H H
1-870 H H H Me 2 -C=C- (CH2) 20- [3- (2-Et-PrO) -cHx] H H
1-871 H H H Me 2-C-C-(CH2)20-[4-(2-Et-PrO)-cHx] H H
1-872 H H H Me 2-C=C-(CH2)20-(3-iBuO-cHx) H H
1-873 H H H Me 2-C=_C-(CH2)20-(4-iBuO-cHx) H H
1-874 H H H Me 2 -C=-C- (CH2) 20- (3-MeS-cHx) H H
1-875 H H H Me 2 -C=C- (CH2) 20- (4-MeS-cHx) H H
S:/Cheinical/Sankyo/FP200301/FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 1-876 H H H Me 2 -C=-C- (CH2) 20- (3-EtS-cHx) H H
1-877 H H H Me 2-C=C-(CH2)20-(4-EtS-cHx) H H
1-878 H H H Me 2 -C=-C- (CH2) 20- (3-PrS-cHx) H H
1-879 H H H Me 2 -C=C- (CH2) 20- (4-PrS-cHx) H H
1-880 H H H Me 2-C=C-(CH2)20-(3-iPrS-cHx) H H
1-881 H H H Me 2-C-C-(CH2)20-(4-iPrS-cHx) H H
1-882 H H H Me 2 -C=C- (CH2) 20- [3- (2-Et-PrS) -cHx] H H
1-883 H H H Me 2-C-C-(CH2)20-[4-(2-Et-PrS)-cHx] H H
1-884 H H H Me 2-C=C-(CH2)20-(3-iBuS-cHx) H H
1-885 H H H Me 2-C=C-(CH2)20-(4-iBuS-cHx) H H
1-886 H H H Me 2 -C-C- (CH2) 20- (3-cHx-cHx) H H
1-887 H H H Me 2 -C=C- (CH2) 20- (4-cHx-cHx) H H
1-888 H H H Me 2-C-C-(CH2)20-(3-Ph-cHx) H H
1-889 H H H Me 2 -C=-C- (CH2) 20- (4-Ph-cHx) H H
1-890 H H H Me 2-C=C-(CH2)20-(2,4-diMe-cHx) H H
1-891 H H H Me 2 -C=-C- (CH2) 20- (3, 4-diMe-cHx) H H
1-892 H H H Me 2-C=C-(CH2)20-(3,5-diMe-cHx) H H
1-893 H H H Me 2 -C=C- (CH2) 20-Ph H H
1-894 H H H Me 2 -C-C- (CH2) 20-Ph Me H
1-895 H H H Me 2 -C=C- (CH2) 20-Ph H Me 1-896 H H H Me 2 -co- -(CH2) 20-Ph F H
1-897 H H H Me 2 -co- =(CH2) 20-Ph H F
1-898 H H H Me 2 -C-C- (CH2) 20- (3-F-Ph) H H
1-899 H H H Me 2 -C=-C- (CH2) 20- (4-F-Ph) H H
1-900 H H H Me 2 -C=C- (CH2) 20- (4-C1-Ph) H H
1-901 H H H Me 2-C=C-(CH2)20-(4-Br-Ph) H H
1-902 H H H Me 2 -C=-C- (CH2) 20- (3-Me-Ph) H H
1-903 H H H Me 2 -C=-C- (CH2) 20- (4-Me-Ph) H H
1-904 H H H Me 2 -C-C- (CH2) 20- (3-Et-Ph) H H
1-905 H H H Me 2-C=C-(CH2)20-(4-Et-Ph) H H
1-906 H H H Me 2-C=C-(CH2)20-(3-Pr-Ph) H H
1-907 H H H Me 2 -C-C- (CH2) 20- (4-Pr-Ph) H H
S:/Chemical/Sankyo/FP20030I /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 1-908 H H H Me 2-C=C-(CH2)2O-(3-iPr-Ph) H H
1-909 H H H Me 2 -C=C- (CH2) 20- (4-iPr-Ph) H H
1-910 H H H Me 2 -C=C- (CH2) 20- (3-Bu-Ph) H H
1-911 H H H Me 2-C=C-(CH2)20-(4-Bu-Ph) H H
1-912 H H H Me 2 -C=C- (CH2) 20- (3-CF3-Ph) H H
1-913 H H H Me 2 -C=C- (CH2) 20- (4-CF3-Ph) H H
1-914 H H H Me 2 -C=C- (CH2) 20- (3-MeO-Ph) H H
1-915 H H H Me 2-C-C-(CH2)2O-(4-MeO-Ph) H H
1-916 H H H Me 2 -C=C- (CH2) 20- (3-EtO-Ph) H H
1-917 H H H Me 2 -C-C- (CH2) 20- (4-EtO-Ph) H H
1-918 H H H Me 2 -C-C- (CH2) 20- (3-PrO-Ph) H H
1-919 H H H Me 2 -C -C- (CH2) 20- (4-PrO-Ph) H H
1-920 H H H Me 2-C=C-(CH2)2O-(3-iPrO-Ph) H H
1-921 H H H Me 2 -C=C- (CH2) 20- (4-iPrO-Ph) H H
1-922 H H H Me 2-C=C-(CH2)2O-[3-(2-Et-PrO)-Ph] H H
1-923 H H H Me 2-C-C-(CH2)2O-[4-(2-Et-PrO)-Ph] H H
1-924 H H H Me 2 -C=C- (CH2) 20- (3-iBuO-Ph) H H
1-925 H H H Me 2-C=C-(CH2)20-(4-iBuO-Ph) H H
1-926 H H H Me 2-C=C-(CH2)2O-(3-MeS-Ph) H H
1-927 H H H Me 2 -C=C- (CH2) 20- (4-MeS-Ph) H H
1-928 H H H Me 2 -C=C- (CH2) 20- (3-EtS-Ph) H H
1-929 H H H Me 2 -C=C- (CH2) 20- (4-EtS-Ph) H H
1-930 H H H Me 2 -C=C- (CH2) 20- (3-PrS-Ph) H H
1-931 H H H Me 2 -C=C- (CH2) 20- (4-PrS-Ph) H H
1-932 H H H Me 2 -C=C- (CH2) 20- (3-iPrS-Ph) H H
1-933 H H H Me 2-C=C-(CH2)2O-(4-iPrS-Ph) H H
1-934 H H H Me 2 -C=C- (CH2) 20- [3- (2-Et-PrS) -Ph] H H
1-935 H H H Me 2 -C=C- (CH2) 20- [4- (2-Et-PrS) -Ph] H H
1-936 H H H Me 2 -C=C- (CH2) 20- (3-iBuS-Ph) H H
1-937 H H H Me 2-C=C-(CH2)20-(4-iBuS-Ph) H H
1-938 H H H Me 2-CC-(CH2)2O-(3-cHx-Ph) H H
1-939 H H H Me 2 -C-C- (CH2) 20- (4-cHx-Ph) H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 1-940 H H JH Me 2 -C=C- (CH2) 20- (3-Ph-Ph) H H
1-941 H H H Me 2 -C=C- (CH2) 20- (4-Ph-Ph) H H
1-942 H H H Me 2-C=C-(CH2)20-(2,4-diMe-Ph) H H
1-943 H H H Me 2 -C=C- (CH2) 20- (3, 4-diMe-Ph) H H
1-944 H H H Me 2-C-C-(CH2)20-(3,5-diMe-Ph) H H
1-945 H H H Me 2 -C=C- (CH2) 30-cHx H H
1-946 H H H Me 2 -C=C- (CH2) 30-Ph H H
1-947 H H H Me 2 -C=C- (CH2) 40-cHx H H
1-948 H H H Me 2 -C=-C- (CH2) 40-Ph H H
1-949 H H H Me 2 -C=C-CH2-OCH2-cHx H H
1-950 H H H Me 2 -C=C-CH2-OCH2-(4-F-cHx) H H
1-951 H H H Me 2 -C=C-CH2-OCH2-(4-Me-cHx) H H
1-952 H H JH Me 2 -C=C-CH2-OCH2-(4-Et-cHx) H H
1-953 H H H Me 2 -C=C-CH2-OCH2- (4-CF3-cHx) H H
1-954 H H H Me 2 -C=C-CH2-OCH2-(4-Me0-cHx) H H
1-955 H H H Me 2 -C=C-CH2-OCH2-(4-EtO-cHx) H H
1-956 H H JH Me 2 -C=C-CH2-OCH2-(4-MeS-cHx) H H
1-957 H H H Me 2 -C=C-CH2-OCH2-(4-cHx-cHx) H H
1-958 H H H Me 2 -C=C-CH2-OCH2- (4-Ph-cHx) H H
1-959 H H H Me 2 -C=C-CH2-OCH2-Ph H H
1-960 H H H Me 2 -C=C-CH2-OCH2-(4-F-Ph) H H
1-961 H H H Me 2 -C=C-CH2-OCH2-(4-Me-Ph) H H
1-962 H H H Me 2 -C=C-CH2-OCH2-(4-Et-Ph) H H
1-963 H H H Me 2 -C=C-CH2-OCH2- (4-CF3-Ph) H H
1-964 H H H Me 2 -C=C-CH2-OCH2-(4-Me0-Ph) H H
1-965 H H H Me 2 -C=C-CH2-OCH2- (4-EtO-Ph) H H
1-966 H H H Me 2 -C=C-CH2-OCH2- (4-MeS-Ph) H H
1-967 H H JH Me 2 -C=C-CH2-OCH2- (4-cHx-Ph) H H
1-968 H H JH Me 2 -C=C-CH2-OCH2- (4-Ph-Ph) H H
1-969 H H H Me 2 -C-=C- (CH2) 2-OCH2-cPn H H
1-970 H H H Me 2-C=C-(CH2)2-OCH2-cHx H H
1-971 H H H Me 2 -C=C- (CH2) 2-OCH2-cHx Me H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 1-972 H H H Me 2-C=C-(CH2)2-OCH2-cHx H Me 1-973 H H H Me 2 -C=C- (CH2) 2-OCH2-cHx F H
1-974 H H H Me 2 -C-C- (CH2) 2-OCH2-cHx H F
1-975 H H H Me 2 -C-C- (CH2) 2-OCH2- (3-F-cHx) H H
1-976 H H H Me 2 -C-C- (CH2) 2-OCH2- (4-F-cHx) H H
1-977 H H H Me 2 -C=C- (CH2) 2-OCH2- (4-C1-cHx) H H
1-978 H H H Me 2 -C=C- (CH2) 2-OCH2- (4-Br-cHx) H H
1-979 H H H Me 2 -C=C- (CH2) 2-OCH2- (3-Me-cHx) H H
1-980 H H H Me 2 -C=C- (CH2) 2-OCH2- (4-Me-cHx) H H
1-981 H H H Me 2 -C=C- (CH2) 2-OCH2- (3-Et-cHx) H H
1-982 H H H Me 2 -C=-C- (CH2) 2-OCH2- (4-Et-cHx) H H
1-983 H H H Me 2-C=C-(CH2)2-OCH2-(3-Pr-cHx) H H
1-984 H H H Me 2 -C=C- (CH2) 2-OCH2- (4-Pr-cHx) H H
1-985 H H H Me 2 -C=C- (CH2) 2-OCH2- (4-iPr-cHx) H H
1-986 H H H Me 2 -C-C- (CH2) 2-OCH2- (3-Bu-cHx) H H
1-987 H H H Me 2 -C-C- (CH2) 2-OCH2- (4-Bu-cHx) H H
1-988 H H H Me 2 -C=C- (CH2) 2-OCH2- (3-CF3-cHx) H H
1-989 H H H Me 2 -C=C- (CH2) 2-OCH2- (4-CF3-cHx) H H
1-990 H H H Me 2-C=C-(CH2)2-OCH2-(3-MeO-cHx) H H
1-991 H H H Me 2 -C=-C- (CH2) 2-OCH2- (4-MeO-cHx) H H
1-992 H H H Me 2 -C=C- (CH2) 2-OCH2- (3-EtO-cHx) H H
1-993 H H H Me 2 -C=C- (CH2) 2-OCH2- (4-EtO-cHx) H H
1-994 H H H Me 2-C=C-(CH2)2-OCH2-(3-PrO-cHx) H H
1-995 H H H Me 2 -C=C- (CH2) 2-OCH2- (4-PrO-cHx) H H
1-996 H H H Me 2 -C=C- (CH2) 2-OCH2- (3-iPrO-cHx) H H
1-997 H H H Me 2-C-C-(CH2)2-OCH2-(4-iPrO-cHx) H H
1-998 H H H Me 2 -C=C- (CH2) 2-OCH2- [3- (2-Et-PrO) cHx] H H
1-999 H H H Me 2 -C=C- (CH2) 2-OCH2- [ 4- (2-Et-PrO) cHx] H H
1-1000 H H H Me 2-C=C-(CH2)2-OCH2-(3-iBuO-cHx) H H
1-1001 H H H Me 2 -C=C- (CH2) 2-OCH2- (4-iBuO-cHx) H H
1-1002 H H H Me 2 -CC- (CH2) 2-OCH2- (3-MeS-cHx) H H
1-1003 H H H Me 2 -C=C- (CH2) 2-OCH2- (4-MeS-cHx) H H
S:/ChemicallSankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 1-1004 H H H Me 2 -C=C- (CH2) 2-OCH2- (3-EtS-cHx) H H
1-1005 H H H Me 2 -C=C- (CH2) 2-OCH2- (4-EtS-cHx) H H
1-1006 H H H Me 2 -C=C- (CH2) 2-OCH2- (3-PrS-cHx) H H
1-1007 H H H Me 2 -C=C- (CH2) 2-OCH2- (4-PrS-cHx) H H
1-1008 H H H Me 2 -C=C- (CH2) 2-OCH2- (3-iPrS-cHx) H H
1-1009 H H H Me 2 -C=C- (CH2) 2-OCH2- (4-iPrS-cHx) H H
1-1010 H H H Me 2 -CC- (CH2) 2-OCH2- [3- (2-Et-PrS) cHx] H H
1-1011 H H H Me 2 -C-C- (CH2) 2-OCH2- [4- (2-Et-PrS) cHx] H H
1-1012 H H H Me 2-C=C-(CH2)2-OCH2-(3-iBuS-cHx) H H
1-1013 H H H Me 2-C-C-(CH2)2-OCH2-(4-iBuS-cHx) H H
1-1014 H H H Me 2-C-C-(CH2)2-OCH2-(3-cHx-cHx) H H
1-1015 H H H Me 2 -C-C- (CH2) 2-OCH2- (4-cHx-cHx) H H
1-1016 H H H Me 2 -C=C- (CH2) 2-OCH2- (3-Ph-cHx) H H
1-1017 H H H Me 2 -C=-C- (CH2) 2-OCH2- (4-Ph-cHx) H H
1-1018 H H H Me 2-C=C-(CH2)2-OCH2-(2,4-diMe-cHx) H H
1-1019 H H H Me 2-C=C-(CH2)2-OCH2-(3,4-diMe-cHx) H H
1-1020 H H H Me 2 -C=C- (CH2) 2-OCH2- (3, 5-diMe-cHx) H H
1-1021 H H H Me 2 -C=-C- (CH2) 2-OCH2-Ph H H
1-1022 H H H Me 2 -C=C- (CH2) 2-OCH2-Ph Me H
1-1023 H H H Me 2 -C=C- (CH2) 2-OCH2-Ph H Me 1-1024 H H H Me 2 -C=C- (CH2) 2-OCH2-Ph F H
1-1025 H H H Me 2 -C=C- (CH2) 2-OCH2-Ph H F
1-1026 H H H Me 2-C=C-(CH2)2-OCH2-(3-F-Ph) H H
1-1027 H H H Me 2-C=C-(CH2)2-OCH2-(4-F-Ph) H H
1-1028 H H H Me 2 -C=C- (CH2) 2-OCH2- (4-C1-Ph) H H
1-1029 H H H Me 2 -C=C- (CH2) 2-OCH2- (4-Br-Ph) H H
1-1030 H H H Me 2 -C=C- (CH2) 2-OCH2- (3-Me-Ph) H H
1-1031 H H H Me 2-C=C-(CH2)2-OCH2-(4-Me-Ph) H H
1-1032 H H H Me 2-C=C-(CH2)2-OCH2-(3-Et-Ph) H H
1-1033 H H H Me 2 -C=C- (CH2) 2-OCH2- (4-Et-Ph) H H
1-1034 H H H Me 2 -C=C- (CH2) 2-OCH2- (3-Pr-Ph) H H
1-1035 H H H Me 2 -C=C- (CH2) 2-OCH2- (4-Pr-Ph) H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 1-1036 H H H Me 2 -C=C- (CH2) 2-OCH2- (3-iPr-Ph) H H
1-1037 H H H Me 2 -C=-C- (CH2) 2-OCH2- (4-iPr-Ph) H H
1-1038 H H H Me 2 -C=C- (CH2) 2-OCH2- (3-Bu-Ph) H H
1-1039 H H H Me 2 -C=_C- (CH2) 2-OCH2- (4-Bu-Ph) H H
1-1040 H H H Me 2 -C=C- (CH2) 2-OCH2- (3-CF3-Ph) H H
1-1041 H H H Me 2 -C=C- (CH2) 2-OCH2- (4-CF3-Ph) H H
1-1042 H H H Me 2 -C=C- (CH2) 2-OCH2- (3-MeO-Ph) H H
1-1043 H H H Me 2 -C=C- (CH2) 2-OCH2- (4-MeO-Ph) H H
1-1044 H H H Me 2 -C=-C- (CH2) 2-OCH2- (3-EtO-Ph) H H
1-1045 H H H Me 2 -C=C- (CH2) 2-OCH2- (4-EtO-Ph) H H
1-1046 H H H Me 2 -C=C- (CH2) 2-OCH2- (3-PrO-Ph) H H
1-1047 H H H Me 2 -C=C- (CH2) 2-OCH2- (4-PrO-Ph) H H
1-1048 H H H Me 2 -C-=C- (CH2) 2-OCH2- (3-iPr0-Ph) H H
1-1049 H H H Me 2 -C=C- (CH2) 2-OCH2- (4-iPrO-Ph) H H
1-1050 H H H Me 2 -C=C- (CH2) 2-OCH2- [3- (2-Et-PrO) Ph] H H
1-1051 H H H Me 2 -C=C- (CH2) 2-OCH2- [4- (2-Et-Pr0) Ph] H H
1-1052 H H H Me 2 H H
-C=C- (CH2) 2-OCH2- (3-iBuO-Ph) 1-1053 H H H Me 2 -C=C- (CH2) 2-OCH2- (4-iBu0-Ph) H H
1-1054 H H H Me 2 -C=C- (CH2) 2-OCH2- (3-MeS-Ph) H H
1-1055 H H H Me 2 -C=C- (CH2) 2-OCH2- (4-MeS-Ph) H H
1-1056 H H H Me 2 -C=C- (CH2) 2-OCH2- (3-EtS-Ph) H H
1-1057 H H H Me 2 -C=C- (CH2) 2-OCH2- (4-EtS-Ph) H H
1-1058 H H H Me 2 -C=C- (CH2) 2-OCH2- (3-PrS-Ph) H H
1-1059 H H H Me 2 -C=C- (CH2) 2-OCH2- (4-PrS-Ph) H H
1-1060 H H H Me 2 -C=C- (CH2) 2-OCH2- (3-iPrS-Ph) H H
1-1061 H H H Me 2 -C=C- (CH2) 2-OCH2- (4-iPrS-Ph) H H
1-1062 H H H Me 2 -C=C- (CH2) 2-OCH2- [3- (2-Et-PrS) Ph] H H
1-1063 H H H Me 2 -C=C- (CH2) 2-OCH2- [4- (2-Et-PrS) Ph] H H
1-1064 H H H Me 2-C=C-(CH2)2-OCH2-(3-iBuS-Ph) H H
1-1065 H H H Me 2-C=C-(CH2)2-OCH2-(4-iBuS-Ph) H H
1-1066 H H H Me 2 -C=C- (CH2) 2-OCH2- (3-cHx-Ph) H H
1-1067 H H H Me 12-C=-C- (CH2)2-OCH2-(4-cHx-Ph) H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 1-1068 H H H Me 2 -C=C- (CH2) 2-OCH2- (3-Ph-Ph) H H
1-1069 H H H Me 2 -C=C- (CH2) 2-OCH2-(4-Ph-Ph) H H
1-1070 H H H Me 2-C=C-(CH2)2-OCH2-(2,4-diMe-Ph) H H
1-1071 H H H Me 2-C=C-(CH2)2-OCH2-(3,4-diMe-Ph) H H
1-1072 H H H Me 2 -C-C- (CH2) 2-OCH2- (3, 5-diMe-Ph) H H
1-1073 H H H Me 2 -C=C- (CH2) 3-OCH2-cHx H H
1-1074 H H H Me 2 -C=C- (CH2) 3-OCH2-Ph H H
1-1075 H H H Me 2-C=C-(CH2)4-OCH2-cHx H H
1-1076 H H H Me 2 -C=C- (CH2) 4-OCH2-Ph H H
1-1077 H H H Me 2 -CO-CH2-(4-cHx-Ph) H H
1-1078 H H H Me 2 -CO-CH2- (4-Ph-Ph) H H
1-1079 H H H Me 2 -CO- (CH2) 2-cHx H H
1-1080 H H H Me 2 -CO- (CH2) 2-Ph H H
1-1081 H H H Me 2 -CO- (CH2) 3-cHx H H
1-1082 H H H Me 2 -CO- (CH2) 3-Ph H H
1-1083 H H H Me 2 -CO- (CH2) 4-cHx H H
1-1084 H H H Me 2 -CO- (CH2) 4- (4-F-cHx) H H
1-1085 H H H Me 2 -CO- (CH2) 4- (4-Me-cHx) H H
1-1086 H H H Me 2 -CO- (CH2) 4- (4-Et-cHx) H H
1-1087 H H H Me 2 -CO- (CH2) 4- (4-CF3-cHx) H H
1-1088 H H H Me 2 -CO- (CH2) 4- (4-MeO-cHx) H H
1-1089 H H H Me 2 -CO- (CH2) 4- (4-EtO-cHx) H H
1-1090 H H H Me 2 -CO- (CH2) 4- (4-MeS-cHx) H H
1-1091 H H H Me 2 -CO- (CH2) 4- (4-cHx-cHx) H H
1-1092 H H H Me 2 -CO- (CH2) 4- (4-Ph-cHx) H H
1-1093 H H H Me 2 -CO- (CH2) 4-Ph H H
1-1094 H H H Me 2 -CO- (CH2) 4- (4-F-Ph) H H
1-1095 H H H Me 2 -CO- (CH2) 4- (4-Me-Ph) H H
1-1096 H H H Me 2 -CO- (CH2) 4- (4-Et-Ph) H H
1-1097 H H H Me 2 -CO- (CH2) 4- (4-CF3-Ph) H H
1-1098 H H H Me 2 -CO- (CH2) 4- (4-MeO-Ph) H H
1-1099 H H H Me 2 -CO- (CH2) 4- (4-EtO-Ph) H H
1-1100 H H H Me 2 -CO- (CH2) 4- (4-MeS-Ph) H H
1-1101 H H H Me 2 -CO- (CH2) 4- (4-cHx-Ph) H H
1-1102 H H H Me 2 -CO- ( CH2 ) 4 - ( 4 - Ph- Ph ) H H
S:/Chemical/Sankyo/FP20030I/FP0301s.doc P87892/FP-0301/Description/gds-mg/30.06.04 1-1103 H H H Me 2 -CO- (CH2) 5-cHx H H
1-1104 H H H Me 2 -CO- (CH2) 5- (4-F-cHx) H H
1-1105 H H H Me 2 -CO- (CH2) 5- (4-Me-cHx) H H
1-1106 H H H Me 2 -CO- (CH2) 5- (4-Et-cHx) H H
1-1107 H H H Me 2 -CO- (CH2) 5- (4-CF3-cHx) H H
1-1108 H H H Me 2 -CO- (CH2) 5- (4-MeO-cHx) H H
1-1109 H H H Me 2 -CO- (CH2) 5- (4-EtO-cHx) H H
1-1110 H H H Me 2 -CO- (CH2) 5- (4-MeS-cHx) H H
1-1111 H H H Me 2 -CO- (CH2) 5- (4-cHx-cHx) H H
1-1112 H H H Me 2 -CO- (CH2) 5- (4-Ph-cHx) H H
1-1113 H H H Me 2 -CO- (CH2) 5-Ph H H
1-1114 H H H Me 2 -CO- (CH2) 5- (4-F-Ph) H H
1-1115 H H H Me 2 -CO- (CH2) 5- (4-Me-Ph) H H
1-1116 H H H Me 2 -CO- (CH2) 5- (4-Et-Ph) H H
1-1117 H H H Me 2 -CO- (CH2) 5- (4-CF3-Ph) H H
1-1118 H H H Me 2-CO-(CH2)5-(4-MeO-Ph) H H
1-1119 H H H Me 2 -CO- (CH2) 5- (4-EtO-Ph) H H
1-1120 H H H Me 2 -CO- (CH2) 5- (4-MeS-Ph) H H
1-1121 H H H Me 2 -CO- (CH2) 5- (4-cHx-Ph) H H
1-1122 H H H Me 2 -CO- (CH2) 5- (4-Ph-Ph) H H
1-1123 H H H Me 2 -CO- (CH2) 6-cHx H H
1-1124 H H H Me 2 -CO- (CH2) 6-Ph H H
1-1125 H H H Me 2 -CO- (CH2) 7-cHx H H
1-1126 H H H Me 2 -CO- (CH2) 7-Ph H H
1-1127 H H H Me 2 -CO- (CH2) 2-O-cHx H H
1-1128 H H H Me 2 -CO- (CH2) 2-0- (4-F-cHx) H H
1-1129 H H H Me 2 -CO- (CH2) 2-0- (4-Me-cHx) H H
1-1130 H H H Me 2 -CO- (CH2) 2-0- (4-Et-cHx) H H
1-1131 H H H Me 2 -CO- (CH2) 2-0- (4-CF3-cHx) H H
1-1132 H H H Me 2 -CO- (CH2) 2-0- (4-MeO-cHx) H H
1-1133 H H H Me 2 -CO- (CH2) 2-0- (4-EtO-cHx) H H
1-1134 H H H Me 2 -CO- (CH2) 2-0- (4-MeS-cHx) H H
1-1135 H H H Me 2 -CO- (CH2) 2-0- (4-cHx-cHx) H H
1-1136 H H H Me 2 -CO- (CH2) 2-0- (4-Ph-cHx) H H
1-1137 H H H Me 2 -CO- (CH2) 2-0-Ph H H
1-1138 H H H Me 2 -CO- (CH2) 2-0- (4-F-Ph) H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 1-1139 H H H Me 2 -CO- (CH2) 2-0- (4-Me-Ph) H H
1-1140 H H H Me 2 -CO- (CHZ) 2-0- (4-Et-Ph) H H
1-1141 H H H Me 2 -CO- (CH2) 2-0- (4-CF3-Ph) H H
1-1142 H H H Me 2 -CO- (CH2) 2-0- (4-MeO-Ph) H H
1-1143 H H H Me 2 -CO- (CH2) 2-0- (4-EtO-Ph) H H
1-1144 H H H Me 2 -CO- (CH2) 2-0- (4-MeS-Ph) H H
1-1145 H H H Me 2 -CO- (CH2) 2-0- (4-cHx-Ph) H H
1-1146 H H H Me 2 -CO- (CH2) 2-0- (4-Ph-Ph) H H
1-1147 H H H Me 2 -CO- (CH2) 3-O-cPn H H
1-1148 H H H Me 2 -CO- (CH2) 3-O-cHx H H
1-1149 H H H Me 2-CO-(CH2)3-O-cHx Me H
1-1150 H H H Me 2 -CO- (CH2) 3-O-cHx H Me 1-1151 H H H Me 2 -CO- (CH2) 3-0-cHx F H
1-1152 H H H Me 2-CO-(CH2)3-O-cHx H F
1-1153 H H H Me 2 -CO- (CH2) 3-0- (3-F-cHx) H H
1-1154 H H H Me 2 -CO- (CH2) 3-0- (4-F-cHx) H H
1-1155 H H H Me 2 -CO- (CH2) 3-0- (4-C1-cHx) H H
1-1156 H H H Me 2 -CO- (CH2) 3-0- (4-Br-cHx) H H
1-1157 H H H Me 2 -CO- (CH2) 3-0- (3-Me-cHx) H H
1-1158 H H H Me 2 -CO- (CH2) 3-0- (4-Me-cHx) H H
1-1159 H H H Me 2 -CO- (CH2) 3-0- (3-Et-cHx) H H
1-1160 H H H Me 2 -CO- (CH2) 3-0- (4-Et-cHx) H H
1-1161 H H H Me 2 -CO- (CH2) 3-0- (3-Pr-cHx) H H
1-1162 H H H Me 2 -CO- (CH2) 3-0- (4-Pr-cHx) H H
1-1163 H H H Me 2 -CO- (CH2) 3-0- (4-iPr-cHx) H H
1-1164 H H H Me 2 -CO- (CH2) 3-0- (3-Bu-cHx) H H
1-1165 H H H Me 2 -CO- (CH2) 3-0- (4-Bu-cHx) H H
1-1166 H H H Me 2 -CO- (CH2) 3-0- (3-CF3-cHx) H H
1-1167 H H H Me 2 -CO- (CH2) 3-0- (4-CF3-cHx) H H
1-1168 H H H Me 2 -CO- (CH2) 3-0- (3-MeO-cHx) H H
1-1169 H H H Me 2 -CO- (CH2) 3-0- (4-MeO-cHx) H H
1-1170 H H H Me 2 -CO- (CH2) 3-0- (3-EtO-cHx) H H
1-1171 H H H Me 2 -CO- (CH2) 3-0- (4-EtO-cHx) H H
1-1172 H H H Me 2 -CO- (CH2) 3-0- (3-PrO-cHx) H H
1-1173 H H H Me 2 -CO- (CH2) 3-0- (4-PrO-cHx) H H
1-1174 H H H Me 2 -CO- (CH2) 3-0- (3-iPrO-cHx) H H
S:/Chemical/Sankyo/FP200301/FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 1-1175 H H H Me 2 -CO- (CH2) 3-0- (4-iPrO-cHx) H H
1-1176 H H H Me 2 -CO- (CH2) 3-0- [3- (2-Et-PrO) cHx] H H
1-1177 H H H Me 2 -CO- (CH2) 3-0- [4- (2-Et-PrO) cHx] H H
1-1178 H H H Me 2 -CO- (CH2) 3-0- (3-iBuO-cHx) H H
1-1179 H H H Me 2 -CO- (CH2) 3-0- (4-iBuO-cHx) H H
1-1180 H H H Me 2 -CO- (CH2) 3-0- (3-MeS-cHx) H H
1-1181 H H H Me 2 -CO- (CH2) 3-0- (4-MeS-cHx) H H
1-1182 H H H Me 2 -CO- (CH2) 3-0- (3-EtS-cHx) H H
1-1183 H H H Me 2 -CO- (CH2) 3-0- (4-EtS-cHx) H H
1-1184 H H H Me 2 -CO- (CH2) 3-0- (3-PrS-cHx) H H
1-1185 H H H Me 2 -CO- (CH2) 3-0- (4-PrS-cHx) H H
1-1186 H H H Me 2 -CO- (CH2) 3-0- (3-iPrS-cHx) H H
1-1187 H H H Me 2 -CO- (CH2) 3-0- (4-iPrS-cHx) H H
1-1188 H H H Me 2 -CO- (CH2) 3-0- [3- (2-Et-PrS) cHx] H H
1-1189 H H H Me 2 -CO- (CH2) 3-0- [4- (2-Et-PrS) cHx] H H
1-1190 H H H Me 2 -CO- (CH2) 3-0- (3-iBuS-cHx) H H
1-1191 H H H Me 2 -CO- (CH2) 3-0- (4-iBuS-cHx) H H
1-1192 H H H Me 2 -CO- (CH2) 3-0- (3-cHx-cHx) H H
1-1193 H H H Me 2 -CO- (CH2) 3-0- (4-cHx-cHx) H H
1-1194 H H H Me 2 -CO- (CH2) 3-0- (3-Ph-cHx) H H
1-1195 H H H Me 2 -CO- (CH2) 3-0- (4-Ph-cHx) H H
1-1196 H H H Me 2 -CO- (CH2) 3-0- (2, 4-diMe-cHx) H H
1-1197 H H H Me 2 -CO- (CH2) 3-0- (3, 4-diMe-cHx) H H
1-1198 H H H Me 2 -CO- (CH2) 3-0- (3, 5-diMe-cHx) H H
1-1199 H H H Me 2 -CO- (CH2) 3-0-Ph H H
1-1200 H H H Me 2 -CO- (CH2) 3-0-Ph Me H
1-1201 H H H Me 2 -CO- (CH2) 3-0-Ph H Me 1-1202 H H H Me 2 -CO- (CH2) 3-0-Ph F H
1-1203 H H H Me 2 -CO- (CH2) 3-0-Ph H F
1-1204 H H H Me 2 -CO- (CH2) 3-0- (3-F-Ph) H H
1-1205 H H H Me 2 -CO- (CH2) 3-0- (4-F-Ph) H H
1-1206 H H H Me 2 -CO- (CH2) 3-0- (4-Cl-Ph) H H
1-1207 H H H Me 2 -CO- (CH2) 3-0- (4-Br-Ph) H H
1-1208 H H H Me 2 -CO- (CH2) 3-0- (3-Me-Ph) H H
1-1209 H H H Me 2 -CO- (CH2) 3-0- (4-Me-Ph) H H
1-1210 H H H Me 2 -CO- (CH2) 3-0- (3-Et-Ph) H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 1-1211 H H H Me 2 -CO- (CH2) 3-0- (4-Et-Ph) H H
1-1212 H H H Me 2 -CO- (CH2) 3-0- (3-Pr-Ph) H H
1-1213 H H H Me 2 -CO- (CH2) 3-0- (4-Pr-Ph) H H
1-1214 H H H Me 2 -CO- (CH2) 3-0- (3-iPr-Ph) H H
1-1215 H H H Me 2 -CO- (CH2) 3-0- (4-iPr-Ph) H H
1-1216 H H H Me 2 -CO- (CH2) 3-0- (3-Bu-Ph) H H
1-1217 H H H Me 2-CO-(CH2)3-0-(4-Bu-Ph) H H
1-1218 H H H Me 2 -CO- (CH2) 3-0- (3-CF3-Ph) H H
1-1219 H H H Me 2 -CO- (CH2) 3-0- (4-CF3-Ph) H H
1-1220 H H H Me 2 -CO- (CH2) 3-0- (3-MeO-Ph) H H
1-1221 H H H Me 2 -CO- (CH2) 3-0- (4-MeO-Ph) H H
1-1222 H H H Me 2 -CO- (CH2) 3-0- (3-EtO-Ph) H H
1-1223 H H H Me 2 -CO- (CH2) 3-0- (4-EtO-Ph) H H
1-1224 H H H Me 2 -CO- (CH2) 3-0- (3-PrO-Ph) H H
1-1225 H H H Me 2 -CO- (CH2) 3-0- (4-PrO-Ph) H H
1-1226 H H H Me 2 -CO- (CH2) 3-0- (3-iPrO-Ph) H H
1-1227 H H H Me 2-CO-(CH2)3-0-(4-iPrO-Ph) H H
1-1228 H H H Me 2 -CO- (CH2) 3-0- [3- (2-Et-PrO) -Ph] H H
1-1229 H H H Me 2 -CO- (CH2) 3-0- [4- (2-Et-PrO) -Ph] H H
1-1230 H H H Me 2 -CO- (CH2) 3-0- (3-iBuO-Ph) H H
1-1231 H H H Me 2-CO-(CH2)3-0-(4-iBuO-Ph) H H
1-1232 H H H Me 2 -CO- (CH2) 3-0- (3-MeS-Ph) H H
1-1233 H H H Me 2 -CO- (CH2) 3-0- (4-MeS-Ph) H H
1-1234 H H H Me 2 -CO- (CH2) 3-0- (3-EtS-Ph) H H
1-1235 H H H Me 2 -CO- (CH2) 3-0- (4-EtS-Ph) H H
1-1236 H H H Me 2 -CO- (CH2) 3-0- (3-PrS-Ph) H H
1-1237 H H H Me 2-CO-(CH2)3-0-(4-PrS-Ph) H H
1-1238 H H H Me 2-CO-(CH2)3-0-(3-iPrS-Ph) H H
1-1239 H H H Me 2-CO-(CH2)3-0-(4-iPrS-Ph) H H
1-1240 H H H Me 2-CO-(CH2)3-0-[3-(2-Et-PrS)-Ph] H H
1-1241 H H H Me 2 -CO- (CH2) 3-0- [4- (2-Et-PrS) -Ph] H H
1-1242 H H H Me 2-CO-(CH2)3-0-(3-iBuS-Ph) H H
1-1243 H H H Me 2 -CO- (CH2) 3-0- (4-iBuS-Ph) H H
1-1244 H H H Me 2 -CO- (CH2) 3-0- (3-cHx-Ph) H H
1-1245 H H H Me 2 -CO- (CH2) 3-0- (4-cHx-Ph) H H
1-1246 H H H Me 2 -CO- (CH2) 3-0- (3-Ph-Ph) H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 1-1247 H H H Me 2 -CO- (CH2) 3-0- (4-Ph-Ph) H H
1-1248 H H H Me 2 -CO- (CH2) 3-0- (2, 4-diMe-Ph) H H
1-1249 H H H Me 2 -CO- (CH2) 3-0- (3, 4-diMe-Ph) H H
1-1250 H H H Me 2 -CO- (CH2) 3-0- (3, 5-diMe-Ph) H H
1-1251 H H H Me 2 -CO- (CH2) 4-0-cHx H H
1-1252 H H H Me 2 -CO- (CH2) 4-0-Ph H H
1-1253 H H H Me 2 -CO- (CH2) 5-0-cHx H H
1-1254 H H H Me 2 -CO- (CH2) 5-0-Ph H H
1-1255 H H H Me 2 -CO- (CH2) 2-OCH2-cHx H H
1-1256 H H H Me 2 -CO- (CH2) 2-OCH2- (4-F-cHx) H H
1-1257 H H H Me 2 -CO- (CH2) 2-OCH2- (4-Me-cHx) H H
1-1258 H H H Me 2 -CO- (CH2) 2-OCH2- (4-Et-cHx) H H
1-1259 H H H Me 2 -CO- (CH2) 2-OCH2- (4-CF3-cHx) H H
1-1260 H H H Me 2 -CO- (CH2) 2-OCH2- (4-MeO-cHx) H H
1-1261 H H H Me 2 -CO- (CH2) 2-OCH2- (4-EtO-cHx) H H
1-1262 H H H Me 2 -CO- (CH2) 2-OCH2- (4-MeS-cHx) H H
1-1263 H H H Me 2 -CO- (CH2) 2-OCH2- (4-cHx-cHx) H H
1-1264 H H H Me 2 -CO- (CH2) 2-OCH2- (4-Ph-cHx) H H
1-1265 H H H Me 2 -CO- (CH2) 2-OCH2-Ph H H
1-1266 H H H Me 2 -CO- (CH2) 2-OCH2- (4-F-Ph) H H
1-1267 H H H Me 2 -CO- (CH2) 2-OCH2- (4-Me-Ph) H H
1-1268 H H H Me 2 -CO- (CH2) 2-OCH2- (4-Et-Ph) H H
1-1269 H H H Me 2 -CO- (CH2) 2-OCH2- (4-CF3-Ph) H H
1-1270 H H H Me 2 -CO- (CH2) 2-OCH2- (4-MeO-Ph) H H
1-1271 H H H Me 2 -CO- (CH2) 2-OCH2- (4-EtO-Ph) H H
1-1272 H H H Me 2 -CO- (CH2) 2-OCH2- (4-MeS-Ph) H H
1-1273 H H H Me 2 -CO- (CH2) 2-OCH2- (4-cHx-Ph) H H
1-1274 H H H Me 2 -CO- (CH2) 2-OCH2- (4-Ph-Ph) H H
1-1275 H H H Me 2 -CO- (CH2) 3-OCH2-CH2-cPn H H
1-1276 H H H Me 2 -CO- (CH2) 3-OCH2-cHx H H
1-1277 H H H Me 2 -CO- (CH2) 3-OCH2-cHx Me H
1-1278 H H H Me 2 -CO- (CH2) 3-OCH2-cHx H Me 1-1279 H H H Me 2 -CO- (CH2) 3-OCH2-cHx F H
1-1280 H H H Me 2 -CO- (CH2) 3-OCH2-cHx H F
1-1281 H H H Me 2 -CO- (CH2) 3-OCH2- (3-F-cHx) H H
1-1282 H H H Me 2 -CO- (CH2) 3-OCH2- (4-F-cHx) H H
S:/ChemicaUSankyo/FP200301/FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 1-1283 H H H Me 2 -CO- (CH2) 3-OCH2- (4-C1-cHx) H H
1-1284 H H H Me 2 -CO- (CH2) 3-OCH2- (4-Br-cHx) H H
1-1285 H H H Me 2 -CO- (CH2) 3-OCH2- (3-Me-cHx) H H
1-1286 H H H Me 2 -CO- (CH2) 3-OCH2- (4-Me-cHx) H H
1-1287 H H H Me 2 -CO- (CH2) 3-OCH2- (3-Et-cHx) H H
1-1288 H H H Me 2 -CO- (CH2) 3-OCH2- (4-Et-cHx) H H
1-1289 H H H Me 2 -CO- (CH2) 3-OCH2- (3-Pr-cHx) H H
1-1290 H H H Me 2 -CO- (CH2) 3-OCH2- (4-Pr-cHx) H H
1-1291 H H H Me 2 -CO- (CH2) 3-OCH2- (4-iPr-cHx) H H
1-1292 H H H Me 2 -CO- (CH2) 3-OCH2- (3-Bu-cHx) H H
1-1293 H H H Me 2 -CO- (CH2) 3-OCH2- (4-Bu-cHx) H H
1-1294 H H H Me 2 -CO- (CH2) 3-OCH2- (3-CF3-cHx) H H
1-1295 H H H Me 2 -CO- (CH2) 3-OCH2- (4-CF3-cHx) H H
1-1296 H H H Me 2 -CO- (CH2) 3-OCH2- (3-MeO-cHx) H H
1-1297 H H H Me 2 -CO- (CH2) 3-OCH2- (4-MeO-cHx) H H
1-1298 H H H Me 2 -CO- (CH2) 3-OCH2- (3-EtO-cHx) H H
1-1299 H H H Me 2 -CO- (CH2) 3-OCH2- (4-EtO-cHx) H H
1-1300 H H H Me 2 -CO- (CH2) 3-OCH2- (3-PrO-cHx) H H
1-1301 H H H Me 2 -CO- (CH2) 3-OCH2- (4-PrO-cHx) H H
1-1302 H H H Me 2 -CO- (CH2) 3-OCH2- (3-iPrO-cHx) H H
1-1303 H H H Me 2 -CO- (CH2) 3-OCH2- (4-iPrO-cHx) H H
1-1304 H H H Me 2 -CO- (CH2) 3-OCH2- [3- (2-Et-PrO) cHx] H H
1-1305 H H H Me 2 -CO- (CH2) 3-OCH2- [4- (2-Et-PrO) cHx] H H
1-1306 H H H Me 2 -CO- (CH2) 3-OCH2- (3-iBuO-cHx) H H
1-1307 H H H Me 2 -CO- (CH2) 3-OCH2- (4-iBuO-cHx) H H
1-1308 H H H Me 2 -CO- (CH2) 3-OCH2- (3-MeS-cHx) H H
1-1309 H H H Me 2 -CO- (CH2) 3-OCH2- (4-MeS-cHx) H H
1-1310 H H H Me 2 -CO- (CH2) 3-OCH2- (3-EtS-cHx) H H
1-1311 H H H Me 2 -CO- (CH2) 3-OCH2- (4-EtS-cHx) H H
1-1312 H H H Me 2 -CO- (CH2) 3-OCH2- (3-PrS-cHx) H H
1-1313 H H H Me 2 -CO- (CH2) 3-OCH2- (4-PrS-cHx) H H
1-1314 H H H Me 2 -CO- (CH2) 3-OCH2- (3-iPrS-cHx) H H
1-1315 H H H Me 2 -CO- (CH2) 3-OCH2- (4-iPrS-cHx) H H
1-1316 H H H Me 2 -CO- (CH2) 3-OCH2- [3- (2-Et-PrS) cHx] H H
1-1317 H H H Me 2 -CO- (CH2) 3-OCH2- [4- (2-Et-PrS) cHx] H H
1-1318 H H H Me 2 -CO- (CH2) 3-OCH2- (3-iBuS-cHx) H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 1-1319 H H H Me 2 -CO- (CH2) 3-OCH2- (4-iBuS-cHx) H H
1-1320 H H H Me 2 -CO- (CH2) 3-OCH2- (3-cHx-cHx) H H
1-1321 H H H Me 2 -CO- (CH2) 3-OCH2- (4-cHx-cHx) H H
1-1322 H H H Me 2 -CO- (CH2) 3-OCH2- (3-Ph-cHx) H H
1-1323 H H H Me 2 -CO- (CH2) 3-OCH2- (4-Ph-cHx) H H
1-1324 H H H Me 2 -CO- (CH2) 3-OCH2- (2, 4-diMe-cHx) H H
1-1325 H H H Me 2 -CO- (CH2) 3-OCH2- (3, 4-diMe-cHx) H H
1-1326 H H H Me 2 -CO- (CH2) 3-OCH2- (3, 5-diMe-cHx) H H
1-1327 H H H Me 2 -CO- (CH2) 3-OCH2-Ph H H
1-1328 H H H Me 2 -CO- (CH2) 3-OCH2-Ph Me H
1-1329 H H H Me 2 -CO- (CH2) 3-OCH2-Ph H Me 1-1330 H H H Me 2 -CO- (CH2) 3-OCH2-Ph F H
1-1331 H H H Me 2 -CO- (CH2) 3-OCH2-Ph H F
1-1332 H H H Me 2 -CO- (CH2) 3-OCH2- (3-F-Ph) H H
1-1333 H H H Me 2 -CO- (CH2) 3-OCH2- (4-F-Ph) H H
1-1334 H H H Me 2 -CO- (CH2) 3-OCH2- (4-Cl-Ph) H H
1-1335 H H H Me 2 -CO- (CH2) 3-OCH2- (4-Br-Ph) H H
1-1336 H H H Me 2 -CO- (CH2) 3-OCH2- (3-Me-Ph) H H
1-1337 H H H Me 2 -CO- (CH2) 3-OCH2- (4-Me-Ph) H H
1-1338 H H H Me 2 -CO- (CH2) 3-OCH2- (3-Et-Ph) H H
1-1339 H H H Me 2 -CO- (CH2) 3-OCH2- (4-Et-Ph) H H
1-1340 H H H Me 2 -CO- (CH2) 3-OCH2- (3-Pr-Ph) H H
1-1341 H H H Me 2 -CO- (CH2) 3-OCH2- (4-Pr-Ph) H H
1-1342 H H H Me 2 -CO- (CH2) 3-OCH2- (3-iPr-Ph) H H
1-1343 H H H Me 2 -CO- (CH2) 3-OCH2- (4-iPr-Ph) H H
1-1344 H H H Me 2 -CO- (CH2) 3-OCH2- (3-Bu-Ph) H H
1-1345 H H H Me 2 -CO- (CH2) 3-OCH2- (4-Bu-Ph) H H
1-1346 H H H Me 2 -CO- (CH2) 3-OCH2- (3-CF3-Ph) H H
1-1347 H H H Me 2 -CO- (CH2) 3-OCH2- (4-CF3-Ph) H H
1-1348 H H H Me 2 -CO- (CH2) 3-OCH2- (3-MeO-Ph) H H
1-1349 H H H Me 2 -CO- (CH2) 3-OCH2- (4-MeO-Ph) H H
1-1350 H H H Me 2 -CO- (CH2) 3-OCH2- (3-EtO-Ph) H H
1-1351 H H H Me 2 -CO- (CH2) 3-OCH2- (4-EtO-Ph) H H
1-1352 H H H Me 2 -CO- (CH2) 3-OCH2- (3-PrO-Ph) H H
1-1353 H H H Me 2 -CO- (CH2) 3-OCH2- (4-Pro-Ph) H H
1-1354 H H H Me 2 -CO- (CH2) 3-OCH2- (3-iPrO-Ph) H H
S:/Chemical/Sankyo/FP20030I /FP030I s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 1-1355 H H H Me 2 -CO- (CH2) 3-OCH2- (4-iPrO-Ph) H H
1-1356 H H H Me 2 -CO- (CH2) 3-OCH2- [3- (2-Et-PrO) Ph] H H
1-1357 H H H Me 2 -CO- (CH2) 3-OCH2- [4- (2-Et-PrO) Ph] H H
1-1358 H H H Me 2 -CO- (CH2) 3-OCH2- (3-iBuO-Ph) H H
1-1359 H H H Me 2 -CO- (CH2) 3-OCH2- (4-iBuO-Ph) H H
1-1360 H H H Me 2 -CO- (CH2) 3-OCH2- (3-MeS-Ph) H H
1-1361 H H H Me 2 -CO- (CH2) 3-OCH2- (4-MeS-Ph) H H
1-1362 H H H Me 2 -CO- (CH2) 3-OCH2- (3-EtS-Ph) H H
1-1363 H H H Me 2 -CO- (CH2) 3-OCH2- (4-EtS-Ph) H H
1-1364 H H H Me 2 -CO- (CH2) 3-OCH2- (3-PrS-Ph) H H
1-1365 H H H Me 2 -CO- (CH2) 3-OCH2- (4-PrS-Ph) H H
1-1366 H H H Me 2 -CO- (CH2) 3-OCH2- (3-iPrS-Ph) H H
1-1367 H H H Me 2 -CO- (CH2) 3-OCH2- (4-iPrS-Ph) H H
1-1368 H H H Me 2 -CO- (CH2) 3-OCH2- [3- (2-Et-PrS) Ph] H H
1-1369 H H H Me 2 -CO- (CH2) 3-OCH2- [4- (2-Et-PrS) Ph] H H
1-1370 H H H Me 2 -CO- (CH2) 3-OCH2- (3-iBuS-Ph) H H
1-1371 H H H Me 2 -CO- (CH2) 3-OCH2- (4-iBuS-Ph) H H
1-1372 H H H Me 2 -CO- (CH2) 3-OCH2- (3-cHx-Ph) H H
1-1373 H H H Me 2 -CO- (CH2) 3-OCH2- (4-cHx-Ph) H H
1-1374 H H H Me 2 -CO- (CH2) 3-OCH2- (3-Ph-Ph) H H
1-1375 H H H Me 2 -CO- (CH2) 3-OCH2- (4-Ph-Ph) H H
1-1376 H H H Me 2 -CO- (CH2) 3-OCH2- (2, 4-diMe-Ph) H H
1-1377 H H H Me 2 -CO- (CH2) 3-OCH2- (3, 4-diMe-Ph) H H
1-1378 H H H Me 2 -CO- (CH2) 3-OCH2- (3, 5-diMe-Ph) H H
1-1379 H H H Me 2 -CO- (CH2) 4-OCH2-cHx H H
1-1380 H H H Me 2 -CO- (CH2) 4-OCH2-Ph H H
1-1381 H H H Me 2 -CO- (CH2) 5-OCH2-cHx H H
1-1382 H H H Me 2 -CO- (CH2) 5-OCH2-Ph H H
1-1383 H H H Me 2 -CH (OH) -CH2-cHx H H
1-1384 H H H Me 2 -CH (OH) -CH2-Ph H H
1-1385 H H H Me 2 -CH (OH) - (CH2) 2-cHx H H
1-1386 H H H Me 2 -CH (OH) - (CH2) 2-Ph H H
1-1387 H H H Me 2 -CH (OH) - (CH2) 3-cHx H H
1-1388 H H H Me 2 -CH (OH) - (CH2) 3-Ph H H
1-1389 H H H Me 2 -CH (OH) - (CH2) 4-cHx H H
1-1390 H H H Me 2 -CH (OH) - (CH2) 4- (4-F-cHx) H H
S:/Chemical/Sankyo/FP200301/FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 1-1391 H H H Me 2 -CH (OH) - (CH2) 4- (4-Me-cHx) H H
1-1392 H H H Me 2 -CH (OH) - (CH2) 4- (4-Et-cHx) H H
1-1393 H H H Me 2 -CH (OH) - (CH2) 4- (4-CF3-cHx) H H
1-1394 H H H Me 2 -CH (OH) - (CH2) 4- (4-MeO-cHx) H H
1-1395 H H H Me 2 -CH (OH) - (CH2) 4- (4-EtO-cHx) H H
1-1396 H H H Me 2 -CH (OH) - (CH2) 4- (4-MeS-cHx) H H
1-1397 H H H Me 2 -CH (OH) - (CH2) 4- (4-cHx-cHx) H H
1-1398 H H H Me 2 -CH (OH) - (CH2) 4- (4-Ph-cHx) H H
1-1399 H H H Me 2 -CH (OH) - (CH2) 4-Ph H H
1-1400 H H H Me 2 -CH (OH) - (CH2) 4- (4-F-Ph) H H
1-1401 H H H Me 2 -CH (OH) - (CH2) 4- (4-Me-Ph) H H
1-1402 H H H Me 2 -CH (OH) - (CH2) 4- (4-Et-Ph) H H
1-1403 H H H Me 2 -CH (OH) - (CH2) 4- (4-CF3-Ph) H H
1-1404 H H H Me 2 -CH (OH) - (CH2) 4- (4-MeO-Ph) H H
1-1405 H H H Me 2 -CH (OH) - (CH2) 4- (4-EtO-Ph) H H
1-1406 H H H Me 2 -CH (OH) - (CH2) 4- (4-MeS-Ph) H H
1-1407 H H H Me 2 -CH (OH) - (CH2) 4- (4-cHx-Ph) H H
1-1408 H H H Me 2 -CH (OH) - (CH2) 4- (4-Ph-Ph) H H
1-1409 H H H Me 2 -CH (OH) - (CH2) 5-cHx H H
1-1410 H H H Me 2 -CH (OH) - (CH2) 5- (4-F-cHx) H H
1-1411 H H H Me 2 -CH (OH) - (CH2) 5- (4-Me-cHx) H H
1-1412 H H H Me 2 -CH (OH) - (CH2) 5- (4-Et-cHx) H H
1-1413 H H H Me 2 -CH (OH) - (CH2) 5- (4-CF3-cHx) H H
1-1414 H H H Me 2 -CH (OH) - (CH2) 5- (4-MeO-cHx) H H
1-1415 H H H Me 2 -CH (OH) - (CH2) 5- (4-EtO-cHx) H H
1-1416 H H H Me 2 -CH (OH) - (CH2) 5- (4-MeS-cHx) H H
1-1417 H H H Me 2 -CH (OH) - (CH2) 5- (4-cHx-cHx) H H
1-1418 H H H Me 2 -CH (OH) - (CH2) 5- (4-Ph-cHx) H H
1-1419 H H H Me 2 -CH (OH) - (CH2) 5-Ph H H
1-1420 H H H Me 2 -CH (OH) - (CH2) 5- (4-F-Ph) H H
1-1421 H H H Me 2 -CH (OH) - (CH2) 5- (4-Me-Ph) H H
1-1422 H H H Me 2 -CH (OH) - (CH2) 5- (4-Et-Ph) H H
1-1423 H H H Me 2 -CH (OH) - (CH2) 5- (4-CF3-Ph) H H
1-1424 H H H Me 2 -CH (OH) - (CH2) 5- (4-MeO-Ph) H H
1-1425 H H H Me 2 -CH (OH) - (CH2) 5- (4-EtO-Ph) H H
1-1426 H H H Me 2 -CH (OH) - (CH2) 5- (4-MeS-Ph) H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 1-1427 H H H Me 2 -CH (OH) - (CH2) 5- (4-cHx-Ph) H H
1-1428 H H H Me 2 -CH (OH) - (CH2) 5- (4-Ph-Ph) H H
1-1429 H H H Me 2 -CH (OH) - (CH2) 6-cHx H H
1-1430 H H H Me 2 -CH (OH) - (CH2) 6-Ph H H
1-1431 H H H Me 2 -CH (OH) - (CH2) 7-cHx H H
1-1432 H H H Me 2 -CH (OH) - (CH2)7-Ph H H
1-1433 H H H Me 2 -4-(cHx-CH2O)Ph H H
1-1434 H H H Me 2 -4-(cHx-CH2O)-2-F-Ph H H
1-1435 H H H Me 2 -4-(cHx-CH2O)-3-F-Ph H H
1-1436 H H H Me 2 -4-(cHx-CH2O)-2,3-diF-Ph H H
1-1437 H H H Me 2 -4-(cHx-CH2O)-2-C1-Ph H H
1-1438 H H H Me 2 -4-(cHx-CH2O)-3-C1-Ph H H
1-1439 H H H Me 2 -4-(cHx-CH2O)-2,3-diCl-Ph H H
1-1440 H H H Me 2 -4-(cHx-CH2O)-2-Me-Ph H H
1-1441 H H H Me 2 -4-(cHx-CH2O)-3-Me-Ph H H
1-1442 H H H Me 2 -4-(cHx-CH2O)-2,3-diMe-Ph H H
1-1443 H H H Me 2 -4- [cHx- (CH2) 20] Ph H H
1-1444 H H H Me 2 -3- [cHx- (CH2) 201 Ph H H
1-1445 H H H Me 2 -(4-BzO-Ph) H H
1-1446 H H H Me 2 -(4-BzO-2-F-Ph) H H
1-1447 H H H Me 2 -(4-BzO-3-F-Ph) H H
1-1448 H H H Me 2 -(4-BzO-2,3-diF-Ph) H H
1-1449 H H H Me 2-(4-BzO-2-Cl-Ph) H H
1-1450 H H H Me 2-(4-BzO-3-C1-Ph) H H
1-1451 H H H Me 2 -(4-BzO-2,3-diCl-Ph) H H
1-1452 H H H Me 2 -(4-BzO-2-Me-Ph) H H
1-1453 H H H Me 2 -(4-BzO-3-Me-Ph) H H
1-1454 H H H Me 2 -(4-BzO-2,3-diMe-Ph) H H
1-1455 H H H Me 2 -4- [Ph- (CH2) 20] -Ph H H
1-1456 H H H Me 2 -4- [Ph- (CH2) 30] -Ph H H
1-1457 H H H Et 2 - (CH2) 3-cHx H H
1-1458 H H H Et 2 - (CH2) 3-Ph H H
1-1459 H H H Et 2 - (CH2) 4-cHx H H
1-1460 H H H Et 2 - (CH2) 4-Ph H H
1-1461 H H H Et 2-(CH2)5-cPn H H
1-1462 H H H Et 2 - (CH2) 5-cHx H H
S:/ChemicaVSankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 1-1463 H H H Et 2 - (CH2) 5-cHx Me H
1-1464 H H H Et 2 - (CH2) 5-cHx H Me 1-1465 H H H Et 2 - (CH2) 5-cHx F H
1-1466 H H H Et 2 - (CH2) 5-cHx H F
1-1467 H H H Et 2 - (CH2) 5- (4-F-cHx) H H
1-1468 H H H Et 2 - (CH2) 5- (4-C1-cHx) H H
1-1469 H H H Et 2-(CH2)5-(4-Br-cHx) H H
1-1470 H H H Et 2 - (CH2) 5- (4-Me-cHx) H H
1-1471 H H H Et 2 - (CH2) 5- (4-Et-cHx) H H
1-1472 H H H Et 2 - (CH2) 5- (4-Pr-cHx) H H
1-1473 H H H Et 2 - (CH2) 5- (4-iPr-cHx) H H
1-1474 H H H Et 2 - (CH2) 5- (4-CF3-cHx) H H
1-1475 H H H Et 2 - (CH2) 5- (4-MeO-cHx) H H
1-1476 H H H Et 2 - (CH2) 5- (4-EtO-cHx) H H
1-1477 H H H Et 2 - (CH2) 5- (4-PrO-cHx) H H
1-1478 H H H Et 2 - (CH2) 5- (4-iPrO-cHx) H H
1-1479 H H H Et 2 - (CH2) 5- (3-MeS-cHx) H H
1-1480 H H H Et 2 - (CH2) 5- (4-MeS-cHx) H H
1-1481 H H H Et 2 - (CH2) 5- (2, 4-diMe-cHx) H H
1-1482 H H H Et 2 - (CH2) 5- (3, 4-diMe-cHx) H H
1-1483 H H H Et 2 - (CH2) 5- (3, 5-diMe-cHx) H H
1-1484 H H H Et 2 - (CH2) 5-Ph H H
1-1485 H H H Et 2 - (CH2) 5-Ph Me H
1-1486 H H H Et 2 - (CH2) 5-Ph H Me 1-1487 H H H Et 2 - (CH2) 5-Ph F H
1-1488 H H H Et 2-(CH2)5-Ph H F
1-1489 H H H Et 2 - (CH2) 5- (4-F-Ph) H H
1-1490 H H H Et 2 - (CH2) 5- (4-C1-Ph) H H
1-1491 H H H Et 2 - (CH2) 5- (4-Br-Ph) H H
1-1492 H H H Et 2 - (CH2) 5- (4-Me-Ph) H H
1-1493 H H H Et 2 - (CH2) 5- (4-Et-Ph) H H
1-1494 H H H Et 2 - (CH2) 5- (4-Pr-Ph) H H
1-1495 H H H Et 2 - (CH2) 5- (4-iPr-Ph) H H
1-1496 H H H Et 2-(CH2)5-(4-Bu-Ph) H H
1-1497 H H H Et 2 - (CH2) 5- (4-CF3-Ph) H H
1-1498 H H H Et 2 - (CH2) 5- (4-MeO-Ph) H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 1-1499 H H H Et 2 - (CH2) 5- (4-EtO-Ph) H H
1-1500 H H H Et 2 - (CH2) 5- (4-PrO-Ph) H H
1-1501 H H H Et 2 - (CH2) 5- (4-iPrO-Ph) H H
1-1502 H H H Et 2 - (CH2) 5- (3-MeS-Ph) H H
1-1503 H H H Et 2-(CH2)5-(4-MeS-Ph) H H
1-1504 H H H Et 2 - (CH2) 5- (2, 4-diMe-Ph) H H
1-1505 H H H Et 2 - (CH2) 5- (3, 4-diMe-Ph) H H
1-1506 H H H Et 2 - (CH2) 5- (3, 5-diMe-Ph) H H
1-1507 H H H Et 2 - (CH2) 6-cPn H H
1-1508 H H H Et 2 - (CH2) 6-cHx H H
1-1509 H H H Et 2 - (CH2) 6-cHx Me H
1-1510 H H H Et 2 - (CH2) 6-cHx H Me 1-1511 H H H Et 2 - (CH2) 6-cHx F H
1-1512 H H H Et 2 - (CH2) 6-cHx H F
1-1513 H H H Et 2 - (CH2) 6- (4-F-cHx) H H
1-1514 H H H Et 2 - (CH2) 6- (4-Cl-cHx) H H
1-1515 H H H Et 2 - (CH2) 6- (4-Br-cHx) H H
1-1516 H H H Et 2 - (CH2) 6- (4-Me-cHx) H H
1-1517 H H H Et 2 - (CH2) 6- (4-Et-cHx) H H
1-1518 H H H Et 2 - (CH2) 6- (4-Pr-cHx) H H
1-1519 H H H Et 2 - (CH2) 6- (4-iPr-cHx) H H
1-1520 H H H Et 2 - (CH2) 6- (4-Bu-cHx) H H
1-1521 H H H Et 2 - (CH2) 6- (4-CF3-cHx) H H
1-1522 H H H Et 2 - (CH2) 6- (4-MeO-cHx) H H
1-1523 H H H Et 2 - (CH2) 6- (4-EtO-cHx) H H
1-1524 H H H Et 2 - (CH2) 6- (4-PrO-cHx) H H
1-1525 H H H Et 2 - (CH2) 6- (4-iPrO-cHx) H H
1-1526 H H H Et 2 - (CH2) 6- (3-MeS-cHx) H H
1-1527 H H H Et 2 - (CH2) 6- (4-MeS-cHx) H H
1-1528 H H H Et 2 - (CH2) 6- (2, 4-diMe-cHx) H H
1-1529 H H H Et 2 - (CH2) 6- (3, 4-diMe-cHx) H H
1-1530 H H H Et 2 - (CH2) 6- (3, 5-diMe-cHx) H H
1-1531 H H H Et 2 - (CH2) 6-Ph H H
1-1532 H H H Et 2 - (CH2) 6-Ph Me H
1-1533 H H H Et 2 - (CH2) 6-Ph H Me 1-1534 H H H Et 2 - (CH2) 6-Ph F H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 1-1535 H H H Et 2 - (CH2) 6-Ph H F
1-1536 H H H Et 2 - (CHZ) 6- (4-F- Ph) H H
1-1537 H H H Et 2 - (CHZ) 6- (4-Cl-Ph) H H
1-1538 H H H Et 2 - (CHZ) 6- (4-Br-Ph) H H
1-1539 H H H Et 2 - (CHZ) 6- (4-Me-Ph) H H
1-1540 H H H Et 2 - (CHZ) 6- (4-Et-Ph) H H
1-1541 H H H Et 2 - (CHZ) 6- (4-Pr-Ph) H H
1-1542 H H H Et 2 - (CH2) 6- (4-iPr-Ph) H H
1-1543 H H H Et 2-(CH2)6-(4-Bu-Ph) H H
1-1544 H H H Et 2 - (CHZ) 6- (4-CF3-Ph) H H
1-1545 H H H Et 2 - (CHZ) 6- (4-MeO-Ph) H H
1-1546 H H H Et 2 - (CHZ) 6- (4-EtO-Ph) H H
1-1547 H H H Et 2 - (CHZ) 6- (4-PrO-Ph) H H
1-1548 H H H Et 2 - (CHZ) 6- (4-iPrO-Ph) H H
1-1549 H H H Et 2 - (CHZ) 6- (3-MeS-Ph) H H
1-1550 H H H Et 2 - (CHZ) 6- (4-MeS-Ph) H H
1-1551 H H H Et 2 - (CHZ) 6- (2, 4-diMe-Ph) H H
1-1552 H H H Et 2-(CH2)6-(3,4-diMe-Ph) H H
1-1553 H H H Et 2 - (CH2) 6- (3, 5-diMe-Ph) H H
1-1554 H H H Et 2 - (CH2) 7-cHx H H
1-1555 H H H Et 2 - (CH2) 7-Ph H H
1-1556 H H H Et 2 -C=C-CH2-cHx H H
1-1557 H H H Et 2 -C=C-CH2-Ph H H
1-1558 H H H Et 2 -C=C- (CH2) 2-cHx H H
1-1559 H H H Et 2 -C=C- (CH2) 2-Ph H H
1-1560 H H H Et 2 -C=C- (CH2) 3-cPn H H
1-1561 H H H Et 2 -C-C- (CH2) 3-cHx H H
1-1562 H H H Et 2-C=C-(CH2)3-cHx Me H
1-1563 H H H Et 2-C=C-(CH2)3-cHx H Me 1-1564 H H H Et 2 -C=C- (CH2) 3-cHx F H
1-1565 H H H Et 2 -C=C- (CH2) 3-cHx H F
1-1566 H H H Et 2 -C=C- (CH2) 3- (4-F-cHx) H H
1-1567 H H H Et 2 -C-C- (CH2) 3- (4-C1-cHx) H H
1-1568 H H H Et 2-C-C-(CH2)3-(4-Br-cHx) H H
S:/ChemicaVSankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 1-1569 H H H Et 2 -C=C- (CH2) 3- (4-Me-cHx) H H
1-1570 H H H Et 2 -C-C- (CH2) 3- (4-Et-cHx) H H
1-1571 H H H Et 2 -C=C- (CH2) 3- (4-Pr-cHx) H H
1-1572 H H H Et 2-C=C-(CH2)3-(4-iPr-cHx) H H
1-1573 H H H Et 2-C=C-(CH2)3-(4-Bu-cHx) H H
1-1574 H H H Et 2 -C=C- (CH2) 3- (4-CF3-cHx) H H
1-1575 H H H Et 2 -C=C- (CH2) 3- (4-MeO-cHx) H H
1-1576 H H H Et 2 -C=-C- (CH2) 3- (4-EtO-cHx) H H
1-1577 H H H Et 2-C=C-(CH2)3-(4-PrO-cHx) H H
1-1578 H H H Et 2-C-C-(CH2)3-(4-iPrO-cHx) H H
1-1579 H H H Et 2 -C-C- (CH2) 3- (3-MeS-cHx) H H
1-1580 H H H Et 2 -C=C- (CH2) 3- (4-MeS-cHx) H H
1-1581 H H H Et 2-C=C-(CH2)3-(2,4-diMe-cHx) H H
1-1582 H H H Et 2-C=C-(CH2)3-(3,4-diMe-cHx) H H
1-1583 H H H Et 2-C=C-(CH2)3-(3,5-diMe-cHx) H H
1-1584 H H H Et 2 -C-C- (CH2) 3-Ph H H
1-1585 H H H Et 2 -C=-C- (CH2) 3-Ph Me H
1-1586 H H H Et 2 -C=C- (CH2) 3-Ph H Me 1-1587 H H H Et 2 -C-C- (CH2) 3-Ph F H
1-1588 H H H Et 2 -C=C- (CH2) 3-Ph H F
1-1589 H H H Et 2-C=C-(CH2)3-(4-F-Ph) H H
1-1590 H H H Et 2 -C=C- (CH2) 3- (4-C1-Ph) H H
1-1591 H H H Et 2 -C=-C- (CH2) 3- (4-Br-Ph) H H
1-1592 H H H Et 2 -C=C- (CH2) 3- (4-Me-Ph) H H
1-1593 H H H Et 2-C-C-(CH2)3-(4-Et-Ph) H H
1-1594 H H H Et 2 -C=-C- (CH2) 3- (4-Pr-Ph) H H
1-1595 H H H Et 2-C=C-(CH2)3-(4-iPr-Ph) H H
1-1596 H H H Et 2 -C=C- (CH2) 3- (4-Bu-Ph) H H
1-1597 H H H Et 2 -C=-C- (CH2) 3- (4-CF3-Ph) H H
1-1598 H H H Et 2 -C=-C- (CH2) 3- (4-MeO-Ph) H H
1-1599 H H H Et 2-C=C-(CH2)3-(4-EtO-Ph) H H
1-1600 H H H Et 2 -C-C- (CH2) 3- (4-Pro-Ph) H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 1-1601 H H H Et 2-C=C-(CH2)3-(4-iPrO-Ph) H H
1-1602 H H H Et 2-C=C-(CH2)3-(3-MeS-Ph) H H
1-1603 H H H Et 2 -C=C- (CH2) 3- (4-MeS-Ph) H H
1-1604 H H H Et 2-C=C-(CH2)3-(2,4-diMe-Ph) H H
1-1605 H H H Et 2-C=C-(CH2)3-(3,4-diMe-Ph) H H
1-1606 H H H Et 2-C=C-(CH2)3-(3,5-diMe-Ph) H H
1-1607 H H H Et 2 -C=C- (CH2) 4-cPn H H
1-1608 H H H Et 2 -C=C- (CH2) 4-cHx H H
1-1609 H H H Et 2 -C=C- (CH2) 4-cHx Me H
1-1610 H H H Et 2 -C=C- (CH2) 4-cHx H Me 1-1611 H H H Et 2 -C=C- (CH2) 4-cHx F H
1-1612 H H H Et 2 -C=C- (CH2) 4-cHx H F
1-1613 H H H Et 2 -C=C- (CH2) 4- (4-F-cHx) H H
1-1614 H H H Et 2 -C=C- (CH2) 4- (4-C1-cHx) H H
1-1615 H H H Et 2 -C=C- (CH2) 4- (4-Br-cHx) H H
1-1616 H H H Et 2-C=C-(CH2)4-(4-Me-cHx) H H
1-1617 H H H Et 2-C=C-(CH2)4-(4-Et-cHx) H H
1-1618 H H H Et 2 -C=C- (CH2) 4- (4-Pr-cHx) H H
1-1619 H H H Et 2-C=C-(CH2)4-(4-iPr-cHx) H H
1-1620 H H H Et 2 -C=-C- (CH2) 4- (4-Bu-cHx) H H
1-1621 H H H Et 2 -C=C- (CH2) 4- (4-CF3-cHx) H H
1-1622 H H H Et 2-C=C-(CH2)4-(4-MeO-cHx) H H
1-1623 H H H Et 2 -C=C- (CH2) 4- (4-EtO-cHx) H H
1-1624 H H H Et 2 -C=C- (CH2) 4- (4-PrO-cHx) H H
1-1625 H H H Et 2-C=C-(CH2)4-(4-iPrO-cHx) H H
1-1626 H H H Et 2 -C=C- (CH2) 4- (4-MeS-cHx) H H
1-1627 H H H Et 2 -C=C- (CH2) 4- (2, 4-dime-cHx) H H
1-1628 H H H Et 2 -C=C- (CH2) 4- (3, 4-diMe-cHx) H H
1-1629 H H H Et 2 -C=-C- (CH2) 4- (3, 5-diMe-cHx) H H
1-1630 H H H Et 2 -C=C- (CH2) 4-Ph H H
1-1631 H H H Et 2 -C=C- (CH2) 4-Ph Me H
1-1632 H H H Et 2 -C=C- (CH2) 4-Ph H Me S:/ChemicalSankyo/FP200301/FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 1-1633 H H H Et 2 -C=C- (CH2) 4-Ph F H
1-1634 H H H Et 2 -C=C- (CH2) 4-Ph H F
1-1635 H H H Et 2-C=C-(CH2)4-(4-F-Ph) H H
1-1636 H H H Et 2 -C=C- (CH2) 4- (4-Cl-Ph) H H
1-1637 H H H Et 2 -C=C- (CHZ) 4- (4-Br-Ph) H H
1-1638 H H H Et 2 -C-C- (CHZ) 4- (4-Me-Ph) H H
1-1639 H H H Et 2-C=C-(CH2)4-(4-Et-Ph) H H
1-1640 H H H Et 2-C=C-(CH2)4-(4-Pr-Ph) H H
1-1641 H H H Et 2 -C=C- (CH2) 4- (4-iPr-Ph) H H
1-1642 H H H Et 2 -C=C- (CH2) 4- (4-Bu-Ph) H H
1-1643 H H H Et 2 -C=C- (CH2) 4- (4-CF3-Ph) H H
1-1644 H H H Et 2 -C=C- (CHZ) 4- (4-MeO-Ph) H H
1-1645 H H H Et 2-C=C-(CH2)4-(4-EtO-Ph) H H
1-1646 H H H Et 2 -C=C- (CH2) 4- (4-PrO-Ph) H H
1-1647 H H H Et 2 -C=C- (CHZ) 4- (4-iPrO-Ph) H H
1-1648 H H H Et 2-C=C-(CH2)4-(3-MeS-Ph) H H
1-1649 H H H Et 2 -C=C- (CHZ) 4- (4-MeS-Ph) H H
1-1650 H H H Et 2-C=C-(CH2)4-(2,4-diMe-Ph) H H
1-1651 H H H Et 2-C=C-(CH2)4-(3,4-diMe-Ph) H H
1-1652 H H H Et 2-C-C-(CH2)4-(3,5-diMe-Ph) H H
1-1653 H H H Et 2 -C=C- (CH2) 5-cHx H H
1-1654 H H H Et 2 -C=C- (CH2) 5-Ph H H
1-1655 H H H Et 2 -C=C- (CH2) 6-cHx H H
1-1656 H H H Et 2 -C=C- (CH2) 6-Ph H H
1-1657 H H H Et 2-C=-C-CH2O-cHx H H
1-1658 H H H Et 2-C=C-CH2O-Ph H H
1-1659 H H H Et 2 -C=-C- (CHZ) 20-cPn H H
1-1660 H H H Et 2 -C=C- (CH2) 20-cHx H H
1-1661 H H H Et 2 -C=-C- (CH2) 20-cHx Me H
1-1662 H H H Et 2-C=C-(CH2)2O-cHx H Me 1-1663 H H H Et 2-C=C-(CH2)2O-cHx F H
1-1664 H H H Et 2 -C=C- (CH2) 20-cHx H F
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 1-1665 H H H Et 2 -C=C- (CH2) 20- (4-F-cHx) H H
1-1666 H H H Et 2 -C=C- (CH2) 20- (4-C1-cHx) H H
1-1667 H H H Et 2 -C=C- (CH2) 20- (4-Br-cHx) H H
1-1668 H H H Et 2-C=C-(CH2)20-(4-Me-cHx) H H
1-1669 H H H Et 2 -C=C- (CH2) 20- (4-Et-cHx) H H
1-1670 H H H Et 2 -C=C- (CH2) 20- (4-Pr-cHx) H H
1-1671 H H H Et 2-C=C-(CH2)20-(4-iPr-cHx) H H
1-1672 H H H Et 2 -C=C- (CH2) 20- (4-Bu-cHx) H H
1-1673 H H H Et 2 -C=C- (CH2) 20- (4-CF3-cHx) H H
1-1674 H H H Et 2-C-C-(CH2)20-(4-MeO-cHx) H H
1-1675 H H H Et 2-C-C-(CH2)2O-(4-EtO-cHx) H H
1-1676 H H H Et 2-C=C-(CH2)20-(4-PrO-cHx) H H
1-1677 H H H Et 2-C=C-(CH2)20-(4-iPrO-cHx) H H
1-1678 H H H Et 2-C=C-(CH2)20-(3-MeS-cHx) H H
1-1679 H H H Et 2-C=C-(CH2)20-(4-MeS-cHx) H H
1-1680 H H H Et 2-C=C-(CH2)2O-(2,4-diMe-cHx) H H
1-1681 H H H Et 2 -C=C- (CH2) 20- (3, 4-diMe-cHx) H H
1-1682 H H H Et 2 -C=C- (CH2) 20- (3, 5-diMe-cHx) H H
1-1683 H H H Et 2 -C=C- (CH2) 20-Ph H H
1-1684 H H H Et 2 -C=C- (CH2) 20-Ph Me H
1-1685 H H H Et 2 -C=-C- (CH2) 20-Ph H Me 1-1686 H H H Et 2 -C=C- (CH2) 20-Ph F H
1-1687 H H H Et 2 -C=C- (CH2) 20-Ph H F
1-1688 H H H Et 2-C-C-(CH2)2O-(4-F-Ph) H H
1-1689 H H H Et 2 -C=C- (CH2) 20- (4-C1-Ph) H H
1-1690 H H H Et 2 -C=-C- (CH2) 20- (4-Br-Ph) H H
1-1691 H H H Et 2-C=C-(CH2)20-(4-Me-Ph) H H
1-1692 H H H Et 2-C-C-(CH2)20-(4-Et-Ph) H H
1-1693 H H H Et 2 -C=-C- (CH2) 20- (4-Pr-Ph) H H
1-1694 H H H Et 2 -C=C- (CH2) 20- (4-iPr-Ph) H H
1-1695 H H H Et 2 -CC- (CH2) 20- (4-Bu-Ph) H H
1-1696 H H H Et 2 -C=C- (CH2) 20- (4-CF3-Ph) H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 1-1697 H H H Et 2-C=C-(CH2)20-(4-MeO-Ph) H H
1-1698 H H H Et 2-C=C-(CH2)20-(4-EtO-Ph) H H
1-1699 H H H Et 2-C=C-(CH2)20-(4-PrO-Ph) H H
1-1700 H H H Et 2-C=C-(CH2)20-(4-iPrO-Ph) H H
1-1701 H H H Et 2 -C=C- (CH2) 20- (4-MeS-Ph) H H
1-1702 H H H Et 2 -C-C- (CH2) 20- (2, 4-diMe-Ph) H H
1-1703 H H H Et 2-C=C-(CH2)20-(3,4-diMe-Ph) H H
1-1704 H H H Et 2 -C=C- (CH2) 20- (3, 5-diMe-Ph) H H
1-1705 H H H Et 2 -CO- (CH2) 3-cHx H H
1-1706 H H H Et 2 -CO- (CH2) 3-Ph H H
1-1707 H H H Et 2 -CO- (CH2) 4-cHx H H
1-1708 H H H Et 2 -CO- (CH2) 4-Ph H H
1-1709 H H H Et 2 -CO- (CH2) 5-cHx H H
1-1710 H H H Et 2 -CO- (CH2) 5-Ph H H
1-1711 H H H Et 2 -CH (OH) - (CH2) 4-cHx H H
1-1712 H H H Et 2-CH(OH)-(CH2)4-Ph H H
1-1713 H H H Et 2 -CH (OH) - (CH2) 5-cHx H H
1-1714 H H H Et 2 -CH (OH) - (CH2) 5-Ph H H
1-1715 H H H Et 2 -4- (cHx-CH2O) Ph H H
1-1716 H H H Et 2 -4- [cHx- (CH2) 20] Ph H H
1-1717 H H H Et 2 -4- [cHx- (CH2) 30] Ph H H
1-1718 H H H Et 2 -(4-BzO-Ph) H H
1-1719 H H H Et 2 -(4-BzO-2-F-Ph) H H
1-1720 H H H Et 2 -(4-BzO-3-F-Ph) H H
1-1721 H H H Et 2-(4-BzO-2,3-diF-Ph) H H
1-1722 H H H Et 2-(4-BzO-2-C1-Ph) H H
1-1723 H H H Et 2-(4-BzO-3-C1-Ph) H H
1-1724 H H H Et 2 -(4-BzO-2,3-diCl-Ph) H H
1-1725 H H H Et 2 -(4-BzO-2-Me-Ph) H H
1-1726 H H H Et 2 -(4-BzO-3-Me-Ph) H H
1-1727 H H H Et 2 -(4-BzO-2,3-diMe-Ph) H H
1-1728 H H H Et 2 -4- [Ph- (CH2) 20] -Ph H H
1-1729 H H H Et 2 -4- [Ph- (CH2) 30] -Ph H H
1-1730 H H H Pr 2 - (CH2) 5-cHx H H
1-1731 H H H Pr 2 - (CH2) 5-Ph H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 1-1732 H H H Pr 2 - (CH2) 6-cHx H H
1-1733 H H H Pr 2 - (CH2) 6-Ph H H
1-1734 H H H Pr 2 -C=C-CH2-cHx H H
1-1735 H H H Pr 2-C=C-(CH2)3-cHx H H
1-1736 H H H Pr 2 -C=-C- (CH2) 3-Ph H H
1-1737 H H H Pr 2 -C=C- (CH2) 4-cHx H H
1-1738 H H H Pr 2 -C=C- (CH2) 4-Ph H H
1-1739 H H H Pr 2 -C=C- (CH2) 20-cHx H H
1-1740 H H H Pr 2 -C=C- (CH2) 20-Ph H H
1-1741 H H H Pr 2 -4- (cHx-CH2O) Ph H H
1-1742 H H H Pr 2 -(4-BzO-Ph) H H
1-1743 H H H Me 2 - (CH2) 4- (3-F-Ph) H H
1-1744 H H H Me 2 - (CH2) 4- (3, 4-diF-Ph) H H
1-1745 H H H Me 2 - (CH2) 4- (3, 5-diF-Ph) H H
1-1746 H H H Me 2-(CH2)4-(3-C1-Ph) H H
1-1747 H H H Me 2 - (CH2) 4- (4-C1-Ph) H H
1-1748 H H H Me 2 - (CH2) 4- (3, 4-diCl-Ph) H H
1-1749 H H H Me 2 - (CH2) 4- (3, 5-diCl-Ph) H H
1-1750 H H H Me 2 - (CH2) 4- (3-Me-Ph) H H
1-1751 H H H Me 2-(CH2)4-(3,4-diMe-Ph) H H
1-1752 H H H Me 2 - (CH2) 4- (3, 5-diMe-Ph) H H
1-1753 H H H Me 2 - (CH2) 4- (3-CF3-Ph) H H
1-1754 H H H Me 2 - (CH2) 4- (3, 4-diCF3-Ph) H H
1-1755 H H H Me 2 - (CH2) 4- (3, 5-diCF3-Ph) H H
1-1756 H H H Me 2 - (CH2) 4- (3-MeO-Ph) H H
1-1757 H H H Me 2 - (CH2) 4- (3, 4-diMeO-Ph) H H
1-1758 H H H Me 2 - (CH2) 4- (3, 5-diMeO-Ph) H H
1-1759 H H H Me 2 - (CH2) 4- (3, 4, 5-triMeO-Ph) H H
1-1760 H H H Me 2-(CH2)4-(3-Ac-Ph) H H
1-1761 H H H Me 2 - (CH2) 4- (4-Ac-Ph) H H
1-1762 H H H Me 2-(CH2)5-(3,4-diF-Ph) H H
1-1763 H H H Me 2 - (CH2) 5- (3, 5-diF-Ph) H H
1-1764 H H H Me 2-(CH2)5-(3-C1-Ph) H H
1-1765 H H H Me 2 - (CH2) 5- (3, 4-diCl-Ph) H H
1-1766 H H H Me 2 - (CH2) 5- (3, 5-diCl-Ph) H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 1-1767 H H H Me 2 - (CH2) 5- (3, 4-diCF3-Ph) H H
1-1768 H H H Me 2 - (CHZ) 5- (3, 5-diCF3-Ph) H H
1-1769 H H H Me 2 - (CHZ) 5- (3, 4-diMeO-Ph) H H
1-1770 H H H Me 2 - (CHZ) 5- (3, 5-diMeO-Ph) H H
1-1771 H H H Me 2-(CH2)5-(3,4,5-triMeO-Ph) H H
1-1772 H H H Me 2-(CH2)5-(3-Ac-Ph) H H
1-1773 H H H Me 2 - (CH2) 5- (4-Ac-Ph) H H
1-1774 H H H Me 2-(CH2)3-0-(3-F-Ph) H H
1-1775 H H H Me 2 - (CHZ) 3-0- (3, 4-diF-Ph) H H
1-1776 H H H Me 2 - (CH2) 3-0- (3, 5-diF-Ph) H H
1-1777 H H H Me 2 - (CH2) 3-0- (3-Me-Ph) H H
1-1778 H H H Me 2 - (CH2) 3-0- (3, 4-diMe-Ph) H H
1-1779 H H H Me 2 - (CH2) 3-0- (3, 5-diMe-Ph) H H
1-1780 H H H Me 2 - (CH2) 3-0- (3-CF3-Ph) H H
1-1781 H H H Me 2 - (CH2) 3-0- (3, 4-diCF3-Ph) H H
1-1782 H H H Me 2 - (CH2) 3-0- (3, 5-diCF3-Ph) H H
1-1783 H H H Me 2 - (CH2) 3-0- (3-MeO-Ph) H H
1-1784 H H H Me 2-(CH2)3-0-(3,4-diMeO-Ph) H H
1-1785 H H H Me 2-(CH2)3-0-(3,5-diMeO-Ph) H H
1-1786 H H H Me 2-(CH2)3-0-(3,4,5-triMeO-Ph) H H
1-1787 H H H Me 2 - (CH2) 3-0- (3-Ac-Ph) H H
1-1788 H H H Me 2 - (CH2) 3-0- (4-Ac-Ph) H H
1-1789 H H H Me 2-(CHZ)4-0- (3, 4-diF-Ph) H H
1-1790 H H H Me 2 - (CH2) 4-0- (3, 5-diF-Ph) H H
1-1791 H H H Me 2-(CH2)4-0-(3,4-diMeO-Ph) H H
1-1792 H H H Me 2 - (CH2) 4-0- (3, 5-diMeO-Ph) H H
1-1793 H H H Me 2-(CH2)4-0-(3,4,5-triMeO-Ph) H H
1-1794 H H H Me 2-(CH2)4-0-(3-Ac-Ph) H H
1-1795 H H H Me 2 - (CH2) 4-0- (4-Ac-Ph) H H
1-1796 H H H Me 2 -C=C- (CH2) 2- (3-F-Ph) H H
1-1797 H H H Me 2-C=C-(CH2)2-(3,4-diF-Ph) H H
1-1798 H H H Me 2-C-C-(CH2)2-(3,5-diF-Ph) H H
1-1799 H H H Me 2 -C=C- (CH2) 2- (3-C1-Ph) H H
1-1800 H H H Me 2 -C-C- (CHZ) 2- (4-C1-Ph) H H
1-1801 H H H Me 2 -C=C- (CH2) 2- (3, 4-diC1-Ph) H H
S:/Chemical/Sankyo/FP20030I /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 1-1802 H H H Me 2 -C=C- (CH2) 2- (3, 5-diCl-Ph) H H
1-1803 H H H Me 2-C=C-(CH2)2-(3-Me-Ph) H H
1-1804 H H H Me 2 -C=C- (CH2) 2- (3, 4-diMe-Ph) H H
1-1805 H H H Me 2 -C=C- (CH2) 2- (3, 5-diMe-Ph) H H
1-1806 H H H Me 2 -C=C- (CH2) 2- (3-CF3-Ph) H H
1-1807 H H H Me 2 -C=C- (CH2) 2- (3, 4-diCF3-Ph) H H
1-1808 H H H Me 2 -C-C- (CH2) 2- (3, 5-diCF3-Ph) H H
1-1809 H H H Me 2 -C-C- (CH2) 2- (3-MeO-Ph) H H
1-1810 H H H Me 2 -C=C- (CH2) 2- (3, 4-diMeO-Ph) H H
1-1811 H H H Me 2-C=C-(CH2)2-(3,5-diMeO-Ph) H H
1-1812 H H H Me 2-C-C-(CH2)2-(3,4,5-triMeO-Ph) H H
1-1813 H H H Me 2 -C=C- (CH2) 2- (3-Ac-Ph) H H
1-1814 H H H Me 2 -C=C- (CH2) 2- (4-Ac-Ph) H H
1-1815 H H H Me 2-C-C-(CH2)3-(3,4-diF-Ph) H H
1-1816 H H H Me 2 -C-C- (CH2) 3- (3, 5-diF-Ph) H H
1-1817 H H H Me 2 -C=C- (CH2) 3- (3-C1-Ph) H H
1-1818 H H H Me 2-C-C-(CH2)3-(3,4-diCl-Ph) H H
1-1819 H H H Me 2 -C=-C- (CH2) 3- (3, 5-diCl-Ph) H H
1-1820 H H H Me 2 -C=C- (CH2) 3- (3, 4-diCF3-Ph) H H
1-1821 H H H Me 2 -C=C- (CH2) 3- (3, 5-diCF3-Ph) H H
1-1822 H H H Me 2-C=C-(CH2)3-(3,4-diMeO-Ph) H H
1-1823 H H H Me 2-C=C-(CH2)3-(3,5-diMeO-Ph) H H
1-1824 H H H Me 2 -C=C- (CH2) 3- (3, 4, 5-triMeO-Ph) H H
1-1825 H H H Me 2 -C-C- (CH2) 3- (3-Ac-Ph) H H
1-1826 H H H Me 2 -C=C- (CH2) 3- (4-Ac-Ph) H H
1-1827 H H H Me 2 -C=C-CH2-0-(3-F-Ph) H H
1-1828 H H H Me 2 -C=C-CH2-O-(3,4-diF-Ph) H H
1-1829 H H H Me 2 -C=C-CH2-0-(3,5-diF-Ph) H H
1-1830 H H H Me 2 -C=C-CH2-0-(3-C1-Ph) H H
1-1831 H H H Me 2 -C=C-CH2-O-(4-C1-Ph) H H
1-1832 H H H Me 2 -C=C-CH2-O-(3,4-diCl-Ph) H H
1-1833 H H H Me 2 -C=C-CH2-O-(3,5-diCl-Ph) H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 1-1834 H H H Me 2 -C=C-CH2-0-(3-Me-Ph) H H
1-1835 H H H Me 2 -C=C-CH2-0-(2,4-diMe-Ph) H H
1-1836 H H H Me 2 -C=C-CH2-0-(3,4-diMe-Ph) H H
1-1837 H H H Me 2 -C=C-CH2-0-(3,5-diMe-Ph) H H
1-1838 H H H Me 2 -C=C-CH2-0-(3-CF3-Ph) H H
1-1839 H H H Me 2 -C=C-CH2-O-(3,4-diCF3-Ph) H H
1-1840 H H H Me 2 -C=C-CH2-0-(3,5-diCF3-Ph) H H
1-1841 H H H Me 2 -C=C-CH2-O-(3-MeO-Ph) H H
1-1842 H H H Me 2 -C=C-CH2-O-(3,4-diMeO-Ph) H H
1-1843 H H H Me 2 -C=C-CH2-0-(3,5-diMeO-Ph) H H
1-1844 H H H Me 2 -C=C-CH2-O-(3,4,5-triMeO-Ph) H H
1-1845 H H H Me 2 -C=C-CH2-0-(3-Ac-Ph) H H
1-1846 H H H Me 2 -C-C-CH2-O-(4-Ac-Ph) H H
1-1847 H H H Me 2 -C=C-CH2-0-(4-CO2H-Ph) H H
1-1848 H H H Me 2 -C=-C- (CH2) 2-0- (3, 4-diF-Ph) H H
1-1849 H H H Me 2-C=C-(CH2)2-0-(3,5-diF-Ph) H H
1-1850 H H H Me 2 -C=C- (CH2) 2-0- (3-C1-Ph) H H
1-1851 H H H Me 2-C=C-(CH2)2-0-(3,4-diCl-Ph) H H
1-1852 H H H Me 2-C=C-(CH2)2-0-(3,5-diCl-Ph) H H
1-1853 H H H Me 2 -C=C- (CH2) 2-0- (3, 4-diCF3-Ph) H H
1-1854 H H H Me 2 -C=C- (CH2) 2-0- (3, 5-diCF3-Ph) H H
1-1855 H H H Me 2-C=C-(CH2)2-0-(3,4-diMeO-Ph) H H
1-1856 H H H Me 2-C=C-(CH2)2-0-(3,5-diMeO-Ph) H H
1-1857 H H H Me 2-C=C-(CH2)2-0-(3,4,5-triMeO-Ph) H H
1-1858 H H H Me 2-C=C-(CH2)2-0-(3-Ac-Ph) H H
1-1859 H H H Me 2-C=C-(CH2)2-0-(4-Ac-Ph) H H
1-1860 H H H Me 2 -CO- (CH2) 3- (3-F-Ph) H H
1-1861 H H H Me 2 -CO- (CH2) 3- (4-F-Ph) H H
1-1862 H H H Me 2 -CO- (CH2) 3- (3, 4-diF-Ph) H H
1-1863 H H H Me 2 -CO- (CH2) 3- (3, 5-diF-Ph) H H
1-1864 H H H Me 2-CO-(CH2)3-(3-C1-Ph) H H

11-1865 H H H Me 2 -CO- (CH2) 3- (4-Cl-Ph) H H
1-1866 H H H Me 2-CO-(CH2)3-(3,4-diCl-Ph) H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Desci iption/gds-mg/30.06.04 1-1867 H H H Me 2 -CO- (CH2) 3- (3, 5-diCl-Ph) H H
1-1868 H H H Me 2 -CO- (CH2) 3- (3-Me-Ph) H H
1-1869 H H H Me 2 -CO- (CH2) 3- (4-Me-Ph) H H
1-1870 H H H Me 2 -CO- (CH2) 3- (3, 4-diMe-Ph) H H
1-1871 H H H Me 2 -CO- (CH2) 3- (3, 5-diMe-Ph) H H
1-1872 H H H Me 2 -CO- (CH2) 3- (3-Et-Ph) H H
1-1873 H H H Me 2 -CO- (CH2) 3- (4-Et-Ph) H H
1-1874 H H H Me 2 -CO- (CH2) 3- (3-CF3-Ph) H H
1-1875 H H H Me 2 -CO- (CH2) 3- (4-CF3-Ph) H H
1-1876 H H H Me 2 -CO- (CH2) 3- (3, 4-diCF3-Ph) H H
1-1877 H H H Me 2 -CO- (CH2) 3- (3, 5-diCF3-Ph) H H
1-1878 H H H Me 2 -CO- (CH2) 3- (3-MeO-Ph) H H
1-1879 H H H Me 2 -CO- (CH2) 3- (4-MeO-Ph) H H
1-1880 H H H Me 2 -CO- (CH2) 3- (3, 4-diMeO-Ph) H H
1-1881 H H H Me 2 -CO- (CH2) 3- (3, 5-diMeO-Ph) H H
1-1882 H H H Me 2 -CO- (CH2) 3- (3, 4, 5-triMeO-Ph) H H
1-1883 H H H Me 2 -CO- (CH2) 3- (4-MeS-Ph) H H
1-1884 H H H Me 2 -CO- (CH2) 3- (3-Ac-Ph) H H
1-1885 H H H Me 2 -CO- (CH2) 3- (4-Ac-Ph) H H
1-1886 H H H Me 2 -CO- (CH2) 4- (3-F-Ph) H H
1-1887 H H H Me 2 -CO- (CH2) 4- (3, 4-diF-Ph) H H
1-1888 H H H Me 2 -CO- (CH2) 4- (3, 5-diF-Ph) H H
1-1889 H H H Me 2-CO-(CH2)4-(3-C1-Ph) H H
1-1890 H H H Me 2 -CO- (CH2) 4- (4-C1-Ph) H H
1-1891 H H H Me 2 -CO- (CH2) 4- (3, 4-diCl-Ph) H H
1-1892 H H H Me 2 -CO- (CH2) 4- (3, 5-diCl-Ph) H H
1-1893 H H H Me 2 -CO- (CH2) 4- (3-Me-Ph) H H
1-1894 H H H Me 2 -CO- (CH2) 4- (3, 4-diMe-Ph) H H
1-1895 H H H Me 2 -CO- (CH2) 4- (3, 5-diMe-Ph) H H
1-1896 H H H Me 2 -CO- (CH2) 4- (3-CF3-Ph) H H
1-1897 H H H Me 2 -CO- (CH2) 4- (3, 4-diCF3-Ph) H H
1-1898 H H H Me 2 -CO- (CH2) 4- (3, 5-diCF3-Ph) H H
1-1899 H H H Me 2 -CO- (CH2) 4- (3-MeO-Ph) H H
1-1900 H H H Me 2 -CO- (CH2) 4- (3, 4-diMeO-Ph) H H
1-1901 H H H Me 2 -CO- (CH2) 4- (3, 5-diMeO-Ph) H H
1-1902 H H H Me 2 -CO- (CH2) 4- (3, 4, 5-triMeO-Ph) H H
S:/ChemicaUSankyo/FP20030I /FP0301 s.doc P87892/FP-0301/Desciiption/gds-mg/30.06.04 a ., w 1-1903 H H H Me 2 -CO- (CH2) 4- (3-Ac-Ph) H H
1-1904 H H H Me 2 -CO- (CH2) 4- (4-Ac-Ph) H H
1-1905 H H H Me 2 -CH (OH) - (CH2) 3- (3-F-Ph) H H
1-1906 H H H Me 2 -CH (OH) - (CH2) 3- (4-F-Ph) H H
1-1907 H H H Me 2 -CH (OH) - (CH2) 3- (3, 4-diF-Ph) H H
1-1908 H H H Me 2 -CH (OH) - (CH2) 3- (3, 5-diF-Ph) H H
1-1909 H H H Me 2 -CH (OH) - (CH2) 3- (3-Cl-Ph) H H
1-1910 H H H Me 2 -CH (OH) - (CH2) 3- (4-Cl-Ph) H H
1-1911 H H H Me 2 -CH (OH) - (CH2) 3- (3, 4-diCl-Ph) H H
1-1912 H H H Me 2 -CH (OH) - (CH2) 3- (3, 5-diCl-Ph) H H
1-1913 H H H Me 2 -CH (OH) - (CH2) 3- (3-Me-Ph) H H
1-1914 H H H Me 2 -CH (OH) - (CH2) 3- (4-Me-Ph) H H
1-1915 H H H Me 2 -CH (OH) - (CH2) 3- (3, 4-diMe-Ph) H H
1-1916 H H H Me 2 -CH (OH) - (CH2) 3- (3, 5-diMe-Ph) H H
1-1917 H H H Me 2 -CH (OH) - (CH2) 3- (3-Et-Ph) H H
1-1918 H H H Me 2 -CH (OH) - (CH2) 3- (4-Et-Ph) H H
1-1919 H H H Me 2 -CH (OH) - (CH2) 3- (3-CF3-Ph) H H
1-1920 H H H Me 2 -CH (OH) - (CH2) 3- (4-CF3-Ph) H H
1-1921 H H H Me 2 -CH (OH) - (CH2) 3- (3, 4-diCF3-Ph) H H
1-1922 H H H Me 2 -CH (OH) - (CH2) 3- (3, 5-diCF3-Ph) H H
1-1923 H H H Me 2 -CH (OH) - (CH2) 3- (3-MeO-Ph) H H
1-1924 H H H Me 2 -CH (OH) - (CH2) 3- (4-MeO-Ph) H H
1-1925 H H H Me 2-CH(OH)-(CH2)3-(3,4-diMeO-Ph) H H
1-1926 H H H Me 2 -CH (OH) - (CH2) 3- (3, 5-diMeO-Ph) H H
1-1927 H H H Me 2 -CH (OH) - (CH2) 3- (3, 4, 5-triMeO-Ph) H H
1-1928 H H H Me 2 -CH (OH) - (CH2) 3- (4-MeS-Ph) H H
1-1929 H H H Me 2 -CH (OH) - (CH2) 3- (3-Ac-Ph) H H
1-1930 H H H Me 2 -CH (OH) - (CH2) 3- (4-Ac-Ph) H H
1-1931 H H H Me 2 -CH (OH) - (CH2) 4- (3-F-Ph) H H
1-1932 H H H Me 2 -CH (OH) - (CH2) 4- (3, 4-diF-Ph) H H
1-1933 H H H Me 2 -CH (OH) - (CH2) 4- (3, 5-diF-Ph) H H
1-1934 H H H Me 2 -CH (OH) - (CH2) 4- (3-Cl-Ph) H H
1-1935 H H H Me 2 -CH (OH) - (CH2) 4- (4-C1-Ph) H H
1-1936 H H H Me 2 -CH (OH) - (CH2) 4- (3, 4-diCl-Ph) H H
1-1937 H H H Me 2 -CH (OH) - (CH2) 4- (3, 5-diCl-Ph) H H
1-1938 H H H Me 2 -CH (OH) - (CH2) 4- (3-Me-Ph) H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P8'7892/FP-0301 /Description/gds-mg/30.06.04 1-1939 H H H Me 2 -CH (OH) - (CH2) 4- (3, 4-diMe-Ph) H H
1-1940 H H H Me 2 -CH (OH) - (CHZ) 4- (3, 5-diMe-Ph) H H
1-1941 H H H Me 2 -CH (OH) - (CHZ) 4- (3-CF3-Ph) H H
1-1942 H H H Me 2 -CH (OH) - (CHZ) 4- (3, 4-diCF3-Ph) H H
1-1943 H H H Me 2 -CH (OH) - (CHZ) 4- (3, 5-diCF3-Ph) H H
1-1944 H H H Me 2 -CH (OH) - (CH2) 4- (3-MeO-Ph) H H
1-1945 H H H Me 2 -CH (OH) - (CH2) 4- (3, 4-diMeO-Ph) H H
1-1946 H H H Me 2 -CH (OH) - (CH2) 4- (3, 5-diMeO-Ph) H H
1-1947 H H H Me 2 -CH (OH) - (CH2) 4- (3, 4, 5-triMeO-Ph) H H
1-1948 H H H Me 2 -CH (OH) - (CH2) 4- (3-Ac-Ph) H H
1-1949 H H H Me 2 -CH (OH) - (CH2) 4- (4-Ac-Ph) H H
Table 2 R30 (CH2)n R 3O~(CH2)n I N \ R7 (Ib-1) (Ib-2) or R3O-1.1-17(CH2)n S R7 (Ib-3) Compd. R R R R4 n -Y-Z-R R R
2-1 H H H Me 2 - (CH2) 3-cHx H H
2-2 H H H Me 2 - (CH2) 3-Ph H H
2-3 H H H Me 2 - (CH2) 4-cHx H H
2-4 H H H Me 2 - (CH2) 4-Ph H H
2-5 H H H Me 2 - (CH2) 5-cPn H H
2-6 H H H Me 2 - (CH2) 5-cHx H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 J a r 2-7 H H H Me 2 - (CH2) 5-cHx Me H
2-8 H H H Me 2 - (CH2) 5-cHx H Me 2-9 H H H Me 2 - (CH2) 5-cHx F H
2-10 H H H Me 2 - (CH2) 5-cHx H F
2-11 H H H Me 2 - (CH2) 5- (4-F-cHx) H H
2-12 H H H Me 2 - (CH2) 5- (4-C1-cHx) H H
2-13 H H H Me 2 - (CH2) 5- (4-Br-cHx) H H
2-14 H H H Me 2 - (CH2) 5- (4-Me-cHx) H H
2-15 H H H Me 2 - (CH2) 5- (4-Et-cHx) H H
2-16 H H H Me 2 - (CH2) 5- (4-Pr-cHx) H H
2-17 H H H Me 2 - (CH2) 5- (4-iPr-cHx) H H
2-18 H H H Me 2 - (CH2) 5- (4-CF3-cHx) H H
2-19 H H H Me 2 - (CH2) 5- (4-MeO-cHx) H H
2-20 H H H Me 2 - (CH2) 5- (4-EtO-cHx) H H
2-21 H H H Me 2 - (CH2) 5- (4-PrO-cHx) H H
2-22 H H H Me 2 - (CH2) 5- (4-iPrO-cHx) H H
2-23 H H H Me 2 - (CH2) 5- (3-MeS-cHx) H H
2-24 H H H Me 2 - (CH2) 5- (4-MeS-cHx) H H
2-25 H H H Me 2 - (CH2) 5- (2, 4-diMe-cHx) H H
2-26 H H H Me 2 - (CH2) 5- (3, 4-diMe-cHx) H H
2-27 H H H Me 2 - (CH2) 5- (3, 5-diMe-cHx) H H
2-28 H H H Me 2 - (CH2) 5-Ph H H
2-29 H H H Me 2 - (CH2) 5-Ph Me H
2-30 H H H Me 2 - (CH2) 5-Ph H Me 2-31 H H H Me 2 - (CH2) 5-Ph F H
2-32 H H H Me 2 - (CH2) 5-Ph H F
2-33 H H H Me 2 - (CH2) 5- (4-F-Ph) H H
2-34 H H H Me 2 - (CH2) 5- (4-Cl-Ph) H H
2-35 H H H Me 2 - (CH2) 5- (4-Br-Ph) H H
2-36 H H H Me 2 - (CH2) 5- (4-Me-Ph) H H
2-37 H H H Me 2 - (CH2) 5- (4-Et-Ph) H H
2-38 H H H Me 2 - (CH2) 5- (4-Pr-Ph) H H
2-39 H H H Me 2 - (CH2) 5- (4-iPr-Ph) H H
2-40 H H H Me 2 - (CH2) 5- (4-Bu-Ph) H H
2-41 H H H Me 2 - (CH2) 5- (4-CF3-Ph) H H
2-42 H H H Me 2 - (CH2) 5- (4-MeO-Ph) H H
S:/ChemicaUSankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 2-43 H H H Me 2 - (CH2) 5- (4-EtO-Ph) H H
2-44 H H H Me 2 - (CH2) 5- (4-PrO-Ph) H H
2-45 H H H Me 2 - (CH2) 5- (4-iPrO-Ph) H H
2-46 H H H Me 2 - (CH2) 5- (3-MeS-Ph) H H
2-47 H H H Me 2 - (CH2) 5- (4-MeS-Ph) H H
2-48 H H H Me 2 - (CH2) 5- (2, 4-diMe-Ph) H H
2-49 H H H Me 2 - (CH2) 5- (3, 4-diMe-Ph) H H
2-50 H H H Me 2 - (CH2) 5- (3, 5-diMe-Ph) H H
2-51 H H H Me 2 - (CH2) 6-cPn H H
2-52 H H H Me 2 - (CH2) 6-cHx H H
2-53 H H H Me 2 - (CH2) 6-cHx Me H
2-54 H H H Me 2 - (CH2) 6-cHx H Me 2-55 H H H Me 2 - (CH2) 6-cHx F H
2-56 H H H Me 2 - (CH2) 6-cHx H F
2-57 H H H Me 2 - (CH2) 6- (4-F-cHx) H H
2-58 H H H Me 2 - (CH2) 6- (4-C1-cHx) H H
2-59 H H H Me 2 - (CH2) 6- (4-Br-cHx) H H
2-60 H H H Me 2 - (CH2) 6- (4-Me-cHx) H H
2-61 H H H Me 2 - (CH2) 6- (4-Et-cHx) H H
2-62 H H H Me 2 - (CH2) 6- (4-Pr-cHx) H H
2-63 H H H Me 2 - (CH2) 6- (4-iPr-cHx) H H
2-64 H H H Me 2 - (CH2) 6- (4-Bu-cHx) H H
2-65 H H H Me 2 - (CH2) 6- (4-CF3-cHx) H H
2-66 H H H Me 2 - (CH2) 6- (4-MeO-cHx) H H
2-67 H H H Me 2 - (CH2) 6- (4-EtO-cHx) H H
2-68 H H H Me 2 - (CH2) 6- (4-PrO-cHx) H H
2-69 H H H Me 2 - (CH2) 6- (4-iPrO-cHx) H H
2-70 H H H Me 2 - (CH2) 6- (3-MeS-cHx) H H
2-71 H H H Me 2 - (CH2) 6- (4-MeS-cHx) H H
2-72 H H H Me 2 - (CH2) 6- (2, 4-diMe-cHx) H H
2-73 H H H Me 2 - (CH2) 6- (3, 4-diMe-cHx) H H
2-74 H H H Me 2 - (CH2) 6- (3, 5-diMe-cHx) H H
2-75 H H H Me 2 - (CH2) 6-Ph H H
2-76 H H H Me 2 - (CH2) 6-Ph Me H
2-77 H H H Me 2 - (CH2) 6-Ph H Me 2-78 H H H Me 2 - (CH2) 6-Ph F H
S:/ChemicaUSankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 2-79 H H H Me 2 - (CH2) 6-Ph H F
2-80 H H H Me 2 - (CH2) 6- (4-F-Ph) H H
2-81 H H H Me 2 - (CH2) 6- (4-C1-Ph) H H
2-82 H H H Me 2 - (CH2) 6- (4-Br-Ph) H H
2-83 H H H Me 2 - (CH2) 6- (4-Me-Ph) H H
2-84 H H H Me 2 - (CH2) 6- (4-Et-Ph) H H
2-85 H H H Me 2 - (CH2) 6- (4-Pr-Ph) H H
2-86 H H H Me 2 - (CH2) 6- (4-iPr-Ph) H H
2-87 H H H Me 2 - (CH2) 6- (4-Bu-Ph) H H
2-88 H H H Me 2 - (CH2) 6- (4-CF3-Ph) H H
2-89 H H H Me 2 - (CH2) 6- (4-MeO-Ph) H H
2-90 H H H Me 2 - (CH2) 6- (4-EtO-Ph) H H
2-91 H H H Me 2 - (CH2) 6- (4-PrO-Ph) H H
2-92 H H H Me 2 - (CH2) 6- (4-iPrO-Ph) H H
2-93 H H H Me 2 - (CH2) 6- (3-MeS-Ph) H H
2-94 H H H Me 2 - (CH2) 6- (4-MeS-Ph) H H
2-95 H H H Me 2 - (CH2) 6- (2, 4-diMe-Ph) H H
2-96 H H H Me 2 - (CH2) 6- (3, 4-diMe-Ph) H H
2-97 H H H Me 2 - (CH2) 6- (3, 5-diMe-Ph) H H
2-98 H H H Me 2 - (CH2) 7-cHx H H
2-99 H H H Me 2 - (CH2) 7-Ph H H
2-100 H H H Me 2 - (CH2) 8-cHx H H
2-101 H H H Me 2 - (CH2) 8-Ph H H
2-102 H H H Me 2 -C=C-CH2-cHx H H
2-103 H H H Me 2 -C-C-CH2-Ph H H
2-104 H H H Me 2 -C-C- (CH2) 2-cHx H H
2-105 H H H Me 2 -C=C- (CH2) 2-Ph H H
2-106 H H H Me 2 -C-C- (CH2) 3-cPn H H
2-107 H H H Me 2 -C-C- (CH2) 3-cHx H H
2-108 H H H Me 2 -C-C- (CH2) 3-cHx Me H
2-109 H H H Me 2 -C=C- (CH2) 3-cHx H Me 2-110 H H H Me 2 -C=C- (CH2) 3-cHx F H
2-111 H H H Me 2-C-C-(CH2)3-cHx H F
2-112 H H H Me 2 -C-C- (CH2) 3- (4-F-cHx) H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 2-113 H H H Me 2-C=C-(CH2)3-(4-C1-cHx) H H
2-114 H H H Me 2 -C=C- (CH2) 3- (4-Br-cHx) H H
2-115 H H H Me 2 -C-C- (CH2) 3- (4-Me-cHx) H H
2-116 H H H Me 2 -C-C- (CH2) 3- (4-Et-cHx) H H
2-117 H H H Me 2 -C=C- (CH2) 3- (4-Pr-cHx) H H
2-118 H H H Me 2 -C=C- (CH2) 3- (4-iPr-cHx) H H
2-119 H H H Me 2 -C-C- (CH2) 3- (4-Bu-cHx) H H
2-120 H H H Me 2 -C=C- (CH2) 3- (4-CF3-cHx) H H
2-121 H H H Me 2 -C=C- (CH2) 3- (4-MeO-cHx) H H
2-122 H H H Me 2 -C=C- (CH2) 3- (4-EtO-cHx) H H
2-123 H H H Me 2 -C=C- (CH2) 3- (4-PrO-cHx) H H
2-124 H H H Me 2 -C-C- (CH2) 3- (4-iPrO-cHx) H H
2-125 H H H Me 2 -C=C- (CH2) 3- (3-MeS-cHx) H H
2-126 H H H Me 2 -C-C- (CH2) 3- (4-MeS-cHx) H H
2-127 H H H Me 2-C=C-(CH2)3-(2,4-diMe-cHx) H H
2-128 H H H Me 2 H H
C=C- (CH2) 3- (3, 4-diMe-cHx) 2-129 H H H Me 2-C=C-(CH2)3-(3,5-diMe-cHx) H H
2-130 H H H Me 2 -C=-C- (CH2) 3-Ph H H
2-131 H H H Me 2 -C-C- (CH2) 3-Ph Me H
2-132 H H H Me 2 -C=C- (CH2) 3-Ph H Me 2-133 H H H Me 2 -C=C- (CH2) 3-Ph F H
2-134 H H H Me 2 -C-C- (CH2) 3-Ph H F
2-135 H H H Me 2 -C=C- (CH2) 3- (4-F-Ph) H H
2-136 H H H Me 2 -C-C- (CH2) 3- (4-C1-Ph) H H
2-137 H H H Me 2 -C-C- (CH2) 3- (4-Br-Ph) H H
2-138 H H H Me 2 -C=C- (CH2) 3- (4-Me-Ph) H H
2-139 H H H Me 2 -C=C- (CH2) 3- (4-Et-Ph) H H
2-140 H H H Me 2 -C-C- (CH2) 3- (4-Pr-Ph) H H
2-141 H H H Me 2-C-C-(CH2)3-(4-iPr-Ph) H H
2-142 H H H Me 2 -C=-C- (CH2) 3- (4-Bu-Ph) H H
2-143 H H H Me 2 -C=C- (CH2) 3- (4-CF3-Ph) H H
2-144 H H H Me 2 -C-C- (CH2) 3- (4-MeO-Ph) H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 2-145 H H H Me 2-C-C-(CH2)3-(4-EtO-Ph) H H
2-146 H H H Me 2-C-C-(CH2)3-(4-PrO-Ph) H H
2-147 H H H Me 2 -C-C- (CH2) 3- (4-iPrO-Ph) H H
2-148 H H H Me 2 -C-C- (CH2) 3- (3-MeS-Ph) H H
2-149 H H H Me 2 -C-C- (CH2) 3- (4-MeS-Ph) H H
2-150 H H H Me 2 -C-C- (CH2) 3- (2, 4-diMe-Ph) H H
2-151 H H H Me 2-C-C-(CH2)3-(3,4-diMe-Ph) H H
2-152 H H H Me 2-C=C-(CH2)3-(3,5-diMe-Ph) H H
2-153 H H H Me 2 -C-C- (CH2) 4-cPn H H
2-154 H H H Me 2 -C=C- (CH2) 4-cHx H H
2-155 H H H Me 2 -C-C- (CH2) 4-cHx Me H
2-156 H H H Me 2 -C-C- (CH2) 4-cHx H Me 2-157 H H H Me 2 -C-C- (CH2) 4-cHx F H
2-158 H H H Me 2 -C-C- (CH2) 4-cHx H F
2-159 H H H Me 2-C-C-(CH2)4-(4-F-cHx) H H
2-160 H H H Me 2-C=C-(CH2)4-(4-C1-cHx) H H
2-161 H H H Me 2 -C-C- (CH2) 4- (4-Br-cHx) H H
2-162 H H H Me 2-C=C-(CH2)4-(4-Me-cHx) H H
2-163 H H H Me 2 -C-C- (CH2) 4- (4-Et-cHx) H H
2-164 H H H Me 2 -C-C- (CH2) 4- (4-Pr-cHx) H H
2-165 H H H Me 2 -C-C- (CH2) 4- (4-iPr-cHx) H H
2-166 H H H Me 2 -C=C- (CH2) 4- (4-Bu-cHx) H H
2-167 H H H Me 2 -C-C- (CH2) 4- (4-CF3-cHx) H H
2-168 H H H Me 2 -C=C- (CH2) 4- (4-MeO-cHx) H H
2-169 H H H Me 2 -C-C- (CH2) 4- (4-EtO-cHx) H H
2-170 H H H Me 2-C-C-(CH2)4-(4-PrO-cHx) H H
2-171 H H H Me 2 -C-C- (CH2) 4- (4-iPrO-cHx) H H
2-172 H H H Me 2 -C=C- (CH2) 4- (4-MeS-cHx) H H
2-173 H H H Me 2-C-C-(CH2)4-(2,4-diMe-cHx) H H
2-174 H H H Me 2-C=C-(CH2)4-(3,4-diMe-cHx) H H
2-175 H H H Me 2-C-C-(CH2)4-(3,5-diMe-cHx) H H
2-176 H H H Me 2 -C-C- (CH2) 4-Ph H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 2-177 H H H Me 2 -C=C- (CH2) 4-Ph Me H
2-178 H H H Me 2 -C=C- (CH2) 4-Ph H Me 2-179 H H H Me 2 -C=C- (CH2) 4-Ph F H
2-180 H H H Me 2 -C=C- (CH2) 4-Ph H F
2-181 H H H Me 2 -C=C- (CH2) 4- (4-F-Ph) H H
2-182 H H H Me 2-C=C-(CH2)4-(4-C1-Ph) H H
2-183 H H H Me 2 -C-C- (CH2) 4- (4-Br-Ph) H H
2-184 H H H Me 2 -C=-C- (CH2) 4- (4-Me-Ph) H H
2-185 H H H Me 2 -C=C- (CH2) 4- (4-Et-Ph) H H
2-186 H H H Me 2 -C=C- (CH2) 4- (4-Pr-Ph) H H
2-187 H H H Me 2-C-C-(CH2)4-(4-iPr-Ph) H H
2-188 H H H Me 2-C=C-(CH2)4-(4-Bu-Ph) H H
2-189 H H H Me 2 -C=-C- (CH2) 4- (4-CF3-Ph) H H
2-190 H H H Me 2 -C=C- (CH2) 4- (4-MeO-Ph) H H
2-191 H H H Me 2-C=C-(CH2)4-(4-EtO-Ph) H H
2-192 H H H Me 2 -C=C- (CH2) 4- (4-PrO-Ph) H H
2-193 H H H Me 2-C=C-(CH2)4-(4-iPrO-Ph) H H
2-194 H H H Me 2 -C=-C- (CH2) 4- (3-MeS-Ph) H H
2-195 H H H Me 2 -C=C- (CH2) 4- (4-MeS-Ph) H H
2-196 H H H Me 2 -C=C- (CH2) 4- (2, 4-diMe-Ph) H H
2-197 H H H Me 2 -C=C- (CH2) 4- (3, 4-diMe-Ph) H H
2-198 H H H Me 2-C-C-(CH2)4-(3,5-diMe-Ph) H H
2-199 H H H Me 2 -C=C- (CH2) 5-cHx H H
2-200 H H H Me 2 -C=C- (CH2) 5-Ph H H
2-201 H H H Me 2 -C=C- (CH2) 6-cHx H H
2-202 H H H Me 2 -C-C- (CH2) 6-Ph H H
2-203 H H H Me 2-C=C-CH2O-cHx H H
2-204 H H H Me 2-C=-C-CH2O-Ph H H
2-205 H H H Me 2 -C=-C- (CH2) 20-cPn H H
2-206 H H H Me 2 -C-C- (CH2) 20-cHx H H
2-207 H H H Me 2 -C-C- (CH2) 20-cHx Me H
2-208 H H H Me 2-C-C-(CH2)2O-cHx H Me S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 2-209 H H H Me 2 -C=C- (CH2) 20-cHx F H
2-210 H H H Me 2 -C=C- (CH2) 20-cHx H F
2-211 H H H Me 2 -C=C- (CH2) 20- (4-F-cHx) H H
2-212 H H H Me 2-C=C-(CH2)2O-(4-C1-cHx) H H
2-213 H H H Me 2 -C=-C- (CH2) 20- (4-Br-cHx) H H
2-214 H H H Me 2 -C=C- (CH2) 20- (4-Me-cHx) H H
2-215 H H H Me 2-C=C-(CH2)2O-(4-Et-cHx) H H
2-216 H H H Me 2 -C=C- (CH2) 20- (4-Pr-cHx) H H
2-217 H H H Me 2 -C-C- (CH2) 20- (4-iPr-cHx) H H
2-218 H H H Me 2-C=C-(CH2)2O-(4-Bu-cHx) H H
2-219 H H H Me 2 -C=_C- (CH2) 20- (4-CF3-cHx) H H
2-220 H H H Me 2-C-C-(CH2)2O-(4-MeO-cHx) H H
2-221 H H H Me 2-C=C-(CH2)2O-(4-EtO-cHx) H H
2-222 H H H Me 2 -C=C- (CH2) 20- (4-PrO-cHx) H H
2-223 H H H Me 2-C=-C-(CH2)2O-(4-iPrO-cHx) H H
2-224 H H H Me 2 -C=C- (CH2) 20- (3-MeS-cHx) H H
2-225 H H H Me 2-C=C-(CH2)2O-(4-MeS-cHx) H H
2-226 H H H Me 2 -C=C- (CH2) 20- (2, 4-diMe-cHx) H H
2-227 H H H Me 2-C=C-(CH2)2O-(3,4-diMe-cHx) H H
2-228 H H H Me 2-C=C-(CH2)20-(3,5-diMe-cHx) H H
2-229 H H H Me 2 -C=_C- (CH2) 20-Ph H H
2-230 H H H Me 2 -C=C- (CH2) 20-Ph Me H
2-231 H H H Me 2 -C=-C- (CH2) 20-Ph H Me 2-232 H H H Me 2 -C-C- (CH2) 20-Ph F H
2-233 H H H Me 2 -C=-C- (CH2) 20-Ph H F
2-234 H H H Me 2-C=C-(CH2)2O-(4-F-Ph) H H
2-235 H H H Me 2 -C=C- (CH2) 20- (4-Cl-Ph) H H
2-236 H H H Me 2 -C-C- (CH2) 20- (4-Br-Ph) H H
2-237 H H H Me 2 -C=C- (CH2) 20- (4-Me-Ph) H H
2-238 H H H Me 2 -C=C- (CH2) 20- (4-Et-Ph) H H
2-239 H H H Me 2 -C=C- (CH2) 20- (4-Pr-Ph) H H
2-240 H H H Me 2 -C=C- (CH2) 20- (4-iPr-Ph) H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 2-241 H H H Me 2 -C=C- (CH2) 20- (4-Bu-Ph) H H
2-242 H H H Me 2 -C=C- (CH2) 20- (4-CF3-Ph) H H
2-243 H H H Me 2-C=C-(CH2)20-(4-MeO-Ph) H H
2-244 H H H Me 2-C=C-(CH2)20-(4-EtO-Ph) H H
2-245 H H H Me 2 -C=C- (CH2) 20- (4-PrO-Ph) H H
2-246 H H H Me 2 -C=C- (CH2) 20- (4-iPrO-Ph) H H
2-247 H H H Me 2 -C=C- (CH2) 20- (4-MeS-Ph) H H
2-248 H H H Me 2-C=C-(CH2)20-(2,4-diMe-Ph) H H
2-249 H H H Me 2-C=C-(CH2)20-(3,4-diMe-Ph) H H
2-250 H H H Me 2 -C=C- (CH2) 20- (3, 5-diMe-Ph) H H
2-251 H H H Me 2 -CO- (CH2) 4-cHx H H
2-252 H H H Me 2 -CO- (CH2) 4-Ph H H
2-253 H H H Me 2 -CO- (CH2) 5-cHx H H
2-254 H H H Me 2 -CO- (CH2) 5-Ph H H
2-255 H H H Me 2 -CH (OH) - (CH2) 4-cHx H H
2-256 H H H Me 2 -CH (OH) - (CH2) 4-Ph H H
2-257 H H H Me 2 -CH (OH) - (CH2) 5-cHx H H
2-258 H H H Me 2 -CH (OH) - (CH2) 5-Ph H H
2-259 H H H Me 2 -4- (cHx-CH2O) Ph H H
2-260 H H H Me 2 -4- [cHx- (CH2) 20] Ph H H
2-261 H H H Me 2 -4- [cHx- (CH2) 30] Ph H H
2-262 H H H Me 2 -(4-BzO-Ph) H H
2-263 H H H Me 2 -(4-BzO-2-F-Ph) H H
2-264 H H H Me 2 -(4-BzO-3-F-Ph) H H
2-265 H H H Me 2 -(4-BzO-2,3-diF-Ph) H H
2-2 66 H H H Me 2 - (4-BzO-2-Cl-Ph) H H
2-267 H H H Me 2-(4-BzO-3-Cl-Ph) H H
2-268 H H H Me 2-(4-BzO-2,3-diCl-Ph) H H
2-269 H H H Me 2-(4-BzO-2-Me-Ph) H H
2-270 H H H Me 2 -(4-BzO-3-Me-Ph) H H
2-271 H H H Me 2 -(4-BzO-2,3-diMe-Ph) H H
2-2 2 -H H H Me 2 -4-[Ph-(CH2)20]-Ph H H
2-273 H H H Me 2 -3-[cHx-(CH2)20]-Ph H H
2-274 H H H Et 2 - (CH2) 5-cHx H H
2-275 H H H Et 2 - (CH2) 6-cHx H H
S:/Chemical/Sankyo/FP20030I /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 2-276 H H H Et 2 -C-C- (CH2) 3-cHx H H
2-277 H H H Et 2 -C=C- (CH2) 4-cHx H H
2-278 H H H Et 2 -4- (cHx-CH2O) Ph H H
2-279 H H H Et 2-(4-BzO-Ph) H H
2-280 H H H Et 2 -C=C- (CH2) 20-cHx H H
2-281 H H H Et 2 -C=C- (CH2) 20-Ph H H
2-282 H H H Pr 2 - (CH2) 5-cHx H H
2-283 H H H Pr 2 - (CH2) 6-cHx H H
2-284 H H H Pr 2 -C=C- (CH2) 3-cHx H H
2-285 H H H Pr 2 -C=C- (CH2) 4-cHx H H
2-286 H H H Pr 2 -4- (cHx-CH2O) Ph H H
2-287 H H H Pr 2 -(4-BzO-Ph) H H
2-288 H H H Pr 2 -C=-C- (CH2) 20-cHx H H
2-289 H H H Pr 2 -C=C- (CH2) 20-Ph H H
Table 3 R3O (CH2)n N Y-Z-R5 (Ia-4) H

Compd. R R R R n -Y-Z-R R 6 R
3-1 H H H Me 2 - (CH2) 4-cHx H H
3-2 H H H Me 2 - (CH2) 4-Ph H H
3-3 H H H Me 2 - (CH2) 5-cHx H H
3-4 H H H Me 2 - (CH2) 5-Ph H H
3-5 H H H Me 2 -C-C- (CH2) 2-cHx H H
3-6 H H H Me 2 -C=C- (CH2) 2-Ph H H
3-7 H H H Me 2 -C=C- (CH2) 3-cHx H H
3-8 H H H Me 2 -C=C- (CH2) 3-Ph H H
3-9 H H H Me 2 -CO- (CH2) 3-cHx H H
3-10 H H H Me 2 -CO- (CH2) 3-Ph H H
3-11 H H H Me 2 -CO- (CH2) 4-cHx H H
3-12 H H H Me 2 -CO-(CH2)4-Ph H H
S:1Chemica1ISankyo/FP2003011FP0301 s.doc P87892JFP-0301/Description/gds-mg/30.06.04 Table 4 R30 (CH2n N Y-Z-R 5 (Ia-5) NR' R2 Et Compd. R R R R n -Y-Z-R5 R6 R
4-1 H H H Me 2 - (CH2) 4-cHx H H
4-2 H H H Me 2 - (CH2) 4-Ph H H
4-3 H H H Me 2 - (CH2) 5-cHx H H
4-4 H H H Me 2 - (CH2) 5-Ph H H
4-5 H H H Me 2 -C=C- (CH2) 2-cHx H H
4-6 H H H Me 2 -C-C- (CH2) 2-Ph H H
4-7 H H H Me 2 -C-C- (CH2) 3-cHx H H
4-8 H H H Me 2 -C=C- (CH2) 3-Ph H H
4-9 H H H Me 2 -CO- (CH2) 3-cHx H H
4-10 H H H Me 2 -CO- (CH2) 3-Ph H H
4-11 H H H Me 2 -CO- (CH2) 4-cHx H H
4-12 H H H Me 2 -CO- (CH2) 4-Ph H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 Table 5 O (CH2)n 1 Y-Z-R5 O (CH2)n Y-Z-R5 11 11 (IIa-1) (IIa-2) O (CH2)n Y-Z-RS (CH2)flY_Z-R5 OR11 OR11 ' (IIa-3) (IIIa-1) 0 / (CH2)n 1 Y-Z-RS R100-P (CH2)n 1 Y-Z-RS
Ra S
8100-P-' R4 N I
OR71 CH3 0R1 t (IIIa-2) or (IIIa-3) Compd. R R' R' n -Y-Z-R R R R 10 R
5-1 H H Me 1 - (CHz) 5-cHx H H H H
5-2 H H Me 1 - (CHz) 6-cHx H H H H
5-3 H H Me 1 -CH=CH- (CH2) 3-cHx H H H H
5-4 H H Me 1 -CH=CH- (CH2) 4-cHx H H H H
5-5 H H Me 1 -C=C- (CH2) 3-cHx H H H H
5-6 H H Me 1 -C-C- (CH2) 4-cHx H H H H
5-7 H H Me 1 -CO- (CH2) 4-cHx H H H H
5-8 H H Me 1 -CO- (CH2) 5-cHx H H H H
5-9 H H Me 1 -CH (OH) - (CH2) 4-cHx H H H H
5-10 H H Me 1 -CH (OH) - (CH2) 5-cHx H H H H
5-11 H H Me 1 - 4- (cHx-CH20) Ph H H H H
5-12 H H Me 1-(4-BzO-Ph) H H H H
5-13 H H Me 1-C=C-CH2O-CPn H H H H
5-14 H H Me 1 -C=C- (CH2) 20-cPn H H H H
5-15 H H Me 1-C-C-CH2O-cHx H H H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-16 H H Me 1 -C=C- (CH2) 20-cHx H H H H
5-17 H H Me 1-C=C-CH2O-Ph H H H H
5-18 H H Me 1 -C=C- (CH2) 20-Ph H H H H
5-19 H H Me 2 - (CH2) 2-cHx H H H H
5-20 H Me Me 2 - (CH2) 2-cHx H H H H
5-21 CO2Me H Me 2 - (CH2) 2-cHx H H H H
5-22 CO2Et H Me 2 - (CH2) 2-cHx H H H H
5-23 H H Me 2 - (CH2) 2- (4-F-cHx) H H H H
5-24 H H Me 2 - (CH2) 2- (4-Me-cHx) H H H H
5-25 H H Me 2 - (CH2) 2- (4-Et-cHx) H H H H
5-26 H H Me 2 - (CH2) 2- (4-CF3-cHx) H H H H
5-27 H H Me 2-(CH2)2-(4-MeO-cHx) H H H H
5-28 H H Me 2-(CH2)2-(4-EtO-cHx) H H H H
5-29 H H Me 2 - (CH2) 2- (4-MeS-cHx) H H H H
5-30 H H Me 2 - (CH2) 2- (4-cHx-cHx) H H H H
5-31 H H Me 2 - (CH2) 2- (4-Ph-cHx) H H H H
5-32 H H Me 2 - (CH2) 2-Ph H H H H
5-33 H Me Me 2 - (CH2) 2-Ph H H H H
5-34 CO2Me H Me 2 - (CH2) 2-Ph H H H H
5-35 CO2Et H Me 2 - (CH2) 2-Ph H H H H
5-36 H H Me 2 - (CH2) 2- (4-F-Ph) H H H H
5-37 H H Me 2 - (CH2) 2- (4-Me-Ph) H H H H
5-38 H H Me 2 - (CH2) 2- (4-Et-Ph) H H H H
5-39 H H Me 2 - (CH2) 2- (4-CF3-Ph) H H H H
5-40 H H Me 2 - (CH2) 2- (4-MeO-Ph) H H H H
5-41 H H Me 2 - (CH2) 2- (4-EtO-Ph) H H H H
5-42 H H Me 2 - (CH2) 2- (4-MeS-Ph) H H H H
5-43 H H Me 2 - (CH2) 2- (4-cHx-Ph) H H H H
5-44 H H Me 2 - (CH2) 2- (4-Ph-Ph) H H H H
5-45 H H Me 2 - (CH2) 3-cHx H H H H
5-46 H Me Me 2 - (CH2) 3-cHx H H H H
5-47 CO2Me H Me 2 - (CH2) 3-cHx H H H H
5-48 CO2Et H Me 2 - (CH2) 3-cHx H H H H
5-49 H H Me 2 - (CH2) 3- (4-F-cHx) H H H H
5-50 H H Me 2 - (CH2) 3- (4-Me-cHx) H H H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 5-51 H H Me 2 - (CH2) 3- (4-Et-cHx) H H H H
5-52 H H Me 2 - (CH2) 3- (4-CF3-cHx) H H H H
5-53 H H Me 2-(CH2)3-(4-MeO-cHx) H H H H
5-54 H H Me 2 - (CHZ) 3- (4-EtO-cHx) H H H H
5-55 H H Me 2 - (CHZ) 3- (4-MeS-cHx) H H H H
5-56 H H Me 2 - (CHZ) 3- (4-cHx-cHx) H H H H
5-57 H H Me 2 - (CHZ) 3- (4-Ph-cHx) H H H H
5-58 H H Me 2 - (CHZ) 3-Ph H H H H
5-59 H Me Me 2 - (CHZ) 3-Ph H H H H
5-60 CO2Me H Me 2 - (CHZ) 3-Ph H H H H
5-61 CO2Et H Me 2 - (CH2) 3-Ph H H H H
5-62 H H Me 2 - (CH2) 3- (4-F- Ph) H H H H
5-63 H H Me 2 - (CH2) 3- (4-Me-Ph) H H H H
5-64 H H Me 2 - (CH2) 3- (4-Et-Ph) H H H H
5-65 H H Me 2 - (CH2) 3- (4-CF3-Ph) H H H H
5-66 H H Me 2 - (CH2) 3- (4-MeO-Ph) H H H H
5-67 H H Me 2 - (CHZ) 3- (4-EtO-Ph) H H H H
5-68 H H Me 2 - (CH2) 3- (4-MeS-Ph) H H H H
5-69 H H Me 2 - (CH2) 3- (4-cHx-Ph) H H H H
5-70 H H Me 2 - (CH2) 3- (4-Ph-Ph) H H H H
5-71 H H Me 2 - (CH2) 4-cHx H H H H
5-72 H Me Me 2-(CH2)4-cHx H H H H
5-73 C02Me H Me 2 - (CH2) 4-cHx H H H H
5-74 C02Et H Me 2 - (CH2) 4-cHx H H H H
5-75 H H Me 2 - (CH2) 4- (4-F-cHx) H H H H
5-76 H H Me 2 - (CH2) 4- (4-Me-cHx) H H H H
5-77 H H Me 2 - (CH2) 4- (4-Et-cHx) H H H H
5-78 H H Me 2 - (CHZ) 4- (4-CF3-cHx) H H H H
5-79 H H Me 2 - (CH2) 4- (4-MeO-cHx) H H H H
5-80 H H Me 2 - (CHZ) 4- (4-EtO-cHx) H H H H
5-81 H H Me 2 - (CH2) 4- (4-MeS-cHx) H H H H
5-82 H H Me 2 - (CH2) 4- (4-cHx-cHx) H H H H
5-83 H H Me 2 - (CH2) 4- (4-Ph-cHx) H H H H
5-84 H H Me 2 - (CH2) 4-Ph H H H H
5-85 H Me Me 2 - (CH2) 4-Ph H H H H
5-86 CO2Me H Me 2 - (CH2) 4-Ph H H H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-87 CO2Et H Me 2 - (CH2) 4-Ph H H H H
5-88 H H Me 2 - (CH2) 4- (4-F-Ph) H H H H
5-89 H H Me 2 - (CH2) 4- (4-Me-Ph) H H H H
5-90 H H Me 2 - (CH2) 4- (4-Et-Ph) H H H H
5-91 H H Me 2 - (CH2) 4- (4-CF3-Ph) H H H H
5-92 H H Me 2 - (CH2) 4- (4-MeO-Ph) H H H H
5-93 H H Me 2 - (CH2) 4- (4-EtO-Ph) H H H H
5-94 H H Me 2 - (CH2) 4- (4-MeS-Ph) H H H H
5-95 H H Me 2 - (CH2) 4- (4-cHx-Ph) H H H H
5-96 H H Me 2 - (CH2) 4- (4-Ph-Ph) H H H H
5-97 H H Me 2 - (CH2) 5-cPn H H H H
5-98 H H Me 2 - (CH2) 5-cHx H H H H
5-99 H H Me 2 - (CH2) 5-cHx Me H H H
5-100 H H Me 2 - (CH2) 5-cHx H Me H H
5-101 H H Me 2 - (CH2) 5-cHx F H H H
5-102 H H Me 2 - (CH2) 5-cHx H F H H
5-103 H Me Me 2 - (CH2) 5-cHx H H H H
5-104 CO2Me H Me 2 - (CH2) 5-cHx H H H H
5-105 CO2Et H Me 2 - (CH2) 5-cHx H H H H
5-106 H H Me 2 - (CH2) 5- (3-F-cHx) H H H H
5-107 H H Me 2 - (CH2) 5- (4-F-cHx) H H H H
5-108 H H Me 2-(CH2)5-(4-Cl-cHx) H H H H
5-109 H H Me 2 - (CH2) 5- (4-Br-cHx) H H H H
5-110 H H Me 2-(CH2)5-(3-Me-cHx) H H H H
5-111 H H Me 2 - (CH2) 5- (4-Me-cHx) H H H H
5-112 H H Me 2 - (CH2) 5- (3-Et-cHx) H H H H
5-113 H H Me 2-(CH2)5-(4-Et-cHx) H H H H
5-114 H H Me 2 - (CH2) 5- (3-Pr-cHx) H H H H
5-115 H H Me 2 - (CH2) 5- (4-Pr-cHx) H H H H
5-116 H H Me 2-(CH2)5-(4-iPr-cHx) H H H H
5-117 H H Me 2 - (CH2) 5- (3-Bu-cHx) H H H H
5-118 H H Me 2 - (CH2) 5- (4-Bu-cHx) H H H H
5-119 H H Me 2 - (CH2) 5- (3-CF3-cHx) H H H H
5-120 H H Me 2 - (CH2) 5- (4-CF3-cHx) H H H H
5-121 H H Me 2 - (CH2) 5- (3-MeO-cHx) H H H H
5-122 H H Me 2 - (CH2) 5- (4-MeO-cHx) H H H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 5-123 H H Me 2-(CH2)5-(3-EtO-cHx) H H H H
5-124 H H Me 2 - (CH2) 5- (4-EtO-cHx) H H H H
5-125 H H Me 2 - (CH2) 5- (3-PrO-cHx) H H H H
5-126 H H Me 2 - (CH2) 5- (4-PrO-cHx) H H H H
5-127 H H Me 2 - (CH2) 5- (3-iPrO-cHx) H H H H
5-128 H H Me 2 - (CH2) 5- (4-iPrO-cHx) H H H H
5-129 H H Me 2 - (CH2) 5- [3- (2-Et-PrO) - H H H H
cHx]
5-130 H H Me 2 - (CH2) 5- [4- (2-Et-PrO) - H H H H
cHx]

5-131 H H Me 2 - (CH2) 5- (3-iBuO-cHx) H H H H
5-132 H H Me 2 - (CH2) 5- (4-iBuO-cHx) H H H H
5-133 H H Me 2 - (CH2) 5- (3-MeS-cHx) H H H H
5-134 H H Me 2 - (CH2) 5- (4-MeS-cHx) H H H H
5-135 H H Me 2 - (CH2) 5- (3-EtS-cHx) H H H H
5-136 H H Me 2 - (CH2) 5- (4-EtS-cHx) H H H H
5-137 H H Me 2 - (CH2) 5- (3-PrS-cHx) H H H H
5-138 H H Me 2 - (CH2) 5- (4-PrS-cHx) H H H H
5-139 H H Me 2 - (CH2) 5- (3-iPrS-cHx) H H H H
5-140 H H Me 2 - (CH2) 5- (4-iPrS-cHx) H H H H
5-141 H H Me 2 - (CH2) 5- [3- (2-Et-PrS) - H H H H
cHx]
5-142 H H Me 2 - (CH2) 5- [ 4- (2-Et-PrS) - H H H H
cHx]

5-143 H H Me 2 - (CH2) 5- (3-iBuS-cHx) H H H H
5-144 H H Me 2 - (CH2) 5- (4-iBuS-cHx) H H H H
5-145 H H Me 2 - (CH2) 5- (3-cHx-cHx) H H H H
5-146 H H Me 2 - (CH2) 5- (4-cHx-cHx) H H H H
5-147 H H Me 2 - (CH2) 5- (3-Ph-cHx) H H H H
5-148 H H Me 2 - (CH2) 5- (4-Ph-cHx) H H H H
5-149 H H Me 2 - (CH2) 5- (2, 4-diMe-cHx) H H H H
5-150 H H Me 2 - (CH2) 5- (3, 4-diMe-cHx) H H H H
5-151 H H Me 2 - (CH2) 5- (3, 5-diMe-cHx) H H H H
5-152 H H Me 2 - (CH2) 5-Ph H H H H
5-153 H H Me 2 - (CH2) 5-Ph Me H H H
5-154 H H Me 2 - (CH2) 5-Ph H Me H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 5-155 H H Me 2 - (CH2) 5-Ph F H H H
5-156 H H Me 2 - (CH2) 5-Ph H F H H
5-157 H Me Me 2 - (CH2) 5-Ph H H H H
5-158 CO2Me H Me 2 - (CH2) 5-Ph H H H H
5-159 CO2Et H Me 2 - (CH2) 5-Ph H H H H
5-160 H H Me 2 - (CH2) 5- (3-F-Ph) H H H H
5-161 H H Me 2 - (CH2) 5- (4-F-Ph) H H H H
5-162 H H Me 2 - (CH2) 5- (4-C1-Ph) H H H H
5-163 H H Me 2 - (CH2) 5- (4-Br-Ph) H H H H
5-164 H H Me 2 - (CH2) 5- (3-Me-Ph) H H H H
5-165 H H Me 2 - (CH2) 5- (4-Me-Ph) H H H H
5-166 H H Me 2 - (CH2) 5- (3-Et-Ph) H H H H
5-167 H H Me 2 - (CH2) 5- (4-Et-Ph) H H H H
5-168 H H Me 2 - (CH2) 5- (3-Pr-Ph) H H H H
5-169 H H Me 2 - (CH2) 5- (4-Pr-Ph) H H H H
5-170 H H Me 2 - (CH2) 5- (3-iPr-Ph) H H H H
5-171 H H Me 2-(CH2)5-(4-iPr-Ph) H H H H
5-172 H H Me 2 - (CH2) 5- (3-Bu-Ph) H H H H
5-173 H H Me 2 - (CH2) 5- (4-Bu-Ph) H H H H
5-174 H H Me 2 - (CH2) 5- (3-CF3-Ph) H H H H
5-175 H H Me 2 - (CH2) 5- (4-CF3-Ph) H H H H
5-176 H H Me 2-(CH2)5-(3-MeO-Ph) H H H H
5-177 H H Me 2 - (CH2) 5- (4-MeO-Ph) H H H H
5-178 H H Me 2-(CH2)5-(3-EtO-Ph) H H H H
5-179 H H Me 2 - (CH2) 5- (4-EtO-Ph) H H H H
5-180 H H Me 2 - (CH2) 5- (3-PrO-Ph) H H H H
5-181 H H Me 2 - (CH2) 5- (4-PrO-Ph) H H H H
5-182 H H Me 2-(CH2)5-(3-iPrO-Ph) H H H H
5-183 H H Me 2 - (CH2) 5- (4-iPrO-Ph) H H H H
5-184 H H Me 2 - (CH2) 5- [ 3- (2-Et-PrO) - H H H H
Ph]
5-185 H H Me 2 - (CH2) 5- [4- (2-Et-PrO) - H H H H
Ph]
5-186 H H Me 2 - (CH2) 5- (3-iBuO-Ph) H H H H
5-187 H H Me 2 - (CH2) 5- (4-iBuO-Ph) H H H H
5-188 H H Me 2 - (CH2) 5- (3-MeS-Ph) H H H H
S:/Chemical/Sankyo/FP200301/FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 5-189 H H Me 2 - (CH2) 5- (4-MeS-Ph) H H H H
5-190 H H Me 2 - (CH2) 5- (3-EtS-Ph) H H H H
5-191 H H Me 2 - (CH2) 5- (4-EtS-Ph) H H H H
5-192 H H Me 2 - (CHZ) 5- (3-PrS-Ph) H H H H
5-193 H H Me 2 - (CH2) 5- (4-PrS-Ph) H H H H
5-194 H H Me 2 - (CHZ) 5- (3-iPrS-Ph) H H H H
5-195 H H Me 2 - (CH2) 5- (4-iPrS-Ph) H H H H
5-196 H H Me 2 - (CH2) 5- [3- (2-Et-PrS) - H H H H
Ph]
5-197 H H Me 2 - (CH2) 5- [ 4- (2-Et-PrS) - H H H H
Ph]

5-198 H H Me 2 - (CH2) 5- (3-iBuS-Ph) H H H H
5-199 H H Me 2 - (CH2) 5- (4-iBuS-Ph) H H H H
5-200 H H Me 2 - (CH2) 5- (3-cHx-Ph) H H H H
5-201 H H Me 2 - (CH2) 5- (4-cHx-Ph) H H H H
5-202 H H Me 2 - (CH2) 5- (3-Ph-Ph) H H H H
5-203 H H Me 2 - (CH2) 5- (4-Ph-Ph) H H H H
5-204 H H Me 2 - (CH2) 5- (2, 4-diMe-Ph) H H H H
5-205 H H Me 2 - (CH2) 5- (3, 4-diMe-Ph) H H H H
5-206 H H Me 2 - (CH2) 5- (3, 5-diMe-Ph) H H H H
5-207 H H Me 2 - (CH2) 5-Np (1) H H H H
5-208 H H Me 2 - (CH2) 5-Np (2) H H H H
5-209 H H Me 2 - (CH2) 6-cPn H H H H
5-210 H H Me 2 - (CH2) 6-cHx H H H H
5-211 H H Me 2 - (CH2) 6-cHx Me H H H
5-212 H H Me 2 - (CH2) 6-cHx H Me H H
5-213 H H Me 2 - (CH2) 6-cHx F H H H
5-214 H H Me 2 - (CH2) 6-cHx H F H H
5-215 H Me Me 2 - (CH2) 6-cHx H H H H
5-216 CO2Me H Me 2 - (CH2) 6-cHx H H H H
5-217 CO2Et H Me 2 - (CHZ) 6-cHx H H H H
5-218 H H Me 2 - (CHZ) 6- (3-F-cHx) H H H H
5-219 H H Me 2 - (CH2) 6- (4-F-cHx) H H H H
5-220 H H Me 2 - (CHZ) 6- (4-Cl-cHx) H H H H
5-221 H H Me 2 - (CH2) 6- (4-Br-cHx) H H H H
5-222 H H Me 2 - (CH2) 6- (3-Me-cHx) H H H H
S:/ChemicaVSankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 5-223 H H Me 2 - (CH2) 6- (4-Me-cHx) H H H H
5-224 H H Me 2 - (CHZ) 6- (3-Et-cHx) H H H H
5-225 H H Me 2 - (CHZ) 6- (4-Et-cHx) H H H H
5-226 H H Me 2 - (CHZ) 6- (3-Pr-cHx) H H H H
5-227 H H Me 2 - (CHZ) 6- (4-Pr-cHx) H H H H
5-228 H H Me 2-(CH2)6-(4-iPr-cHx) H H H H
5-229 H H Me 2 - (CHZ) 6- (3-Bu-cHx) H H H H
5-230 H H Me 2 - (CHZ) 6- (4-Bu-cHx) H H H H
5-231 H H Me 2 - (CHZ) 6- (3-CF3-cHx) H H H H
5-232 H H Me 2 - (CHZ) 6- (4-CF3-cHx) H H H H
5-233 H H Me 2 - (CH2) 6- (3-MeO-cHx) H H H H
5-234 H H Me 2 - (CH2) 6- (4-MeO-cHx) H H H H
5-235 H H Me 2 - (CH2) 6- (3-EtO-cHx) H H H H
5-236 H H Me 2 - (CH2) 6- (4-EtO-cHx) H H H H
5-237 H H Me 2 - (CHZ) 6- (3-PrO-cHx) H H H H
5-238 H H Me 2 - (CH2) 6- (4-PrO-cHx) H H H H
5-239 H H Me 2 - (CH2) 6- (3-iPrO-cHx) H H H H
5-240 H H Me 2 - (CH2) 6- (4-iPrO-cHx) H H H H
5-241 H H Me 2 - (CH2) 6- [3- (2-Et-PrO) - H H H H
cHx]
5-242 H H Me 2 - (CH2) 6- [4- (2-Et-PrO) - H H H H
cHx]
5-243 H H Me 2 - (CH2) 6- (3-iBuO-cHx) H H H H
5-244 H H Me 2 - (CH2) 6- (4-iBuO-cHx) H H H H
5-245 H H Me 2 - (CH2) 6- (3-MeS-cHx) H H H H
5-246 H H Me 2 - (CH2) 6- (4-MeS-cHx) H H H H
5-247 H H Me 2 - (CH2) 6- (3-EtS-cHx) H H H H
5-248 H H Me 2 - (CH2) 6- (4-EtS-cHx) H H H H
5-249 H H Me 2 - (CH2) 6- (3-PrS-cHx) H H H H
5-250 H H Me 2 - (CH2) 6- (4-PrS-cHx) H H H H
5-251 H H Me 2 - (CH2) 6- (3-iPrS-cHx) H H H H
5-252 H H Me 2 - (CH2) 6- (4-iPrS-cHx) H H H H
5-253 H H Me 2 - (CH2) 6- [3- (2-Et-PrS) - H H H H
cHx]
5-254 H H Me 2 - (CH2) 6- [4- (2-Et-PrS) - H H H H
cHx]

S:/Chemical/Sankyo/FP200301/FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 5-255 H H Me 2 - (CH2) 6- (3-iBuS-cHx) H H H H
5-256 H H Me 2 - (CHZ) 6- (4-iBuS-cHx) H H H H
5-257 H H Me 2 - (CH2) 6- (3-cHx-cHx) H H H H
5-258 H H Me 2 - (CH2) 6- (4-cHx-cHx) H H H H
5-259 H H Me 2 - (CHZ) 6- (3-Ph-cHx) H H H H
5-260 H H Me 2 - (CH2) 6- (4-Ph-cHx) H H H H
5-261 H H Me 2 - (CH2) 6- (2, 4-diMe-cHx) H H H H
5-262 H H Me 2 - (CHZ) 6- (3, 4-diMe-cHx) H H H H
5-263 H H Me 2 - (CH2) 6- (3, 5-diMe-cHx) H H H H
5-264 H H Me 2 - (CH2) 6-Ph H H H H
5-265 H H Me 2 - (CHZ) 6-Ph Me H H H
5-266 H H Me 2 - (CHZ) 6-Ph H Me H H
5-267 H H Me 2 - (CHZ) 6-Ph F H H H
5-268 H H Me 2 - (CHZ) 6-Ph H F H H
5-269 H Me Me 2 - (CHZ) 6-Ph H H H H
5-270 CO2Me H Me 2 - (CHZ) 6-Ph H H H H
5-271 C02Et H Me 2 - (CH2) 6-Ph H H H H
5-272 H H Me 2 - (CH2) 6- (3-F-Ph) H H H H
5-273 H H Me 2 - (CH2) 6- (4-F-Ph) H H H H
5-274 H H Me 2-(CH2)6-(4-C1-Ph) H H H H
5-275 H H Me 2 - (CHZ) 6- (4-Br-Ph) H H H H
5-276 H H Me 2 - (CH2) 6- (3-Me-Ph) H H H H
5-277 H H Me 2 - (CHZ) 6- (4-Me-Ph) H H H H
5-278 H H Me 2 - (CHZ) 6- (3-Et-Ph) H H H H
5-279 H H Me 2 - (CH2) 6- (4-Et-Ph) H H H H
5-280 H H Me 2 - (CH2) 6- (3-Pr-Ph) H H H H
5-281 H H Me 2 - (CHZ) 6- (4-Pr-Ph) H H H H
5-282 H H Me 2 - (CH2) 6- (3-iPr-Ph) H H H H
5-283 H H Me 2 - (CH2) 6- (4-iPr-Ph) H H H H
5-284 H H Me 2 - (CH2) 6- (3-Bu-Ph) H H H H
5-285 H H Me 2 - (CH2) 6- (4-Bu-Ph) H H H H
5-286 H H Me 2 - (CH2) 6- (3-CF3-Ph) H H H H
5-287 H H Me 2 - (CH2) 6- (4-CF3-Ph) H H H H
5-288 H H Me 2 - (CH2) 6- (3-MeO-Ph) H H H H
5-289 H H Me 2 - (CHZ) 6- (4-MeO-Ph) H H H H
5-290 H H Me 2 - (CH2) 6- (3-EtO-Ph) H H H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-291 H H Me 2 - (CH2) 6- (4-EtO- Ph) H H H H
5-292 H H Me 2 - (CH2) 6- (3-PrO-Ph) H H H H
5-293 H H Me 2 - (CH2) 6- (4-Pro-Ph) H H H H
5-294 H H Me 2 - (CH2) 6- (3-iPrO-Ph) H H H H
5-295 H H Me 2 - (CH2) 6- (4-iPrO-Ph) H H H H
5-296 H H Me 2 - (CH2) 6- [3- (2-Et-PrO) - H H H H
Ph]

5-297 H H Me 2 - (CH2) 6- [4- (2-Et-PrO) - H H H H
Ph]

5-298 H H Me 2 - (CH2) 6- (3-iBuO-Ph) H H H H
5-299 H H Me 2-(CH2)6-(4-iBuO-Ph) H H H H
5-300 H H Me 2 - (CH2) 6- (3-MeS-Ph) H H H H
5-301 H H Me 2 - (CH2) 6- (4-MeS-Ph) H H H H
5-302 H H Me 2 - (CH2) 6- (3-EtS-Ph) H H H H
5-303 H H Me 2 - (CH2) 6- (4-EtS-Ph) H H H H
5-304 H H Me 2 - (CH2) 6- (3-PrS-Ph) H H H H
5-305 H H Me 2 - (CH2) 6- (4-PrS-Ph) H H H H
5-306 H H Me 2 - (CH2) 6- (3-iPrS-Ph) H H H H
5-307 H H Me 2 - (CH2) 6- (4-iPrS-Ph) H H H H
5-308 H H Me 2 - (CH2) 6- [3- (2-Et-PrS) - H H H H
Ph]
5-309 H H Me 2 - (CH2) 6- [4- (2-Et-PrS) - H H H H
Ph]

5-310 H H Me 2 - (CH2) 6- (3-iBuS-Ph) H H H H
5-311 H H Me 2 - (CH2) 6- (4-iBuS-Ph) H H H H
5-312 H H Me 2 - (CH2) 6- (3-cHx-Ph) H H H H
5-313 H H Me 2 - (CH2) 6- (4-cHx-Ph) H H H H
5-314 H H Me 2 - (CH2) 6- (3-Ph-Ph) H H H H
5-315 H H Me 2 - (CH2) 6- (4-Ph-Ph) H H H H
5-316 H H Me 2 - (CH2) 6- (2, 4-diMe-Ph) H H H H
5-317 H H Me 2 - (CH2) 6- (3, 4-diMe-Ph) H H H H
5-318 H H Me 2 - (CH2) 6- (3, 5-diMe-Ph) H H H H
5-319 H H Me 2 - (CH2) 6-Np (1) H H H H
5-320 H H Me 2 - (CH2) 6-Np (2) H H H H
5-321 H H Me 2 - (CH2) 7-cHx H H H H
5-322 H H Me 2 - (CH2) 7-cHx H H H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 5-323 C02Me H Me 2 - (CH2) 7-cHx H H H H
5-324 C02Et H Me 2 - (CH2) 7-cHx H H H H
5-325 H H Me 2 - (CH2) 7- (4-F-cHx) H H H H
5-326 H H Me 2 - (CH2) 7- (4-Me-cHx) H H H H
5-327 H H Me 2 - (CH2) 7- (4-Et-cHx) H H H H
5-328 H H Me 2 - (CH2) 7- (4-CF3-cHx) H H H H
5-329 H H Me 2 - (CH2) 7- (4-MeO-cHx) H H H H
5-330 H H Me 2-(CH2)7-(4-EtO-cHx) H H H H
5-331 H H Me 2 - (CH2) 7- (4-MeS-cHx) H H H H
5-332 H H Me 2 - (CH2) 7- (4-cHx-cHx) H H H H
5-333 H H Me 2 - (CH2) 7- (4-Ph-cHx) H H H H
5-334 H H Me 2 - (CH2) 7-Ph H H H H
5-335 H Me Me 2-(CH2)7-Ph H H H H
5-336 CO2Me H Me 2 - (CH2) 7-Ph H H H H
5-337 C02Et H Me 2 - (CH2) 7-Ph H H H H
5-338 H H Me 2 - (CH2) 7- (4-F-Ph) H H H H
5-339 H H Me 2 - (CH2) 7- (4-Me-Ph) H H H H
5-340 H H Me 2 - (CH2) 7- (4-Et-Ph) H H H H
5-341 H H Me 2 - (CH2) 7- (4-CF3-Ph) H H H H
5-342 H H Me 2 - (CH2) 7- (4-MeO-Ph) H H H H
5-343 H H Me 2 - (CH2) 7- (4-EtO-Ph) H H H H
5-344 H H Me 2 - (CH2) 7- (4-MeS-Ph) H H H H
5-345 H H Me 2 - (CH2) 7- (4-cHx-Ph) H H H H
5-346 H H Me 2 - (CH2) 7- (4-Ph-Ph) H H H H
5-347 H H Me 2 - (CH2) 8-cHx H H H H
5-348 H Me Me 2 - (CH2) 8-cHx H H H H
5-349 C02Me H Me 2 - (CH2) 8-cHx H H H H
5-350 C02Et H Me 2 - (CH2) 8-cHx H H H H
5-351 H H Me 2 - (CH2) 8- (4-F-cHx) H H H H
5-352 H H Me 2 - (CH2) 8- (4-Me-cHx) H H H H
5-353 H H Me 2 - (CH2) 8- (4-Et-cHx) H H H H
5-354 H H Me 2 - (CH2) 8- (4-CF3-cHx) H H H H
5-355 H H Me 2 - (CH2) 8- (4-MeO-cHx) H H H H
5-356 H H Me 2 - (CH2) 8- (4-EtO-cHx) H H H H
5-357 H H Me 2 - (CH2) 8- (4-MeS-cHx) H H H H
5-358 H H Me 2 - (CH2) 8- (4-cHx-cHx) H H H H
S:/ChemicailSankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 5-359 H H Me 2 - (CH2) 8- (4-Ph-cHx) H H H H
5-360 H H Me 2 - (CH2) 8-Ph H H H H
5-361 H Me Me 2 - (CH2) 8-Ph H H H H
5-362 CO2Me H Me 2 - (CH2) 8-Ph H H H H
5-363 CO2Et H Me 2 - (CH2) 8-Ph H H H H
5-364 H H Me 2 - (CH2) 8- (4-F-Ph) H H H H
5-365 H H Me 2 - (CH2) 8- (4-Me-Ph) H H H H
5-366 H H Me 2 - (CH2) 8- (4-Et-Ph) H H H H
5-367 H H Me 2 - (CH2) 8- (4-CF3-Ph) H H H H
5-368 H H Me 2 - (CH2) 8- (4-MeO-Ph) H H H H
5-369 H H Me 2 - (CH2) 8- (4-EtO-Ph) H H H H
5-370 H H Me 2 - (CH2) 8- (4-MeS-Ph) H H H H
5-371 H H Me 2-(CH2)8-(4-cHx-Ph) H H H H
5-372 H H Me 2 - (CH2) 8- (4-Ph-Ph) H H H H
5-373 H H Me 2 - (CH2) 3-O-cHx H H H H
5-374 H Me Me 2 - (CH2) 3-0-cHx H H H H
5-375 CO2Me H Me 2 - (CH2) 3-O-cHx H H H H
5-376 CO2Et H Me 2 - (CH2) 3-0-cHx H H H H
5-377 H H Me 2 - (CH2) 3-0- (4-F-cHx) H H H H
5-378 H H Me 2 - (CH2) 3-0- (4-Me-cHx) H H H H
5-379 H H Me 2 - (CH2) 3-0- (4-Et-cHx) H H H H
5-380 H H Me 2 - (CH2) 3-0- (4-CF3-cHx) H H H H
5-381 H H Me 2 - (CH2) 3-0- (4-MeO-cHx) H H H H
5-382 H H Me 2 - (CH2) 3-0- (4-EtO-cHx) H H H H
5-383 H H Me 2 - (CH2) 3-0- (4-MeS-cHx) H H H H
5-384 H H Me 2 - (CH2) 3-0- (4-cHx-cHx) H H H H
5-385 H H Me 2 - (CH2) 3-0- (4-Ph-cHx) H H H H
5-386 H H Me 2-(CH2)3-O-Ph H H H H
5-387 H Me Me 2 - (CH2) 3-0-Ph H H H H
5-388 CO2Me H Me 2 - (CH2) 3-0- Ph H H H H
5-389 CO2Et H Me 2 - (CH2) 3-0-Ph H H H H
5-390 H H Me 2 - (CH2) 3-0- (4-F-Ph) H H H H
5-391 H H Me 2 - (CH2) 3-0- (4-Me-Ph) H H H H
5-392 H H Me 2 - (CH2) 3-0- (4-Et-Ph) H H H H
5-393 H H Me 2 - (CH2) 3-0- (4-CF3-Ph) H H H H
5-394 H H Me 2 - (CH2) 3-0- (4-MeO-Ph) H H H H
S:/ChemicalSankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-395 H H Me 2 - (CH2) 3-0- (4-EtO-Ph) H H H H
5-396 H H Me 2 - (CH2) 3-0- (4-MeS-Ph) H H H H
5-397 H H Me 2 - (CH2) 3-0- (4-cHx-Ph) H H H H
5-398 H H Me 2 - (CH2) 3-0- (4-Ph-Ph) H H H H
5-399 H H Me 2 - (CH2) 4-0-cPn H H H H
5-400 H H Me 2 - (CH2) 4-0-cHx H H H H
5-401 H H Me 2 - (CH2) 4-0-cHx Me H H H
5-402 H H Me 2 - (CH2) 4-0-cHx H Me H H
5-403 H H Me 2 - (CH2) 4-0-cHx F H H H
5-404 H H Me 2 - (CH2) 4-0-cHx H F H H
5-405 H Me Me 2 - (CH2) 4-0-cHx H H H H
5-406 CO2Me H Me 2 - (CH2) 4-0-cHx H H H H
5-407 CO2Et H Me 2 - (CH2) 4-0-cHx H H H H
5-408 H H Me 2 - (CH2) 4-0- (3-F-cHx) H H H H
5-409 H H Me 2 - (CH2) 4 -0- (4 - F- cHx) H H H H
5-410 H H Me 2 - (CH2) 4-0- (4-C1-cHx) H H H H
5-411 H H Me 2 - (CH2) 4-0- (4-Br-cHx) H H H H
5-412 H H Me 2 - (CH2) 4-0- (3-Me-cHx) H H H H
5-413 H H Me 2 - (CH2) 4-0- (4-Me-cHx) H H H H
5-414 H H Me 2 - (CH2) 4-0- (3-Et-cHx) H H H H
5-415 H H Me 2 - (CH2) 4-0- (4-Et-cHx) H H H H
5-416 H H Me 2 - (CH2) 4-0- (3-Pr-cHx) H H H H
5-417 H H Me 2 - (CH2) 4-0- (4-Pr-cHx) H H H H
5-418 H H Me 2 - (CH2) 4-0- (4-iPr-cHx) H H H H
5-419 H H Me 2 - (CH2) 4-0- (3-Bu-cHx) H H H H
5-420 H H Me 2 - (CH2) 4-0- (4-Bu-cHx) H H H H
5-421 H H Me 2 - (CH2) 4-0- (3-CF3-cHx) H H H H
5-422 H H Me 2 - (CH2) 4-0- (4-CF3-cHx) H H H H
5-423 H H Me 2 - (CH2) 4-0- (3-MeO-cHx) H H H H
5-424 H H Me 2 - (CH2) 4-0- (4-MeO-cHx) H H H H
5-425 H H Me 2 - (CH2) 4-0- (3-EtO-cHx) H H H H
5-426 H H Me 2 - (CH2) 4-0- (4-EtO-cHx) H H H H
5-427 H H Me 2 - (CH2) 4-0- (3-PrO-cHx) H H H H
5-428 H H Me 2 - (CH2) 4-0- (4-PrO-cHx) H H H H
5-429 H H Me 2 - (CH2) 4-0- (3-iPrO-cHx) H H H H
5-430 H H Me 2 - (CH2) 4-0- (4-iPrO-cHx) H H H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 5-431 H H Me 2 - (CH2) 4-0- [3- (2-Et-PrO) - H H H H
cHx]

5-432 H H Me 2 - (CH2) 4-0- [4- (2-Et-PrO) - H H H H
cHx]

5-433 H H Me 2 - (CH2) 4-0- (3-iBuO-cHx) H H H H
5-434 H H Me 2 - (CH2) 4-0- (4-iBuO-cHx) H H H H
5-435 H H Me 2 - (CH2) 4-0- (3-MeS-cHx) H H H H
5-436 H H Me 2 - (CH2) 4-0- (4-MeS-cHx) H H H H
5-437 H H Me 2 - (CH2) 4-0- (3-EtS-cHx) H H H H
5-438 H H Me 2 - (CH2) 4-0- (4-EtS-cHx) H H H H
5-439 H H Me 2 - (CH2) 4-0- (3-PrS-cHx) H H H H
5-440 H H Me 2 - (CH2) 4-0- (4-PrS-cHx) H H H H
5-441 H H Me 2 - (CH2) 4-0- (3-iPrS-cHx) H H H H
5-442 H H Me 2 - (CH2) 4-0- (4-iPrS-cHx) H H H H
5-443 H H Me 2 - (CH2) 4-0- [3- (2-Et-PrS) - H H H H
cHx]
5-444 H H Me 2 - (CH2) 4-0- [4- (2-Et-PrS) H H H H
cHx]
5-445 H H Me 2 - (CH2) 4-0- (3-iBuS-cHx) H H H H
5-446 H H Me 2 - (CH2) 4-0- (4-iBuS-cHx) H H H H
5-447 H H Me 2 - (CH2) 4-0- (3-cHx-cHx) H H H H
5-448 H H Me 2 - (CH2) 4-0- (4-cHx-cHx) H H H H
5-449 H H Me 2 - (CH2) 4-0- (3-Ph-cHx) H H H H
5-450 H H Me 2 - (CH2) 4-0- (4-Ph-cHx) H H H H
5-451 H H Me 2 - (CH2) 4-0- (2, 4-diMe-cHx) H H H H
5-452 H H Me 2 - (CH2) 4-0- (3, 4-diMe-cHx) H H H H
5-453 H H Me 2 - (CH2) 4-0- (3, 5-diMe-cHx) H H H H
5-454 H H Me 2-(CH2)4-O-Ph H H H H
5-455 H H Me 2 - (CH2) 4-0-Ph Me H H H
5-456 H H Me 2 - (CH2) 4-0-Ph H Me H H
5-457 H H Me 2-(CH2)4-O-Ph F H H H
5-458 H H Me 2 - (CH2) 4-0-Ph H F H H
5-459 H Me Me 2 - (CH2) 4-0-Ph H H H H
5-460 CO2Me H Me 2 - (CH2) 4-0-Ph H H H H
5-461 CO2Et H Me 2 - (CH2) 4-0- Ph H H H H
5-462 H H Me 2 - (CH2) 4-0- (3-F-Ph) H H H H
S:/ChemicaVSankyo/FP20030I /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-463 H H Me 2 - (CH2) 4-0- (4-F-Ph) H H H H
5-464 H H Me 2 - (CH2) 4-0- (4-C1-Ph) H H H H
5-465 H H Me 2 - (CH2) 4-0- (4-Br-Ph) H H H H
5-466 H H Me 2 - (CH2) 4-0- (3-Me-Ph) H H H H
5-467 H H Me 2 - (CH2) 4-0- (4-Me-Ph) H H H H
5-468 H H Me 2 - (CH2) 4-0- (3-Et-Ph) H H H H
5-469 H H Me 2 - (CH2) 4-0- (4-Et-Ph) H H H H
5-470 H H Me 2 - (CH2) 4-0- (3-Pr-Ph) H H H H
5-471 H H Me 2 - (CH2) 4-0- (4-Pr-Ph) H H H H
5-472 H H Me 2 - (CH2) 4-0- (3-iPr-Ph) H H H H
5-473 H H Me 2-(CH2)4-0-(4-iPr-Ph) H H H H
5-474 H H Me 2 - (CH2) 4-0- (3-Bu-Ph) H H H H
5-475 H H Me 2-(CH2)4-0-(4-Bu-Ph) H H H H
5-476 H H Me 2 - (CH2) 4-0- (3-CF3-Ph) H H H H
5-477 H H Me 2 - (CH2) 4-0- (4-CF3-Ph) H H H H
5-478 H H Me 2-(CH2)4-0-(3-MeO-Ph) H H H H
5-479 H H Me 2 - (CH2) 4-0- (4-MeO-Ph) H H H H
5-480 H H Me 2 - (CH2) 4-0- (3-EtO-Ph) H H H H
5-481 H H Me 2 - (CH2) 4-0- (4-EtO-Ph) H H H H
5-482 H H Me 2 - (CH2) 4-0- (3-Pro-Ph) H H H H
5-483 H H Me 2-(CH2)4-0-(4-Pro-Ph) H H H H
5-484 H H Me 2 - (CH2) 4-0- (3-iPr0-Ph) H H H H
5-485 H H Me 2 - (CH2) 4-0- (4-iPr0-Ph) H H H H
5-486 H H Me 2 - (CH2) 4-0- [3- (2-Et-PrO) - H H H H
Ph]
5-487 H H Me 2 - (CH2) 4-0- [ 4- (2-Et-Pr0) - H H H H
Ph]
5-488 H H Me 2 - (CH2) 4-0- (3-iBuO-Ph) H H H H
5-489 H H Me 2 - (CH2) 4-0- (4-iBuO-Ph) H H H H
5-490 H H Me 2-(CH2)4-0-(3-MeS-Ph) H H H H
5-491 H H Me 2 - (CH2) 4-0- (4-MeS-Ph) H H H H
5-492 H H Me 2 - (CH2) 4-0- (3-EtS-Ph) H H H H
5-493 H H Me 2 - (CH2) 4-0- (4-EtS-Ph) H H H H
5-494 H H Me 2 - (CH2) 4-0- (3-PrS-Ph) H H H H
5-495 H H Me 2 - (CH2) 4-0- (4-PrS-Ph) H H H H
5-496 H H Me 2 - (CH2) 4-0- (3-iPrS-Ph) H H H H
S:/Chemical/Sankyo/FP20030I /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-497 H H Me 2 - (CH2) 4-0- (4-iPrS-Ph) H H H H
5-498 H H Me 2 - (CH2) 4-0- [3- (2-Et-PrS) - H H H H
Ph) 5-499 H H Me 2 - (CH2) 4-0- [ 4- (2-Et-PrS) - H H H H
Ph]

5-500 H H Me 2 - (CH2) 4-0- (3-iBuS-Ph) H H H H
5-501 H H Me 2 - (CH2) 4-0- (4-iBuS-Ph) H H H H
5-502 H H Me 2 - (CH2) 4-0- (3-cHx-Ph) H H H H
5-503 H H Me 2 - (CH2) 4-0- (4-cHx-Ph) H H H H
5-504 H H Me 2-(CH2)4-0-(3-Ph-Ph) H H H H
5-505 H H Me 2 - (CH2) 4-0- (4-Ph-Ph) H H H H
5-506 H H Me 2-(CH2)4-0-(2,4-diMe-Ph) H H H H
5-507 H H Me 2 - (CH2) 4-0- (3, 4-diMe-Ph) H H H H
5-508 H H Me 2 - (CH2) 4-0- (3, 5-diMe-Ph) H H H H
5-509 H H Me 2 - (CH2) 5-0-cHx H H H H
5-510 H H Me 2 - (CH2) 5-0-Ph H H H H
5-511 H H Me 2 - (CH2) 6-0-cHx H H H H
5-512 H H Me 2 - (CH2) 6-0- Ph H H H H
5-513 H H Me 2 - (CH2) 3-OCH2-cHx H H H H
5-514 H Me Me 2 - (CH2) 3-OCH2-cHx H H H H
5-515 C02Me H Me 2 - (CH2) 3-OCH2-cHx H H H H
5-516 C02Et H Me 2 - (CH2) 3-OCH2-cHx H H H H
5-517 H H Me 2 - (CH2) 3-OCH2- (4-F-cHx) H H H H
5-518 H H Me 2 - (CH2) 3-OCH2- (4-Me-cHx) H H H H
5-519 H H Me 2 - (CH2) 3-OCH2- (4-Et-cHx) H H H H
5-520 H H Me 2 - (CH2) 3-OCH2- (4-CF3-cHx) H H H H
5-521 H H Me 2 - (CH2) 3-OCH2- (4-MeO-cHx) H H H H
5-522 H H Me 2 - (CH2) 3-OCH2- (4-EtO-cHx) H H H H
5-523 H H Me 2 - (CH2) 3-OCH2- (4-MeS-cHx) H H H H
5-524 H H Me 2 - (CH2) 3-OCH2- (4-cHx-cHx) H H H H
5-525 H H Me 2 - (CH2) 3-OCH2- (4-Ph-cHx) H H H H
5-526 H H Me 2 - (CH2) 3-OCH2-Ph H H H H
5-527 H Me Me 2 - (CH2) 3-OCH2-Ph H H H H
5-528 CO2Me H Me 2 - (CH2) 3-OCH2-Ph H H H H
5-529 CO2Et H Me 2 - (CH2) 3-OCH2-Ph H H H H
5-530 H H Me 2 - (CH2) 3-OCH2- (4-F-Ph) H H H H
S:/Chemical/Sankyo/FP200301/FP0301 s.doc P87892/FP-030]/Description/gds-mg/30.06.04 5-531 H H Me 2 - (CH2) 3-OCH2- (4-Me-Ph) H H H H
5-532 H H Me 2 - (CH2) 3-OCH2- (4-Et-Ph) H H H H
5-533 H H Me 2 - (CH2) 3-OCH2- (4-CF3-Ph) H H H H
5-534 H H Me 2 - (CH2) 3-OCH2- (4-MeO-Ph) H H H H
5-535 H H Me 2 - (CH2) 3-OCH2- (4-EtO-Ph) H H H H
5-536 H H Me 2 - (CH2) 3-OCH2- (4-MeS-Ph) H H H H
5-537 H H Me 2 - (CH2) 3-OCH2- (4-cHx-Ph) H H H H
5-538 H H Me 2 - (CH2) 3-OCH2- (4-Ph-Ph) H H H H
5-539 H H Me 2 - (CH2) 4-OCH2-cPn H H H H
5-540 H H Me 2 - (CH2) 4-OCH2-cHx H H H H
5-541 H H Me 2 - (CH2) 4-OCH2-cHx Me H H H
5-542 H H Me 2 - (CH2) 4-OCH2-cHx H Me H H
5-543 H H Me 2 - (CH2) 4-OCH2-cHx F H H H
5-544 H H Me 2 - (CH2) 4-OCH2-cHx H F H H
5-545 H Me Me 2 - (CH2) 4-OCH2-cHx H H H H
5-546 CO2Me H Me 2 - (CH2) 4-OCH2-cHx H H H H
5-547 CO2Et H Me 2 - (CH2) 4-OCH2-cHx H H H H
5-548 H H Me 2 - (CH2) 4-OCH2- (3-F-cHx) H H H H
5-549 H H Me 2 - (CH2) 4-OCH2- (4-F-cHx) H H H H
5-550 H H Me 2 - (CH2) 4-OCH2- (4-C1-cHx) H H H H
5-551 H H Me 2 - (CH2) 4-OCH2- (4-Br-cHx) H H H H
5-552 H H Me 2 - (CH2) 4-OCH2- (3-Me-cHx) H H H H
5-553 H H Me 2 - (CH2) 4-OCH2- (4-Me-cHx) H H H H
5-554 H H Me 2 - (CH2) 4-OCH2- (3-Et-cHx) H H H H
5-555 H H Me 2-(CH2)4-OCH2-(4-Et-cHx) H H H H
5-556 H H Me 2 - (CH2) 4-OCH2- (3-Pr-cHx) H H H H
5-557 H H Me 2 - (CH2) 4-OCH2- (4-Pr-cHx) H H H H
5-558 H H Me 2 - (CH2) 4-OCH2- (4-iPr-cHx) H H H H
5-559 H H Me 2 - (CH2) 4-OCH2- (3-Bu-cHx) H H H H
5-560 H H Me 2 - (CH2) 4-OCH2- (4-Bu-cHx) H H H H
5-561 H H Me 2 - (CH2) 4-OCH2- (3-CF3-cHx) H H H H
5-562 H H Me 2 - (CH2) 4-OCH2- (4-CF3-cHx) H H H H
5-563 H H Me 2 - (CH2) 4-OCH2- (3-MeO-cHx) H H H H
5-564 H H Me 2 - (CH2) 4-OCH2- (4-MeO-cHx) H H H H
5-565 H H Me 2 - (CH2) 4-OCH2- (3-EtO-cHx) H H H H
5-566 H H Me 2-(CH2)4-OCH2-(4-EtO-cHx) H H H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-567 H H Me 2 - (CH2) 4-OCH2- (3-Pro-cHx) H H H H
5-568 H H Me 2 - (CH2) 4-OCH2- (4-PrO-cHx) H H H H
5-569 H H Me 2 - (CH2) 4-OCH2- (3-iPrO-cHx) H H H H
5-570 H H Me 2 - (CH2) 4-OCH2- (4-iPrO-cHx) H H H H
5-571 H H Me 2 - (CH2) 4-OCH2- [3- (2-Et- H H H H
Pro)-cHx]

5-572 H H Me 2 - (CH2) 4-OCH2- [ 4- (2-Et- H H H H
Pro)-cHx]
5-573 H H Me 2 - (CH2) 4-OCH2- (3-iBuO-cHx) H H H H
5-574 H H Me 2 - (CH2) 4-OCH2- (4-iBuO-cHx) H H H H
5-575 H H Me 2 - (CH2) 4-OCH2- (3-MeS-cHx) H H H H
5-576 H H Me 2 - (CH2) 4-OCH2- (4-MeS-cHx) H H H H
5-577 H H Me 2 - (CH2) 4-OCH2- (3-EtS-cHx) H H H H
5-578 H H Me 2 - (CH2) 4-OCH2- (4-EtS-cHx) H H H H
5-579 H H Me 2 - (CH2) 4-OCH2- (3-PrS-cHx) H H H H
5-580 H H Me 2 - (CH2) 4-OCH2- (4-PrS-cHx) H H H H
5-581 H H Me 2 - (CH2) 4-OCH2- (3-iPrS-cHx) H H H H
5-582 H H Me 2 - (CH2) 4-OCH2- (4-iPrS-cHx) H H H H
5-583 H H Me 2 - (CH2) 4-OCH2- [3- (2-Et- H H H H
PrS) -cHx]
5-584 H H Me 2 - (CH2) 4-OCH2- [ 4- (2-Et- H H H H
PrS) -cHx]
5-585 H H Me 2 - (CH2) 4-OCH2- (3-iBuS-cHx) H H H H
5-586 H H Me 2 - (CH2) 4-OCH2- (4-iBuS-cHx) H H H H
5-587 H H Me 2 - (CH2) 4-OCH2- (3-cHx-cHx) H H H H
5-588 H H Me 2 - (CH2) 4-OCH2- (4-cHx-cHx) H H H H
5-589 H H Me 2 - (CH2) 4-OCH2- (3-Ph-cHx) H H H H
5-590 H H Me 2 - (CH2) 4-OCH2- (4-Ph-cHx) H H H H
5-591 H H Me 2 - (CH2) 4-OCH2- (2, 4-diMe- H H H H
cHx) 5-592 H H Me 2 - (CH2) 4-OCH2- (3, 4-diMe- H H H H
cHx) 5-593 H H Me 2 - (CH2) 4-OCH2- (3, 5-diMe- H H H H
cHx) 5-594 H H Me 2 - (CH2) 4-OCH2-Ph H H H H
5-595 H H Me 2 - (CH2) 4-OCH2-Ph Me H H H
S:/ChemicaVSankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-596 H H Me 2 - (CH2) 4-OCH2-Ph H Me H H
5-597 H H Me 2 - (CH2) 4-OCH2-Ph F H H H
5-598 H H Me 2 - (CH2) 4-OCH2-Ph H F H H
5-599 H Me Me 2 - (CH2) 4-OCH2-Ph H H H H
5-600 CO2Me H Me 2 - (CH2) 4-OCH2-Ph H H H H
5-601 CO2Et H Me 2 - (CH2) 4-OCH2-Ph H H H H
5-602 H H Me 2 - (CH2) 4-OCH2- (3-F-Ph) H H H H
5-603 H H Me 2 - (CH2) 4-OCH2- (4-F-Ph) H H H H
5-604 H H Me 2 - (CH2) 4-OCH2- (4-C1-Ph) H H H H
5-605 H H Me 2 - (CH2) 4-OCH2- (4-Br-Ph) H H H H
5-606 H H Me 2 - (CH2) 4-OCH2- (3-Me-Ph) H H H H
5-607 H H Me 2 - (CH2) 4-OCH2- (4-Me-Ph) H H H H
5-608 H H Me 2 - (CH2) 4-OCH2- (3-Et-Ph) H H H H
5-609 H H Me 2 - (CH2) 4-OCH2- (4-Et-Ph) H H H H
5-610 H H Me 2 - (CH2) 4-OCH2- (3-Pr-Ph) H H H H
5-611 H H Me 2 - (CH2) 4-OCH2- (4-Pr-Ph) H H H H
5-612 H H Me 2 - (CH2) 4-OCH2- (3-iPr-Ph) H H H H
5-613 H H Me 2 - (CH2) 4-OCH2- (4-iPr-Ph) H H H H
5-614 H H Me 2 - (CH2) 4-OCH2- (3-Bu-Ph) H H H H
5-615 H H Me 2 - (CH2) 4-OCH2- (4-Bu-Ph) H H H H
5-616 H H Me 2 - (CH2) 4-OCH2- (3-CF3-Ph) H H H H
5-617 H H Me 2 - (CH2) 4-OCH2- (4-CF3-Ph) H H H H
5-618 H H Me 2 - (CH2) 4-OCH2- (3-MeO-Ph) H H H H
5-619 H H Me 2 - (CH2) 4-OCH2- (4-MeO-Ph) H H H H
5-620 H H Me 2 - (CH2) 4-OCH2- (3-EtO-Ph) H H H H
5-621 H H Me 2 - (CH2) 4-OCH2- (4-EtO-Ph) H H H H
5-622 H H Me 2 - (CH2) 4-OCH2- (3-PrO-Ph) H H H H
5-623 H H Me 2 - (CH2) 4-OCH2- (4-Pro-Ph) H H H H
5-624 H H Me 2 - (CH2) 4-OCH2- (3-iPrO-Ph) H H H H
5-625 H H Me 2 - (CH2) 4-OCH2- (4-iPrO-Ph) H H H H
5-626 H H Me 2 - (CH2) 4-OCH2- [ 3- (2-Et- H H H H
Pro)-Ph]
5-627 H H Me 2 - (CH2) 4-OCH2- (4- (2-Et- H H H H
PrO) -Ph]
5-628 H H Me 2 - (CH2) 4-OCH2- (3-iBuO-Ph) H H H H
5-629 H H Me 2 - (CH2) 4-OCH2- (4-iBuO-Ph) H H H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 5-630 H H Me 2 - (CH2) 4-OCH2- (3-MeS-Ph) H H H H
5-631 H H Me 2 - (CH2) 4-OCH2- (4-MeS-Ph) H H H H
5-632 H H Me 2 - (CH2) 4-OCH2- (3-EtS-Ph) H H H H
5-633 H H Me 2 - (CH2) 4-0CH2- (4-EtS-Ph) H H H H
5-634 H H Me 2 - (CH2) 4-OCH2- (3-PrS-Ph) H H H H
5-635 H H Me 2 - (CH2) 4-OCH2- (4-PrS-Ph) H H H H
5-636 H H Me 2 - (CH2) 4-OCH2- (3-iPrS-Ph) H H H H
5-637 H H Me 2 - (CH2) 4-OCH2- (4-iPrS-Ph) H H H H
5-638 H H Me 2 - (CH2) 4-OCH2- [3- (2-Et- H H H H
PrS) -Ph]

5-639 H H Me 2- - (CH2) 4-OCH2- [4- (2-Et- H H H H
PrS) -Ph]

5-640 H H Me 2 - (CH2) 4-0CH2- (3-iBuS-Ph) H H H H
5-641 H H Me 2 - (CH2) 4-OCH2- (4-iBuS-Ph) H H H H
5-642 H H Me 2 - (CH2) 4-OCH2- (3-cHx-Ph) H H H H
5-643 H H Me 2 - (CH2) 4-OCH2- (4-cHx-Ph) H H H H
5-644 H H Me 2 - (CH2) 4-OCH2- (3-Ph-Ph) H H H H
5-645 H H Me 2 - (CH2) 4-OCH2- (4-Ph-Ph) H H H H
5-646 H H Me 2 - (CH2) 4-OCH2- (2, 4-diMe- H H H H
Ph) 5-647 H H Me 2 - (CH2) 4-OCH2- (3, 4-diMe- H H H H
Ph) 5-648 H H Me 2 - (CH2) 4-OCH2- (3, 5-diMe- H H H H
Ph) 5-649 H H Me 2 - (CH2) 5-OCH2-cHx H H H H
5-650 H H Me 2 - (CH2) 5-OCH2-Ph H H H H
5-651 H H Me 2 - (CH2) 6-OCH2-cHx H H H H
5-652 H H Me 2 - (CH2) 6-OCH2-Ph H H H H
5-653 H H Me 2 -CH=CH-cHx H H H H
5-654 H H Me 2 -CH=CH-Ph H H H H
5-655 H H Me 2 -CH=CH- (CH2) 2-cHx H H H H
5-656 H H Me 2 -CH=CH- (CH2) 2-Ph H H H H
5-657 H H Me 2 -CH=CH- (CH2) 3-cHx H H H H
5-658 H Me Me 2-CH=CH-(CH2)3-cHx H H H H
5-659 C02Me H Me 2 -CH=CH- (CH2) 3-cHx H H H H
5-660 CO2Et H Me 2 -CH=CH- (CH2) 3-cHx H H H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-661 H H Me 2 -CH=CH- (CHz) 3- (4-F-cHx) H H H H
5-662 H H Me 2 -CH=CH- (CH2) 3- (4-Me-cHx) H H H H
5-663 H H Me 2 -CH=CH- (CHz) 3- (4-Et-cHx) H H H H
5-664 H H Me 2 -CH=CH- (CH2) 3- (4-CF3-cHx) H H H H
5-665 H H Me 2 -CH=CH- (CH2) 3- (4-MeO- H H H H
cHx) 5-666 H H Me 2 -CH=CH- (CH2) 3- (4-EtO- H H H H
cHx) 5-667 H H Me 2 -CH=CH- (CH2) 3- (4-MeS- H H H H
cHx) 5-668 H H Me 2 -CH=CH- (CH2) 3- (4-cHx- H H H H
cHx) 5-669 H H Me 2 -CH=CH- (CH2) 3- (4-Ph-cHx) H H H H
5-670 H H Me 2 -CH=CH- (CH2) 3-Ph H H H H
5-671 H Me Me 2 -CH=CH- (CH2) 3-Ph H H H H
5-672 CO2Me H Me 2 -CH=CH- (CH2) 3-Ph H H H H
5-673 CO2Et H Me 2 -CH=CH- (CH2) 3-Ph H H H H
5-674 H H Me 2 -CH=CH- (CH2) 3- (4-F-Ph) H H H H
5-675 H H Me 2 -CH=CH- (CH2) 3- (4-Me-Ph) H H H H
5-676 H H Me 2 -CH=CH- (CH2) 3- (4-Et-Ph) H H H H
5-677 H H Me 2 -CH=CH- (CH2) 3- (4-CF3-Ph) H H H H
5-678 H H Me 2 -CH=CH- (CH2) 3- (4-MeO-Ph) H H H H
5-679 H H Me 2 -CH=CH- (CH2) 3- (4-EtO-Ph) H H H H
5-680 H H Me 2 -CH=CH- (CH2) 3- (4-MeS-Ph) H H H H
5-681 H H Me 2 -CH=CH- (CH2) 3- (4-cHx-Ph) H H H H
5-682 H H Me 2 -CH=CH- (CH2) 3- (4-Ph-Ph) H H H H
5-683 H H Me 2 -CH=CH- (CH2) 4-cHx H H H H
5-684 H Me Me 2 -CH=CH- (CH2) 4-cHx H H H H
5-685 CO2Me H Me 2 -CH=CH- (CH2) 4-cHx H H H H
5-686 CO2Et H Me 2 -CH=CH- (CH2) 4-cHx H H H H
5-687 H H Me 2 -CH=CH- (CH2) 4- (4-F-cHx) H H H H
5-688 H H Me 2 -CH=CH- (CHz) 4- (4-Me-cHx) H H H H
5-689 H H Me 2 -CH=CH- (CH2) 4- (4-Et-cHx) H H H H
5-690 H H Me 2 -CH=CH- (CH2) 4- (4-CF3-cHx) H H H H
5-691 H H Me 2 -CH=CH- (CH2) 4- (4-MeO- H H H H
cHx) S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 5-692 H H Me 2 -CH=CH- (CH2) 4- (4-EtO- H H H H
cHx) 5-693 H H Me 2 -CH=CH- (CH2) 4- (4-MeS- H H H H
cHx) 5-694 H H Me 2 -CH=CH- (CH2) 4- (4-cHx- H H H H
cHx) 5-695 H H Me 2 -CH=CH- (CH2) 4- (4-Ph-cHx) H H H H
5-696 H H Me 2 -CH=CH- (CH2) 4-Ph H H H H
5-697 H Me Me 2 -CH=CH- (CH2) 4-Ph H H H H
5-698 CO2Me H Me 2 -CH=CH- (CH2) 4-Ph H H H H
5-699 CO2Et H Me 2 -CH=CH- (CH2) 4-Ph H H H H
5-700 H H Me 2 -CH=CH- (CH2) 4- (4-F-Ph) H H H H
5-701 H H Me 2 -CH=CH- (CH2) 4- (4-Me-Ph) H H H H
5-702 H H Me 2 -CH=CH- (CH2) 4- (4-Et-Ph) H H H H
5-703 H H Me 2 -CH=CH- (CH2) 4- (4-CF3-Ph) H H H H
5-704 H H Me 2 -CH=CH- (CH2) 4- (4-MeO-Ph) H H H H
5-705 H H Me 2 -CH=CH- (CH2) 4- (4-EtO-Ph) H H H H
5-706 H H Me 2 -CH=CH- (CH2) 4- (4-MeS-Ph) H H H H
5-707 H H Me 2 -CH=CH- (CH2) 4- (4-cHx-Ph) H H H H
5-708 H H Me 2 -CH=CH- (CH2) 4- (4-Ph-Ph) H H H H
5-709 H H Me 2 -CH=CH- (CH2) 5-cHx H H H H
5-710 H H Me 2 -CH=CH- (CHZ) 5-Ph H H H H
5-711 H H Me 2 -CH=CH- (CH2) 6-cHx H H H H
5-712 H H Me 2 -CH=CH- (CH2) 6-Ph H H H H
5-713 H H Me 2-C=C-CH2O-cHx H H H H
5-714 H H Me 2-C=C-CH2O-Ph H H H H
5-715 H H Me 2 -C=C- (CH2) 20-cHx H H H H
5-716 H H Me 2 -C=C- (CH2) 20-Ph H H H H
5-717 H H Me 2 -C=C-cHx H H H H
5-718 H Me Me 2 -C=-C-cHx H H H H
5-719 CO2Me H Me 2 -C=C-cHx H H H H
5-720 CO2Et H Me 2 -C=-C-cHx H H H H
5-721 H H Me 2-C=C-(4-F-cHx) H H H H
5-722 H H Me 2-C=C-(4-Me-cHx) H H H H
5-723 H H Me 2-C=C-(4-Et-cHx) H H H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Desci iption/gds-mg/30.06.04 5-724 H H Me 2-C-C-(4-CF3-cHx) H H H H
5-725 H H Me 2-C=C-(4-MeO-cHx) H H H H
5-726 H H Me 2-C-C-(4-EtO-cHx) H H H H
5-727 H H Me 2-C-C-(4-MeS-cHx) H H H H
5-728 H H Me 2-C-C-(4-cHx-cHx) H H H H
5-729 H H Me 2-C=C-(4-Ph-cHx) H H H H
5-730 H H Me 2-C-C-Ph H H H H
5-731 H Me Me 2-C-C-Ph H H H H
5-732 CO2Me H Me 2-C-C-Ph H H H H
5-733 CO2Et H Me 2-C=C-Ph H H H H
5-734 H H Me 2-C-C-(4-F-Ph) H H H H
5-735 H H Me 2-C-C-(4-Me-Ph) H H H H
5-736 H H Me 2-C=C-(4-Pr-Ph) H H H H
5-737 H H Me 2-C-C-(4-Bu-Ph) H H H H
5-738 H H Me 2-C-C-(4-MeO-Ph) H H H H
5-739 H H Me 2-C=C-(4-EtO-Ph) H H H H
5-740 H H Me 2-C=_C-(4-PrO-Ph) H H H H
5-741 H H Me 2-C=C-(4-cHx-Ph) H H H H
5-742 H H Me 2-C=C-(4-Ph-Ph) H H H H
5-743 H H Me 2-C=C-(CH2)2-cHx H H H H
5-744 H Me Me 2 -C=-C- (CH2) 2-cHx H H H H
5-745 CO2Me H Me 2 -C=C- (CH2) 2-cHx H H H H
5-746 CO2Et H Me 2 -C=C- (CH2) 2-cHx H H H H
5-747 H H Me 2 -C=C- (CH2) 2- (4-F-cHx) H H H H
5-748 H H Me 2 -C=C- (CH2) 2- (4-Me-cHx) H H H H
5-749 H H Me 2 -C=C- (CH2) 2- (4-Et-cHx) H H H H
5-750 H H Me 2 -C=C- (CH2) 2- (4-CF3-cHx) H H H H
5-751 H H Me 2 -C=C- (CH2) 2- (4-MeO-cHx) H H H H
5-752 H H Me 2 -C=C- (CH2) 2- (4-EtO-cHx) H H H H
5-753 H H Me 2 -C=C- (CH2) 2- (4-MeS-cHx) H H H H
5-754 H H Me 2 -C=C- (CH2) 2- (4-cHx-cHx) H H H H
5-755 H H Me 2 -C=-C- (CH2) 2- (4-Ph-cHx) H H H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-756 H H Me 2 -C=C- (CH2) 2-Ph H H H H
5-7 7 _H Me Me 2 -C=C- (CH2) 2-Ph H H H H
5-7 8 _CO2Me H Me 2 -C=C- (CH2) 2-Ph H H H H
5-7 9 _CO2 Et -H Me 2 -C=C- (CH2) 2-Ph H H H H
5-7 00 H H Me 2 -C=C- (CH2) 2- (4-F-Ph) H H H H
5-7 11 H H Me 2 -C=C- (CH2) 2- (4-Me-Ph) H H H H
5-7 22 H H Me 2 -C=C- (CH2) 2- (4-Et-Ph) H H H H
5-7 33 H H Me 2 -C=-C- (CH2) 2- (4-CF3-Ph) H H H H
5-7 44 H H Me 2 -C=C- (CH2) 2- (4-MeO-Ph) H H H H
5-7 55 H H Me 2 -C=C- (CH2) 2- (4-EtO-Ph) H H H H
5-766 H H Me 2 -C=C- (CH2) 2- (4-MeS-Ph) H H H H
5-767 H H Me 2-C=C-(CH2)2-(4-cHx-Ph) H H H H
5-7 88 H H Me 2 -C=C- (CH2) 2- (4-Ph-Ph) H H H H
5-769 H H Me 2 -C=C- (CH2) 3-cPn H H H H
5-7 0 -H H Me 2 -C=C- (CH2) 3-cHx H H H H
5-771 H H Me 2 -C=-C- (CH2) 3-cHx Me H H H
5-772 H H Me 2 -C=C- (CH2) 3-cHx H Me H H
H H Me 2 5-773 -C=C- (CH2) 3-cHx F H H H
5-774 H H Me 2 -C=C- (CH2) 3-cHx H F H H
5-775 H Me Me 2 -C=C- (CH2) 3-cHx H H H H
5-776 CO2Me H Me 2 -C=C- (CH2) 3-cHx H H H H
5-777 CO2Et H Me 2 -C=C- (CH2) 3-cHx H H H H
5-778 H H Me 2 -C=C- (CH2) 3- (3-F-cHx) H H H H
5-779 H H Me 2 -C=C- (CH2) 3- (4-F-cHx) H H H H
5-780 H H Me 2 -C=C- (CH2) 3- (4-C1-cHx) H H H H
5-781 H H Me 2-C=C-(CH2)3-(4-Br-cHx) H H H H
5-782 H H Me 2 -C=C- (CH2) 3- (3-Me-cHx) H H H H
5-783 H H Me 2 -C=C- (CH2) 3- (4-Me-cHx) H H H H
5-784 H H Me 2-C=C-(CH2)3-(3-Et-cHx) H H H H
5-785 H H Me 2 -C-C- (CH2) 3- (4-Et-cHx) H H H H
5-786 H M2-C C- (CH2) 3- (3-Pr-cHx) H H H H

-711 5-787 H H Me 2 -C=C- (CH 2) 3- (4-Pr-cHx) H H H H

S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-788 H H Me 2 -C=C- (CH2) 3- (4-iPr-cHx) H H H H
5-789 H H Me 2 -C=-C- (CH2) 3- (3-Bu-cHx) H H H H
5-790 H H Me 2 -C=C- (CH2) 3- (4-Bu-cHx) H H H H
5-791 H H Me 2 -C=C- (CH2) 3- (3-CF3-cHx) H H H H
5-792 H H Me 2 -C=C- (CH2) 3- (4-CF3-cHx) H H H H
5-793 H H Me 2 -C=C- (CH2) 3- (3-MeO-cHx) H H H H
5-794 H H Me 2 -C=C- (CH2) 3- (4-MeO-cHx) H H H H
5-795 H H Me 2 -C=C- (CH2) 3- (3-EtO-cHx) H H H H
5-796 H H Me 2 -C=C- (CH2) 3- (4-EtO-cHx) H H H H
5-797 H H Me 2-C=C-(CH2)3-(3-PrO-cHx) H H H H
5-798 H H Me 2 -C=C- (CH2) 3- (4-PrO-cHx) H H H H
5-799 H H Me 2 -C=C- (CH2) 3- (3-iPrO-cHx) H H H H
5-800 H H Me 2-C=C-(CH2)3-(4-iPrO-cHx) H H H H
5-801 H H Me 2 -C=C- (CH2) 3- [3- (2-Et- H H H H
Pro) -cHx]

5-802 H H Me 2 -C=C- (CH2) 3- [4- (2-Et- H H H H
Pro)-cHx]
5-803 H H Me 2 -C=C- (CH2) 3- (3-iBuO-cHx) H H H H
5-804 H H Me 2 -C=C- (CH2) 3- (4-iBuO-cHx) H H H H
5-805 H H Me 2-C=C-(CH2)3-(3-MeS-cHx) H H H H
5-806 H H Me 2 -C=C- (CH2) 3- (4-MeS-cHx) H H H H
5-807 H H Me 2-C=_C-(CH2)3-(3-EtS-cHx) H H H H
5-808 H H Me 2-C=C-(CH2)3-(4-EtS-cHx) H H H H
5-809 H H Me 2 -C-C- (CH2) 3- (3-PrS-cHx) H H H H
5-810 H H Me 2 -C-C- (CH2) 3- (4-PrS-cHx) H H H H
5-811 H H Me 2-C=C-(CH2)3-(3-iPrS-cHx) H H H H
5-812 H H Me 2 -C=C- (CH2) 3- (4-iPrS-cHx) H H H H
5-813 H H Me 2 -C-C- (CH2) 3- [3- (2-Et- H H H H

PrS)-cHx]
5-814 H H Me 2 -C=C- (CH2) 3- [ 4- (2-Et- H H H H
PrS) - cHx]

5-815 H H Me 2 -C=C- (CH2) 3- (3-iBuS-cHx) H H H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-816 H H Me 2 -C-C- (CH2) 3- (4-iBuS-cHx) H H H H
5-817 H H Me 2-C-C-(CH2)3-(3-cHx-cHx) H H H H
5-818 H H Me 2 -C=C- (CH2) 3- (4-cHx-cHx) H H H H
5-819 H H Me 2 -C-C- (CH2) 3- (3-Ph-cHx) H H H H
5-820 H H Me 2 -C=C- (CH2) 3- (4-Ph-cHx) H H H H
5-821 H H Me 2 -C=C- (CH2) 3- (2, 4-diMe- H H H H
cHx) 5-822 H H Me 2 -C=C- (CH2) 3- (3, 4-diMe- H H H H
cHx) 5-823 H H Me 2 -C-C- (CH2) 3- (3, 5-diMe- H H H H
cHx) 5-824 H H Me 2-C=C-(CH2)3-Ph H H H H
5-825 H H Me 2 -C-C- (CH2) 3-Ph Me H H H
5-826 H H Me 2 -C=C- (CH2) 3-Ph H Me H H
5-827 H H Me 2 -C-C- (CHZ) 3-Ph F H H H
5-828 H H Me 2 -C=-C- (CH2) 3-Ph H F H H
5-829 H Me Me 2 -C=C- (CH2) 3-Ph H H H H
5-830 CO2Me H Me 2 -C=-C- (CH2) 3-Ph H H H H
5-831 CO2Et H Me 2 -C=-C- (CH2) 3-Ph H H H H
5-832 H H Me 2 -C-C- (CH2) 3- (3-F-Ph) H H H H
5-833 H H Me 2 -C=C- (CH2) 3- (4-F- Ph) H H H H
5-834 H H Me 2 -C-C- (CH2) 3- (4-C1-Ph) H H H H
5-835 H H Me 2-C-C-(CH2)3-(4-Br-Ph) H H H H
5-836 H H Me 2 -C=C- (CHZ) 3- (3-Me-Ph) H H H H
5-837 H H Me 2 -C=C- (CH2) 3- (4-Me-Ph) H H H H
5-838 H H Me 2 -C=C- (CH2) 3- (3-Et-Ph) H H H H
5-839 H H Me 2 -C-C- (CH2) 3- (4-Et-Ph) H H H H
5-840 H H Me 2 -C-C- (CH2) 3- (3-Pr-Ph) H H H H
5-841 H H Me 2-C=C-(CH2)3-(4-Pr-Ph) H H H H
5-842 H H Me 2-C-C-(CH2)3-(3-iPr-Ph) H H H H
5-843 H H Me 2 -C-C- (CH2) 3- (4-iPr-Ph) H H H H
5-844 H H Me 2 -C=_C- (CH2) 3- (3-Bu-Ph) H H H H
S:/ChemicallSankyo/FP200301/FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 5-845 H H Me 2-C=C-(CH2)3-(4-Bu-Ph) H H H H
5-846 H H Me 2 -C=C- (CH2) 3- (3-CF3-Ph) H H H H
5-847 H H Me 2 -C=C- (CH2) 3- (4-CF3-Ph) H H H H
5-848 H H Me 2 -C=C- (CH2) 3- (3-MeO-Ph) H H H H
5-849 H H Me 2 -C=C- (CH2) 3- (4-MeO-Ph) H H H H
5-850 H H Me 2 -C=C- (CH2) 3- (3-EtO-Ph) H H H H
5-851 H H Me 2 -C=C- (CH2) 3- (4-EtO-Ph) H H H H
5-852 H H Me 2 -C=C- (CH2) 3- (3-Pro-Ph) H H H H
5-853 H H Me 2-C=C-(CH2)3-(4-PrO-Ph) H H H H
5-854 H H Me 2 -C=C- (CH2) 3- (3-iPrO-Ph) H H H H
5-855 H H Me 2 -C-C- (CH2) 3- (4-iPrO-Ph) H H H H
5-856 H H Me 2 -C=C- (CH2) 3-13- (2-Et- H H H H
Pro) -Ph]

5-857 H H Me 2 -C=C- (CH2) 3- [4- (2-Et- H H H H
Pro) -Ph]

5-858 H H Me 2 -C-C- (CH2) 3- (3-iBuO-Ph) H H H H
5-859 H H Me 2 -C=C- (CH2) 3- (4-iBuO-Ph) H H H H
5-860 H H Me 2-C-C-(CH2)3-(3-MeS-Ph) H H H H
5-861 H H Me 2-C=C-(CH2)3-(4-MeS-Ph) H H H H
5-862 H H Me 2 -C=C- (CH2) 3- (3-EtS-Ph) H H H H
5-863 H H Me 2 -C=C- (CH2) 3- (4-EtS-Ph) H H H H
5-864 H H Me 2-C=C-(CH2)3-(3-PrS-Ph) H H H H
5-865 H H Me 2 -C=C- (CH2) 3- (4-PrS-Ph) H H H H
5-866 H H Me 2 -C=C- (CH2) 3- (3-iPrS-Ph) H H H H
5-867 H H Me 2 -C=C- (CH2) 3- (4-iPrS-Ph) H H H H
5-868 H H Me 2 -C=C- (CH2) 3-13- (2-Et- H H H H
PrS)-Ph]

5-869 H H Me 2 -C=C- (CH2) 3- [ 4- (2-Et- H H H H
PrS) -Ph]

5-870 H H Me 2 -C=C- (CH2) 3- (3-iBuS-Ph) H H H H
5-871 H H Me 2 -C=C- (CH2) 3- (4-iBuS-Ph) H H H H
5-872 H H Me 2 -C=C- (CH2) 3- (3-cHx-Ph) H H H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-873 H H Me 2 -C=C- (CH2) 3- (4-cHx-Ph) H H H H
5-874 H H Me 2 -C=C- (CH2) 3- (3-Ph-Ph) H H H H
5-875 H H Me 2 -C=C- (CH2) 3- (4-Ph-Ph) H H H H
5-876 H H Me 2 -C;C- (CH2) 3- (2, 4-diMe- H H H H
Ph) 5-8 77 H H Me 2 -C=C- (CH2) 3- (3, 4-diMe- H H H H
Ph) 5-8 8 -H H Me 2-C=C-(CH2)3-(3,5-diMe- H H H H
Ph) 5-8 99 H H Me 2 -C=C- (CH2) 3-Np (1) H H H H
5-880 H H Me 2 -C-C- (CHZ) 3-Np (2) H H H H
5-881 H H Me 2 -C-C- (CHZ) 4-cPn H H H H
5-882 H H Me 2 -C=_C- (CH2) 4-cHx H H H H
5-883 H H Me 2-C5-=C-(CH2)4-cHx Me H H H
5-884 H H Me 2 -C-C- (CH2) 4-cHx H Me H H
5-885 H H Me 2 -C_C- (CH2) 4-cHx F H H H
5-886 H H Me 2 -C-C- (CHZ) 4-cHx H F H H
5-887 H Me Me 2 -C=C- (CH2) 4-cHx H H H H
5-888 CO2Me H Me 2 -C=C- (CH2) 4-cHx H H H H
5-889 CO 2 -Et H Me 2 -C=C- (CH2) 4-cHx H H--ii H
5-890 H H Me 2-C=C-(CH2)4-(3-F-cHx) H H H H
5-891 H H Me 2 -C=C- (CH2) 4- (4-F-cHx) H H H H
5-892 jH Me 2 -C=C- (CH2) 4- (4-C1-cHx) H H H H
5-893 H H Me 2-C=C-(CH2)4-(4-Br-cHx) H H H H
5-894 IH Me 2-C=C-(CH2)4-(3-Me-cHx) H H H H
5-895 H H Me 2-C=C-(CH2)4-(4-Me-cHx) H H H H
5-896 H H Me 2-C=C-(CH2)4-(3-Et-cHx) H H H H
5-897 H H Me 2 -C=C- (CHZ) 4- (4-Et-cHx) IT- -if- H H
5-898 H H Me 2-C=C-(CH2)4-(3-Pr-cHx) H H H H
5-899 H H Me 2-C=C-(CH2)4-(4-Pr-cHx) H H H H

-C=C-(CH24-(4-iPr-cHx) H H
5-900 H H Me 2 H H

5-901 H H Me 2-C-C-(CH2)4-(3-Bu-cHx) H H H 1H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 5-902 H H Me 2 -C-C- (CH2) 4- (4-Bu-cHx) H H H H
5-903 H H Me 2 -C=C- (CH2) 4- (3-CF3-cHx) H H H H
5-904 H H Me 2 -C=C- (CH2) 4- (4-CF3-cHx) H H H H
5-905 H H Me 2-C-C-(CH2)4-(3-MeO-cHx) H H H H
5-906 H H Me 2 -C-C- (CH2) 4- (4-MeO-cHx) H H H H
5-907 H H Me 2-C=C-(CH2)4-(3-EtO-cHx) H H H H
5-908 H H Me 2 -C-C- (CH2) 4- (4-EtO-cHx) H H H H
5-909 H H Me 2 -C=C- (CH2) 4- (3-PrO-cHx) H H H H
5-910 H H Me 2 -C=C- (CH2) 4- (4-PrO-cHx) H H H H
5-911 H H Me 2 -C=C- (CH2) 4- (3-iPrO-cHx) H H H H
5-912 H H Me 2 -C=C- (CH2) 4- (4-iPrO-cHx) H H H H
5-913 H H Me 2 -C=C- (CH2) 4- [3- (2-Et- H H H H
PrO) -cHx]

5-914 H H Me 2 -C=C- (CH2) 4- [4- (2-Et- H H H H
PrO)-cHx]
5-915 H H Me 2-C-C-(CH2)4-(3-iBuO-cHx) H H H H
5-916 H H Me 2 -C=C- (CH2) 4- (4-iBuO-cHx) H H H H
5-917 H H Me 2 -C=C- (CH2) 4- (3-MeS-cHx) H H H H
5-918 H H Me 2-C-C-(CH2)4-(4-MeS-cHx) H H H H
5-919 H H Me 2 -C=C- (CH2) 4- (3-EtS-cHx) H H H H
5-920 H H Me 2 -C=C- (CH2) 4- (4-EtS-cHx) H H H H
5-921 H H Me 2 -C=C- (CH2) 4- (3-PrS-cHx) H H H H
5-922 H H Me 2 -C=C- (CH2) 4- (4-PrS-cHx) H H H H
5-923 H H Me 2 - C=C- (CH2) 4- (3-iPrS-cHx) H H H H
5-924 H H Me 2 -C==C- (CH2) 4- (4-iPrS-cHx) H H H H
5-925 H H Me 2 -C=C- (CH2) 4- [3- (2-Et- H H H H

PrS) -cHx]

5-926 H H Me 2 -C=-C- (CH2) 4- [4- (2-Et- H H H H
PrS)-cHx]
5-927 H H Me 2 -C-C- (CH2) 4- (3-iBuS-cHx) H H H H
5-928 H H Me 2 -C=C- (CH2) 4- (4-iBuS-cHx) H H H H
5-929 H H Me 2-C=C-(CH2)4-(3-cHx-cHx) H H H H
S:/ChemicalSankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-930 H H Me 2 -C=C- (CH2) 4- (4-cHx-cHx) H H JH H
5-9 1 -H H Me 2 -C-C- (CHz) 4- (3-Ph-cHx) H H H H
5-932 H H Me 2 -C=C- (CHz) 4- (4-Ph-cHx) H H H H
5-933 H H Me 2 -C-C- (CH2) 4- (2, 4-diMe- H H H H
cHx) 5-934 H H Me 2 -C-C- (CHz) 4- (3, 4-diMe- H H H H
cHx) 5-935 H H Me 2 -C=-C- (CHz) 4- (3, 5-diMe- H H H H
cHx) 5-936 H H Me 2-C-C-(CH2)4-Ph H H H H
5-937 H H Me 2 -C-C- (CH2) 4-Ph Me H H H
5-938 H H Me 2 -C-C- (CH2) 4-Ph H Me H H
5-9 99 H H Me 2 -C=C- (CH2) 4-Ph F H H H
5-940 H H Me 2-C=C-(CH2)4-Ph H F H H
5-9 11 H Me Me 2 -C-C- (CHz) 4-Ph H H H H
5-942 COZMe H Me 2 -C-C- (CH2) 4-Ph H H H H
5-943 CO2Et H Me 2 -C-C- (CHz) 4-Ph H H H H
5-944 H H Me 2 -C=C- (CH2) 4- (3-F-Ph) H H H H
5-945 H H Me 2-C=C-(CH2)4-(4-F-Ph) H H H H
5-946 H H Me 2-C-C-(CH2)4-(4-C1-Ph) H H H H
5-947 H H Me 2 -C=C- (CH2) 4- (4-Br-Ph) H H H H
5-948 H H Me 2 -C=C- (CH2) 4- (3-Me-Ph) H H H H
5-949 H H Me 2 -C=C- (CH2) 4- (4-Me-Ph) H H H H
5-950 H H Me 2-C=_C-(CH2)4-(3-Et-Ph) H H H H
5-951 H H Me 2 -C=_C- (CH2) 4- (4-Et-Ph) H H H H
5-952 H H Me 2 -C=-C- (CH2) 4- (3-Pr-Ph) H H H H
5-953 H H Me 2 -C-C- (CH2) 4- (4-Pr-Ph) H H H H
5-954 H H Me 2 -C=C- (CH2) 4- (3-iPr-Ph) H H H H
5-955 H H Me 2-C=C-(CH2)4-(4-iPr-Ph) H H H H
5-956 H H Me 2 -C==C- (CH2) 4- (3-Bu-Ph) H H H H
5-957 H H Me 2 -C=C- (CH2) 4- (4-Bu-Ph) H H H H
5-958 H H Me 2 -C=C- (CH2) 4- (3-CF3-Ph) H H H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Desci iption/gds-mg/30.06,04 5-959 H H Me 2 -C=C- (CH2) 4- (4-CF3-Ph) H H H H
5-960 H H Me 2 -C=C- (CH2) 4- (3-MeO-Ph) H H H H
5-961 H H Me 2-C=C-(CH2)4-(4-MeO-Ph) H H H H
5-962 H H Me 2 -C=C- (CH2) 4- (3-EtO-Ph) H H H H
5-963 H H Me 2 -C=C- (CH2) 4- (4-EtO-Ph) H H H H
5-964 H H Me 2 -C=C- (CH2) 4- (3-Pro-Ph) H H H H
5-965 H H Me 2 -C=C- (CH2) 4- (4-Pro-Ph) H H H H
5-966 H H Me 2 -C=C- (CH2) 4- (3-iPrO-Ph) H H H H
5-967 H H Me 2 -C=C- (CH2) 4- (4-iPrO-Ph) H H H H
5-968 H H Me 2 -C=C- (CH2) 4- [3- (2-Et- H H H H
PrO) -Ph]

5-969 H H Me 2 -C=C- (CH2) 4- [ 4- (2-Et- H H H H
Pro) -Ph]

5-970 H H Me 2 -C=C- (CH2) 4- (3-iBuO-Ph) H H H H
5-971 H H Me 2 -C=C- (CH2) 4- (4-iBuO-Ph) H H H H
5-972 H H Me 2 -C-C- (CH2) 4- (3-MeS-Ph) H H H H
5-973 H H Me 2 -C=C- (CH2) 4- (4-MeS-Ph) H H H H
5-974 H H Me 2 -C=C- (CH2) 4- (3-EtS-Ph) H H H H
5-975 H H Me 2 -C=-C- (CH2) 4- (4-EtS-Ph) H H H H
5-976 H H Me 2 -C=C- (CH2) 4- (3-PrS-Ph) H H H H
5-977 H H Me 2 -C=C- (CH2) 4- (4-PrS-Ph) H H H H
5-978 H H Me 2-C=C-(CH2)4-(3-iPrS-Ph) H H H H
5-979 H H Me 2-C=C-(CH2)4-(4-iPrS-Ph) H H H H
5-980 H H Me 2 -C=C- (CH2) 4- [3- (2-Et- H H H H
PrS) -Ph]

5-981 H H Me 2 -C=C- (CH2) 4- [4- (2-Et- H H H H
PrS) -Ph]

5-982 H H Me 2 -C=-C- (CH2) 4- (3-iBuS-Ph) H H H H
5-983 H H Me 2 -C=C- (CH2) 4- (4-iBuS-Ph) H H H H
5-984 H H Me 2 -C=C- (CH2) 4- (3-cHx-Ph) H H H H
5-985 H H Me 2 -C=C- (CH2) 4- (4-cHx-Ph) H H H H
5-986 H H Me 2-C-C-(CH2)4-(3-Ph-Ph) H H H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-030I /Description/gds-mg/30.06.04 5-987 H H Me 2 -C=C- (CH2) 4- (4-Ph-Ph) H H H H
5-988 H H Me 2-C=C-(CH2)4-(2,4-diMe- H H H H
Ph) 5-989 H H Me 2-C=C-(CHZ)4-(3,4-diMe- H H H H
Ph) 5-990 H H Me 2 -C=C- (CHZ) 4- (3, 5-diMe- H H H H
Ph) 5-991 H H Me 2 -C=-C- (CHZ) 4-Np (1) H H H H
5-992 H H Me 2 -C=C- (CHZ) 4-Np (2) H H H H
5-993 H H Me 2 -C=C- (CHZ) 5-cHx H H H H
5-994 H Me Me 2-C=C-(CH2)5-cHx H H H H
5-995 COZMe H Me 2 -C=C- (CH2) 5-cHx H H H H
5-996 C02Et H Me 2 -C=C- (CH2) 5-cHx H H H H
5-997 H H Me 2 -C=C- (CH2) 5- (4-F-cHx) H H H H
5-998 H H Me 2 -C=C- (CHZ) 5- (4-Me-cHx) H H H H
5-999 H H Me 2 -C=-C- (CH2) 5- (4-Et-cHx) H H H H
5-1000 H H Me 2 -C=C- (CH2) 5- (4-CF3-cHx) H H H H
5-1001 H H Me 2 -C=C- (CH2) 5- (4-MeO-cHx) H H H H
5-1002 H H Me 2 -C=C- (CH2) 5- (4-EtO-cHx) H H H H
5-1003 H H Me 2 -C=C- (CH2) 5- (4-MeS-cHx) H H H H
5-1004 H H Me 2 -C=C- (CH2) 5- (4-cHx-cHx) H H H H
5-1005 H H Me 2 -C=C- (CH2) 5- (4-Ph-cHx) H H H H
5-1006 H H Me 2 -C=C- (CH2) 5-Ph H H H H
5-1007 H Me Me 2 -C-C- (CH2) 5-Ph H H H H
5-1008 C02Me H Me 2 -C-C- (CH2) 5-Ph H H H H
5-1009 C02Et H Me 2 -C=-C- (CH2) 5-Ph H H H H
5-1010 H H Me 2 -C=C- (CH2) 5- (4-F-Ph) H H H H
5-1011 H H Me 2-C-C-(CH2)5-(4-Me-Ph) H H H H
5-1012 H H Me 2-C=C-(CH2)5-(4-Et-Ph) H H H H
5-1013 H H Me 2 -C=C- (CH2) 5- (4-CF3-Ph) H H H H
5-1014 H H Me 2 -C=C- (CH2) 5- (4-MeO-Ph) H H H H
5-1015 H H Me 2 -C=C- (CH2) 5- (4-EtO-Ph) H H H H
S:[Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-030 ] /Description/gds-mg/30.06.04 5-1016 H H Me 2 -C-C- (CH2) 5- (4-MeS-Ph) H H H H
5-1017 H H Me 2 -C-C- (CH2) 5- (4-cHx-Ph) H H H H
5-1018 H H Me 2 -C-C- (CH2) 5- (4-Ph-Ph) H H H H
5-1019 H H Me 2 -C=C- (CH2) 6-cHx H H H H
5-1020 H Me Me 2 -C=C- (CH2) 6-CHx H H H H
5-1021 CO2Me H Me 2-C-C-(CH2)6-cHx H H H H
5-1022 CO2Et H Me 2 -C-C- (CH2) 6-cHx H H H H
5-1023 H H Me 2 -C=C- (CH2) 6- (4-F-cHx) H H H H
5-1024 H H Me 2 -C-C- (CH2) 6- (4-Me-cHx) H H H H
5-1025 H H Me 2 -C=C- (CH2) 6- (4-Et-cHx) H H H H
5-1026 H H Me 2 -C=C- (CH2) 6- (4-CF3-cHx) H H H H
5-1027 H H Me 2 -C=C- (CH2) 6- (4-MeO-cHx) H H H H
5-1028 H H Me 2 -C=C- (CH2) 6- (4-EtO-cHx) H H H H
5-1029 H H Me 2 -C=C- (CHZ) 6- (4-MeS-cHx) H H H H
5-1030 H H Me 2 -C=C- (CHZ) 6- (4-cHx-cHx) H H H H
5-1031 H H Me 2 -C=C- (CH2) 6- (4-Ph-cHx) H H H H
5-1032 H H Me 2 -C=C- (CH2) 6-Ph H H H H
5-1033 H Me Me 2 -C-C- (CH2) 6-Ph H H H H
5-1034 CO2Me H Me 2-C=C-(CH2)6-Ph H H H H
5-1035 CO2Et H Me 2 -C-C- (CH2) 6-Ph H H H H
5-1036 H H Me 2 -C=C- (CH2) 6- (4-F-Ph) H H H H
5-1037 H H Me 2 -C-C- (CH2) 6- (4-Me-Ph) H H H H
5-1038 H H Me 2 -C-=C- (CHZ) 6- (4-Et-Ph) H H H H
5-1039 H H Me 2 -C-C- (CH2) 6- (4-CF3-Ph) H H H H
5-1040 H H Me 2-C=C-(CH2)6-(4-MeO-Ph) H H H H
5-1041 H H Me 2 -C-C- (CH2) 6- (4-EtO-Ph) H H H H
5-1042 H H Me 2 -C=C- (CH2) 6- (4-MeS-Ph) H H H H
5-1043 H H Me 2 -C-C- (CH2) 6- (4-cHx-Ph) H H H H
5-1044 H H Me 2 -C=C- (CH2) 6- (4-Ph-Ph) H H H H
5-1045 H H Me 2 -C-C-CHZ-O-cHx H H H H
5-1046 H Me Me 2 -C-C-CH2-0-cHx H H H H
5-1047 CO2Me H Me 2 -C-C-CH2-O-cHx H H H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-1048 CO2Et H Me 2 -C=C-CH2-O-cHx H H H H
5-1049 H H Me 2 -C-C-CH2-O-(4-F-cHx) H H H H
5-1050 H H Me 2 -C-C-CH2-O-(4-Me-cHx) H H H H
5-1051 H H Me 2 -C-C-CH2-0-(4-Et-cHx) H H H H
5-1052 H H Me 2 -C-C-CH2-0-(4-CF3-cHx) H H H H
5-1053 H H Me 2 -C=C-CH2-O-(4-MeO-cHx) H H H H
5-1054 H H Me 2 -C-C-CH2-O-(4-EtO-cHx) H H H H
5-1055 H H Me 2 -C-C-CH2-0-(4-MeS-cHx) H H H H
5-1056 H H Me 2 -C-C-CH2-O-(4-cHx-cHx) H H H H
5-1057 H H Me 2 -C-C-CH2-0-(4-Ph-cHx) H H H H
5-1058 H H Me 2 -C-C-CH2-O-Ph H H H H
5-1059 H Me Me 2 -C=C-CH2-O-Ph H H H H
5-1060 CO2Me H Me 2 -C=C-CH2-0-Ph H H H H
5-1061 CO2Et H Me 2 -C=C-CH2-0-Ph H H H H
5-1062 H H Me 2 -C=C-CH2-0-(4-F-Ph) H H H H
5-1063 H H Me 2 -C-C-CH2-O-(4-Me-Ph) H H H H
5-1064 H H Me 2 -C=C-CH2-O-(4-Et-Ph) H H H H
5-1065 H H Me 2 -C=C-CH2-O- (4-CF3-Ph) H H H H
5-1066 H H Me 2 -C=C-CH2-O- (4-MeO-Ph) H H H H
5-1067 H H Me 2 -C=-C-CH2-O-(4-EtO-Ph) H H H H
5-1068 H H Me 2 -C=C-CH2-O-(4-MeS-Ph) H H H H
5-1069 H H Me 2 -C=C-CH2-0- (4-cHx-Ph) H H H H
5-1070 H H Me 2 -C-C-CH2-0-(4-Ph-Ph) H H H H
5-1071 H H Me 2-C=C-(CH2)2O-cPn H H H H
5-1072 H H Me 2-C=C-(CH2)20-cHx H H H H
5-1073 H H Me 2-C=C-(CH2)20-cHx Me H H H
5-1074 H H Me 2-C-C-(CH2)2O-cHx H Me H H
5-1075 H H Me 2 -C=C- (CH2) 20-cHx F H H H
5-1076 H H Me 2 -C=_C- (CH2) 20-cHx H F H H
5-1077 H Me Me 2 -C=C- (CH2) 20-cHx H H H H
5-1078 CO2Me H Me 2 -C-C- (CH2) 20-cHx H H H H
5-1079 CO2Et H Me 2 -C-C-(CH2)2O-cHx H H H H
S:/ChemicaVSankyo/FP200301 /FP0301 s.doc P878922FP-0301 /Description/gds-mg/30.06.04 5-1080 H H Me 2 -C=C- (CH2) 20- (3-F-cHx) H H H H
5-1081 H H Me 2-C=C-(CH2)20-(4-F-cHx) H H H H
5-1082 H H Me 2 -C=C- (CH2) 20- (4-C1-cHx) H H H H
5-1083 H H Me 2 -C=C- (CH2) 20- (4-Br-cHx) H H H H
5-1084 H H Me 2 -C=C- (CH2) 20- (3-Me-cHx) H H H H
5-1085 H H Me 2 -C=C- (CH2) 20- (4-Me-cHx) H H H H
5-1086 H H Me 2 -C=C- (CH2) 20- (3-Et-cHx) H H H H
5-1087 H H Me 2 -C=-C- (CH2) 20- (4-Et-cHx) H H H H
5-1088 H H Me 2 -C=C- (CH2) 20- (3-Pr-cHx) H H H H
5-1089 H H Me 2-C=C-(CH2)20-(4-Pr-cHx) H H H H
5-1090 H H Me 2-C=C-(CH2)20-(4-iPr-cHx) H H H H
5-1091 H H Me 2 -CSC- (CH2) 20- (3-Bu-cHx) H H H H
5-1092 H H Me 2 -C-C- (CH2) 20- (4-Bu-cHx) H H H H
5-1093 H H Me 2 -C-C- (CH2) 20- (3-CF3-cHx) H H H H
5-1094 H H Me 2 -CEC- (CH2) 20- (4-CF3-cHx) H H H H
5-1095 H H Me 2 -C-C- (CH2) 20- (3-MeO-cHx) H H H H
5-1096 H H Me 2-C-C-(CH2)20-(4-Me0-cHx) H H H H
5-1097 H H Me 2-C=C-(CH2)20-(3-Et0-cHx) H H H H
5-1098 H H Me 2-C=C-(CH2)20-(4-EtO-cHx) H H H H
5-1099 H H Me 2-C=_C-(CH2)20-(3-PrO-cHx) H H H H
5-1100 H H Me 2-C=C-(CH2)20-(4-PrO-cHx) H H H H
5-1101 H H Me 2 -C-C- (CH2) 20- (3-iPrO- H H H H
cHx) 5-1102 H H Me 2 -C-C- (CH2) 20- (4-iPrO- H H H H
cHx) 5-1103 H H Me 2 -C=C- (CH2) 20- [3- (2 -Et- H H H H
Pro)-cHx]
5-1104 H H Me 2 -C-C- (CH2) 20- [4- (2-Et- H H H H

Pro)-cHx]
5-1105 H H Me 2 -C=_C-(CH2) 20-(3-iBuO- H H H H
cHx) 5-1106 H H Me 2 -C=C- (CH2) 20-(4-iBuO- H H H H
cHx) S:/ChemicaJSankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 5-1107 H H Me 2-C=C-(CH2)20-(3-MeS-cHx) H H H H
5-1108 H H Me 2-C-C-(CH2)20-(4-MeS-cHx) H H H H
5-1109 H H Me 2 -CSC- (CH2) 20- (3-EtS-cHx) H H H H
5-1110 H H Me 2 -C=C- (CH2) 20- (4-EtS-cHx) H H H H
5-1111 H H Me 2-C_C-(CH2)20-(3-PrS-cHx) H H H H
5-1112 H H Me 2-C=C-(CH2)20-(4-PrS-cHx) H H H H
5-1113 H H Me 2-C-C-(CH2)20-(3-iPrS- H H H H
cHx) 5-1114 H H Me 2 -C=C- (CH2) 20- (4-iPrS- H H H H
cHx) 5-1115 H H Me 2 -C-C- (CH2) 20- [3- (2-Et- H H H H
PrS)-cHx]
5-1116 H H Me 2 -C=_C- (CH2) 20- [4- (2-Et- H H H H

PrS) -cHx]

5-1117 H H Me 2-C=C-(CH2)20-(3-iBuS- H H H H
cHx) 5-1118 H H Me 2-C=_C-(CH2)20-(4-iBuS- H H H H
cHx) 5-1119 H H Me 2-C-C-(CH2)20-(3-cHx-cHx) H H H H
5-1120 H H Me 2-C=C-(CH2)20-(4-cHx-cHx) H H H H
5-1121 H H Me 2 -C=C- (CH2) 20- (3-Ph-cHx) H H H H
5-1122 H H Me 2 -C=C- (CH2) 20- (4-Ph-cHx) H H H H
5-1123 H H Me 2 -C=-C- (CH2) 20- (2, 4-diMe- H H H H
cHx) 5-1124 H H Me 2 -C=C- (CH2) 20- (3, 4-diMe- H H H H
cHx) 5-1125 H H Me 2 -C=C- (CH2) 20- (3, 5-diMe- H H H H
cHx) 5-1126 H H Me 2 -C=-C- (CH2) 20-Ph H H H H
5-1127 H H Me 2 -C=C- (CH2) 20-Ph Me H H H
5-1128 H H Me 2 -C=C- (CH2) 20-Ph H Me H H
5-1129 H H Me 2 -C=C- (CH2) 20-Ph F H H H
5-1130 H H Me 2 -C=-C- (CH2) 20-Ph H F H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-1131 H Me Me 2-C=C-(CH2)2O-Ph H H H H
5-1132 CO2Me H Me 2 -C=C- (CH2) 20-Ph H H H H
5-1133 CO2Et H Me 2 -C=C- (CH2) 20-Ph H H H H
5-1134 H H Me 2 -C-C- (CH2) 20- (3-F-Ph) H H H H
5-1135 H H Me 2 -C-C- (CH2) 20- (4-F-Ph) H H H H
5-1136 H H Me 2 -C=C- (CH2) 20- (4-C1-Ph) H H H H
5-1137 H H Me 2 -C-C- (CH2) 20- (4-Br-Ph) H H H H
5-1138 H H Me 2 -C-C- (CH2) 20- (3-Me-Ph) H H H H
5-1139 H H Me 2 -C=C- (CH2) 20- (4-Me-Ph) H H H H
5-1140 H H Me 2-C=C-(CH2)2O-(3-Et-Ph) H H H H
5-1141 H H Me 2 -C=C- (CH2) 20- (4-Et-Ph) H H H H
5-1142 H H Me 2 -C=C- (CH2) 20- (3-Pr-Ph) H H H H
5-1143 H H Me 2 -C=-C- (CH2) 20- (4-Pr-Ph) H H H H
5-1144 H H Me 2-C=C-(CH2)2O-(3-iPr-Ph) H H H H
5-1145 H H Me 2 -C=C- (CH2) 20- (4-iPr-Ph) H H H H
5-1146 H H Me 2 -C=-C- (CH2) 20- (3-Bu-Ph) H H H H
5-1147 H H Me 2 -C=C- (CH2) 20- (4-Bu-Ph) H H H H
5-1148 H H Me 2 -C=C- (CH2) 20- (3-CF3-Ph) H H H H
5-1149 H H Me 2 -C=C- (CH2) 20- (4-CF3-Ph) H H H H
5-1150 H H Me 2 -C=C- (CH2) 20- (3-MeO-Ph) H H H H
5-1151 H H Me 2 -C=C- (CH2) 20- (4-MeO-Ph) H H H H
5-1152 H H Me 2 -C=C- (CH2) 20- (3-EtO-Ph) H H H H
5-1153 H H Me 2 -C=C- (CH2) 20- (4-EtO-Ph) H H H H
5-1154 H H Me 2 -C=C- (CH2) 20- (3-PrO-Ph) H H H H
5-1155 H H Me 2 -C=-C- (CH2) 20- (4-Pro-Ph) H H H H
5-1156 H H Me 2-C=C-(CH2)20-(3-iPrO-Ph) H H H H
5-1157 H H Me 2-C=C-(CH2)2O-(4-iPrO-Ph) H H H H
5-1158 H H Me 2 -C=C- (CH2) 20- [3- (2-Et- H H H H
PrO) -Ph]

5-1159 H H Me 2 -C=C- (CH2) 20- [4- (2-Et- H H H H
PrO) -Ph]

5-1160 H H Me 2 -C=-C- (CH2) 20- (3-iBuO-Ph) H H H H
S:/Chemical/Sankyo/FP200301/FP0301s.doc P87892/FP-0301/Description/gds-mg/30.06.04 5-1161 H H Me 2-C=C-(CH2)2O-(4-iBuO-Ph) H H H H
5-1162 H H Me 2 -C=C- (CH2) 20- (3-MeS-Ph) H H H H
5-1163 H H Me 2 -C=C- (CH2) 20- (4-MeS-Ph) H H H H
5-1164 H H Me 2 -C=C- (CH2) 20- (3-EtS-Ph) H H H H
5-1165 H H Me 2-C=-C-(CH2)2O-(4-EtS-Ph) H H H H
5-1166 H H Me 2-C=C-(CH2)2O-(3-PrS-Ph) H H H H
5-1167 H H Me 2 -C=C- (CH2) 20- (4-PrS-Ph) H H H H
5-1168 H H Me 2-C=C-(CH2)2O-(3-iPrS-Ph) H H H H
5-1169 H H Me 2-C=C-(CH2)20-(4-iPrS-Ph) H H H H
5-1170 H H Me 2-C=C-(CH2)2O-[3-(2-Et- H H H H
PrS) -Ph]

5-1171 H H Me 2 -C=C- (CH2) 20- [4- (2-Et- H H H H
PrS)-Ph]
5-1172 H H Me 2-C=C-(CH2)2O-(3-iBuS-Ph) H H H H
5-1173 H H Me 2 -C=C- (CH2) 20- (4-iBuS-Ph) H H H H
5-1174 H H Me 2-C=C-(CH2)20-(3-cHx-Ph) H H H H
5-1175 H H Me 2-C=C-(CH2)20-(4-cHx-Ph) H H H H
5-1176 H H Me 2 -C=C- (CH2) 20- (3-Ph-Ph) H H H H
5-1177 H H Me 2 -C=C- (CH2) 20- (4-Ph-Ph) H H H H
5-1178 H H Me 2 -C=C- (CH2) 20- (2, 4-diMe- H H H H
Ph) 5-1179 H H Me 2-C=C-(CH2)2O-(3,4-diMe- H H H H
Ph) 5-1180 H H Me 2 -C=C- (CH2) 20- (3, 5-diMe- H H H H
Ph) 5-1181 H H Me 2 -C=C- (CH2) 30-cHx H H H H
5-1182 H H Me 2 -C=-C- (CH2) 30-Ph H H H H
5-1183 H H Me 2 -C=-C- (CH2) 40-cHx H H H H
5-1184 H H Me 2 -C=C- (CH2) 40-Ph H H H H
5-1185 H H Me 2 -C=C-CH2-OCH2-cHx H H H H
5-1186 H Me Me 2 -C=C-CH2-OCH2-cHx H H H H
5-1187 CO2Me H Me 2 -C=C-CH2-OCH2-cHx H H H H
S:/ChemicaUSankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 5-1188 CO2Et H Me 2 -C=C-CH2-OCH2-cHx H H H H
5-1189 H H Me 2 -C=C-CH2-OCH2-(4-F-cHx) H H H H
5-1190 H H Me 2 -C=C-CH2-OCH2-(4-Me-cHx) H H H H
5-1191 H H Me 2 -C=C-CH2-OCH2-(4-Et-cHx) H H H H
5-1192 H H Me 2 -C=C-CH2-OCH2- (4-CF3-cHx) H H H H
5-1193 H H Me 2 -C=c-CH2-OCH2-(4-MeO- H H H H
cHx) 5-1194 H H Me 2 -C=C-CH2-OCH2-(4-EtO- H H H H
cHx) 5-1195 H H Me 2 -C=C-CH2-OCH2- (4-MeS- H H H H
cHx) 5-1196 H H Me 2 -C=C-CH2-OCH2-(4-cHx- H H H H
cHx) 5-1197 H H Me 2 - C=C-CH2-OCH2- (4-Ph-cHx) H H H H
5-1198 H H Me 2 -C=C-CH2-OCH2-Ph H H H H
5-1199 H Me Me 2 -C=C-CH2-OCH2-Ph H H H H
5-1200 CO2Me H Me 2 -C=C-CH2-OCH2-Ph H H H H
5-1201 CO2Et H Me 2 -C=C-CH2-OCH2-Ph H H H H
5-1202 H H Me 2 -C=C-CH2-OCH2- (4-F-Ph) H H H H
5-1203 H H '-me --[2 -C=C-CH2-OCH2-(4-Me-Ph) H H H H
5-1204 H H Me 2 -C=-C-CH2-OCH2- (4-Et-Ph) H H H H
5-1205 H H Me 2 -C=C-CH2-OCH2- (4-CF3-Ph) H H H H
5-1206 H H Me 2 -C=C-CH2-OCH2-(4-MeO-Ph) H H H H
5-1207 H H Me 2 -C=C-CH2-OCH2-(4-EtO-Ph) H H H H
5-1208 H H Me 2 -C=C-CH2-OCH2- (4-MeS-Ph) H H H H
5-1209 H H Me 2 -C=C-CH2-OCH2- (4-cHx-Ph) H H H H
5-1210 H H Me 2 -C=-C-CH2-OCH2- (4-Ph-Ph) H H H H
5-1211 H H Me 2 -C=C- (CH2) 2-OCH2-cPn H H H H
5-1212 H H Me 2 -C=C- (CH2) 2-OCH2-cHx H H H H
5-1213 H H Me 2 -C=-C- (CH2) 2-OCH2-cHx Me H H H
5-1214 H H Me 2 -C=C- (CH2) 2-OCH2-cHx H Me H H
5-1215 H H Me 2 -C=-C- (CH2) 2-OCH2-cHx F H H H
S:/Chemical/Sankyo/FP200301/FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 5-1216 H H Me 2 -C=C- (CH2) 2-OCH2-cHx H F H H
5-1217 H Me Me 2 -C-C- (CH2) 2-OCH2-CH2-cHx H H H H
5-1218 CO2Me H Me 2 -C=C- (CH2) 2-OCH2-cHx H H H H
5-1219 CO2Et H Me 2 -C=C- (CH2) 2-OCH2-cHx H H H H
5-1220 H H Me 2 -C=C- (CH2) 2-OCH2- (3-F- H H H H
cHx) 5-1221 H H Me 2 -C=C- (CH2) 2-OCH2- (4-F- H H H H
cHx) 5-1222 H H Me 2 -C=C- (CH2) 2-OCH2- (4-C1- H H H H
cHx) 5-1223 H H Me 2 -C=-C- (CH2) 2-OCH2- (4-Br- H H H H
cHx) 5-1224 H H Me 2 -C=C- (CH2) 2-OCH2- (3-Me- H H H H
cHx) 5-1225 H H Me 2 -C=C- (CH2) 2-OCH2- (4-Me- H H H H
cHx) 5-1226 H H Me 2 -C-C- (CH2) 2-OCH2- (3-Et- H H H H
cHx) 5-1227 H H Me 2 -C=-C- (CH2) 2-OCH2- (4-Et- H H H H
cHx) 5-1228 H H Me 2 -C=C- (CH2) 2-OCH2- (3-Pr- H H H H
cHx) 5-1229 H H Me 2 -C-C- (CH2) 2-OCH2- (4-Pr- H H H H
cHx) 5-1230 H H Me 2 -C=-C- (CH2) 2-OCH2- (4-iPr- H H H H
cHx) 5-1231 H H Me 2 -C-C- (CH2) 2-OCH2- (3-Bu- H H H H
cHx) 5-1232 H H Me 2 -C=-C- (CH2) 2-OCH2- (4-Bu- H H H H
cHx) 5-1233 H H Me 2 -C=C- (CH2) 2-OCH2- (3-CF3- H H H H
cHx) 5-1234 _jH Me 2 -C==-C- (CH2) 2-OCH2- (4-CF3- H H H H
cHx) S:/ChemicallSankyo/FP20030I /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-1235 H H Me 2 -C=C- (CH2) 2-OCH2- (3-MeO- H H H H
cHx) 5-1236 H H Me 2 -C=C- (CH2) 2-OCH2- (4-MeO- H H H H
cHx) 5-1237 H H Me 2 -C=C- (CH2) 2-OCH2- (3-EtO- H H H H
cHx) 5-1238 H H Me 2 -C=C- (CH2) 2-OCH2- (4-EtO- H H H H
cHx) 5-1239 H H Me 2 -C=C- (CH2) 2-OCH2- (3-PrO- H H H H
cHx) 5-1240 H H Me 2 -C=C- (CH2) 2-OCH2- (4-PrO- H H H H
cHx) 5-1241 H H Me 2 -C=C- (CH2) 2-OCH2- (3-iPrO- H H H H
cHx) 5-1242 H H Me 2 -C=C- (CH2) 2-OCH2- (4-iPrO- H H H H
cHx) 5-1243 H H Me 2 -C=C- (CH2) 2-OCH2- [3- (2- H H H H
Et-PrO)cHx]
5-1244 H H Me 2 -C=C- (CH2) 2-OCH2- [4- (2- H H H H

Et-PrO)cHx]
5-1245 H H Me 2 -C=C- (CH2) 2-OCH2- (3-iBuO- H H H H
cHx) 5-1246 H H Me 2 -C=C- (CH2) 2-OCH2- (4-iBuO- H H H H
cHx) 5-1247 H H Me 2-C=C-(CH2)2-OCH2-(3-MeS- H H H H
cHx) 5-1248 H H Me 2 -C=C- (CH2) 2-OCH2- (4-MeS- H H H H
cHx) 5-1249 H H Me 2 -C=C- (CH2) 2-OCH2- (3-EtS- H H H H
cHx) 5-1250 H H Me 2 -C=C- (CH2) 2-OCH2- (4-EtS- H H H H
cHx) 5-1251 H H Me 2-C=C-(CH2)2-OCH2-(3-PrS- H H H H
cHx) S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 5-1252 H H Me 2 -C-C- (CH2) 2-OCH2- (4-PrS- H H H H
cHx) 5-1253 H H Me 2 -C=C- (CH2) 2-OCH2- (3-iPrS- H H H H
cHx) 5-1254 H H Me 2 -C=C- (CH2) 2-OCH2- (4-iPrS- H H H H
cHx) 5-1255 H H Me 2 -C=C- (CH2) 2-OCH2- [3- (2- H H H H
Et-PrS)cHx]
5-1256 H H Me 2 -C=C- (CH2) 2-OCH2- [4- (2- H H H H

Et-PrS)cHx]
5-1257 H H Me 2 -C-C- (CH2) 2-OCH2- (3-iBuS- H H H H
cHx) 5-1258 H H Me 2 -C=C- (CH2) 2-OCH2- (4-iBuS- H H H H
cHx) 5-1259 H H Me 2 -C=C- (CH2) 2-OCH2- (3-cHx- H H H H
cHx) 5-1260 H H Me 2 -C=C- (CH2) 2-OCH2- (4-cHx- H H H H
cHx) 5-1261 H H Me 2 -C=C- (CH2) 2-OCH2- (3-Ph- H H H H
cHx) 5-1262 H H Me 2 -C-C- (CH2) 2-OCH2- (4-Ph- H H H H
cHx) 5-1263 H H Me 2 -C=C- (CH2) 2-OCH2- (2, 4- H H H H
diMe-cHx) 5-1264 H H Me 2 -C-C- (CH2) 2-OCH2- (3, 4- H H H H

diMe-cHx) 5-1265 H H Me 2 -C-C- (CH2) 2-OCH2- (3, 5- H H H H
diMe-cHx) 5-1266 H H Me 2 -C=-C- (CH2) 2-OCH2-Ph H H H H
5-1267 H H Me 2 -C=-C- (CH2) 2-OCH2-Ph Me H H H
5-1268 H H Me 2 -C=C- (CH2) 2-OCH2-Ph H Me H H
5-1269 H H Me 2 -C-C- (CH2) 2-OCH2-Ph F H H H
5-1270 H H Me 2 -C=C- (CH2) 2-OCH2-Ph H F H H
5-1271 H Me Me 2 -C-C- (CH2) 2-OCH2-CH2-Ph H H H H
S:/Chemical/Sankyo/FP200301/FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 5-1272 C02Me H Me 2 -C=C- (CH2) 2-OCH2-Ph H H H H
5-1273 CO2Et H Me 2 -C=C- (CH2) 2-OCH2-Ph H H H H
5-1274 H H Me 2 -C=-C- (CH2) 2-OCH2- (3-F-Ph) H H H H
5-1275 H H Me 2 C-=C- (CH2) 2-OCH2- (4-F-Ph) H H H H
5-1276 H H Me 2 -C=C- (CH2) 2-OCH2- (4-C1- H H H H
Ph) 5-1277 H H Me 2 -C=-C- (CH2) 2-OCH2- (4-Br- H H H H
Ph) 5-1278 H H Me 2 -C=C- (CH2) 2-OCH2- (3-Me- H H H H
Ph) 5-1279 H H Me 2 -C=C- (CH2) 2-OCH2- (4-Me- H H H H
Ph) 5-1280 H H Me 2 -C=C- (CH2) 2-OCH2- (3-Et- H H H H
Ph) 5-1281 H H Me 2 -C=C- (CH2) 2-OCH2- (4-Et- H H H H
Ph) 5-1282 H H Me 2 -C=-C- (CH2) 2-OCH2- (3-Pr- H H H H
Ph) 5-1283 H H Me 2 -C=-C- (CH2) 2-OCH2- (4-Pr- H H H H
Ph) 5-1284 H H Me 2 -C=C- (CH2) 2-OCH2- (3-iPr- H H H H
Ph) 5-1285 H H Me 2 -C=C- (CH2) 2-OCH2- (4-iPr- H H H H
Ph) 5-1286 H H Me 2 -C=C- (CH2) 2-OCH2- (3-Bu- H H H H
Ph) 5-1287 H H Me 2-C=C-(CH2)2-OCH2-(4-Bu- H H H H
Ph) 5-1288 H H Me 2 -C=C- (CH2) 2-OCH2- (3-CF3- H H H H
Ph) 5-1289 H H Me 2 -C=C- (CH2) 2-OCH2- (4-CF3- H H H H
Ph) 5-1290 H H Me 2 -C=C- (CH2) 2-OCH2- (3-MeO- H H H H
Ph) S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 5-1291 H H Me 2 -C=C- (CH2) 2-OCH2- (4-MeO- H H H H
Ph) 5-1292 H H Me 2 -C=C- (CH2) 2-OCH2- (3-EtO- H H H H
Ph) 5-1293 H H Me 2 -C=C- (CH2) 2-OCH2- (4-EtO- H H H H
Ph) 5-1294 H H Me 2 -C=C- (CH2) 2-OCH2- (3-PrO- H H H H
Ph) 5-1295 H H Me 2 -C=C- (CH2) 2-OCH2- (4-PrO- H H H H
Ph) 5-1296 H H Me 2 -C=C- (CH2) 2-OCH2- (3-iPrO- H H H H
Ph) 5-1297 H H Me 2-C=C-(CH2)2-OCH2-(4-iPrO- H H H H
Ph) 5-1298 H H Me 2 -C=C- (CH2) 2-OCH2-[3- (2- H H H H
Et-PrO)Ph]
5-1299 H H Me 2 -C=C- (CH2) 2-OCH2- [4- (2- H H H H

Et-PrO)Ph]
5-1300 H H Me 2 -C=C- (CH2) 2-OCH2- (3-iBuO- H H H H
Ph) 5-1301 H H Me 2 -C=C- (CH2) 2-OCH2- (4-iBuO- H H H H
Ph) 5-1302 H H Me 2 -C=C- (CH2) 2-OCH2- (3-MeS- H H H H
Ph) 5-1303 H H Me 2-C=C-(CH2)2-OCH2-(4-MeS- H H H H
Ph) 5-1304 H H Me 2 -C=C- (CH2) 2-OCH2- (3-EtS- H H H H
Ph) 5-1305 H H Me 2 -C-C- (CH2) 2-OCH2- (4-EtS- H H H H
Ph) 5-1306 H H Me 2 -C=C- (CH2) 2-OCH2- (3-PrS- H H H H
Ph) 5-1307 H H Me 2 -C-C- (CH2) 2-OCH2- (4-PrS- H H H H
Ph) S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-1308 H H Me 2 -C=C- (CH2) 2-OCH2- (3-iPrS- H H H H
Ph) 5-1309 H H Me 2 -C=C- (CH2) 2-OCH2- (4-iPrS- H H H H
Ph) 5-1310 H H Me 2 -C=C- (CH2) 2-OCH2- [3- (2- H H H H
Et-PrS) Ph]

5-1311 H H Me 2 -C=C- (CH2) 2-OCH2- [4- (2- H H H H
Et-PrS) Ph]

5-1312 H H Me 2 -C=C- (CH2) 2-OCH2- (3-iBuS- H H H H
Ph) 5-1313 H H Me 2 -C=C- (CH2) 2-OCH2- (4-iBuS- H H H H
Ph) 5-1314 H H Me 2 -C-=C- (CH2) 2-OCH2- (3-cHx- H H H H
Ph) 5-1315 H H Me 2 -C-C- (CH2) 2-OCH2- (4-cHx- H H H H
Ph) 5-1316 H H Me 2-C=C-(CH2)2-OCH2-(3-Ph- H H H H
Ph) 5-1317 H H Me 2 -C-C- (CH2) 2-OCH2- (4-Ph- H H H H
Ph) 5-1318 H H Me 2 -C-C- (CH2) 2-OCH2- (2, 4- H H H H
diMe-Ph) 5-1319 H H Me 2 -C-C- (CH2) 2-OCH2- (3, 4- H H H H
diMe-Ph) 5-1320 H H Me 2 -C-C- (CH2) 2-OCH2- (3, 5- H H H H
diMe-Ph) 5-1321 H H Me 2 -C=_C- (CH2) 3-OCH2-cHx H H H H
5-1322 H H Me 2-C=C-(CH2)3-OCH2-Ph H H H H
5-1323 H H Me 2 -C=C- (CH2) 4-OCH2-cHx H H H H
5-1324 H H Me 2-C=_C-(CH2)4-OCH2-Ph H H H H
5-1325 H H Me 2 -CO-CH2-(4-cHx-Ph) H H H H
5-1326 H H Me 2 -CO-CH2-(4-Ph-Ph) H H H H
5-1327 H H Me 2 -CO- (CH2) 2-cHx H H H H
5-1328 H H Me 2 -CO- (CH2) 2-Ph H H H H
S:/Chemical/Sankyo/FP20030 I /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-1329 H H Me 2-CO-(CH2)3-cHx H H H H
5-1330 H H Me 2 -CO- (CH2) 3-Ph H H H H
5-1331 H H Me 2 -CO- (CH2) 4-cHx H H H H
5-1332 H Me Me 2 -CO- (CH2) 4-cHx H H H H
5-1333 CO2Me H Me 2 -CO- (CH2) 4-cHx H H H H
5-1334 C02Et H Me 2 -CO- (CH2) 4-cHx H H H H
5-1335 H H Me 2 -CO- (CH2) 4- (4-F-cHx) H H H H
5-1336 H H Me 2 -CO- (CH2) 4- (4-Me-cHx) H H H H
5-1337 H H Me 2 -CO- (CH2) 4- (4-Et-cHx) H H H H
5-1338 H H Me 2 -CO- (CH2) 4- (4-CF3-cHx) H H H H
5-1339 H H Me 2 -CO- (CH2) 4- (4-MeO-cHx) H H H H
5-1340 H H Me 2 -CO- (CH2) 4- (4-EtO-cHx) H H H H
5-1341 H H Me 2 -CO- (CH2) 4- (4-MeS-cHx) H H H H
5-1342 H H Me 2 -CO- (CH2) 4- (4-cHx-cHx) H H H H
5-1343 H H Me 2 -CO- (CH2) 4- (4-Ph-cHx) H H H H
5-1344 H H Me 2 -CO- (CH2) 4-Ph H H H H
5-1345 H Me Me 2 -CO- (CH2) 4-Ph H H H H
5-1346 C02Me H Me 2 -CO- (CH2) 4-Ph H H H H
5-1347 CO2Et H Me 2-CO-(CH2)4-Ph H H H H
5-1348 H H Me 2 -CO- (CH2) 4- (4-F-Ph) H H H H
5-1349 H H Me 2 -CO- (CH2) 4- (4-Me-Ph) H H H H
5-1350 H H Me 2 -CO- (CH2) 4- (4-Et-Ph) H H H H
5-1351 H H Me 2 -CO- (CH2) 4- (4-CF3-Ph) H H H H
5-1352 H H Me 2 -CO- (CH2) 4- (4-MeO-Ph) H H H H
5-1353 H H Me 2-CO-(CH2)4-(4-Et0-Ph) H H H H
5-1354 H H Me 2 -CO- (CH2) 4- (4-MeS-Ph) H H H H
5-1355 H H Me 2 -CO- (CH2) 4- (4-cHx-Ph) H H H H
5-1356 H H Me 2 -CO- (CH2) 4- (4-Ph-Ph) H H H H
5-1357 H H Me 2 -CO- (CH2) 5-cHx H H H H
5-1358 H Me Me 2 -CO- (CH2) 5-cHx H H H H
5-1359 CO2Me H Me 2 -CO- (CH2) 5-cHx H H H H
5-1360 CO2Et H Me 2 -CO- (CH2) 5-cHx H H H H
5-1361 H H Me 2 -CO- (CH2) 5- (4-F-cHx) H H H H
5-1362 H H Me 2 -CO- (CH2) 5- (4-Me-cHx) H H H H
5-1363 H H Me 2 -CO- (CH2) 5- (4-Et-cHx) H H H H
5-1364 H H Me 2 -CO- (CH2) 5- (4-CF3-cHx) H H H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-1365 H H Me 2 -CO- (CH2) 5- (4-MeO-cHx) H H H H
5-1366 H H Me 2 -CO- (CH2) 5- (4-EtO-cHx) H H H H
5-1367 H H Me 2 -CO- (CH2) 5- (4-MeS-cHx) H H H H
5-1368 H H Me 2 -CO- (CH2) 5- (4-cHx-cHx) H H H H
5-1369 H H Me 2 -CO- (CHZ) 5- (4-Ph-cHx) H H H H
5-1370 H H Me 2 -CO- (CHZ) 5-Ph H H H H
5-1371 H Me Me 2 -CO- (CH2) 5-Ph H H H H
5-1372 CO2Me H Me 2 -CO- (CHZ) 5-Ph H H H H
5-1373 C02Et H Me 2 -CO- (CH2) 5-Ph H H H H
5-1374 H H Me 2 -CO- (CHZ) 5- (4-F-Ph) H H H H
5-1375 H H Me 2-CO-(CH2)5-(4-Me-Ph) H H H H
5-1376 H H Me 2 -CO- (CH2) 5- (4-Et-Ph) H H H H
5-1377 H H Me 2 -CO- (CHZ) 5- (4-CF3-Ph) H H H H
5-1378 H H Me 2-CO-(CH2)5-(4-Me0-Ph) H H H H
5-1379 H H Me 2 -CO- (CHZ) 5- (4-Et0-Ph) H H H H
5-1380 H H Me 2 -CO- (CH2) 5- (4-MeS-Ph) H H H H
5-1381 H H Me 2 -CO- (CHZ) 5- (4-cHx-Ph) H H H H
5-1382 H H Me 2 -CO- (CH2) 5- (4-Ph-Ph) H H H H
5-1383 H H Me 2 -CO- (CHZ) 6-cHx H H H H
5-1384 H H Me 2 -CO- (CHZ) 6-Ph H H H H
5-1385 H H Me 2 -CO- (CHZ) 7-cHx H H H H
5-1386 H H Me 2 -CO- (CHZ) -,-Ph H H H H
5-1387 H H Me 2 -CO- (CH2) 2-0-cHx H H H H
5-1388 H Me Me 2-CO-(CH2)2-O-cHx H H H H
5-1389 C02Me H Me 2 -CO- (CH2) 2-O-cHx H H H H
5-1390 C02Et H Me 2 -CO- (CH2) 2-O-cHx H H H H
5-1391 H H Me 2 -CO- (CH2) 2-0- (4-F-cHx) H H H H
5-1392 H H Me 2 -CO- (CH2) 2-0- (4-Me-cHx) H H H H
5-1393 H H Me 2 -CO- (CH2) 2-0- (4 -Et-cHx) H H H H
5-1394 H H Me 2 -CO- (CH2) 2-0- (4-CF3-cHx) H H H H
5-1395 H H Me 2-CO-(CH2)2-0-(4-Me0-cHx) H H H H
5-1396 H H Me 2 -CO- (CH2) 2-0- (4-Et0-cHx) H H H H
5-1397 H H Me 2-CO-(CH2)2-0-(4-MeS-cHx) H H H H
5-1398 H H Me 2 -CO- (CH2) 2-0- (4-cHx-cHx) H H H H
5-1399 H H Me 2-CO-(CH2)2-0-(4-Ph-cHx) H H H H
5-1400 H H Me 2 -CO- (CH2) 2-0-Ph H H H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-1401 H Me Me 2 -CO- (CH2) 2-0-Ph H H H H
5-1402 CO2Me H Me 2 -CO- (CH2) 2-0-Ph H H H H
5-1403 C02Et H Me 2 -CO- (CH2) 2-0-Ph H H H H
5-1404 H H Me 2 -CO- (CH2) 2-0- (4-F-Ph) H H H H
5-1405 H H Me 2 -CO- (CH2) 2-0- (4-Me-Ph) H H H H
5-1406 H H Me 2 -CO- (CH2) 2-0- (4-Et-Ph) H H H H
5-1407 H H Me 2 -CO- (CH2) 2-0- (4-CF3-Ph) H H H H
5-1408 H H Me 2 -CO- (CH2) 2-0- (4-MeO-Ph) H H H H
5-1409 H H Me 2-CO-(CH2)2-0-(4-EtO-Ph) H H H H
5-1410 H H Me 2 -CO- (CH2) 2-0- (4-MeS-Ph) H H H H
5-1411 H H Me 2 -CO- (CH2) 2-0- (4-cHx-Ph) H H H H
5-1412 H H Me 2 -CO- (CH2) 2-0- (4-Ph-Ph) H H H H
5-1413 H H Me 2 -CO- (CH2) 3-0-cPn H H H H
5-1414 H H Me 2 -CO- (CH2) 3-0-cHx H H H H
5-1415 H H Me 2 -CO- (CH2) 3-0-cHx Me H H H
5-1416 H H Me 2 -CO- (CH2) 3-0-cHx H Me H H
5-1417 H H Me 2 -CO- (CH2) 3-0-cHx F H H H
5-1418 H H Me 2 -CO- (CH2) 3-0-cHx H F H H
5-1419 H Me Me 2 -CO- (CH2) 3-0-cHx H H H H
5-1420 CO2Me H Me 2 -CO- (CH2) 3-0-cHx H H H H
5-1421 C02Et H Me 2 -CO- (CH2) 3-0-cHx H H H H
5-1422 H H Me 2 -CO- (CH2) 3-0- (3-F-cHx) H H H H
5-1423 H H Me 2 -CO- (CH2) 3-0- (4-F-cHx) H H H H
5-1424 H H Me 2 -CO- (CH2) 3-0- (4-C1-cHx) H H H H
5-1425 H H Me 2 -CO- (CH2) 3-0- (4-Br-cHx) H H H H
5-1426 H H Me 2 -CO- (CH2) 3-0- (3-Me-cHx) H H H H
5-1427 H H Me 2 -CO- (CH2) 3-0- (4-Me-cHx) H H H H
5-1428 H H Me 2 -CO- (CH2) 3-0- (3-Et-cHx) H H H H
5-1429 H H Me 2 -CO- (CH2) 3-0- (4-Et-cHx) H H H H
5-1430 H H Me 2 -CO- (CH2) 3-0- (3-Pr-cHx) H H H H
5-1431 H H Me 2 -CO- (CH2) 3-0- (4-Pr-cHx) H H H H
5-1432 H H Me 2 -CO- (CH2) 3-0- (4-iPr-cHx) H H H H
5-1433 H H Me 2 -CO- (CH2) 3-0- (3-Bu-cHx) H H H H
5-1434 H H Me 2-CO-(CH2)3-0-(4-Bu-cHx) H H H H
5-1435 H H Me 2 -CO- (CH2) 3-0- (3-CF3-cHx) H H H H
5-1436 H H Me 2 -CO- (CH2) 3-0- (4-CF3-cHx) H H H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-1437 H H Me 2 -CO- (CH2) 3-0- (3-MeO-cHx) H H H H
5-1438 H H Me 2 -CO- (CH2) 3-0- (4-MeO-cHx) H H H H
5-1439 H H Me 2 -CO- (CH2) 3-0- (3-EtO-cHx) H H H H
5-1440 H H Me 2 -CO- (CH2) 3-0- (4-EtO-cHx) H H H H
5-1441 H H Me 2 -CO- (CH2) 3-0- (3-PrO-cHx) H H H H
5-1442 H H Me 2 -CO- (CH2) 3-0- (4-PrO-cHx) H H H H
5-1443 H H Me 2 -CO- (CH2) 3-0- (3-iPrO- H H H H
cHx) 5-1444 H H Me 2 -CO- (CH2) 3-0- (4-iPrO- H H H H
cHx) 5-1445 H H Me 2 -CO- (CH2) 3-0- [3- (2-Et- H H H H
PrO) cHx]

5-1446 H H Me 2 -CO- (CH2) 3-0- [4- (2-Et- H H H H
Pro) cHx]

5-1447 H H Me 2-CO-(CH2)3-0-(3-iBuO- H H H H
cHx) 5-1448 H H Me 2 -CO- (CH2) 3-0- (4-iBuO- H H H H
cHx) 5-1449 H H Me 2 -CO- (CH2) 3-0- (3-MeS-cHx) H H H H
5-1450 H H Me 2 -CO- (CH2) 3-0- (4-MeS-cHx) H H H H
5-1451 H H Me 2 -CO- (CH2) 3-0- (3-EtS-cHx) H H H H
5-1452 H H Me 2-CO-(CH2)3-0-(4-EtS-cHx) H H H H
5-1453 H H Me 2-CO-(CH2)3-0-(3-PrS-cHx) H H H H
5-1454 H H Me 2 -CO- (CH2) 3-0- (4-PrS-cHx) H H H H
5-1455 H H Me 2 -CO- (CH2) 3-0- (3-iPrS- H H H H
cHx) 5-1456 H H Me 2 -CO- (CH2) 3-0- (4-iPrS- H H H H
cHx) 5-1457 H H Me 2 -CO- (CH2) 3-0- [3- (2-Et- H H H H
PrS)cHx]
5-1458 H H Me 2 -CO- (CH2) 3-0- [4- (2-Et- H H H H
PrS) cHx]

5-1459 H H Me 2 -CO- (CH2) 3-0- (3-iBuS- H H H H
cHx) 5-1460 H H Me 2 -CO- (CH2) 3-0- (4-iBuS- H H H H
cHx) S:/ChemicaUSankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 5-1461 H H Me 2-CO-(CH2)3-0-(3-cHx-cHx) H H H H
5-1462 H H Me 2 -CO- (CH2) 3-0- (4-cHx-cHx) H H H H
5-1463 H H Me 2 -CO- (CH2) 3-0- (3-Ph-cHx) H H H H
5-1464 H H Me 2 -CO- (CH2) 3-0- (4-Ph-cHx) H H H H
5-1465 H H Me 2 -CO- (CH2) 3-0- (2, 4-diMe- H H H H
cHx) 5-1466 H H Me 2 -CO- (CH2) 3-0- (3, 4-diMe- H H H H
cHx) 5-1467 H H Me 2 -CO- (CH2) 3-0- (3, 5-diMe- H H H H
cHx) 5-1468 H H Me 2 -CO- (CH2) 3-0-Ph H H H H
5-1469 H H Me 2 -CO- (CH2) 3-0-Ph Me H H H
5-1470 H H Me 2 -CO- (CH2) 3-0-Ph H Me H H
5-1471 H H Me 2 -CO- (CH2) 3-0-Ph F H H H
5-1472 H H Me 2-CO-(CH2)3-O-Ph H F H H
5-1473 H Me Me 2 -CO- (CH2) 3-0-Ph H H H H
5-1474 CO2Me H Me 2 -CO- (CH2) 3-0-Ph H H H H
5-1475 C02Et H Me 2 -CO- (CH2) 3-0-Ph H H H H
5-1476 H H Me 2 -CO- (CH2) 3-0- (3-F-Ph) H H H H
5-1477 H H Me 2 -CO- (CH2) 3-0- (4-F-Ph) H H H H
5-1478 H H Me 2 -CO- (CH2) 3-0- (4-C1-Ph) H H H H
5-1479 H H Me 2 -CO- (CH2) 3-0- (4-Br-Ph) H H H H
5-1480 H H Me 2-CO-(CH2)3-0-(3-Me-Ph) H H H H
5-1481 H H Me 2 -CO- (CH2) 3-0- (4-Me-Ph) H H H H
5-1482 H H Me 2 -CO- (CH2) 3-0- (3-Et-Ph) H H H H
5-1483 H H Me 2 -CO- (CH2) 3-0- (4-Et-Ph) H H H H
5-1484 H H Me 2 -CO- (CH2) 3-0- (3-Pr-Ph) H H H H
5-1485 H H Me 2 -CO- (CH2) 3-0- (4-Pr-Ph) H H H H
5-1486 H H Me 2 -CO- (CH2) 3-0- (3-iPr-Ph) H H H H
5-1487 H H Me 2 -CO- (CH2) 3-0- (4-iPr-Ph) H H H H
5-1488 H H Me 2-CO-(CH2)3-0-(3-Bu-Ph) H H H H
5-1489 H H Me 2 -CO- (CH2) 3-0- (4-Bu-Ph) H H H H
5-1490 H H Me 2 -CO- (CH2) 3-0- (3-CF3-Ph) H H H H
5-1491 H H Me 2 -CO- (CH2) 3-0- (4-CF3-Ph) H H H H
5-1492 H H Me 2 -CO- (CH2) 3-0- (3-MeO-Ph) H H H H
5-1493 H H Me 2 -CO- (CH2) 3-0- (4-MeO-Ph) H H H H
S:/ChemicaUSankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 5-1494 H H Me 2 -CO- (CH2) 3-0- (3-EtO-Ph) H H H H
5-1495 H H Me 2 -CO- (CH2) 3-0- (4-EtO-Ph) H H H H
5-1496 H H Me 2 -CO- (CH2) 3-0- (3-Pro-Ph) H H H H
5-1497 H H Me 2 -CO- (CH2) 3-0- (4-PrO-Ph) H H H H
5-1498 H H Me 2 -CO- (CH2) 3-0- (3-iPrO-Ph) H H H H
5-1499 H H Me 2-CO-(CH2)3-0-(4-iPrO-Ph) H H H H
5-1500 H H Me 2 -CO- (CH2) 3-0- [3- (2-Et- H H H H
Pro)-Ph]

5-1501 H H Me 2 -CO- (CH2) 3-0- [4- (2-Et- H H H H
Pro) -Ph]

5-1502 H H Me 2 -CO- (CH2) 3-0- (3-iBuO-Ph) H H H H
5-1503 H H Me 2-CO-(CH2)3-0-(4-iBuO-Ph) H H H H
5-1504 H H Me 2 -CO- (CH2) 3-0- (3-MeS-Ph) H H H H
5-1505 H H Me 2 -CO- (CH2) 3-0- (4-MeS-Ph) H H H H
5-1506 H H Me 2 -CO- (CH2) 3-0- (3-EtS-Ph) H H H H
5-1507 H H Me 2 -CO- (CH2) 3-0- (4-EtS-Ph) H H H H
5-1508 H H Me 2 -CO- (CH2) 3-0- (3-PrS-Ph) H H H H
5-1509 H H Me 2 -CO- (CH2) 3-0- (4-PrS-Ph) H H H H
5-1510 H H Me 2 -CO- (CH2) 3-0- (3-iPrS-Ph) H H H H
5-1511 H H Me 2-CO-(CH2)3-0-(4-iPrS-Ph) H H H H
5-1512 H H Me 2 -CO- (CH2) 3-0- [3- (2-Et- H H H H
PrS) -Ph]
5-1513 H H Me 2 -CO- (CH2) 3-0- [4- (2-Et- H H H H
PrS) -Ph]

5-1514 H H Me 2 -CO- (CH2) 3-0- (3-iBuS-Ph) H H H H
5-1515 H H Me 2 -CO- (CH2) 3-0- (4-iBuS-Ph) H H H H
5-1516 H H Me 2 -CO- (CH2) 3-0- (3-cHx-Ph) H H H H
5-1517 H H Me 2 -CO- (CH2) 3-0- (4-cHx-Ph) H H H H
5-1518 H H Me 2 -CO- (CH2) 3-0- (3-Ph-Ph) H H H H
5-1519 H H Me 2-CO-(CH2)3-0-(4-Ph-Ph) H H H H
5-1520 H H Me 2 -CO- (CH2) 3-0- (2, 4-diMe- H H H H
Ph) 5-1521 H H Me 2-CO-(CH2)3-0-(3,4-diMe- H H H H
Ph) 5-1522 H H Me 2 -CO- (CH2) 3-0- (3, 5-diMe- H H H H
Ph) S:/Chemical/Sankyo/FP20030I /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 5-1523 H H Me 2 -CO- (CH2) 4-O-cHx H H H H
5-1524 H H Me 2 -CO- (CH2) 4-0-Ph H H H H
5-1525 H H Me 2 -CO- (CH2) 5-0-cHx H H H H
5-1526 H H Me 2 -CO- (CH2) 5-0-Ph H H H H
5-1527 H H Me 2 -CO- (CH2) 2-OCH2-cHx H H H H
5-1528 H Me Me 2 -CO- (CH2) 2-OCH2-cHx H H H H
5-1529 CO2Me H Me 2 -CO- (CH2) 2-OCH2-cHx H H H H
5-1530 CO2Et H Me 2 -CO- (CH2) 2-OCH2-cHx H H H H
5-1531 H H Me 2 -CO- (CH2) 2-OCH2- (4-F-cHx) H H H H
5-1532 H H Me 2 -CO- (CH2) 2-OCH2- (4-Me- H H H H
cHx) 5-1533 H H Me 2 -CO- (CH2) 2-OCH2- (4-Et- H H H H
cHx) 5-1534 H H Me 2 -CO- (CH2) 2-OCH2- (4-CF3- H H H H
cHx) 5-1535 H H Me 2 -CO- (CH2) 2-OCH2- (4-MeO- H H H H
cHx) 5-1536 H H Me 2 -CO- (CH2) 2-OCH2- (4-EtO- H H H H
cHx) 5-1537 H H Me 2 -CO- (CH2) 2-OCH2- (4-MeS- H H H H
cHx) 5-1538 H H Me 2 -CO- (CH2) 2-OCH2- (4-cHx- H H H H
cHx) 5-1539 H H Me 2 -CO- (CH2) 2-OCH2- (4-Ph- H H H H
cHx) 5-1540 H H Me 2 -CO- (CH2) 2-OCH2-Ph H H H H
5-1541 H Me Me 2 -CO- (CH2) 2-OCH2-Ph H H H H
5-1542 CO2Me H Me 2 -CO- (CH2) 2-OCH2-Ph H H H H
5-1543 CO2Et H Me 2 -CO- (CH2) 2-OCH2-Ph H H H H
5-1544 H H Me 2 -CO- (CH2) 2-OCH2- (4-F-Ph) H H H H
5-1545 H H Me 2 -CO- (CH2) 2-OCH2- (4-Me-Ph) H H H H
5-1546 H H Me 2 -CO- (CH2) 2-OCH2- (4-Et-Ph) H H H H
5-1547 H H Me 2 -CO- (CH2) 2-OCH2- (4-CF3- H H H H
Ph) 5-1548 H H Me 2 -CO- (CH2) 2-OCH2- (4-MeO- H H H H
Ph) S:/Chemical/Sankyo/FP200301/FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 5-1549 H H Me 2 -CO- (CH2) 2-OCH2- (4-Et0- H H H H
Ph) 5-1550 H H Me 2 -CO- (CH2) 2-OCH2- (4-MeS- H H H H
Ph) 5-1551 H H Me 2 -CO- (CH2) 2-OCH2- (4-cHx- H H H H
Ph) 5-1552 H H Me 2 -CO- (CH2) 2-OCH2- (4-Ph-Ph) H H H H
5-1553 H H Me 2 -CO- (CH2) 3-OCH2-CH2-cPn H H H H
5-1554 H H Me 2 -CO- (CH2) 3-OCH2-cHx H H H H
5-1555 H H Me 2 -CO- (CH2) 3-OCH2-cHx Me H H H
5-1556 H H Me 2 -CO- (CH2) 3-OCHE-cHx H Me H H
5-1557 H H Me 2 -CO- (CH2) 3-OCH2-cHx F H H H
5-1558 H H Me 2 -CO- (CH2) 3-OCH2-cHx H F H H
5-1559 H Me Me 2 -CO- (CH2) 3-OCH2-cHx H H H H
5-1560 COMe H Me 2 -CO- (CH2) 3-OCH2-cHx H H H H
5-1561 C02Et H Me 2 -CO- (CH2) 3-OCH2-cHx H H H H
5-1562 H H Me 2-CO-(CH2)3-OCH2-(3-F-cHx) H H H H
5-1563 H H Me 2-CO-(CH2)3-OCH2-(4-F-cHx) H H H H
5-1564 H H Me 2 -CO- (CH2) 3-OCH2- (4-C1- H H H H
cHx) 5-1565 H H Me 2 -CO- (CH2) 3-OCH2- (4-Br- H H H H
cHx) 5-1566 H H Me 2 -CO- (CH2) 3-OCH2- (3-Me- H H H H
cHx) 5-1567 H H Me 2 -CO- (CH2) 3-OCH2- (4-Me- H H H H
cHx) 5-1568 H H Me 2 -CO- (CH2) 3-OCH2- (3-Et- H H H H
cHx) 5-1569 H H Me 2 -CO- (CH2) 3-OCH2- (4-Et- H H H H
cHx) 5-1570 H H Me 2 -CO- (CH2) 3-OCH2- (3-Pr- H H H H
cHx) 5-1571 H H Me 2 -CO- (CH2) 3-OCH2- (4-Pr- H H H H
cHx) 5-1572 H H Me 2 -CO- (CH2) 3-OCH2- (4-iPr- H H H H
cHx) S:/ChemicaVSankyo/FP200301/FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 5-1573 H H Me 2 -CO- (CH2) 3-OCH2- (3-Bu- H H H H
cHx) 5-1574 H H Me 2 -CO- (CH2) 3-OCH2- (4-Bu- H H H H
cHx) 5-1575 H H Me 2 -CO- (CH2) 3-OCH2- (3-CF3- H H H H
cHx) 5-1576 H H Me 2 -CO- (CH2) 3-OCH2- (4-CF3- H H H H
cHx) 5-1577 H H Me 2 -CO- (CH2) 3-OCH2- (3-MeO- H H H H
cHx) 5-1578 H H Me 2 -CO- (CH2) 3-OCH2- (4-MeO- H H H H
cHx) 5-1579 H H Me 2 -CO- (CH2) 3-OCH2- (3-EtO- H H H H
cHx) 5-1580 H H Me 2 -CO- (CH2) 3-OCH2- (4-EtO- H H H H
cHx) 5-1581 H H Me 2 -CO- (CH2) 3-OCH2- (3-PrO- H H H H
cHx) 5-1582 H H Me 2 -CO- (CH2) 3-OCH2- (4-PrO- H H H H
cHx) 5-1583 H H Me 2 -CO- (CH2) 3-OCH2- (3-iPrO- H H H H
cHx) 5-1584 H H Me 2 -CO- (CH2) 3-OCH2- (4-iPrO- H H H H
cHx) 5-1585 H H Me 2 -CO- (CH2) 3-OCH2- [3- (2-Et- H H H H
PrO)CHX]
5-1586 H H Me 2 -CO- (CH2) 3-OCH2- [4- (2-Et- H H H H
Pro) cHx]
5-1587 H H Me 2 -CO- (CH2) 3-OCH2- (3-iBuO- H H H H
cHx) 5-1588 H H Me 2 -CO- (CH2) 3-OCH2- (4-iBuO- H H H H
cHx) 5-1589 H H Me 2 -CO- (CH2) 3-OCH2- (3-MeS- H H H H
cHx) 5-1590 H H Me 2 -CO- (CH2) 3-OCH2- (4-MeS- H H H H
cHx) S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 5-1591 H H Me 2 -CO- (CH2) 3-OCH2- (3-EtS- H H H H
cHx) 5-1592 H H Me 2 -CO- (CH2) 3-OCH2- (4-EtS- H H H H
cHx) 5-1593 H H Me 2 -CO- (CH2) 3-OCH2- (3-PrS- H H H H
cHx) 5-1594 H H Me 2 -CO- (CH2) 3-OCH2- (4-PrS- H H H H
cHx) 5-1595 H H Me 2 -CO- (CH2) 3-OCH2- (3-iPrS- H H H H
cHx) 5-1596 H H Me 2 -CO- (CH2) 3-OCH2- (4-iPrS- H H H H
cHx) 5-1597 H H Me 2 -CO- (CH2) 3-OCH2- [3- (2-Et- H H
PrS) cHx]
5-1598 H H Me 2 -CO- (CH2) 3-OCH2- [ 4- (2-Et- H H
PrS) cHx]

5-1599 H H Me 2 -CO- (CH2) 3-OCH2- (3-iBuS- H H H H
cHx) 5-1600 H H Me 2 -CO- (CH2) 3-OCH2- (4-iBuS- H H H H
cHx) 5-1601 H H Me 2 -CO- (CH2) 3-OCH2- (3-cHx- H H H H
cHx) 5-1602 H H Me 2 -CO- (CH2) 3-OCH2- (4-cHx- H H H H
cHx) 5-1603 H H Me 2 -CO- (CH2) 3-OCH2- (3-Ph- H H H H
cHx) 5-1604 H H Me 2 -CO- (CH2) 3-OCH2- (4-Ph- H H H H
cHx) 5-1605 H H Me 2 -CO- (CH2) 3-OCH2- (2, 4- H H H H
diMe-cHx) 5-1606 H H Me 2 -CO- (CH2) 3-OCH2- (3, 4- H H H H
diMe-cHx) 5-1607 H H Me 2 -CO- (CH2) 3-OCH2- (3, 5- H H H H
diMe-cHx) 5-1608 H H Me 2 -CO- (CH2) 3-OCH2-Ph H H H H
5-1609 H H Me 2 -CO- (CH2) 3-OCH2-Ph Me H H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-1610 H H Me 2 -CO- (CH2) 3-OCH2-Ph H Me H H
5-1611 H H Me 2 -CO- (CH2) 3-OCH2-Ph F H H H
5-1612 H H Me 2 -CO- (CH2) 3-OCH2-Ph H F H H
5-1613 H Me Me 2 -CO- (CH2) 3-OCH2-Ph H H H H
5-1614 CO2Me H Me 2 -CO- (CH2) 3-OCH2-Ph H H H H
5-1615 CO2Me H Me 2 -CO- (CH2) 3-OCH2-Ph H H H H
5-1616 H H Me 2 -CO- (CH2) 3-OCH2- (3-F-Ph) H H H H
5-1617 H H Me 2 -CO- (CH2) 3-OCH2- (4-F-Ph) H H H H
5-1618 H H Me 2 -CO- (CH2) 3-OCH2- (4-Cl-Ph) H H H H
5-1619 H H Me 2 -CO- (CH2) 3-OCH2- (4-Br-Ph) H H H H
5-1620 H H Me 2 -CO- (CH2) 3-OCH2- (3-Me-Ph) H H H H
5-1621 H H Me 2-CO-(CH2)3-OCH2-(4-Me-Ph) H H H H
5-1622 H H Me 2-CO-(CH2)3-OCH2-(3-Et-Ph) H H H H
5-1623 H H Me 2 -CO- (CH2) 3-OCH2- (4-Et-Ph) H H H H
5-1624 H H Me 2 -CO- (CH2) 3-OCH2- (3-Pr-Ph) H H H H
5-1625 H H Me 2 -CO- (CH2) 3-OCH2- (4-Pr-Ph) H H H H
5-1626 H H Me 2 -CO- (CH2) 3-OCH2- (3-iPr- H H H H
Ph) 5-1627 H H Me 2 -CO- (CH2) 3-OCH2- (4-iPr- H H H H
Ph) 5-1628 H H Me 2 -CO- (CH2) 3-OCH2- (3-Bu-Ph) H H H H
5-1629 H H Me 2 -CO- (CH2) 3-OCH2- (4-Bu-Ph) H H H H
5-1630 H H Me 2 -CO- (CH2) 3-OCH2- (3-CF3- H H H H
Ph) 5-1631 H H Me 2 -CO- (CH2) 3-OCH2- (4-CF3- H H H H
Ph) 5-1632 H H Me 2 -CO- (CH2) 3-OCH2- (3-MeO- H H H H
Ph) 5-1633 H H Me 2 -CO- (CH2) 3-OCH2- (4-MeO- H H H H
Ph) 5-1634 H H Me 2 -CO- (CH2) 3-OCH2- (3-EtO- H H H H
Ph) 5-1635 H H Me 2 -CO- (CH2) 3-OCH2- (4-EtO- H H H H
Ph) 5-1636 H H Me 2 -CO- (CH2) 3-OCH2- (3-PrO- H H H H
Ph) S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-1637 H H Me 2 -CO- (CH2) 3-OCH2- (4-PrO- H H H H
Ph) 5-1638 H H Me 2 -CO- (CH2) 3-OCH2- (3-iPrO- H H H H
Ph) 5-1639 H H Me 2 -CO- (CH2) 3-OCH2- (4-iPrO- H H H H
Ph) 5-1640 H H Me 2 -CO- (CH2) 3-OCH2- [3- (2-Et- H H H H
PrO) Ph]

5-1641 H H Me 2 -CO- (CH2) 3-OCH2- [4- (2-Et- H H H H
Pro) Ph]
5-1642 H H Me 2 -CO- (CH2) 3-OCH2- (3-iBuO- H H H H
Ph) 5-1643 H H Me 2 -CO- (CH2) 3-OCH2- (4-iBuO- H H H H
Ph) 5-1644 H H Me 2 -CO- (CH2) 3-OCH2- (3-MeS- H H H H
Ph) 5-1645 H H Me 2 -CO- (CH2) 3-OCH2- (4-MeS- H H H H
Ph) 5-1646 H H Me 2-CO-(CH2)3-OCH2-(3-EtS- H H H H
Ph) 5-1647 H H Me 2 -CO- (CH2) 3-OCH2- (4-EtS- H H H H
Ph) 5-1648 H H Me 2 -CO- (CH2) 3-OCH2- (3-PrS- H H H H
Ph) 5-1649 H H Me 2 -CO- (CH2) 3-OCH2- (4-PrS- H H H H
Ph) 5-1650 H H Me 2 -CO- (CH2) 3-OCH2- (3-iPrS- H H H H
Ph) 5-1651 H H Me 2 -CO- (CH2) 3-OCH2- (4-iPrS- H H H H
Ph) 5-1652 H H Me 2 -CO- (CH2) 3-OCH2- [3- (2-Et- H H H H
PrS) Ph ]

5-1653 H H Me 2 -CO- (CH2) 3-OCH2- [ 4- (2-Et- H H H H
PrS) Ph]
5-1654 H H Me 2-CO-(CH2)3-OCH2-(3-iBuS- H H H H
Ph) S:/ChemicaUSankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-1655 H H Me 2 -CO- (CH2) 3-OCH2- (4-iBuS- H H H H
Ph) 5-1656 H H Me 2 -CO- (CH2) 3-OCH2- (3-cHx- H H H H
Ph) 5-1657 H H Me 2 -CO- (CH2)3-OCH2- (4-cHx- H H H H
Ph) 5-1658 H H Me 2 -CO- (CH2) 3-OCH2- (3-Ph-Ph) H H H H
5-1659 H H Me 2 -CO- (CH2) 3-OCH2- (4-Ph-Ph) H H H H
5-1660 H H Me 2 -CO- (CH2) 3-OCH2- (2, 4- H H H H
diMe-Ph) 5-1661 H H Me 2 -CO- (CH2) 3-OCH2- (3, 4- H H H H
diMe-Ph) 5-1662 H H Me 2 -CO- (CH2) 3-OCH2- (3, 5- H H H H
diMe-Ph) 5-1663 H H Me 2 -CO- (CH2) 4-OCH2-cHx H H H H
5-1664 H H Me 2 -CO- (CH2) 4-OCH2-Ph H H H H
5-1665 H H Me 2 -CO- (CH2) 5-OCH2-cHx H H H H
5-1666 H H Me 2 -CO- (CH2) 5-OCH2-Ph H H H H
5-1667 H H Me 2 -CH (OH) -CH2-cHx H H H H
5-1668 H H Me 2 -CH (OH) -CH2-Ph H H H H
5-1669 H H Me 2 -CH (OH) - (CH2) 2-cHx H H H H
5-1670 H H Me 2 -CH (OH) - (CH2) 2-Ph H H H H
5-1671 H H Me 2 -CH (OH) - (CH2) 3-cHx H H H H
5-1672 H H Me 2 -CH (OH) - (CH2) 3-Ph H H H H
5-1673 H H Me 2 -CH (OH) - (CH2) 4-cHx H H H H
5-1674 H Me Me 2 -CH (OH) - (CH2) 4-cHx H H H H
5-1675 CO2Me H Me 2 -CH (OH) - (CH2) 4-cHx H H H H
5-1676 CO2Et H Me 2 -CH (OH) - (CH2) 4-cHx H H H H
5-1677 H H Me 2-CH(OH)-(CH2)4-(4-F-cHx) H H H H
5-1678 H H Me 2 -CH (OH) - (CH2) 4- (4-Me- H H H H
cHx) 5-1679 H H Me 2 -CH (OH) - (CH2) 4- (4-Et- H H H H
cHx) 5-1680 H H Me 2 -CH (OH) - (CH2) 4- (4-CF3- H H H H
cHx) 5-1681 H H Me 2 -CH (OH) - (CH2) 4- (4-MeO- H H H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Desci iption/gds-mg/30.06.04 cHx) 5-1682 H H Me 2 -CH (OH) - (CH2) 4- (4-EtO- H H H H
cHx) 5-1683 H H Me 2 -CH (OH) - (CH2) 4- (4-MeS- H H H H
cHx) 5-1684 H H Me 2 -CH (OH) - (CH2) 4- (4-cHx- H H H H
cHx) 5-1685 H H Me 2 -CH (OH) - (CH2) 4- (4-Ph- H H H H
CHX) 5-1686 H H Me 2 -CH (OH) - (CH2) 4-Ph H H H H
5-1687 H Me Me 2 -CH (OH) - (CH2) 4-Ph H H H H
5-1688 CO2Me H Me 2 -CH (OH) - (CH2) 4-Ph H H H H
5-1689 CO2Et H Me 2 -CH (OH) - (CH2) 4-Ph H H H H
5-1690 H H Me 2 -CH (OH) - (CH2) 4- (4-F-Ph) H H H H
5-1691 H H Me 2 -CH (OH) - (CH2) 4- (4-Me-Ph) H H H H
5-1692 H H Me 2 -CH (OH) - (CH2) 4- (4-Et-Ph) H H H H
5-1693 H H Me 2 -CH (OH) - (CH2) 4- (4-CF3-Ph) H H H H
5-1694 H H Me 2 -CH (OH) - (CH2) 4- (4-MeO- H H H H
Ph) 5-1695 H H Me 2 -CH (OH) - (CH2) 4- (4-EtO- H H H H
Ph) 5-1696 H H Me 2 -CH (OH) - (CH2) 4- (4-MeS- H H H H
Ph) 5-1697 H H Me 2 -CH (OH) - (CH2) 4- (4-cHx- H H H H
Ph) 5-1698 H H Me 2 -CH (OH) - (CH2) 4- (4-Ph-Ph) H H H H
5-1699 H H Me 2 -CH (OH) - (CH2) 5-cHx H H H H
5-1700 H Me Me 2 -CH (OH) - (CH2) 5-cHx H H H H
5-1701 CO2Me H Me 2 -CH (OH) - (CH2) 5-cHx H H H H
5-1702 CO2Et H Me 2 -CH (OH) - (CH2) 5-cHx H H H H
5-1703 H H Me 2 -CH (OH) - (CH2) 5- (4-F-cHx) H H H H
5-1704 H H Me 2 -CH (OH) - (CH2) 5- (4-Me- H H H H
cHx) 5-1705 H H Me 2 -CH (OH) - (CH2) 5- (4-Et- H H H H
cHx) 5-1706 H H Me 2 -CH (OH) - (CH2) 5- (4-CF3- H H H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 cHx) 5-1707 H H Me 2 -CH (OH) - (CH2) 5- (4-MeO- H H H H
CHx) 5-1708 H H Me 2 -CH (OH) - (CH2) 5- (4-EtO- H H H H
cHx) 5-1709 H H Me 2 -CH (OH) - (CH2) 5- (4-MeS- H H H H
cHx) 5-1710 H H Me 2 -CH (OH) - (CH2) 5- (4-cHx- H H H H
cHx) 5-1711 H H Me 2 -CH (OH) - (CH2) 5- (4-Ph- H H H H
cHx) 5-1712 H H Me 2 -CH (OH) - (CH2) 5-Ph H H H H
5-1713 H Me Me 2 -CH (OH) - (CH2) 5-Ph H H H H
5-1714 CO2Me H Me 2 -CH (OH) - (CH2) 5-Ph H H H H
5-1715 CO2Et H Me 2 -CH (OH) - (CH2) 5-Ph H H H H
5-1716 H H Me 2 -CH (OH) - (CH2) 5- (4-F-Ph) H H H H
5-1717 H H Me 2 -CH (OH) - (CH2) 5- (4-Me-Ph) H H H H
5-1718 H H Me 2 -CH (OH) - (CH2) 5- (4-Et-Ph) H H H H
5-1719 H H Me 2 -CH (OH) - (CH2) 5- (4-CF3-Ph) H H H H
5-1720 H H Me 2 -CH (OH) - (CH2) 5- (4-MeO- H H H H
Ph) 5-1721 H H Me 2 -CH (OH) - (CH2) 5- (4-EtO- H H H H
Ph) 5-1722 H H Me 2 -CH (OH) - (CH2) 5- (4-MeS- H H H H
Ph) 5-1723 H H Me 2 -CH (OH) - (CH2) 5- (4-cHx- H H H H
Ph) 5-1724 H H Me 2 -CH (OH) - (CH2) 5- (4-Ph-Ph) H H H H
5-1725 H H Me 2 -CH (OH) - (CH2) 6-cHx H H H H
5-1726 H H Me 2-CH(OH)-(CH2)6-Ph H H H H
5-1727 H H Me 2 -CH (OH) - (CH2) 7-cHx H H H H
5-1728 H H Me 2 -CH(OH)-(CH2)7-Ph H H H H
5-1729 H H Me 2 -4- (cHx-CH2O) Ph H H H H
5-1730 H Me Me 2 -4- (cHx-CH2O) Ph H H H H
5-1731 CO2Me H Me 2 -4- (cHx-CH2O) Ph H H H H
5-1732 CO2Et H Me 2 -4- (cHx-CH2O) Ph H H H H
S:/ChemicallSankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-1733 H H Me 2 -4-(cHx-CH2O)-2-F-Ph H H H H
5-1734 H H Me 2 -4-(cHx-CH2O)-3-F-Ph H H H H
5-1735 H H Me 2 -4-(cHx-CH2O)-2,3-diF-Ph H H H H
5-1736 H H Me 2 -4-(cHx-CH2O)-2-Cl-Ph H H H H
5-1737 H H Me 2 -4-(cHx-CH2O)-3-C1-Ph H H H H
5-1738 H H Me 2 -4-(cHx-CH2O)-2,3-diCl- H H H H
Ph 5-1739 H H Me 2 -4-(cHx-CH2O)-2-Me-Ph H H H H
5-1740 H H Me 2 -4-(cHx-CH2O)-3-Me-Ph H H H H
5-1741 H H Me 2 -4-(cHx-CH2O)-2,3-diMe- H H H H
Ph 5-1742 H H Me 2 -4- [cHx- (CH2) 20] Ph H H H H
5-1743 H H Me 2 -4- [cHx- (CH2) 30] Ph H H H H
5-1744 H H Me 2 -(4-BzO-Ph) H H H H
5-1745 H Me Me 2 -(4-BzO-Ph) H H H H
5-1746 CO2Me H Me 2 -(4-BzO-Ph) H H H H
5-1747 CO2Et H Me 2 -(4-BzO-Ph) H H H H
5-1748 H H Me 2 -(4-BzO-2-F-Ph) H H H H
5-1749 H H Me 2 -(4-BzO-3-F-Ph) H H H H
5-1750 H H Me 2 -(4-BzO-2,3-diF-Ph) H H H H
5-1751 H H Me 2-(4-BzO-2-C1-Ph) H H H H
5-1752 H H Me 2-(4-BzO-3-C1-Ph) H H H H
5-1753 H H Me 2 -(4-BzO-2,3-diCl-Ph) H H H H
5-1754 H H Me 2 -(4-BzO-2-Me-Ph) H H H H
5-1755 H H Me 2 -(4-BzO-3-Me-Ph) H H H H
5-1756 H H Me 2-(4-BzO-2,3-diMe-Ph) H H H H
5-1757 H H Me 2 -4- [Ph- (CH2) 20] -Ph H H H H
5-1758 H H Me 2 -4- [Ph- (CH2) 30] -Ph H H H H
5-1759 H H Et 2 - (CH2) 3-cHx H H H H
5-1760 H H Et 2 - (CH2) 3-Ph H H H H
5-1761 H H Et 2 - (CH2) 4-cHx H H H H
5-1762 H H Et 2 - (CH2) 4-Ph H H H H
5-1763 H H Et 2 - (CH2) 5-cPn H H H H
5-1764 H H Et 2 - (CH2) 5-cHx H H H H
5-1765 H H Et 2 - (CH2) 5-cHx Me H H H
5-1766 H H Et 2 - (CH2) 5-cHx H Me H H
S:/ChemicallSankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-1767 H H Et 2 - (CH2) 5-cHx F H H H
5-1768 H H Et 2 - (CH2) 5-cHx H F H H
5-1769 H Me Et 2 - (CH2) 5-cHx H H H H
5-1770 CO2Me H Et 2 - (CH2) 5-cHx H H H H
5-1771 CO2Et H Et 2 - (CH2) 5-cHx H H H H
5-1772 H H Et 2 - (CH2) 5- (4-F-cHx) H H H H
5-1773 H H Et 2-(CH2)5-(4-C1-cHx) H H H H
5-1774 H H Et 2 - (CH2) 5- (4-Br-cHx) H H H H
5-1775 H H Et 2 - (CH2) 5- (4-Me-cHx) H H H H
5-1776 H H Et 2 - (CH2) 5- (4-Et-cHx) H H H H
5-1777 H H Et 2-(CH2)5-(4-Pr-cHx) H H H H
5-1778 H H Et 2 - (CH2) 5- (4-iPr-cHx) H H H H
5-1779 H H Et 2 - (CH2) 5- (4-CF3-cHx) H H H H
5-1780 H H Et 2-(CH2)5-(4-MeO-cHx) H H H H
5-1781 H H Et 2 - (CH2) 5- (4-EtO-cHx) H H H H
5-1782 H H Et 2 - (CH2) 5- (4-PrO-cHx) H H H H
5-1783 H H Et 2 - (CH2) 5- (4-iPrO-cHx) H H H H
5-1784 H H Et 2-(CH2)5-(3-MeS-cHx) H H H H
5-1785 H H Et 2 - (CH2) 5- (4-MeS-cHx) H H H H
5-1786 H H Et 2 - (CH2) 5- (2, 4-diMe-cHx) H H H H
5-1787 H H Et 2 - (CH2) 5- (3, 4-diMe-cHx) H H H H
5-1788 H H Et 2 - (CH2) 5- (3, 5-diMe-cHx) H H H H
5-1789 H H Et 2 - (CH2) 5-Ph H H H H
5-1790 H H Et 2 - (CH2) 5-Ph Me H H H
5-1791 H H Et 2 - (CH2) 5-Ph H Me H H
5-1792 H H Et 2 - (CH2) 5-Ph F H H H
5-1793 H H Et 2 - (CH2) 5-Ph H F H H
5-1794 H Me Et 2 - (CH2) 5-Ph H H H H
5-1795 CO2Me H Et 2 - (CH2) 5-Ph H H H H
5-1796 CO2Et H Et 2 - (CH2) 5-Ph H H H H
5-1797 H H Et 2 - (CH2) 5- (4-F- Ph) H H H H
5-1798 H H Et 2 - (CH2) 5- (4-C1-Ph) H H H H
5-1799 H H Et 2 - (CH2) 5- (4-Br-Ph) H H H H
5-1800 H H Et 2 - (CH2) 5- (4-Me-Ph) H H H H
5-1801 H H Et 2 - (CH2) 5- (4-Et-Ph) H H H H
5-1802 H H Et 2 - (CH2) 5- (4-Pr-Ph) H H H H
S:/Chemical/Sankyo/FP20030I /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-1803 H H Et 2 - (CH2) 5- (4-iPr-Ph) H H H H
5-1804 H H Et 2 - (CH2) 5- (4-Bu-Ph) H H H H
5-1805 H H Et 2 - (CH2) 5- (4-CF3-Ph) H H H H
5-1806 H H Et 2 - (CH2) 5- (4-MeO-Ph) H H H H
5-1807 H H Et 2 - (CHZ) 5- (4-EtO-Ph) H H H H
5-1808 H H Et 2 - (CH2) 5- (4-PrO-Ph) H H H H
5-1809 H H Et 2 - (CH2) 5- (4-iPrO-Ph) H H H H
5-1810 H H Et 2 - (CH2) 5- (3-MeS-Ph) H H H H
5-1811 H H Et 2 - (CHZ) 5- (4-MeS-Ph) H H H H
5-1812 H H Et 2 - (CH2) 5- (2, 4-diMe-Ph) H H H H
5-1813 H H Et 2 - (CH2) 5- (3, 4-diMe-Ph) H H H H
5-1814 H H Et 2-(CH2)5-(3,5-diMe-Ph) H H H H
5-1815 H H Et 2 - (CH2) 6-cPn H H H H
5-1816 H H Et 2 - (CH2) 6-cHx H H H H
5-1817 H H Et 2 - (CHZ) 6-cHx Me H H H
5-1818 H H Et 2 - (CHZ) 6-cHx H Me H H
5-1819 H H Et 2 - (CH2) 6-cHx F H H H
5-1820 H H Et 2 - (CH2) 6-cHx H F H H
5-1821 H Me Et 2 - (CH2) 6-cHx H H H H
5-1822 CO2Me H Et 2 - (CHZ) 6-cHx H H H H
5-1823 CO2Et H Et 2 - (CH2) 6-cHx H H H H
5-1824 H H Et 2 - (CHZ) 6- (4-F-cHx) H H H H
5-1825 H H Et 2-(CH2)6-(4-C1-cHx) H H H H
5-1826 H H Et 2 - (CH2) 6- (4-Br-cHx) H H H H
5-1827 H H Et 2 - (CH2) 6- (4-Me-cHx) H H H H
5-1828 H H Et 2 - (CHZ) 6- (4-Et-cHx) H H H H
5-1829 H H Et 2 - (CH2) 6- (4-Pr-cHx) H H H H
5-1830 H H Et 2 - (CH2) 6- (4-iPr-cHx) H H H H
5-1831 H H Et 2 - (CHZ) 6- (4-Bu-cHx) H H H H
5-1832 H H Et 2 - (CH2) 6- (4-CF3-cHx) H H H H
5-1833 H H Et 2 - (CH2) 6- (4-MeO-cHx) H H H H
5-1834 H H Et 2 - (CH2) 6- (4-EtO-cHx) H H H H
5-1835 H H Et 2-(CH2)6-(4-PrO-cHx) H H H H
5-1836 H H Et 2 - (CH2) 6- (4-iPrO-cHx) H H H H
5-1837 H H Et 2 - (CHZ) 6- (3-MeS-cHx) H H H H
5-1838 H H Et 2 - (CH2) 6- (4-MeS-cHx) H H H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-1839 H H Et 2 - (CH2) 6- (2, 4-diMe-cHx) H H H H
5-1840 H H Et 2 - (CH2) 6- (3, 4-diMe-cHx) H H H H
5-1841 H H Et 2 - (CH2) 6- (3, 5-diMe-cHx) H H H H
5-1842 H H Et 2 - (CH2) 6-Ph H H H H
5-1843 H H Et 2 - (CH2) 6-Ph Me H H H
5-1844 H H Et 2 - (CH2) 6-Ph H Me H H
5-1845 H H Et 2 - (CH2) 6-Ph F H H H
5-1846 H H Et 2 - (CH2) 6-Ph H F H H
5-1847 H Me Et 2 - (CH2) 6-Ph H H H H
5-1848 CO2Me H Et 2 - (CH2) 6-Ph H H H H
5-1849 CO2Et H Et 2 - (CH2) 6-Ph H H H H
5-1850 H H Et 2 - (CH2) 6- (4-F-Ph) H H H H
5-1851 H H Et 2 - (CH2) 6- (4-C1-Ph) H H H H
5-1852 H H Et 2 - (CH2) 6- (4-Br-Ph) H H H H
5-1853 H H Et 2 - (CH2) 6- (4-Me-Ph) H H H H
5-1854 H H Et 2 - (CH2) 6- (4-Et-Ph) H H H H
5-1855 H H Et 2 - (CH2) 6- (4-Pr-Ph) H H H H
5-1856 H H Et 2 - (CH2) 6- (4-iPr-Ph) H H H H
5-1857 H H Et 2 - (CH2) 6- (4-Bu-Ph) H H H H
5-1858 H H Et 2 - (CH2) 6- (4-CF3-Ph) H H H H
5-1859 H H Et 2 - (CH2) 6- (4-MeO-Ph) H H H H
5-1860 H H Et 2 - (CH2) 6- (4-EtO-Ph) H H H H
5-1861 H H Et 2 - (CH2) 6- (4-PrO-Ph) H H H H
5-1862 H H Et 2 - (CH2) 6- (4-iPrO-Ph) H H H H
5-1863 H H Et 2 - (CH2) 6- (3-MeS-Ph) H H H H
5-1864 H H Et 2 - (CH2) 6- (4-MeS-Ph) H H H H
5-1865 H H Et 2 - (CH2) 6- (2, 4-diMe-Ph) H H H H
5-1866 H H Et 2 - (CH2) 6- (3, 4-diMe-Ph) H H H H
5-1867 H H Et 2 - (CH2) 6- (3, 5-diMe-Ph) H H H H
5-1868 H H Et 2 - (CH2) 7-cHx H H H H
5-1869 H H Et 2 - (CH2) 7-Ph H H H H
5-1870 H H Et 2 -CH=CH-cHx H H H H
5-1871 H H Et 2 -CH=CH-Ph H H H H
5-1872 H H Et 2 -CH=CH- (CH2) 3-cHx H H H H
5-1873 H Me Et 2 -CH=CH- (CH2) 3-cHx H H H H
5-1874 C02Me H Et 2 -CH=CH- (CH2) 3-cHx H H H H
S:/Chemical/Sankyo/FP20030 I /FP030I s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-1875 C02Et H Et 2 -CH=CH- (CH2) 3-cHx H H H H
5-1876 H H Et 2 -CH=CH- (CH2) 3-Ph H H H H
5-1877 H Me Et 2 -CH=CH- (CH2) 3-Ph H H H H
5-1878 C02Me H Et 2 -CH=CH- (CH2) 3-Ph H H H H
5-1879 CO2Et H Et 2 -CH=CH- (CH2) 3-Ph H H H H
5-1880 H H Et 2 -CH=CH- (CH2) 4-cHx H H H H
5-1881 H Me Et 2 -CH=CH- (CH2) 4-cHx H H H H
5-1882 C02Me H Et 2 -CH=CH- (CH2) 4-cHx H H H H
5-1883 C02Et H Et 2 -CH=CH- (CH2) 4-cHx H H H H
5-1884 H H Et 2 -CH=CH- (CH2) 4-Ph H H H H
5-1885 H Me Et 2 -CH=CH- (CH2) 4-Ph H H H H
5-1886 C02Me H Et 2 -CH=CH- (CH2) 4-Ph H H H H
5-1887 C02Et H Et 2 -CH=CH- (CH2) 4-Ph H H H H
5-1888 H H Et 2-CH=CH-CH2O-cHx H H H H
5-1889 H H Et 2-CH=CH-CH2O-Ph H H H H
5-1890 H H Et 2 -CH=CH- (CH2) 20-cHx H H H H
5-1891 H H Et 2 -CH=CH- (CH2) 20-Ph H H H H
5-1892 H H Et 2 -C=C-CH2-cHx H H H H
5-1893 H Me Et 2 -C=C-CH2-cHx H H H H
5-1894 C02Me H Et 2 -C=C-CH2-cHx H H H H
5-1895 C02Et H Et 2 -C=C-CH2-cHx H H H H
5-1896 H H Et 2 -C=C-CH2-Ph H H H H
5-1897 H Me Et 2 -C=C-CH2-Ph H H H H
5-1898 C02Me H Et 2 -C=C-CH2-Ph H H H H
5-1899 C02Et H Et 2 -C=C-CH2-Ph H H H H
5-1900 H H Et 2 -C=C- (CH2) 2-cHx H H H H
5-1901 H Me Et 2 -C=C- (CH2) 2-cHx H H H H
5-1902 C02Me H Et 2 -co- =(CH2) 2-cHx H H H H
5-1903 C02Et H Et 2 -C=C- (CH2) 2-cHx H H H H
5-1904 H H Et 2 -C=C- (CH2) 2-Ph H H H H
5-1905 H Me Et 2 -C=-C- (CH2) 2-Ph H H H H
5-1906 CO2Me H Et 2 -C=C- (CH2) 2-Ph H H H H
5-1907 C02Et H Et 2 -C=C- (CH2) 2-Ph H H H H
5-1908 H H Et 2 -C=-C- (CH2) 3-cPn H H H H
S:/ChemicaUSankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-1909 H H Et 2-C-C-(CH2)3-cHx H H H H
5-1910 H H Et 2 -C=C- (CH2) 3-cHx Me H H H
5-1911 H H Et 2-C=C-(CH2)3-cHx H Me H H
5-1912 H H Et 2 -C-C- (CH2) 3-cHx F H H H
5-1913 H H Et 2-C=C-(CH2)3-cHx H F H H
5-1914 H Me Et 2 -C=C- (CH2) 3-cHx H H H H
5-1915 CO2Me H Et 2 -C-C- (CH2) 3-cHx H H H H
5-1916 CO2Et H Et 2 -C=C- (CH2) 3-cHx H H H H
5-1917 H H Et 2 -C-C- (CH2) 3- (4-F-cHx) H H H H
5-1918 H H Et 2 -C=C- (CH2) 3- (4-C1-cHx) H H H H
5-1919 H H Et 2 -C=C- (CH2) 3- (4-Br-cHx) H H H H
5-1920 H H Et 2 -C=C- (CH2) 3- (4-Me-cHx) H H H H
5-1921 H H Et 2 -C=C- (CH2) 3- (4-Et-cHx) H H H H
5-1922 H H Et 2-C-C-(CH2)3-(4-Pr-cHx) H H H H
5-1923 H H Et 2 -C-C- (CH2) 3- (4-iPr-cHx) H H H H
5-1924 H H Et 2 -C=C- (CH2) 3- (4-Bu-cHx) H H H H
5-1925 H H Et 2 -C=C- (CH2) 3- (4-CF3-cHx) H H H H
5-1926 H H Et 2 -C-C- (CH2) 3- (4-MeO-cHx) H H H H
5-1927 H H Et 2 -C=C- (CH2) 3- (4-EtO-cHx) H H H H
5-1928 H H Et 2-C-C-(CH2)3-(4-PrO-cHx) H H H H
5-1929 H H Et 2 -C=C- (CH2) 3- (4-iPrO-cHx) H H H H
5-1930 H H Et 2 -C=C- (CH2) 3- (3-MeS-cHx) H H H H
5-1931 H H Et 2 -C=-C- (CH2) 3- (4-MeS-cHx) H H H H
5-1932 H H Et 2 -C=C- (CH2) 3- (2, 4-diMe- H H H H
cHx) 5-1933 H H Et 2 -C=C- (CH2) 3- (3, 4-diMe- H H H H
cHx) 5-1934 H H Et 2 -C=C- (CH2) 3- (3, 5-diMe- H H H H
cHx) 5-1935 H H Et 2 -C=C- (CH2) 3-Ph H H H H
5-1936 H H Et 2 -C=-C- (CH2) 3-Ph Me H H H
5-1937 H H Et 2 -C-C- (CH2) 3-Ph H Me H H
S:/ChemicalSankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-1938 H H Et 2 -C=C- (CH2) 3-Ph F H H H
5-1939 H H Et 2 -C-C- (CH2) 3-Ph H F H H
5-1940 H Me Et 2 -C-C- (CH2) 3-Ph H H H H
5-1941 CO2Me H Et 2 -C=C- (CH2) 3-Ph H H H H
5-1942 CO2Et H Et 2 -C=C- (CH2) 3-Ph H H H H
5-1943 H H Et 2 -C=C- (CH2) 3- (4-F-Ph) H H H H
5-1944 H H Et 2 -C-C- (CH2) 3- (4-Cl-Ph) H H H H
5-1945 H H Et 2-C=C-(CH2)3-(4-Br-Ph) H H H H
5-1946 H H Et 2 -C-C- (CH2) 3- (4-Me-Ph) H H H H
5-1947 H H Et 2 -C=C- (CH2) 3- (4-Et-Ph) H H H H
5-1948 H H Et 2 -C=-C- (CH2) 3- (4-Pr-Ph) H H H H
5-1949 H H Et 2 -C=C- (CH2) 3- (4-iPr-Ph) H H H H
5-1950 H H Et 2 -C===C- (CH2) 3- (4-Bu-Ph) H H H H
5-1951 H H Et 2 -C=C- (CH2) 3- (4-CF3-Ph) H H H H
5-1952 H H Et 2 -C=C- (CH2) 3- (4-MeO-Ph) H H H H
5-1953 H H Et 2 -C===C- (CH2) 3- (4-EtO-Ph) H H H H
5-1954 H H Et 2 -C=C- (CH2) 3- (4-PrO-Ph) H H H H
5-1955 H H Et 2 -C=C- (CH2) 3- (4-iPrO-Ph) H H H H
5-1956 H H Et 2 -C=C- (CH2) 3- (3-MeS-Ph) H H H H
5-1957 H H Et 2 -C-C- (CH2) 3- (4-MeS-Ph) H H H H
5-1958 H H Et 2-C-C-(CH2)3-(2,4-diMe- H H H H
Ph) 5-1959 H H Et 2 -C=C- (CH2) 3- (3, 4-diMe- H H H H
Ph) 5-1960 H H Et 2-C-C-(CH2)3-(3,5-diMe- H H H H
Ph) 5-1961 H H Et 2-C=C-(CH2)4-CPn H H H H
5-1962 H H Et 2 -C-C- (CH2) 4-cHx H H H H
5-1963 H H Et 2-C=C-(CH2)4-cHx Me H H H
5-1964 H H Et 2 -C=C- (CH2) 4-cHx H Me H H
5-1965 H H Et 2-C=C-(CH2)4-cHx F H H H
5-1966 H H Et 2 -C-C- (CH2) 4-cHx H F H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P878 92/FP-0301 /Description/gds-mg/30.06.04 5-1967 H Me Et 2 -C=C- (CH2) 4-cHx H H H H
5-1968 CO2Me H Et 2 -C=C- (CH2) 4-cHx H H H H
5-1969 CO2Et H Et 2 -C=C- (CH2) 4-cHx H H H H
5-1970 H H Et 2 -C=C- (CH2) 4- (4-F-cHx) H H H H
5-1971 H H Et 2 -C=C- (CH2) 4- (4-Cl-cHx) H H H H
5-1972 H H Et 2-C=C-(CH2)4-(4-Br-cHx) H H H H
5-1973 H H Et 2-C=C-(CH2)4-(4-Me-cHx) H H H H
5-1974 H H Et 2 -C=C- (CH2) 4- (4-Et-cHx) H H H H
5-1975 H H Et 2 -C=C- (CH2) 4- (4-Pr-cHx) H H H H
5-1976 H H Et 2 -C=C- (CH2) 4- (4-iPr-cHx) H H H H
5-1977 H H Et 2-C=C-(CH2)4-(4-Bu-cHx) H H H H
5-1978 H H Et 2 -C=C- (CH2) 4- (4-CF3-cHx) H H H H
5-1979 H H Et 2-C=C-(CH2)4-(4-MeO-cHx) H H H H
5-1980 H H Et 2 -C=C- (CH2) 4- (4-EtO-cHx) H H H H
5-1981 H H Et 2-C=C-(CH2)4-(4-PrO-cHx) H H H H
5-1982 H H Et 2-C=C-(CH2)4-(4-iPrO-cHx) H H H H
5-1983 H H Et 2-C=C-(CH2)4-(4-MeS-cHx) H H H H
5-1984 H H Et 2 -C=C- (CH2) 4- (2, 4-diMe- H H H H
cHx) 5-1985 H H Et 2 -C=C- (CH2) 4- (3, 4-diMe- H H H H
cHx) 5-1986 H H Et 2 -C=C- (CH2) 4- (3, 5-diMe- H H H H
cHx) 5-1987 H H Et 2 -C=-C- (CH2) 4-Ph H H H H
5-1988 H H Et 2 -C=C- (CH2) 4-Ph Me H H H
5-1989 H H Et 2 -C=-C- (CH2) 4-Ph H Me H H
5-1990 H H Et 2 -C=C- (CH2) 4-Ph F H H H
5-1991 H H Et 2 -C=C- (CH2) 4-Ph H F H H
5-1992 H Me Et 2 -C=C- (CH2) 4-Ph H H H H
5-1993 CO2Me H Et 2 -C=C- (CH2) 4-Ph H H H H
5-1994 CO2Et H Et 2 -C=C- (CH2) 4-Ph H H H H
5-1995 H H Et 2 -C=C- (CH2) 4- (4-F-Ph) H H H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Deseription/gds-mg/30.06.04 5-1996 H H Et 2 -C=C- (CH2) 4- (4-Cl-Ph) H H H H
5-1997 H H Et 2 -C=C- (CHZ) 4- (4-Br-Ph) H H H H
5-1998 H H Et 2 -C=C- (CHZ) 4- (4-Me-Ph) H H H H
5-1999 H H Et 2 -C=C- (CHZ) 4- (4-Et-Ph) H H H H
5-2000 H H Et 2-C=C-(CH2)4-(4-Pr-Ph) H H H H
5-2001 H H Et 2 -C-C- (CH2) 4- (4-iPr-Ph) H H H H
5-2002 H H Et 2 -C=C- (CH2) 4- (4-Bu-Ph) H H H H
5-2003 H H Et 2 -C=C- (CH2) 4- (4-CF3-Ph) H H H H
5-2004 H H Et 2-C-C-(CH2)4-(4-MeO-Ph) H H H H
5-2005 H H Et 2 -C=C- (CH2) 4- (4-EtO-Ph) H H H H
5-2006 H H Et 2 -C=C- (CH2) 4- (4-PrO-Ph) H H H H
5-2007 H H Et 2 -C===C- (CH2) 4- (4-iPrO-Ph) H H H H
5-2008 H H Et 2 -C=C- (CH2) 4- (3-MeS-Ph) H H H H
5-2009 H H Et 2 -C-C- (CH2) 4- (4-MeS-Ph) H H H H
5-2010 H H Et 2 -C=C- (CH2) 4- (2, 4-diMe- H H H H
Ph) 5-2011 H H Et 2-C=C-(CH2)4-(3,4-diMe- H H H H
Ph) 5-2012 H H Et 2 -C=C- (CHZ) 4- (3, 5-diMe- H H H H
Ph) 5-2013 H H Et 2-C=C-(CH2)5-cHx H H H H
5-2014 H Me Et 2 -C-C- (CH2) 5-cHx H H H H
5-2015 CO2Me H Et 2-C=C-(CH2)5-cHx H H H H
5-2016 CO2Et H Et 2 -C-C- (CHZ) 5-cHx H H H H
5-2017 H H Et 2 -C=C- (CH2) 5-Ph H H H H
5-2018 H Me Et 2 -C=C- (CH2) 5-Ph H H H H
5-2019 CO2Me H Et 2 -C-C- (CH2) 5-Ph H H H H
5-2020 CO2Et H Et 2 -C-C- (CH2) 5-Ph H H H H
5-2021 H H Et 2 -C-C- (CH2) 6-cHx H H H H
5-2022 H Me Et 2-C=C-(CH2)6-cHx H H H H
5-2023 CO2Me H Et 2 -C=C- (CH2) 6-cHx H H H H
5-2024 CO2Et H Et 2 -C-C- (CH2) 6-cHx H H H H
S:/ChemicallSankyo/FP20030I /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 5-2025 H H Et 2 -C=C- (CH2) 6-Ph H H H H
5-2026 H Me Et 2 -C=C- (CH2) 6-Ph H H H H
5-2027 CO2Me H Et 2 -C=C- (CH2) 6-Ph H H H H
5-2028 CO2Et H Et 2 -C=C- (CH2) 6-Ph H H H H
5-2029 H H Et 2-C=C-CH2O-cHx H H H H
5-2030 H Me Et 2-C=C-CH2O-cHx H H H H
5-2031 CO2Me H Et 2-C=C-CH2O-cHx H H H H
5-2032 CO2Et H Et 2-C=C-CH2O-cHx H H H H
5-2033 H H Et 2-C=C-CH2O-Ph H H H H
5-2034 H Me Et 2-C=C-CH2O-Ph H H H H
5-2035 CO2Me H Et 2 -C=C-CH20-Ph H H H H
5-2036 CO2Et H Et 2-C=C-CH2O-Ph H H H H
5-2037 H H Et 2 -C=C- (CH2) 20-cPn H H H H
5-2038 H H Et 2 -C=C- (CH2) 20-cHx H H H H
5-2039 H H Et 2 -C=C- (CH2) 20-cHx Me H H H
5-2040 H H Et 2 -C=C- (CH2) 20-cHx H Me H H
5-2041 H H Et 2-C=C-(CH2)2O-cHx F H H H
5-2042 H H Et 2-C=C-(CH2)2O-cHx H F H H
5-2043 H Me Et 2-C=C-(CH2)2O-cHx H H H H
5-2044 CO2Me H Et 2 -C=C- (CH2) 20-cHx H H H H
5-2045 CO2Et H Et 2 -C=C- (CH2) 20-cHx H H H H
5-2046 H H Et 2 -C=C- (CH2) 20- (4-F-cHx) H H H H
5-2047 H H Et 2-C=C-(CH2)20-(4-Cl-cHx) H H H H
5-2048 H H Et 2 -C=-C- (CH2) 20- (4-Br-cHx) H H H H
5-2049 H H Et 2-C=C-(CH2)20-(4-Me-cHx) H H H H
5-2050 H H Et 2-C=C-(CH2)20-(4-Et-cHx) H H H H
5-2051 H H Et 2-C=C-(CH2)2O-(4-Pr-cHx) H H H H
5-2052 H H Et 2-C=C-(CH2)2O-(4-iPr-cHx) H H H H
5-2053 H H Et 2 -C=C- (CH2) 20- (4-Bu-cHx) H H H H
5-2054 H H Et 2 -C=C- (CH2) 20- (4-CF3-cHx) H H H H
5-2055 H H Et 2 -C=C- (CH2) 20- (4-MeO-cHx) H H H H
5-2056 H H Et 2-C=C-(CH2)2O-(4-EtO-cHx) H H H H
S:/Chemical/Sankyo/FP20030I /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-2057 H H Et 2 -C=C- (CH2) 20- (4-PrO-cHx) H H H H
5-2058 H H Et 2-C-C-(CH2)20-(4-iPrO- H H H H
cHx) 5-2059 H H Et 2-C=C-(CH2)20-(3-MeS-cHx) H H H H
5-2060 H H Et 2-C-C-(CH2)20-(4-MeS-cHx) H H H H
5-2061 H H Et 2 -C-C- (CH2) 20- (2, 4-diMe- H H H H
cHx) 5-2062 H H Et 2 -C-C- (CH2) 20- (3, 4-diMe- H H H H
cHx) 5-2063 H H Et 2 -C=C- (CH2) 20- (3, 5-diMe- H H H H
cHx) 5-2064 H H Et 2 -C=-C- (CH2) 20-Ph H H H H
5-2065 H H Et 2 -C-C- (CH2) 20-Ph Me H H H
5-2066 H H Et 2-C=C-(CH2)20-Ph H Me H H
5-2067 H H Et 2-C-C-(CH2)20-Ph F H H H
5-2068 H H Et 2 -C-C- (CH2) 20-Ph H F H H
5-2069 H Me Et 2 -C=_C- (CH2) 2-OCH2-Ph H H H H
5-2070 CO2Me H Et 2 -C=C- (CH2) 20-Ph H H H H
5-2071 CO2Et H Et 2 -C=C- (CH2) 20-Ph H H H H
5-2072 H H Et 2-C-C-(CH2)20-(4-F-Ph) H H H H
5-2073 H H Et 2-C-C-(CH2)20-(4-C1-Ph) H H H H
5-2074 H H Et 2-C-C-(CH2)20-(4-Br-Ph) H H H H
5-2075 H H Et 2 -C=C- (CH2) 20- (4-Me-Ph) H H H H
5-2076 H H Et 2 -C=C- (CH2) 20- (4-Et-Ph) H H H H
5-2077 H H Et 2 -C=C- (CH2) 20- (4-Pr-Ph) H H H H
5-2078 H H Et 2 -C-C- (CH2) 20- (4-iPr-Ph) H H H H
5-2079 H H Et 2 -C=C- (CH2) 20- (4-Bu-Ph) H H H H
5-2080 H H Et 2 -C-C- (CH2) 20- (4-CF3-Ph) H H H H
5-2081 H H Et 2 -C=_C- (CH2) 20- (4-MeO-Ph) H H H H
5-2082 H H Et 2 -C-C- (CH2) 20- (4-EtO-Ph) H H H H
5-2083 H H Et 2 -C=C- (CH2) 20- (4-PrO-Ph) H H H H
5-2084 H H Et 2 -C=C- (CH2) 20- (4-iPrO-Ph) H H H H
S:/Chemical/Sankyo/FP20030 I /FP0301 s.doc P87892/FP-0301 /Desci iption/gds-mg/30.06.04 5-2085 H H Et 2-C=C-(CH2)2O-(4-MeS-Ph) H H H H
5-2086 H H Et 2-C=C-(CH2)20-(2,4-diMe- H H H H
Ph) 5-2087 H H Et 2-C=C-(CH2)20-(3,4-diMe- H H H H
Ph) 5-2088 H H Et 2 -C=C- (CH2) 20- (3, 5-diMe- H H H H
Ph) 5-2089 H H Et 2 -CO- (CH2) 3-cHx H H H H
5-2090 H Me Et 2 -CO- (CH2) 3-cHx H H H H
5-2091 CO2Me H Et 2 -CO- (CH2) 3-cHx H H H H
5-2092 CO2Et H Et 2 -CO- (CH2) 3-cHx H H H H
5-2093 H H Et 2 -CO- (CH2) 3-Ph H H H H
5-2094 H Me Et 2 -CO- (CH2) 3-Ph H H H H
5-2095 CO2Me H Et 2 -CO- (CH2) 3-Ph H H H H
5-2096 CO2Et H Et 2 -CO- (CH2) 3-Ph H H H H
5-2097 H H Et 2 -CO- (CH2) 4-cHx H H H H
5-2098 H Me Et 2 -CO- (CH2) 4-cHx H H H H
5-2099 CO2Me H Et 2 -CO- (CH2) 4-cHx H H H H
5-2100 C02Et H Et 2 -CO- (CH2) 4-cHx H H H H
5-2101 H H Et 2 -CO- (CH2) 4-Ph H H H H
5-2102 H Me Et 2 -CO- (CH2) 4-Ph H H H H
5-2103 C02Me H Et 2 -CO- (CH2) 4-Ph H H H H
5-2104 CO2Et H Et 2 -CO- (CH2) 4-Ph H H H H
5-2105 H H Et 2 -CO- (CH2) 5-cHx H H H H
5-2106 H Me Et 2 -CO- (CH2) 5-cHx H H H H
5-2107 CO2Me H Et 2 -CO- (CH2) 5-cHx H H H H
5-2108 CO2Et H Et 2 -CO- (CH2) 5-cHx H H H H
5-2109 H H Et 2 -CO- (CH2) 5-Ph H H H H
5-2110 H Me Et 2 -CO- (CH2) 5-Ph H H H H
5-2111 C02Me H Et 2 -CO- (CH2) 5-Ph H H H H
5-2112 CO2Et H Et 2 -CO- (CH2) 5-Ph H H H H
5-2113 H H Et 2 -CH (OH) - (CH2) 4-cHx H H H H
5-2114 H Me Et 2 -CH (OH) - (CH2) 4-cHx H H H H
5-2115 CO2Me H Et 2 -CH (OH) - (CH2) 4-cHx H H H H
5-2116 C02Et H Et 2 -CH (OH) - (CH2) 4-cHx H H H H
S:/ChemicaVSankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 5-2117 H H Et 2 -CH (OH) - (CH2) 4-Ph H H H H
5-2118 H Me Et 2 -CH (OH) - (CH2) 4-Ph H H H H
5-2119 CO2Me H Et 2 -CH (OH) - (CH2) 4-Ph H H H H
5-2120 CO2Et H Et 2 -CH (OH) - (CH2) 4-Ph H H H H
5-2121 H H Et 2 -CH (OH) - (CH2) 5-cHx H H H H
5-2122 H Me Et 2 -CH (OH) - (CH2) 5-cHx H H H H
5-2123 CO2Me H Et 2 -CH (OH) - (CH2) 5-cHx H H H H
5-2124 CO2Et H Et 2 -CH (OH) - (CH2) 5-cHx H H H H
5-2125 H H Et 2 -CH (OH) - (CH2) 5-Ph H H H H
5-2126 H Me Et 2 -CH (OH) - (CH2) 5-Ph H H H H
5-2127 CO2Me H Et 2 -CH (OH) - (CH2) 5-Ph H H H H
5-2128 CO2Et H Et 2 -CH (OH) - (CH2) 5-Ph H H H H
5-2129 H H Et 2 -4- (cHx-CH2O) Ph H H H H
5-2130 H Me Et 2 -4- (cHx-CH2O) Ph H H H H
5-2131 CO2Me H Et 2 -4- (cHx-CH2O) Ph H H H H
5-2132 CO2Et H Et 2 -4- (cHx-CH2O) Ph H H H H
5-2133 H H Et 2 -4- [cHx- (CH2) 20] Ph H H H H
5-2134 H H Et 2 -4- [cHx- (CH2) 301 Ph H H H H
5-2135 H H Et 2 -(4-BzO-Ph) H H H H
5-2136 H Me Et 2 -(4-BzO-Ph) H H H H
5-2137 CO2Me H Et 2 -(4-BzO-Ph) H H H H
5-2138 CO2Et H Et 2-(4-BzO-Ph) H H H H
5-2139 H H Et 2 -(4-BzO-2-F-Ph) H H H H
5-2140 H H Et 2 -(4-BzO-3-F-Ph) H H H H
5-2141 H H Et 2 -(4-BzO-2,3-diF-Ph) H H H H
5-2142 H H Et 2-(4-BzO-2-Cl-Ph) H H H H
5-2143 H H Et 2-(4-BzO-3-C1-Ph) H H H H
5-2144 H H Et 2-(4-BzO-2,3-diCl-Ph) H H H H
5-2145 H H Et 2 -(4-BzO-2-Me-Ph) H H H H
5-2146 H H Et 2 -(4-BzO-3-Me-Ph) H H H H
5-2147 H H Et 2 -(4-BzO-2,3-diMe-Ph) H H H H
5-2148 H H Et 2 -4- [Ph- (CH2) 201 -Ph H H H H
5-2149 H H Et 2 -4- [Ph- (CH2) 30] -Ph H H H H
5-2150 H H Pr 2 - (CH2) 5-cHx H H H H
5-2151 H H Pr 2-(CH2)5-Ph H H H H
5-2152 H H Pr 2 - (CH2) 6-cHx H H H H
S:/Chemical/Sankyo/FP20030I /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-2153 H H Pr 2 - (CH2) 6-Ph H H H H
5-2154 H H Pr 2 -C-C-CH2-cHx H H H H
5-2155 H H Pr 2 -C=C- (CH2) 3-cHx H H H H
5-2156 H H Pr 2 -C-C- (CH2) 3-Ph H H H H
5-2157 H H Pr 2 -C-C- (CH2)4-cHx H H H H
5-2158 H H Pr 2 -C-C- (CH2) 4-Ph H H H H
5-2159 CO2Me H Pr 2-C C-CH2O-Ph H H H H
5-2160 CO2Et H Pr 2 -C=C-CH2O-Ph H H H H
5-2161 H H Pr 2-C-C-(CH2)2O-cHx H H H H
5-2162 H H Pr 2 -C-C- (CH2) 20-Ph H H H H
5-2163 H H Pr 2 -4- (cHx-CH20) Ph H H H H
5-2164 H H Pr 2 -(4-BzO-Ph) H H H H
5-2165 H H Me 3 - (CH2) 5-cHx H H H H
5-2166 H H Me 3 - (CH2) 6-cHx H H H H
5-2167 H H Me 3-CH=CH-(CH2)3-cHx H H H H
5-2168 H H Me 3-CH=CH-(CH2)4-cHx H H H H
5-2169 H H Me 3 -C-C- (CH2) 3-cHx H H H H
5-2170 H H Me 3 -C-C- (CH2) 4-cHx H H H H
5-2171 H H Me 3-CO-(CH2)4-cHx H H H H
5-2172 H H Me 3 -CO- (CH2) 5-cHx H H H H
5-2173 H H Me 3 -CO- (CH2) 4-Ph H H H H
5-2174 H H Me 3 -CO- (CH2) 5-Ph H H H H
5-2175 H H Me 3 -CH (OH) - (CH2) 4-cHx H H H H
5-2176 H H Me 3 -CH (OH) - (CH2) 5-cHx H H H H
5-2177 H H Me 3 -4-(cHx-CH20)Ph H H H H
5-2178 H H Me 3 -(4-BzO-Ph) H H H H
5-2179 H H Me 3-C-C-CH2O-cPn H H H H
5-2180 H H Me 3-C-C-(CH2)2O-cPn H H H H
5-2181 H H Me 3-C=C-CH2O-cHx H H H H
5-2182 H H Me 3-C-C-(CH2)2O-cHx H H H H
5-2183 H H Me 3-C-C-CH2O-Ph H H H H
5-2184 H H Me 3 -C-C- (CH2) 20-Ph H H H H
5-2185 H H Me 2 - (CH2) 4- (3-F-Ph) H H H H
5-2186 H H Me 2-(CH2)4-(3,4-diF-Ph) H H H H
S:/Chemical/Sankyo/FP200301 /FP030I s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-2187 H H Me 2 - (CH2) 4- (3, 5-diF-Ph) H H H H
5-2188 H H Me 2 - (CH2) 4- (3-C1-Ph) H H H H
5-2189 H H Me 2 - (CH2) 4- (4-C1-Ph) H H H H
5-2190 H H Me 2 - (CH2) 4- (3, 4-diCl-Ph) H H H H
5-2191 H H Me 2 - (CH2) 4- (3, 5-diCl-Ph) H H H H
5-2192 H H Me 2-(CH2)4-(3-Me-Ph) H H H H
5-2193 H H Me 2 - (CH2) 4- (3, 4-diMe-Ph) H H H H
5-2194 H H Me 2 - (CH2) 4- (3, 5-diMe-Ph) H H H H
5-2195 H H Me 2 - (CH2) 4- (3-CF3-Ph) H H H H
5-2196 H H Me 2 - (CH2) 4- (3, 4-diCF3-Ph) H H H H
5-2197 H H Me 2 - (CH2) 4- (3, 5-diCF3-Ph) H H H H
5-2198 H H Me 2 - (CH2) 4- (3-MeO-Ph) H H H H
5-2199 H H Me 2 - (CH2) 4- (3, 4-diMeO-Ph) H H H H
5-2200 H H Me 2 - (CH2) 4- (3, 5-diMeO-Ph) H H H H
5-2201 H H Me 2 - (CH2) 4- (3, 4, 5-triMeO- H H H H
Ph) 5-2202 H H Me 2 - (CH2) 4- (3-Ac-Ph) H H H H
5-2203 H H Me 2 - (CH2) 4- (4-Ac-Ph) H H H H
5-2204 H H Me 2 - (CH2) 5- (3, 4-diF-Ph) H H H H
5-2205 H H Me 2 - (CH2) 5- (3, 5-diF-Ph) H H H H
5-2206 H H Me 2 - (CH2) 5- (3-C1-Ph) H H H H
5-2207 H H Me 2 - (CH2) 5- (3, 4-diCl-Ph) H H H H
5-2208 H H Me 2 - (CH2) 5- (3, 5-diCl-Ph) H H H H
5-2209 H H Me 2 - (CH2) 5- (3, 4-diCF3-Ph) H H H H
5-2210 H H Me 2 - (CH2) 5- (3, 5-diCF3-Ph) H H H H
5-2211 H H Me 2 - (CH2) 5- (3, 4-diMeO-Ph) H H H H
5-2212 H H Me 2 - (CH2) 5- (3, 5-diMeO-Ph) H H H H
5-2213 H H Me 2-(CH2)5-(3,4,5-triMeO- H H H H
Ph) 5-2214 H H Me 2 - (CH2) 5- (3-Ac-Ph) H H H H
5-2215 H H Me 2 - (CH2) 5- (4-Ac-Ph) H H H H
5-2216 H H Me 2 - (CH2) 3-0- (3-F-Ph) H H H H
5-2217 H H Me 2 - (CH2) 3-0- (3, 4-diF-Ph) H H H H
5-2218 H H Me 2 - (CH2) 3-0- (3, 5-diF-Ph) H H H H
5-2219 H H Me 2 - (CH2) 3-0- (3-Me-Ph) H H H H
5-2220 H H Me 2 - (CH2) 3-0- (3, 4-diMe-Ph) H H H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 5-2221 H H Me 2-(CH2)3-0-(3,5-diMe-Ph) H H H H
5-2222 H H Me 2 - (CH2) 3-0- (3-CF3-Ph) H H H H
5-2223 H H Me 2 - (CH2) 3-0- (3, 4-diCF3-Ph) H H H H
5-2224 H H Me 2 - (CH2) 3-0- (3, 5-diCF3-Ph) H H H H
5-2225 H H Me 2 - (CH2) 3-0- (3-MeO-Ph) H H H H
5-2226 H H Me 2 - (CH2) 3-0- (3, 4-diMeO-Ph) H H H H
5-2227 H H Me 2 - (CH2) 3-0- (3, 5-diMeO-Ph) H H H H
5-2228 H H Me 2 - (CH2) 3-0- (3, 4, 5-triMeO- H H H H
Ph) 5-2229 H H Me 2 - (CH2) 3-0- (3-Ac-Ph) H H H H
5-2230 H H Me 2 - (CH2) 3-0- (4-Ac-Ph) H H H H
5-2231 H H Me 2 - (CH2) 4-0- (3, 4-diF-Ph) H H H H
5-2232 H H Me 2 - (CH2) 4-0- (3, 5-diF-Ph) H H H H
5-2233 H H Me 2-(CH2)4-0-(3,4-diMeO-Ph) H H H H
5-2234 H H Me 2-(CH2)4-0-(3,5-diMeO-Ph) H H H H
5-2235 H H Me 2 - (CH2) 4-0- (3, 4, 5-triMeO- H H H H
Ph) 5-2236 H H Me 2 - (CH2) 4-0- (3-Ac-Ph) H H H H
5-2237 H H Me 2 - (CH2) 4-0- (4-Ac-Ph) H H H H
5-2238 H H Me 2 -C=C- (CH2) 2- (3-F-Ph) H H H H
5-2239 H H Me 2-C=C-(CH2)2-(3,4-diF-Ph) H H H H
5-2240 H H Me 2-C-C-(CH2)2-(3,5-diF-Ph) H H H H
5-2241 H H Me 2 -C-C- (CH2) 2- (3-C1-Ph) H H H H
5-2242 H H Me 2 -C-C- (CH2) 2- (4-Cl-Ph) H H H H
5-2243 H H Me 2 -C-C- (CH2) 2- (3, 4-diC1- H H H H
Ph) 5-2244 H H Me 2 -C=C- (CH2) 2- (3, 5-diCl- H H H H
Ph) 5-2245 H H Me 2 -C-C- (CH2) 2- (3-Me-Ph) H H H H
5-2246 H H Me 2 -C=C- (CH2) 2- (3, 4-diMe- H H H H
Ph) 5-2247 H H Me 2 -C=C- (CH2) 2- (3, 5-diMe- H H H H
Ph) 5-2248 H H Me 2 -C-C- (CH2) 2- (3-CF3-Ph) H H H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 5-2249 H H Me 2 -C-C- (CH2) 2- (3, 4-diCF3- H H H H
Ph) 5-2250 H H Me 2 -C=C- (CH2) 2- (3, 5-diCF3- H H H H
Ph) 5-2251 H H Me 2-C-C-(CH2)2-(3-MeO-Ph) H H H H
5-2252 H H Me 2 -C=C- (CH2) 2- (3, 4-diMeO- H H H H
Ph) 5-2253 H H Me 2 -C=C- (CH2) 2- (3, 5-diMeO- H H H H
Ph) 5-2254 H H Me 2-C=C-(CH2)2-(3,4,5- H H H H
triMeO-Ph) 5-2255 H H Me 2 -C-C- (CH2) 2- (3-Ac-Ph) H H H H
5-2256 H H Me 2 -C-C- (CH2) 2- (4-Ac-Ph) H H H H
5-2257 H H Me 2 -C=C- (CH2) 3- (3, 4-diF-Ph) H H H H
5-2258 H H Me 2-C-C-(CH2)3-(3,5-diF-Ph) H H H H
5-2259 H H Me 2-C-C-(CH2)3-(3-Cl-Ph) H H H H
5-2260 H H Me 2 -C-C- (CH2) 3- (3, 4-diCl- H H H H
Ph) 5-2261 H H Me 2-C=C-(CH2)3-(3,5-diCl- H H H H
Ph) 5-2262 H H Me 2 -C-C- (CH2) 3- (3, 4-diCF3- H H H H
Ph) 5-2263 H H Me 2 -C=C- (CH2) 3- (3, 5-diCF3- H H H H
Ph) 5-2264 H H Me 2 -C=_C- (CH2) 3- (3, 4-diMeO- H H H H
Ph) 5-2265 H H Me 2-C-C-(CH2)3-(3,5-diMeO- H H H H
Ph) 5-2266 H H Me 2 -C-C- (CH2) 3- (3, 4, 5- H H H H
triMeO-Ph) 5-2267 H H Me 2 -C-C- (CH2) 3- (3-Ac-Ph) H H H H
5-2268 H H Me 2 -C=-C- (CH2) 3- (4-Ac-Ph) H H H H
5-2269 H H Me 2 -C=C-CH2-O-(3-F-Ph) H H H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Desciiption/gds-mg/30.06.04 5-2270 H H Me 2 -C=C-CH2-O-(3,4-diF-Ph) H H H H
5-2271 H H Me 2 -C-C-CH2-0-(3,5-diF-Ph) H H H H
5-2272 H H Me 2 -C=C-CH2-0-(3-C1-Ph) H H H H
5-2273 H H Me 2 -C=C-CH2-O-(4-C1-Ph) H H H H
5-2274 H H Me 2 -C-C-CH2-O-(3,4-diCl-Ph) H H H H
5-2275 H H Me 2 -C=C-CH2-O-(3,5-diCl-Ph) H H H H
5-2276 H H Me 2 -C=C-CH2-O-(3-Me-Ph) H H H H
5-2277 H H Me 2 -C-C-CH2-O-(2,4-diMe-Ph) H H H H
5-2278 H H Me 2 -C-C-CH2-O-(3,4-diMe-Ph) H H H H
5-2279 H H Me 2 -C C-CH2-O-(3,5-diMe-Ph) H H H H
5-2280 H H Me 2 -C=C-CH2-O- (3-CF3-Ph) H H H H
5-2281 H H Me 2 -C=C-CH2-O-(3,4-diCF3- H H H H
Ph) 5-2282 H H Me 2 -C=C-CH2-O- (3, 5-diCF3- H H H H
Ph) 5-2283 H H Me 2 -C-=C-CH2-O-(3-MeO-Ph) H H H H
5-2284 H H Me 2 -C=C-CH2-O-(3,4-diMeO- H H H H
Ph) 5-2285 H H Me 2 -C=C-CH2-0-(3,5-diMeO- H H H H
Ph) 5-2286 H H Me 2 -C=C-CH2-O-(3,4,5- H H H H
triMeO-Ph) 5-2287 H H Me 2 -C-C-CH2-0-(3-Ac-Ph) H H H H
5-2288 H H Me 2 -C=C-CHZ-O-(4-Ac-Ph) H H H H
5-2289 H H Me 2 -C=C-CH2-0- (4-CO2H-Ph) H H H H
5-2290 H H Me 2-C=C-(CH2)2-0-(3,4-diF- H H H H
Ph) 5-2291 H H Me 2 -C-C- (CH2) 2-0- (3, 5-diF- H H H H
Ph) 5-2292 H H Me 2 -C-C- (CH2) 2-0- (3-C1-Ph) H H H H
5-2293 H H Me 2-C=C-(CH2)2-0-(3,4-diC1- H H H H
Ph) 5-2294 H H Me 2-C=C-(CH2)2-0-(3,5-diCl- H H H H
S:/Chemical/Sankyo/FP20030I /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 Ph) 5-2295 H H Me 2 -C-C- (CH2) 2-0- (3, 4-diCF3- H H H H
Ph) 5-2296 H H Me 2 -C=-C- (CH2) 2-0- (3, 5-diCF3- H H H H
Ph) 5-2297 H H Me 2 -C=C- (CH2) 2-0- (3, 4- H H H H
diMeO-Ph) 5-2298 H H Me 2 -C=C- (CH2) 2-0- (3, 5- H H H H

diMeO-Ph) 5-2299 H H Me 2 -C=C- (CH2) 2-0- (3, 4, 5- H H H H
triMeO-Ph) 5-2300 H H Me 2 -C=C- (CH2) 2-0- (3-Ac-Ph) H H H H
5-2301 H H Me 2 -C=C- (CH2) 2-0- (4-Ac-Ph) H H H H
5-2302 H H Me 2 -CO- (CH2) 3- (3-F-Ph) H H H H
5-2303 H H Me 2 -CO- (CH2) 3- (4-F-Ph) H H H H
5-2304 H H Me 2 -CO- (CH2) 3- (3, 4-diF-Ph) H H H H
5-2305 H H Me 2 -CO- (CH2) 3- (3, 5-diF-Ph) H H H H
5-2306 H H Me 2 -CO- (CH2) 3- (3-Cl-Ph) H H H H
5-2307 H H Me 2 -CO- (CH2) 3- (4-C1-Ph) H H H H
5-2308 H H Me 2 -CO- (CH2) 3- (3, 4-diCl-Ph) H H H H
5-2309 H H Me 2 -CO- (CH2) 3- (3, 5-diCl-Ph) H H H H
5-2310 H H Me 2 -CO- (CH2) 3- (3-Me-Ph) H H H H
5-2311 H H Me 2 -CO- (CH2) 3- (4-Me-Ph) H H H H
5-2312 H H Me 2 -CO- (CH2) 3- (3, 4-diMe-Ph) H H H H
5-2313 H H Me 2 -CO- (CH2) 3- (3, 5-diMe-Ph) H H H H
5-2314 H H Me 2 -CO- (CH2) 3- (3-Et-Ph) H H H H
5-2315 H H Me 2 -CO- (CH2) 3- (4-Et-Ph) H H H H
5-2316 H H Me 2 -CO- (CH2) 3- (3-CF3-Ph) H H H H
5-2317 H H Me 2 -CO- (CH2) 3- (4-CF3-Ph) H H H H
5-2318 H H Me 2 -CO- (CH2) 3- (3, 4-diCF3-Ph) H H H H
5-2319 H H Me 2 -CO- (CH2) 3- (3, 5-diCF3-Ph) H H H H
5-2320 H H Me 2 -CO- (CH2) 3- (3-MeO-Ph) H H H H
5-2321 H H Me 2 -CO- (CH2) 3- (4-MeO-Ph) H H H H
5-2322 H H Me 2 -CO- (CH2) 3- (3, 4-diMeO- H H H H
Ph) S:/Chemical/Sankyo/FP200301/FP0301s.doc P87892/FP-030]/Description/gds-mg/30.06.04 5-2323 H H Me 2 -CO- (CH2) 3- (3, 5-diMeO- H H H H
Ph) 5-2324 H H Me 2 -CO- (CH2) 3- (3, 4, 5- H H H H
triMeO-Ph) 5-2325 H H Me 2 -CO- (CH2) 3- (4-MeS-Ph) H H H H
5-2326 H H Me 2 -CO- (CH2) 3- (3-Ac-Ph) H H H H
5-2327 H H Me 2 -CO- (CH2) 3- (4-Ac-Ph) H H H H
5-2328 H H Me 2 -CO- (CH2) 4- (3-F-Ph) H H H H
5-2329 H H Me 2 -CO- (CH2) 4- (3, 4-diF-Ph) H H H H
5-2330 H H Me 2 -CO- (CH2) 4- (3, 5-diF-Ph) H H H H
5-2331 H H Me 2 -CO- (CH2) 4- (3-C1-Ph) H H H H
5-2332 H H Me 2 -CO- (CH2) 4- (4-Cl-Ph) H H H H
5-2333 H H Me 2 -CO- (CH2) 4- (3, 4 -diCl -Ph) H H H H
5-2334 H H Me 2 -CO- (CH2) 4- (3, 5-diCl-Ph) H H H H
5-2335 H H Me 2 -CO- (CH2) 4- (3-Me-Ph) H H H H
5-2336 H H Me 2 -CO- (CH2) 4- (3, 4-diMe-Ph) H H H H
5-2337 H H Me 2 - CO- (CH2) 4- (3, 5-diMe-Ph) H H H H
5-2338 H H Me 2 -CO- (CH2) 4- (3-CF3-Ph) H H H H
5-2339 H H Me 2 -CO- (CH2) 4- (3, 4-diCF3-Ph) H H H H
5-2340 H H Me 2 -CO- (CH2) 4- (3, 5-diCF3-Ph) H H H H
5-2341 H H Me 2 -CO- (CH2) 4- (3-MeO-Ph) H H H H
5-2342 H H Me 2 -CO - (CH2) 4 - (3, 4 -diMeO- H H H H
Ph) 5-2343 H H Me 2 -CO- (CH2) 4- (3, 5-diMeO- H H H H
Ph) 5-2344 H H Me 2 -CO- (CH2) 4- (3, 4, 5- H H H H
triMeO-Ph) 5-2345 H H Me 2 -CO- (CH2) 4- (3-Ac-Ph) H H H H
5-2346 H H Me 2 -CO- (CH2) 4- (4-Ac-Ph) H H H H
5-2347 H H Me 2 -CH (OH) - (CH2) 3- (3-F-Ph) H H H H
5-2348 H H Me 2 -CH (OH) - (CH2) 3- (4-F-Ph) H H H H
5-2349 H H Me 2 -CH (OH) - (CH2) 3- (3, 4-diF- H H H H
Ph) 5-2350 H H Me 2 -CH (OH) - (CH2) 3- (3, 5-diF- H H H H
Ph) 5-2351 H H Me 2-CH(OH)-(CH2)3-(3-C1-Ph) H H H H
S:/ChemicaUSankyo/FP200301 /FP0301 s.doc P87892/FP-0301/Description/gds-mg/30.06.04 5-2352 H H Me 2 -CH (OH) - (CH2) 3- (4-C1-Ph) H H H H
5-2353 H H Me 2 -CH (OH) - (CH2) 3- (3, 4- H H H H
diCl-Ph) 5-2354 H H Me 2 -CH (OH) - (CH2) 3- (3, 5- H H H H
diCl-Ph) 5-2355 H H Me 2 -CH (OH) - (CH2) 3- (3-Me-Ph) H H H H
5-2356 H H Me 2 -CH (OH) - (CH2) 3- (4-Me-Ph) H H H H
5-2357 H H Me 2 -CH (OH) - (CH2) 3- (3, 4- H H H H
diMe-Ph) 5-2358 H H Me 2 -CH (OH) - (CH2) 3- (3, 5- H H H H
diMe-Ph) 5-2359 H H Me 2-CH(OH)-(CH2)3-(3-Et-Ph) H H H H
5-2360 H H Me 2 -CH (OH) - (CH2) 3- (4-Et-Ph) H H H H
5-2361 H H Me 2 -CH (OH) - (CH2) 3- (3-CF3-Ph) H H H H
5-2362 H H Me 2 -CH (OH) - (CH2) 3- (4-CF3-Ph) H H H H
5-2363 H H Me 2 -CH (OH) - (CH2) 3- (3, 4- H H H H
diCF3-Ph) 5-2364 H H Me 2 -CH (OH) - (CH2) 3- (3, 5- H H H H
diCF3-Ph) 5-2365 H H Me 2 -CH (OH) - (CH2) 3- (3-MeO- H H H H
Ph) 5-2366 H H Me 2 -CH (OH) - (CH2) 3- (4-MeO- H H H H
Ph) 5-2367 H H Me 2 -CH (OH) - (CH2) 3- (3, 4- H H H H
diMeO-Ph) 5-2368 H H Me 2 -CH (OH) - (CH2) 3- (3, 5- H H H H
diMeO-Ph) 5-2369 H H Me 2 -CH (OH) - (CH2) 3- (3, 4, 5- H H H H
triMeO-Ph) 5-2370 H H Me 2 -CH (OH) - (CH2) 3- (4-MeS- H H H H
Ph) 5-2371 H H Me 2-CH(OH)-(CH2)3-(3-Ac-Ph) H H H H
5-2372 H H Me 2-CH(OH)-(CH2)3-(4-Ac-Ph) H H H H
5-2373 H H Me 2 -CH (OH) - (CH2) 4- (3-F-Ph) H H H H
5-2374 H H Me 2 -CH (OH) - (CH2) 4- (3, 4-di F- H H H H
Ph) S:/Chemical/Sankyo/FP200301/FP030Is.doc P87892/FP-0301/Description/gds-mg/30.06.04 5-2375 H H Me 2 -CH(OH)-(CH2)4-(3,5-diF- H H H H
Ph) 5-2376 H H Me 2-CH(OH)-(CH2)4-(3-C1-Ph) H H H H
5-2377 H H Me 2-CH(OH)-(CH2)4-(4-C1-Ph) H H H H
5-2378 H H Me 2 -CH (OH) - (CH2) 4- (3, 4- H H H H
diCl-Ph) 5-2379 H H Me 2 -CH (OH) - (CH2) 4- (3, 5- H H H H
diCl-Ph) 5-2380 H H Me 2 -CH (OH) - (CH2) 4- (3-Me-Ph) H H H H
5-2381 H H Me 2 -CH (OH) - (CH2) 4- (3, 4- H H H H
diMe-Ph) 5-2382 H H Me 2 -CH (OH) - (CH2) 4- (3, 5- H H H H
diMe-Ph) 5-2383 H H Me 2 -CH (OH) - (CH2) 4- (3-CF3-Ph) H H H H
5-2384 H H Me 2 -CH (OH) - (CH2) 4- (3, 4- H H H H
diCF3-Ph) 5-2385 H H Me 2-CH(OH)-(CH2)4-(3,5- H H H H
diCF3-Ph) 5-2386 H H Me 2-CH(OH)-(CH2)4-(3-MeO- H H H H
Ph) 5-2387 H H Me 2 -CH (OH) - (CH2) 4- (3, 4- H H H H
diMe0-Ph) 5-2388 H H Me 2 -CH (OH) - (CH2) 4- (3, 5- H H H H
diMeO-Ph) 5-2389 H H Me 2 -CH (OH) - (CH2) 4- (3, 4, 5- H H H H
triMeO-Ph) 5-2390 H H Me 2 -CH (OH) - (CH2) 4- (3-Ac-Ph) H H H H
5-2391 H H Me 2 -CH (OH) - (CH2) 4- (4-Ac-Ph) H H H H
5-2392 H H Me 2 -0- (CH2) 3-cHx H H H H
5-2393 H H Me 2 -0- (CH2)4-cHx H H H H
5-2394 H H Me 2 -0- (CH2) 5-cHx H H H H
5-2395 H H Me 2 -0- (CH2) 3-Ph H H H H
5-2396 H H Me 2 -0- (CH2) 4-Ph H H H H
5-2397 H H Me 2 -0- (CH2) 5-Ph H H H H
5-2398 COCH3 H Me 2 - (CH2) 4-cHx H H H H
5-2399 COC2H5 H Me 2 - (CH2) 4-cHx H H H H
S:/ChemicaVSankyo/FP200301/FP0301s.doc P878921FP-0301/Description/gds-mg/30.06.04 5-2400 COC3H7 H Me 2 - (CH2) 4-cHx H H H H
5-2401 COC4H9 H Me 2 - (CH2) 4-cHx H H H H
5-2402 COC5H11 H Me 2 - (CH2) 4-cHx H H H H
5-2403 COC6H13 H Me 2 - (CH2) 4-cHx H H H H
5-2404 COC7H15 H Me 2 - (CH2) 4-cHx H H H H
5-2405 COC8H17 H Me 2-(CH2)4-cHx H H H H
5-2406 COCH3 H Me 2 - (CH2) 4-Ph H H H H
5-2407 COC2H5 H Me 2 - (CH2) 4-Ph H H H H
5-2408 COC3H7 H Me 2 - (CH2) 4-Ph H H H H
5-2409 COC4H9 H Me 2 - (CH2) 4-Ph H H H H
5-2410 COC5H11 H Me 2 - (CH2) 4-Ph H H H H
5-2411 COC6H13 H Me 2 - (CH2) 4-Ph H H H H
5-2412 COC7H15 H Me 2 - (CH2) 4-Ph H H H H
5-2413 COCBH17 H Me 2 - (CH2) 4-Ph H H H H
5-2414 COCH3 H Me 2 - (CH2) 5-cHx H H H H
5-2415 COC2H5 H Me 2 - (CH2) 5-cHx H H H H
5-2416 COC3H7 H Me 2 - (CH2) 5-cHx H H H H
5-2417 COC4H9 H Me 2 - (CH2) 5-cHx H H H H
5-2418 COC5H11 H Me 2 - (CH2) 5-cHx H H H H
5-2419 COC6H13 H Me 2 - (CH2) 5-cHx H H H H
5-2420 COC7H15 H Me 2 - (CH2) 5-cHx H H H H
5-2421 COC8H17 H Me 2 - (CH2) 5-cHx H H H H
5-2422 COCH3 H Me 2 - (CH2) 5-Ph H H H H
5-2423 COC2H5 H Me 2 - (CH2) 5-Ph H H H H
5-2424 COC3H7 H Me 2 - (CH2) 5-Ph H H H H
5-2425 COC4H9 H Me 2 - (CH2) 5-Ph H H H H
5-2426 COC5H11 H Me 2 - (CH2) 5-Ph H H H H
5-2427 COC6H13 H Me 2 - (CH2) 5-Ph H H H H
5-2428 COC7H15 H Me 2 - (CH2) 5-Ph H H H H
5-2429 COC8H17 H Me 2 - (CH2) 5-Ph H H H H
5-2430 COCH3 H Me 2-C-C-(CH2)2-cHx H H H H
5-2431 COC2H5 H Me 2 -C-C- (CH2) 2-cHx H H H H
5-2432 COC3H7 H Me 2 -C=C- (CH2) 2-cHx H H H H
5-2433 COC4H9 H Me 2-C-C-(CH2)2-cHx H H H H
5-2434 COC5H11 H Me 2 -C-C- (CH2) 2-cHx H H H H
S:/Chemical/Sankyo/FP200301 /FP0301 s.doc P87892/FP-0301 /Description/gds-mg/30.06.04 DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.

NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.

JUMBO APPLICATIONS / PATENTS

THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.

NOTE: For additional volumes please contact the Canadian Patent Office.

Claims (31)

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:
1. A compound of formula (Ia) wherein R1 and R2 are each a hydrogen atom;
R3 is a hydrogen atom;

R4 is a C1-C2 alkyl group;
n is 2;
X is =N-R14, wherein R14 is a hydrogen atom, a C1-C4 alkyl group or a phenyl group;
Y is an ethylene group, an ethynylene group, a group of a formula -CO-CH2 or a phenylene group;

Z is an ethylene group or a trimethylene group;
R5 is an unsubstituted C3-C10 cycloalkyl group, an unsubstituted C6-C10 aryl group, or a C3-C10 cycloalkyl group or a C6-C10 aryl group substituted with from 1 to 3 substituents each of which is a halogen atom, a C1-C6 alkyl group, a halogeno C1-C6 alkyl group or a C1-C6 alkoxy group;

R6 and R7 are each a hydrogen atom;

or a pharmacologically acceptable salt thereof, or a pharmacologically acceptable ester thereof.
2. The compound according to claim 1 or a pharmacologically acceptable salt thereof, wherein R4 is a methyl group.
3. The compound according to claim 2 or a pharmacologically acceptable salt thereof, wherein X is a group of a formula =N-CH3.
4. The compound according to claim 1, wherein the compound is:
2-amino-2-methyl-4-{1-methyl-5-[4-(3,4-dimethylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol;
2-amino-2-methyl-4-{1-methyl-5-[4-(3,5-dimethylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol;
2-amino-2-methyl-4-{1-methyl-5-[4-(3-trifluoromethylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol;

2-amino-2-methyl-4-{1-methyl-5-[4-(4-trifluoromethylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol;
2-amino-2-methyl-4-{1-methyl-5-[4-(4-methylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol;
2-amino-2-methyl-4-{1-methyl-5-[4-(4-methoxyphenyl)butanoyl]pyrrol-2-yl}butan-1-ol;

2-amino-2-methyl-4-{1-methyl-5-[4-(3-methylphenyl)butyl]pyrrol-2-yl}butan-1-ol;
2-amino-2-methyl-4-{1-methyl-5-[4-(3,4-dimethylphenyl)butyl]pyrrol-2-yl}butan-1-ol;
2-amino-2-methyl-4-{1-methyl-5-[4-(3,5-dimethylphenyl)butyl]pyrrol-2-yl}butan-1-ol;
2-amino-2-methyl-4-{1-methyl-5-[4-(3-trifluoromethylphenyl)butyl]pyrrol-2-yl}butan-1-ol; or a compound of the formula (Ia), wherein R1, R2 and R3 are each a hydrogen atom, R4 is a methyl group, n is 2 and Y-Z-R5 is -CO-(CH2)3-(4-F-phenyl), or a pharmacologically acceptable salt thereof.
5. The compound according to claim 4, wherein said compound is 2-amino-2-methyl-4-{1-methyl-5-[4-(3,4-dimethylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol, or a pharmacologically acceptable salt thereof.
6. The compound according to claim 4, wherein said compound is 2-amino-2-methyl-4-{1-methyl-5-[4-(3,5-dimethylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol, or a pharmacologically acceptable salt thereof.
7. The compound according to claim 4, wherein said compound is 2-amino-2-methyl-4-{1-methyl-5-[4-(3-trifluoromethylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol, or a pharmacologically acceptable salt thereof.
8. The compound according to claim 4, wherein said compound is 2-amino-2-methyl-4-{1-methyl-5-[4-(4-trifluoromethylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol.
9. The compound according to claim 4, wherein said compound is 2-amino-2-methyl-4-{1-methyl-5-[4-(4-methylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol.
10. The compound according to claim 4, wherein said compound is 2-amino-2-methyl-4-{1-methyl-5-[4-(4-methoxyphenyl)butanoyl]pyrrol-2-yl}butan-l-ol.
11. The compound according to claim 4, wherein said compound is 2-amino-2-methyl-4-{1-methyl-5-[4-(3-methylphenyl)butyl]pyrrol-2-yl}butan-1-ol.
12. The compound according to claim 4, wherein said compound is 2-amino-2-methyl-4-{1-methyl-5-[4-(3,4-dimethylphenyl)butyl]pyrrol-2-yl}butan-1-ol.
13. The compound according to claim 4, wherein said compound is 2-amino-2-methyl-4-{1-methyl-5-[4-(3,5-dimethylphenyl)butyl]pyrrol-2-yl}butan-1-ol.
14. The compound according to claim 4, wherein said compound is 2-amino-2-methyl-4-{1methyl-5-[4-(3-triflouromethylphenyl)butyl]pyrrol-2-yl}butan-1-ol.
15. The compound according to claim 4, wherein said compound is a compound of formula (Ia), wherein R1, R2 and R3 are each a hydrogen atom, R4 is a methyl group, n is 2 and Y-Z-R5 is -CO-(CH2)3-(4-F-phenyl).
16. The compound according to claim 5, wherein the configuration at the carbon atom to which the group of the formula -NR1R2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.
17. The compound according to claim 6, wherein the configuration at the carbon atom to which the group of the formula -NR1R2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.
18. The compound according to claim 7, wherein the configuration at the carbon atom to which the group of the formula -NR1R2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.
19. The compound according to claim 8, wherein the configuration at the carbon atom to which the group of the formula -NR1R2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.
20. The compound according to claim 9, wherein the configuration at the carbon atom to which the group of the formula -NR1R2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.
21. The compound according to claim 10, wherein the configuration at the carbon atom to which the group of the formula -NR1R2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.
22. The compound according to claim 11, wherein the configuration at the carbon atom to which the group of the formula -NR1R2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.
23. The compound according to claim 12, wherein the configuration at the carbon atom to which the group of the formula -NR1R2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.
24. The compound according to claim 13, wherein the configuration at the carbon atom to which the group of the formula -NR1R2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.
25. The compound according to claim 14, wherein the configuration at the carbon atom to which the group of the formula -NR1R2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.
26. The compound according to claim 15, wherein the configuration at the carbon atom to which the group of the formula -NR1R2 attaches is the R configuration, or a pharmacologically acceptable salt thereof.
27. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 26, or a pharmacologically acceptable salt thereof or a pharmacologically acceptable ester thereof, in combination with a pharmacologically acceptable carrier.
28. Use of a pharmaceutically effective amount of a compound as defined in any one of claims 1 to 26, or a pharmacologically acceptable salt thereof or a pharmacologically acceptable ester thereof, in the manufacture of a medicament for the treatment of rheumatoid arthritis or psoriasis in a human.
29. The use according to claim 28, wherein the disease is rheumatoid arthritis.
30. The use according to claim 28, wherein the disease is psoriasis.
31. Use of a pharmaceutically effective amount of a compound as defined in any one of claims 1 to 26, or a pharmacologically acceptable salt thereof or a pharmacologically acceptable ester thereof, in the manufacture of a medicament for the treatment of rheumatoid arthritis or psoriasis in a mammal.
CA2473461A 2002-01-11 2003-01-09 Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these Expired - Fee Related CA2473461C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2002004456 2002-01-11
JP2002-004456 2002-01-11
JP2002-004484 2002-01-11
JP2002004484 2002-01-11
PCT/JP2003/000136 WO2003059880A1 (en) 2002-01-11 2003-01-09 Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these

Publications (2)

Publication Number Publication Date
CA2473461A1 CA2473461A1 (en) 2003-07-24
CA2473461C true CA2473461C (en) 2011-11-01

Family

ID=26625490

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2473461A Expired - Fee Related CA2473461C (en) 2002-01-11 2003-01-09 Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these

Country Status (26)

Country Link
US (5) US7199150B2 (en)
EP (1) EP1471054B1 (en)
JP (1) JP4270541B2 (en)
KR (2) KR100836547B1 (en)
CN (1) CN100406437C (en)
AT (1) ATE435202T1 (en)
AU (1) AU2003202495B2 (en)
BR (1) BR0306811A (en)
CA (1) CA2473461C (en)
CO (1) CO5640126A2 (en)
CY (1) CY1109457T1 (en)
DE (1) DE60328161D1 (en)
DK (1) DK1471054T3 (en)
ES (1) ES2327825T3 (en)
HK (1) HK1066532A1 (en)
IL (1) IL162874A0 (en)
MX (1) MXPA04006709A (en)
NO (1) NO329134B1 (en)
NZ (1) NZ533994A (en)
PL (1) PL211954B1 (en)
PT (1) PT1471054E (en)
RU (1) RU2330839C2 (en)
SI (1) SI1471054T1 (en)
TW (1) TWI283574B (en)
WO (1) WO2003059880A1 (en)
ZA (1) ZA200406333B (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4771511B2 (en) * 2003-07-08 2011-09-14 第一三共株式会社 Pharmaceutical composition containing amino alcohol derivative or phosphonic acid derivative
PL211954B1 (en) * 2002-01-11 2012-07-31 Sankyo Co Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these
US7241790B2 (en) * 2002-07-30 2007-07-10 University Of Virginia Patent Foundation Compounds active in spinigosine 1-phosphate signaling
GB0302094D0 (en) * 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
WO2005005383A1 (en) * 2003-07-11 2005-01-20 Sankyo Company, Limited Amino alcohol compound
US20070037894A1 (en) * 2003-09-19 2007-02-15 Hahnfeld Jerry L Multifunctional menomers and polyarylene compsotions therefrom
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
US7638637B2 (en) 2003-11-03 2009-12-29 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
ES2232306B1 (en) * 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA.
AU2005215320B2 (en) * 2004-02-24 2008-04-17 Sankyo Company, Limited Amino alcohol compound
PL1772145T3 (en) * 2004-07-16 2011-08-31 Kyorin Seiyaku Kk Method of effectively using medicine and method concerning prevention of side effect
TW200611687A (en) * 2004-07-29 2006-04-16 Sankyo Co Pharmaceutical compositions used for immunosuppressant
JP4919374B2 (en) * 2004-07-29 2012-04-18 第一三共株式会社 Pharmaceutical composition as an immunosuppressant
CA2583846C (en) * 2004-10-12 2013-10-01 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol hydrochloride or hydrates thereof, and intermediates in the production thereof
US7547790B2 (en) 2004-10-28 2009-06-16 Sankyo Company, Limited Optically active 4,4-di-substituted oxazolidine derivative and method for producing same
JP5024851B2 (en) * 2004-10-28 2012-09-12 第一三共株式会社 Optically active 4,4-disubstituted oxazolidine derivatives and process for producing the same
KR20070104407A (en) 2005-02-14 2007-10-25 유니버시티 오브 버지니아 페이턴트 파운데이션 Sphingosine 1-phosphate agonists comprising cycloalkanes and 5-membered heterocycles substitued by amino and phenyl groups
TWI418350B (en) * 2005-06-24 2013-12-11 Sankyo Co Use of pharmaceutical compositions comprising ppar modulator
US8048928B2 (en) * 2005-10-07 2011-11-01 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent for treating liver disease containing 2-amino-1,3-propanediol derivative as active ingredient, and method for treating liver disease
BRPI0707281A2 (en) 2006-01-27 2011-04-26 Univ Virginia method for prevention or treatment of neuropathic pain in a mammal
TWI389683B (en) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
JP2009526073A (en) 2006-02-09 2009-07-16 ユニバーシティ オブ バージニア パテント ファンデーション Bicyclic sphingosine-1-phosphate receptor analogs
TW200815600A (en) 2006-08-04 2008-04-01 Daiichi Sankyo Co Ltd An enzyme for phosphorizing a medicine
RU2430925C2 (en) * 2006-08-08 2011-10-10 Киорин Фармасьютикал Ко., Лтд. Aminophosphate derivative and s1p receptor modulator containing said derivative as active ingredient
SG174029A1 (en) * 2006-08-08 2011-09-29 Kyorin Seiyaku Kk Aminoalcohol derivative and immunosuppressant containing the same as active ingredient
EP2099741A2 (en) 2006-11-21 2009-09-16 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
JP2010510249A (en) 2006-11-21 2010-04-02 ユニバーシティ オブ バージニア パテント ファンデーション Sphingosine = 1-tetralin analog having 1-phosphate agonist activity
EP2097371A2 (en) 2006-11-21 2009-09-09 University Of Virginia Patent Foundation Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
TW200906389A (en) 2007-05-25 2009-02-16 Daiichi Sankyo Co Ltd Pharmaceutical composition comprising of therapeutic or prophylactic agents for hepatitis
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
FR2963238B1 (en) * 2010-07-29 2012-12-28 Fournier Lab Sa 15-DESOXYSPERGUALINE DERIVATIVES FOR THE TREATMENT AND / OR PREVENTION OF OCULAR INFLAMMATORY DISEASES
WO2012013884A1 (en) * 2010-07-29 2012-02-02 Laboratoires Fournier Sa Compounds for the treatment/prevention of ocular inflammatory diseases
JP5728027B2 (en) * 2010-12-02 2015-06-03 第一三共株式会社 Pyrrole derivative and method for producing the same
US9447078B2 (en) 2012-01-20 2016-09-20 Acucela Inc. Substituted heterocyclic compounds for disease treatment
KR20180093177A (en) 2017-02-10 2018-08-21 (주)홍익바이오텍 A method of making a gum using bamboo salt and porous minerals
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1134687A (en) 1966-04-28 1968-11-27 Beecham Group Ltd Acetylenic compounds
IL36730A0 (en) * 1970-05-28 1971-06-23 Chemagro Corp Phosphonamidothioates,their preparation and their use as herbicides and/or plant growth regulators
DK150068C (en) 1978-06-02 1987-06-29 Pfizer METHOD OF ANALOGUE FOR THE PREPARATION OF AMINOTHIAZOLES
FR2460919A1 (en) 1979-07-11 1981-01-30 Prod Synthese Ste Indle AMINO-ETHERS OXIDES, PROCESS FOR PREPARING THEM AND THEIR THERAPEUTIC APPLICATION
US4363918A (en) * 1979-09-11 1982-12-14 Janssen Pharmaceutica N.V. Method of preparing 1-alkyl-3-carboxy-1H pyrrole-2-acetic acids
US4386090A (en) * 1980-12-22 1983-05-31 Delalande S.A. Nitrogen containing 2,3-dihydro naphthalenes, compositions and use
US4716155A (en) * 1981-12-24 1987-12-29 E. R. Squibb & Sons, Inc. Phosphorus containing compounds and hypotensive use thereof
IT1190793B (en) * 1982-04-27 1988-02-24 Magis Farmaceutici ACTIVE COMPOUNDS IN THE TREATMENT OF THE ULCER AND ALLERGIC SKIN SYMPTOMS
US4536601A (en) * 1982-09-28 1985-08-20 Dainippon Pharmaceutical Co., Ltd. Optically active N-substituted phenylalaninols and use thereof
JPS5988467A (en) 1982-11-09 1984-05-22 Yoshitomi Pharmaceut Ind Ltd Phenoxyaminopropanol derivative
DK302185A (en) 1984-07-05 1986-01-06 Rolland Sa A 2-AMINO-OXAZOLINES AND PROCEDURES FOR THEIR PREPARATION
US4634689A (en) * 1985-10-31 1987-01-06 Schering Corporation Phosphinylalkanoyl imino acids
US4667038A (en) * 1985-12-02 1987-05-19 Syntex (U.S.A.) Inc. Tetrahydroisoquinoline derivatives
US4792568A (en) * 1986-04-14 1988-12-20 Rorer Pharmaceutical Corporation Aryl pyrroles as useful antiallergy compounds
JPS63126897A (en) * 1986-05-02 1988-05-30 Yoshitomi Pharmaceut Ind Ltd Immunosuppressive factor
US5135947A (en) * 1987-04-09 1992-08-04 Eli Lilly And Company 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
GB8712694D0 (en) * 1987-05-29 1987-07-01 Scras Tetrahydrofurans etc
IL86740A (en) 1987-06-30 1992-11-15 Tanabe Seiyaku Co Thiphene derivatives,their preparation and pharmaceutical compositions containing them
EP0300688A1 (en) 1987-07-21 1989-01-25 FISONS plc Pyrrole derivatives, process for their preparation and pharmaceutical compositions containing them
CA1334975C (en) * 1987-11-13 1995-03-28 James H. Holms Furan and pyrrole containing lipoxygenase inhibiting compounds
US5039706A (en) * 1987-11-30 1991-08-13 Du Pont Merck Pharmaceutical Company Antiinflammatory PLA2 inhibitors
DK702188A (en) * 1987-12-18 1989-06-19 Glaxo Group Ltd ETHANOLAMINE DERIVATIVES
US4977171A (en) * 1988-06-09 1990-12-11 Yashima Chemical Industrial Co., Ltd. Oxa- or thia-zoline derivative
WO1990002727A1 (en) * 1988-09-14 1990-03-22 Yoshitomi Pharmaceutical Industries, Ltd. Immunosuppressant
US5266599A (en) * 1989-02-20 1993-11-30 Jouveinal S.A. Use of (+)-1-[(3,4,5-trimethoxy)-benzyloxymethyl]-1-phenyl-N,N-dimethyl-n-propylamine to increase gastric discharge in a subject
EP0410176A1 (en) * 1989-07-07 1991-01-30 Yoshitomi Pharmaceutical Industries, Ltd. 2-Aminopentanoic acid compounds and their use as immunosuppressants
HU212415B (en) * 1989-08-25 1996-06-28 Egyt Gyogyszervegyeszeti Gyar Process for producing new cyclic oxym derivatives and pharmaceutical compositions containing them as active components
US5234934A (en) * 1989-08-25 1993-08-10 Egis Gyogyszergyar Aminopropanol derivatives, process for their preparation and pharmaceutical compositions comprising the same
FR2655043B1 (en) * 1989-11-24 1992-02-07 Adir NOVEL THIOPHENE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US5037853A (en) * 1989-12-28 1991-08-06 Abbott Laboratories Cyclopropyl derivative lipoxygenase inhibitors
GB9000644D0 (en) * 1990-01-11 1990-03-14 Erba Carlo Spa New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5723218A (en) 1990-04-16 1998-03-03 Molecular Probes, Inc. Dipyrrometheneboron difluoride labeled flourescent microparticles
US5433896A (en) * 1994-05-20 1995-07-18 Molecular Probes, Inc. Dibenzopyrrometheneboron difluoride dyes
US5648270A (en) * 1995-02-06 1997-07-15 Molecular Probes, Inc. Methods of sensing with fluorescent conjugates of metal-chelating nitrogen heterocycles
US5501980A (en) * 1994-05-20 1996-03-26 Molecular Probes, Inc. Benzazolylcoumarin-based ion indicators
US5326692B1 (en) * 1992-05-13 1996-04-30 Molecular Probes Inc Fluorescent microparticles with controllable enhanced stokes shift
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
GB9027055D0 (en) * 1990-12-13 1991-02-06 Sandoz Ltd Organic compounds
DK0492497T3 (en) 1990-12-24 1997-01-06 Hoechst Ag Process for acylating alcohols with an immobilized pseudomonas lipase
CA2071621C (en) 1991-06-19 1996-08-06 Ahihiko Hosoda Aldehyde derivatives
NL9101623A (en) * 1991-09-26 1993-04-16 Dsm Nv PROCESS FOR PREPARING AN ALCOHOL.
DE69230891T2 (en) * 1991-12-11 2000-10-05 Yoshitomi Pharmaceutical Medicines used to treat autoimmune diseases
WO1994004491A1 (en) * 1992-08-25 1994-03-03 G.D. Searle & Co. N-(alkanoylamino-2-hydroxypropyl)-sulfonamides useful as retroviral protease inhibitors
JP2579602B2 (en) * 1992-10-21 1997-02-05 吉富製薬株式会社 2-amino-1,3-propanediol compound and immunosuppressant
US5288751A (en) * 1992-11-06 1994-02-22 Abbott Laboratories [(Substituted) phenyalkyl]furylalkynyl-and [substituted) phenyalkyl] thienylalkynyl-N-hydroxyurea inhibitors or leukotriene biosynthesis
GB9304589D0 (en) * 1993-03-05 1993-04-21 Erba Carlo Spa Biologically active ureido derivatives useful as antimetastic agents
GB9306473D0 (en) * 1993-03-29 1993-05-19 Bioglan Lab Ltd Pharmaceutically useful compounds
US5641783A (en) * 1993-11-12 1997-06-24 Cell Therapeutics, Inc. Substituted amino alcohol compounds
US5837703A (en) * 1993-03-31 1998-11-17 Cell Therapeutics, Inc. Amino-alcohol substituted cyclic compounds
JPH06345728A (en) 1993-06-11 1994-12-20 Nissan Chem Ind Ltd Production of n-substituted azole derivative
US5717605A (en) * 1993-10-14 1998-02-10 Olympus Optical Co., Ltd. Color classification apparatus
US5534980A (en) * 1994-05-31 1996-07-09 Mita Industrial Co., Ltd. Electrophotographic image forming apparatus having a charge removing means
US5948820A (en) * 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
DE69524962D1 (en) 1994-08-22 2002-02-14 Welfide Corp BENZENE DERIVATIVES AND THEIR MEDICAL USE
ATE279185T1 (en) * 1995-12-28 2004-10-15 Mitsubishi Pharma Corp 2-AMINO-2-(2-(4-OCTYLPHENYL)ETHYL)PROPANE-1,3-DI L CONTAINING MEDICINAL PRODUCT FOR TOPICAL USE FOR THE TREATMENT OF DISEASES CAUSED BY A DISRUPTION OF THE IMMUNE SYSTEM
US6686353B1 (en) * 1996-05-20 2004-02-03 Teijin Intellectual Property Center Limited Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JPH11209277A (en) 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd Pharmaceutical composition
EP0923539B1 (en) * 1996-07-22 2002-06-05 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6077954A (en) * 1996-08-01 2000-06-20 Isis Pharmaceuticals, Inc. Substituted heterocyclic compounds
WO1998015278A1 (en) 1996-10-07 1998-04-16 Smithkline Beecham Corporation Method for stimulating bone formation
US5891892A (en) * 1996-10-29 1999-04-06 Warner-Lambert Company Small molecule biaryl compounds as inhibitors of endothelin converting enzyme
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
US5732218A (en) * 1997-01-02 1998-03-24 Lucent Technologies Inc. Management-data-gathering system for gathering on clients and servers data regarding interactions between the servers, the clients, and users of the clients during real use of a network of clients and servers
DK0990440T3 (en) * 1997-02-27 2009-02-23 Novartis Ag Pharmaceutical composition containing 2-amino-2 [2- (4-octylphenyl) ethyl] propane-1,3-diol, a lecithin and a saccharide
US6214873B1 (en) * 1997-04-04 2001-04-10 Welfide Corporation 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
WO1999001420A1 (en) * 1997-07-03 1999-01-14 Taito Co., Ltd. Process for the preparation of 2-aminomalonic acid derivatives and intermediates used in the process
AU737735B2 (en) * 1997-08-28 2001-08-30 Novartis Ag Lymphocyte function antigen-1 antagonists
JPH1180026A (en) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd New immunosuppressant, its use and its identification
ATE293603T1 (en) * 1997-10-14 2005-05-15 Mitsubishi Pharma Corp PIPERAZINE COMPOUNDS AND THEIR MEDICAL USES
DE19745904A1 (en) * 1997-10-17 1999-04-22 Hoechst Ag Water-soluble metal colloid solution, used as catalyst for fuel cells and electrolysis cells
DE19817459A1 (en) * 1998-04-20 1999-10-21 Basf Ag New heterocyclic amide derivatives useful as cysteine protease inhibitors for treating neurodegenerative diseases, neuronal damage, stroke, cranial trauma, Alzheimer's disease, etc.
KR20010100965A (en) * 1998-11-02 2001-11-14 가마꾸라 아끼오 Pyrrolidine compounds and medicinal utilization thereof
EP1457478B1 (en) * 1998-11-11 2017-07-19 Novartis AG Production of 2-amino-2-[2-(4-alkyl-phenyl)ethyl]propane-1,3-diols
WO2000033836A1 (en) 1998-12-04 2000-06-15 Ontogen Corporation 5-membered heterocycles for the treatment of human diseases involving modulators of selectins
CA2347770A1 (en) * 1998-12-18 2000-06-22 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6525069B1 (en) * 1998-12-18 2003-02-25 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6178821B1 (en) * 1999-01-25 2001-01-30 General Electric Company Vibration sensing device
EP1176140B1 (en) 1999-02-10 2004-12-29 Mitsubishi Pharma Corporation Amide compounds and medicinal use thereof
CN1144779C (en) 1999-03-11 2004-04-07 杭州中美华东制药有限公司 Process for preparing alkylphenylethyl aminopropanediol and intermediate obtained therein
JP4627356B2 (en) 1999-06-30 2011-02-09 松森　　昭 Drugs for preventing or treating viral myocarditis
AU6497200A (en) 1999-07-30 2001-02-19 Vertex Pharmaceuticals Incorporated Acyclic and cyclic amine derivatives
US6462092B1 (en) * 1999-09-23 2002-10-08 G.D. Searle & Co. Use of substituted N, N-disubstituted reverse aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity
DE19963174A1 (en) * 1999-12-27 2001-07-12 Gruenenthal Gmbh Substituted pyrrole Mannich bases
WO2001049685A2 (en) 1999-12-31 2001-07-12 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US6803375B1 (en) 2000-01-06 2004-10-12 The Regents Of The University Of California Non-peptide inhibition of T-lymphocyte activation and therapies related thereto
CN1450999A (en) * 2000-03-31 2003-10-22 辉瑞产品公司 Novel piperazine derivatives
US6964676B1 (en) * 2000-04-14 2005-11-15 Scimed Life Systems, Inc. Stent securement system
CN100374416C (en) * 2000-04-28 2008-03-12 霍夫曼-拉罗奇有限公司 P-(sulfonyl)-aryl and heteroaryls amines
CA2413418A1 (en) * 2000-06-21 2001-12-27 Joseph B. Santella Piperidine amides as modulators of chemokine receptor activity
IL153594A0 (en) * 2000-07-13 2003-07-06 Sankyo Co Amino alcohol derivatives and pharmaceutical compositions containing the same
JP2002053575A (en) 2000-08-09 2002-02-19 Sankyo Co Ltd Aminoalcohols
WO2002018395A1 (en) * 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
DE10049483A1 (en) * 2000-09-29 2002-05-02 Gruenenthal Gmbh Substituted 1-aminobutan-3-ol derivatives
DE10048714A1 (en) * 2000-09-30 2002-04-11 Gruenenthal Gmbh 5-amino-1-penlen-3-ol derivatives
CA2435739A1 (en) 2001-02-22 2002-09-06 Novartis Ag Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function
MXPA03008755A (en) * 2001-03-26 2004-02-18 Novartis Ag 2-amino-propanol derivatives.
JP2002316985A (en) 2001-04-20 2002-10-31 Sankyo Co Ltd Benzothiophene derivative
CN1236831C (en) 2001-05-21 2006-01-18 茵捷特数码浮质有限公司 Compositions for protein delivery via the pulmonary route
GB0117921D0 (en) 2001-07-23 2001-09-12 Novartis Ag Organic compounds
GB0119172D0 (en) 2001-08-06 2001-09-26 Melacure Therapeutics Ab Phenyl pyrrole derivatives
EP1431275B1 (en) 2001-09-27 2010-04-07 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
AU2002332289B2 (en) 2001-09-27 2007-05-10 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
GB0125443D0 (en) 2001-10-23 2001-12-12 Novartis Ag Organic Compounds
US7361671B2 (en) 2001-11-15 2008-04-22 The Institute For Pharmaceutical Discovery, Inc. Substituted heteroarylalkanoic acids
JP2005511735A (en) * 2001-12-06 2005-04-28 イーラン ファーマスーティカルズ、インコーポレイテッド Substituted hydroxyethylamine
PL211954B1 (en) * 2002-01-11 2012-07-31 Sankyo Co Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these
JP2003267974A (en) 2002-01-11 2003-09-25 Sankyo Co Ltd Medicine composition containing aminoalcohol derivative
US20040058894A1 (en) * 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
MXPA04011384A (en) 2002-05-16 2005-02-14 Novartis Ag Use of edg receptor binding agents in cancer.
EP1539674A1 (en) 2002-09-13 2005-06-15 Novartis AG Amino-propanol derivatives
MXPA05003254A (en) 2002-09-24 2005-06-08 Novartis Ag Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders.
AU2005215320B2 (en) * 2004-02-24 2008-04-17 Sankyo Company, Limited Amino alcohol compound
TW200611687A (en) * 2004-07-29 2006-04-16 Sankyo Co Pharmaceutical compositions used for immunosuppressant
TWI418350B (en) 2005-06-24 2013-12-11 Sankyo Co Use of pharmaceutical compositions comprising ppar modulator

Also Published As

Publication number Publication date
RU2330839C2 (en) 2008-08-10
JP4270541B2 (en) 2009-06-03
US7199150B2 (en) 2007-04-03
DK1471054T3 (en) 2009-11-09
US8067396B2 (en) 2011-11-29
US20070142335A1 (en) 2007-06-21
JP2003267950A (en) 2003-09-25
AU2003202495B2 (en) 2006-07-20
ATE435202T1 (en) 2009-07-15
EP1471054B1 (en) 2009-07-01
CY1109457T1 (en) 2014-08-13
US7638551B2 (en) 2009-12-29
ES2327825T3 (en) 2009-11-04
NZ533994A (en) 2006-10-27
CO5640126A2 (en) 2006-05-31
US20090326038A1 (en) 2009-12-31
HK1066532A1 (en) 2005-03-24
EP1471054A1 (en) 2004-10-27
EP1471054A4 (en) 2005-06-08
TW200302087A (en) 2003-08-01
NO20043319L (en) 2004-10-05
KR20040075068A (en) 2004-08-26
IL162874A0 (en) 2005-11-20
SI1471054T1 (en) 2009-12-31
CA2473461A1 (en) 2003-07-24
PL370790A1 (en) 2005-05-30
CN1630635A (en) 2005-06-22
BR0306811A (en) 2004-10-26
US8101650B2 (en) 2012-01-24
PT1471054E (en) 2009-09-23
KR100836547B1 (en) 2008-06-10
TWI283574B (en) 2007-07-11
US20100035842A1 (en) 2010-02-11
CN100406437C (en) 2008-07-30
RU2004121143A (en) 2006-02-27
DE60328161D1 (en) 2009-08-13
NO329134B1 (en) 2010-08-30
ZA200406333B (en) 2005-12-28
WO2003059880A1 (en) 2003-07-24
MXPA04006709A (en) 2004-10-04
PL211954B1 (en) 2012-07-31
KR20080035702A (en) 2008-04-23
US20050043386A1 (en) 2005-02-24
US20070105933A1 (en) 2007-05-10
AU2003202495A1 (en) 2003-07-30

Similar Documents

Publication Publication Date Title
CA2473461C (en) Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these
AU2001269503B2 (en) Amino alcohol derivatives
JP2002316985A (en) Benzothiophene derivative
US8048825B2 (en) Haloalkylsulfonanilide derivatives or salt thereof, herbicide comprising the derivatives as active ingredient, and use of the herbicide
TW200300349A (en) A 4-oxoqinoline derivative
CA2126994A1 (en) Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses
TW200906400A (en) Aryl derivative
AU2013366898A1 (en) Halogen-substituted heterocyclic compound
JP4771511B2 (en) Pharmaceutical composition containing amino alcohol derivative or phosphonic acid derivative
US5559109A (en) Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist
JP4140698B2 (en) Phosphoric acid or phosphonic acid derivatives
JP2002167382A (en) Amino alcohol derivative
AU2007205452B2 (en) Pyrrolopyridazinone compound
US6313071B1 (en) Phenylacetylene derivatives and agricultural/horticultural fungicides
CZ281417B6 (en) Derivative of n-acryloylpiperazine or n-acryloylhomopiperazine, process of its preparation and pharmaceutical composition containing thereof
JP2003267974A (en) Medicine composition containing aminoalcohol derivative

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170109